



- (51) **International Patent Classification:**
C12N1/15 (2006.01)
- (21) **International Application Number:**
PCT/EP20 13/050 126
- (22) **International Filing Date:**
4 January 2013 (04.01.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/583,559 5 January 2012 (05.01.2012) US
- (71) **Applicants:** NOVARTIS INTERNATIONAL PHAR-
MACEUTICAL LTD.; 131 Front Street, Hamilton (BM).
GLYKOS FINLAND OY [FI/FI]; Viikinkaari 6, FI-
00790 Helsinki (FI).
- (72) **Inventors:** LANDOWSKI, Christopher; Lohkopellontie
3 A 15, FI-00650 Helsinki (FI). HUUSKONEN, Anne;
Mechelininkatu 47 A 29, FI-00250 Helsinki (FI). SAAR-
INEN, Juhani; Eljaksentie 3, FI-00370 Helsinki (FI).
WESTERHOLM-PARVINEN, Ann; Kuninkaantie 20 A,
FI-02400 Kirkkonummi (FI). KANERVA, Anne; Riihikal-
lionkuja 8, FI-00890 Helsinki (FI). NATUNEN, Jari;
Oolannintie 10 E 18, FI-01520 Vantaa (FI). HÄNNINEN,
Anna-Liisa; Karhusuontie 74 A 4, FI-00780 Helsinki (FI).
SALOVUORI, Noora; Laivalahden puistotie 7 A 11, FI-
00810 Helsinki (FI). PENTTILÄ, Merja; Purjeen-
tekijankuja 3 A 1, FI-00210 Helsinki (FI). SALOHEIMO,
Markku; Kyntäjantie 18b, FI-00390 Helsinki (FI).
- (74) **Agent:** CABINET PLASSERAUD; 235 cours Lafayette,
F-69006 Lyon (FR).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).
- Published:**
- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
 - with sequence listing part of description (Rule 5.2(a))



WO 2013/102674 A2

(54) **Title:** PROTEASE DEFICIENT FILAMENTOUS FUNGAL CELLS AND METHODS OF USE THEREOF

(57) **Abstract:** The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

PROTEASE DEFICIENT FILAMENTOUS FUNGAL CELLS AND METHODS OF USE THEREOF

FIELD OF THE INVENTION

[0001] The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

BACKGROUND

[0002] Posttranslational modification of eukaryotic proteins, particularly therapeutic proteins such as immunoglobulins, is often necessary for proper protein folding and function. Because standard prokaryotic expression systems lack the proper machinery necessary for such modifications, alternative expression systems have to be used in production of these therapeutic proteins. Even where eukaryotic proteins do not have posttranslational modifications, prokaryotic expression systems often lack necessary chaperone proteins required for proper folding. Yeast and fungi are attractive options for expressing proteins as they can be easily grown at a large scale in simple media, which allows low production costs, and yeast and fungi have posttranslational machinery and chaperones that perform similar functions as found in mammalian cells. Moreover, tools are available to manipulate the relatively simple genetic makeup of yeast and fungal cells as well as more complex eukaryotic cells such as mammalian or insect cells (De Pourcq et al., *Appl Microbiol Biotechnol*, 87(5): 1617-31). Despite these advantages, many therapeutic proteins are still being produced in mammalian cells, which produce therapeutic proteins with posttranslational modifications most resembling the native human proteins, whereas the posttranslational modifications naturally produced by yeast and fungi often differ from that found in mammalian cells.

[0003] To address this deficiency, new strains of yeast and fungi are being developed that produce posttranslational modifications that more closely resemble those found in native human proteins. Thus, there has been renewed interest in using yeast and fungal cells to express more complex proteins. However, due to the industry's focus on mammalian cell culture technology for such a long time, the fungal cell expression systems such as *Trichoderma* are not as well

established as mammalian cell culture and therefore suffer from drawbacks when expressing mammalian proteins.

[0004] Thus, a need remains in the art for improved filamentous fungal cells, such as Trichoderma fungus cells, that can stably produce heterologous proteins, such as immunoglobulins, preferably at high levels of expression.

SUMMARY

[0005] Described herein are compositions including filamentous fungal cells, such as Trichoderma fungal cells having reduced or no detectable activity of at least three proteases, and having a recombinant polynucleotide encoding a heterologous polypeptide that is produced at increased levels. Further described herein are methods of improving heterologous polypeptide stability and methods of making heterologous polypeptides in which the proteases do not have the reduced activity.

[0006] Thus one aspect includes filamentous fungal cells having reduced or no detectable activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a heterologous polypeptide produced at a level of at least 2-fold higher than the production level of the polypeptide in a corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity. In certain embodiments, when the cell is an Aspergillus cell, the total protease activity is reduced to 50% or less of the total protease activity of the corresponding parental Aspergillus cell in which the protease do not have reduced activity. In other embodiments, the total protease activity of the filamentous fungal cell is reduced to 49% or less, 31% or less, of the total protease activity of the corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity.

[0007] In certain embodiments, the expression level of the at least three proteases is reduced or eliminated. In certain embodiments, genes encoding the three proteases each comprise a mutation that reduces or eliminates the corresponding protease activity. In certain embodiments that may be combined with the preceding embodiments, the three protease encoding genes are

pepl, *tspl*, and *slpl*. In other embodiments, the three protease encoding genes are *gapl*, *slpl*, and *pepl*.

[0008] In certain embodiments, the fungal cells have reduced or no detectable activity of four endogenous proteases; genes encoding the four proteases each comprise a mutation that reduces or eliminates the corresponding protease activity. In certain embodiments that may be combined with the preceding embodiments, the four protease encoding genes are *pepl*, *tspl*, *slpl*, and *gapl*.

[0009] In certain embodiments that may be combined with the preceding embodiments, the three or four protease encoding genes are selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pepl1*, *pepl2*, *tspl*, *slpl*, *slp2*, *slp3*, *slp7*, *gapl*, and *gap2*. In certain embodiments that may be combined with the preceding embodiments, the three or four protease encoding genes are selected from *pepl*, *pep3*, *pep4*, *tspl*, *slpl*, *slp2*, *gapl*, and *gap2*. In certain embodiments, the three or four protease encoding genes are selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *gapl*, *gap2*, *slpl*, *slp2*, and *tspl*.

[0010] In other embodiments, the fungal cells have reduced or no detectable activity of five endogenous proteases; genes encoding the five proteases each comprise a mutation that reduces or eliminates the corresponding protease activity. In certain embodiments that may be combined with the preceding embodiments, the five protease encoding genes are *pepl*, *tspl*, *slpl*, *gapl*, and *pep4*. In other embodiments, the five protease encoding genes are *pepl*, *tspl*, *slpl*, *gapl*, and *gap2*.

[0011] In certain embodiments, the fungal cells have reduced or no detectable activity of six endogenous proteases; genes encoding the six proteases each comprise a mutation that reduces or eliminates the corresponding protease activity. In certain embodiments, the cell has six protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the six protease encoding genes are *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, and *pep4*.

[0012] In certain embodiments that may be combined with the preceding embodiments, the fungal cells have three to six proteases having reduced or no detectable activity each of the three

to six proteases selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *tspl*, *slpl*, *slp2*, *slp3*, *gapl*, and *gap2*.

[0013] In certain embodiments that may be combined with the preceding embodiments, the cell has seven protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the seven protease encoding genes are *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, *pep4*, and *pep3*.

[0014] In certain embodiments that may be combined with the preceding embodiments, the cell has eight protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the eight protease encoding genes are *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, *pep4*, *pep3*, and *pep5*.

[0015] In certain embodiments that may be combined with the preceding embodiments, the fungal cell has an additional protease having reduced activity, the gene encoding the additional protease comprises a mutation that reduces or eliminates the corresponding protease activity, and the additional protease is selected from *pep7*, *pep8*, *pepl1*, *pepl2*, *tppl*, *gap2*, *slp3*, *slp5*, *slp6*, *slp7*, and *slp8*.

[0016] In certain embodiments that may be combined with the preceding embodiments, the heterologous polypeptide is a mammalian polypeptide. In certain embodiments, the mammalian polypeptide is glycosylated.

[0017] In certain embodiments, the mammalian polypeptide is selected from an immunoglobulin, an antibody and their antigen-binding fragments, a growth factor, an interferon, a cytokine, and an interleukin. In certain embodiments, the mammalian polypeptide is an immunoglobulin or an antibody. In certain embodiments, the mammalian polypeptide is selected from insulin-like growth factor 1 (IGF1), human growth hormone (hGH), and interferon alpha 2b (IFNa2b).

[0018] In certain embodiments that may be combined with the preceding embodiments, the heterologous polypeptide is a non-mammalian polypeptide. In certain embodiments, the non-

mammalian polypeptide is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase or xylanase.

[0019] In certain embodiments that may be combined with the preceding embodiments, the fungal cell further contains reduced or no detectable activity of ALG3, a mannosyltransferase enzyme. In certain embodiments, the gene encoding ALG3 contains a mutation that reduces or eliminates the corresponding activity. In certain embodiments that may be combined with the preceding embodiments, the fungal cell further contains a polynucleotide encoding an α -1,2-mannosidase.

[0020] In certain embodiments that may be combined with the preceding embodiments, the fungal cell has a mutation that reduces the expression of a protease desired to have reduced activity. In certain embodiments that may be combined with the preceding embodiments, the mutation is a deletion within the gene encoding the protease. In certain embodiments that may be combined with the preceding embodiments, the mutation is a deletion of the portion of the gene encoding the catalytic domain of the protease. In certain embodiments that may be combined with the preceding embodiments, the fungal cell has a point mutation in the portion of the gene encoding the catalytic domain of the protease.

[0021] In other embodiments, the reduction or elimination of protease activity of one or more proteases results from RNAi constructs specific for i) one protease or ii) two or more proteases selected from the group consisting of *apep*-type protease, a trypsin-like serine protease, a gap-type protease, a sedolisin protease and a *slp*-type protease. In certain embodiments, RNAi constructs are specific for *slp2*, *slp3*, *slp5* and/or *slp6*.

[0022] In certain embodiments that may be combined with the preceding embodiments, the fungal cell further contains an N-acetylglucosaminyltransferase I catalytic domain and an N-acetylglucosaminyltransferase II catalytic domain. In certain embodiments, the N-

acetylglucosaminyltransferase I catalytic domain and the N-acetylglucosaminyltransferase II catalytic domain are encoded by a polynucleotide. In certain embodiments, the N-acetylglucosaminyltransferase I catalytic domain is encoded by a first polynucleotide and the N-acetylglucosaminyltransferase II catalytic domain is encoded by a second polynucleotide. In certain embodiments that may be combined with the preceding embodiments, the fungal cell further contains a polynucleotide encoding a mannosidase II and/or a galactosyl transferase. In certain embodiments, the fungal cell contains enzymes selected from the group consisting of α 1,2 mannosidase, N-acetylglucosaminyltransferase I, N-acetylglucosaminyltransferase II, mannosidase II and/or galactosyltransferase, said enzymes further comprising a targeting peptide, for example a heterologous targeting peptide for proper localization of the corresponding enzyme. In certain embodiments, the targeting peptide is selected from SEQ ID NOs: 589-594.

[0023] In certain embodiments that may be combined with the preceding embodiments, the fungal cell is a *Trichoderma* fungal cell, a *Myceliophthora* fungal cell, an *Aspergillus* fungal cell, a *Neurospora* fungal cell, a *Fusarium* or *Penicilium* fungal cell, or a *Chrysosporium* fungal cell. In certain embodiments that may be combined with the preceding embodiments, the fungal cell is *Trichoderma reesei*.

[0024] In certain embodiments that may be combined with the preceding embodiments, the fungal cell is wild type for pep4 protease.

[0025] Another aspect includes methods of improving heterologous polypeptide stability, by: a) providing the filamentous fungal cell of any of the preceding embodiments; and b) culturing the cell such that the heterologous polypeptide is expressed, where the heterologous polypeptide has increased stability compared to the heterologous polypeptide produced in a corresponding parental filamentous fungal cell in which the proteases do not have reduced activity, for example, as not containing the mutations of the genes encoding the proteases. Another aspect includes methods of making a heterologous polypeptide, by: a) providing the filamentous fungal cell of any of the preceding embodiments; b) culturing the host cell such that the heterologous polypeptide is expressed; and c) purifying the heterologous polypeptide. In certain embodiments that may be combined with the preceding embodiments, the filamentous fungal cell further

contains a carrier protein. In certain embodiments, the carrier protein is CBH1. In certain embodiments that may be combined with the preceding embodiments, the culturing is in a medium comprising a protease inhibitor. In certain embodiments, the culturing is in a medium having one or two protease inhibitors selected from SBT1 and chymostatin. In certain embodiments, the heterologous polypeptide produced according to the method is a glycosylated mammalian polypeptide and at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mole%) of the total N-glycans of the polypeptide consists of $\text{Man}_3\text{GlcNAc}_2$ N-glycan. In other embodiments, the heterologous polypeptide produced according to the method is a glycosylated mammalian polypeptide and at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mole%) of the total N-glycans of the polypeptide consists of complex N-glycan. In certain embodiments, the heterologous polypeptide produced according to the method is a glycosylated mammalian polypeptide and at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mole%) of the total N-glycans of the polypeptide consists of hybrid N-glycan. In certain embodiments, the heterologous polypeptide produced according to the method is a glycosylated mammalian polypeptide and at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mole%) of the total N-glycans of the polypeptide consists of G1 or G2 N-glycan. Another aspect includes the heterologous polypeptides obtainable by the methods as described above.

[0026] Another aspect includes *Trichoderma* fungal cells having reduced or no detectable activity of at least three proteases selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *tspl*, *slpl*, *slp2*, *gapl*, and *gap2*, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide produced at a level of at least 2-fold higher than the production level of the polypeptide in a corresponding parental *Trichoderma* fungal cell.

[0027] In certain embodiments, the expression level of the at least three proteases is reduced or eliminated in the *Trichoderma* fungal cell. In certain embodiments, genes encoding the at least three proteases each comprise a mutation that reduces or eliminates the corresponding protease activity in the *Trichoderma* fungal cell. In certain embodiments, the *Trichoderma* fungal cell

includes three protease encoding genes with a mutation that reduces or eliminates protease activity, which are selected from *gapl*, *slpl*, and *pepl*. In certain embodiments that may be combined with the preceding embodiments, the mammalian polypeptide in the Trichoderma fungal cell is an antibody, or their antigen-binding fragments, or an immunoglobulin, and the at least three proteases are selected from *pepl*, *pep3*, *pep4*, *tspl*, *slpl*, *slp2*, *gapl*, and *gap2*. In certain embodiments, the Trichoderma fungal cell contains four protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the four protease encoding genes with such mutation are *pepl*, *tspl*, *slpl*, and *gapl*. In certain embodiments, the Trichoderma fungal cell has five protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the five protease encoding genes with such mutation are *pepl*, *tspl*, *slpl*, *gapl*, and *pep4*. In certain embodiments that may be combined with the preceding embodiments, the mammalian polypeptide in the Trichoderma fungal cell is a growth factor, interferon, cytokine, or interleukin, and the three proteases with reduced activity are selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pepl1*, *pepl2*, *gapl*, *gap2*, *slpl*, *slp2*, *slp7*, and *tspl*. In certain embodiments, the Trichoderma fungal cell has five protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the five protease encoding genes with such mutation are *pepl*, *tspl*, *slpl*, *gapl*, and *gap2*. In certain embodiments, the Trichoderma fungal cell has six protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the six protease encoding genes with such mutation are *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, and *pep4*. In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell has seven protease encoding genes, each of which comprise a mutation that reduces or eliminates the corresponding protease activity, and the seven protease encoding genes are *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, *pep4*, and *pep3*. In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell has eight protease encoding genes, each of which comprise a mutation that reduces the corresponding protease activity, and the eight protease encoding genes with such mutation are *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, *pep4*, *pep3*, and *pep5*.

[0028] In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell further contains reduced or no detectable activity of one or more additional proteases. In certain embodiments, the expression level of the one or more additional proteases in the Trichoderma fungal cell is reduced or eliminated. In certain embodiments, genes encoding the one or more additional protease in the Trichoderma fungal cell each have a mutation that reduces or eliminates the corresponding protease activity. In certain embodiments that may be combined with the preceding embodiments, the one or more additional protease encoding genes are selected from *pep7*, *pep8*, *pepl1*, *pepl2*, *tppl*, *gap2*, *slp3*, *slp5*, *slp6*, *slp7*, and *slp8*.

[0029] In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell further contains reduced or no detectable activity of ALG3. In certain embodiments, the gene encoding ALG3 in the Trichoderma fungal cell contains a mutation that reduces or eliminates the corresponding activity. In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell further contains a polynucleotide encoding an α -1,2-mannosidase. In certain embodiments that may be combined with the preceding embodiments, the mutation reduces or eliminates the expression of the gene in the Trichoderma fungal cell. In certain embodiments that may be combined with the preceding embodiments, the mutation is a deletion of the gene in the Trichoderma fungal cell. In certain embodiments that may be combined with the preceding embodiments, the mutation is a deletion of the portion of the gene encoding the catalytic domain of the protease in the Trichoderma fungal cell. In certain embodiments that may be combined with the preceding embodiments, the mutation is a point mutation in the portion of the gene encoding the catalytic domain of the protease in the Trichoderma fungal cell. In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell further contains a N-acetylglucosaminyltransferase I catalytic domain and an N-acetylglucosaminyltransferase II catalytic domain. In certain embodiments, the N-acetylglucosaminyltransferase I catalytic domain and the N-acetylglucosaminyltransferase II catalytic domain are encoded by a polynucleotide of the Trichoderma fungal cell. In certain embodiments, the N-acetylglucosaminyltransferase I catalytic domain is encoded by a first polynucleotide and the N-acetylglucosaminyltransferase II catalytic domain is encoded by a second polynucleotide of the

Trichoderma fungal cell. In certain embodiments that may be combined with the preceding embodiments, the Trichoderma fungal cell further contains a polynucleotide encoding a mannosidase II. In certain embodiments, the proteases each have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 17, 37, 58, 66, 82, 98, 118, 129, 166, and 182. In certain embodiments, the total protease activity in the Trichoderma fungal cell is reduced to 49% or less, 31% or less of the total protease activity of the corresponding Trichoderma parental cell in which the proteases do not have the reduced activity. In certain embodiments that may be combined with the preceding embodiments, the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide produced at a level of at least 2-fold higher than the production level of the polypeptide in a corresponding parental Trichoderma fungal cell. In certain embodiments that may be combined with the preceding embodiments, the mammalian polypeptide is produced in a full length version at a level higher than the production level of the full-length version of the polypeptide in a corresponding parental Trichoderma fungal cell.

[0030] Another aspect includes methods of improving heterologous polypeptide stability, by: a) providing the Trichoderma fungal cell of any of the preceding embodiments; and b) culturing the cell such that the heterologous polypeptide is expressed, where the heterologous polypeptide has increased stability compared to a host cell not containing the mutations of the genes encoding the proteases. Another aspect includes methods of making a heterologous polypeptide, by: a) providing the Trichoderma fungal cell of any of the preceding embodiments; b) culturing the host cell such that the heterologous polypeptide is expressed; and c) purifying the heterologous polypeptide. In certain embodiments that may be combined with the preceding embodiments, the filamentous fungal cell further contains a carrier protein. In certain embodiments, the carrier protein is CBH1.

DESCRIPTION OF THE FIGURES

[0031] Figure 1 depicts a PAGE gel showing fractions eluted from affinity column purification of aspartic proteases.

[0032] Figure 2 depicts a PAGE gel showing the results of incubating IgG with aspartic proteases.

[0033] Figure 3 depicts Southern blot analysis showing the generation of single protease deletion strains M181 and M195. Figure 3A depicts the expected signal of *pepl* ORF: >8 kb from parent M127, no signal from transformants. Figure 3B depicts the expected signal of *pepl* 5'flank: >8 kb from parent M127, 4 kb from transformants. Figure 3C depicts the expected signal of *pepl* 3'flank: >8 kb from parent M127, 4.2 kb from transformants

[0034] Figure 4 depicts Southern blot analysis showing the generation of rituximab antibody in the *pepl* deletion strain M182. Figure 4A depicts the expected signal of *pepl* ORF: >8 kb from parent M169, no signal from transformants. Figure 4B depicts the expected signal of *bar*. 1.0 + 1.7 kb from transformants, 3.1 kb from pTTv41, nothing from M169. Figure 4C depicts the expected signal of *bar*. 1.8 + 2.8 kb from transformants, 3.1 kb from pTTv41, nothing from M169.

[0035] Figure 5 depicts a protein gel showing peak fractions from aspartic protease purifications of *a-pepl* containing strain and *A-pepl* strain.

[0036] Figures 6A-B depict an immunoblot illustrating that deleting *pep2* protease from the rituximab production strain M169 improved the (A) light and (B) heavy chain production in transformant 206A (strain M455). The bands representing the light chain fragment at 18 kD and the heavy chain fragment at 38 kD were more intense in strain M455 compared to the parent strain M169.

[0037] Figure 7 graphically depicts the protease activity of supernatant from the rituximab production strain M169 and the *pep2* protease deletion transformants 98A, 116A, 198A, 201A, and 206A (M455). Transformants 116A, 198A, and 206A show reduced protease activity against casein compared to their parent strain M169.

[0038] Figure 8 depicts an immunoblot showing the effects of protease activity of PEP3 and PEP7 on MAB01 heavy chain and native IGF-1. Figure 8A depicts the effects of protease activity

on MABOI at pH 5.5. Figure 8B depicts the effects of protease activity on MABOI at pH 4.5. Figure 8C depicts the effects of protease activity on native IGF-1 at pH 4.5

[0039] Figure 9 depicts a PAGE gel showing protease containing fractions purified from SIP peptide affinity column.

[0040] Figure 10 depicts an immunoblot showing SIP protease activity on the MABOI heavy chain.

[0041] Figure 11 graphically depicts protease activity against casein with and without inhibitors.

[0042] Figure 12 depicts an immunoblot showing the levels of MABOI heavy and light chain production after deletion of each of *slp1*, *slp2*, *slp3*, and *gap1* proteases. Figure 12A shows MABOI heavy chain production. Figure 12B shows MABOI light chain production.

[0043] Figure 13 graphically depicts the fold improvement in MABOI heavy and light chain production after deletion of each of *slp1*, *slp2*, *slp3*, and *gap1* proteases. Each bar represents the average from several of the clones shown in Figure 12.

[0044] Figure 14 depicts an immunoblot showing the levels of MABOI production from the *gap2* deletion strain M244. Figure 14A shows production of MABOI heavy chain (HC). Figure 14B shows the production of MABOI light chain (LC).

[0045] Figure 15 depicts an immunoblot showing the levels of MABOI antibody after incubation with *Pichia* supernatant containing the GAP2 protease.

[0046] Figure 16 depicts an immunoblot showing the level of protease degradation of human IgG1.

[0047] Figure 17 depicts the results of an MABO2 antibody zymogram from affinity purification with an aminobenzamidine column (purified fractions), and from supernatant samples (supernatant).

[0048] Figure 18 depicts the generation of the *ApeplAtspl* double protease deletion strain M219. Figure 18A depicts the expected signal of *tspl* ORF: 6.4 kb from parent M196. Figure 18B depicts the expected signal of *tspl* 5' flank: 3.9 kb from transformants, >8 kb from M196, 3.9 kb from pTTv72. Figure 18C depicts the expected signal of *tspl* 3' flank: 2.8 kb from transformants, >8 kb from M196, 3.9 kb from pTTv72.

[0049] Figure 19 depicts Southern blot analysis showing the generation of the *ApeplAtsp2* double deletion strain M194. Figure 19A depicts the expected signal of *tspl* ORF: kb from parent M181. Figure 19B depicts the expected signal of *bar*. 1.4 + 2.5 kb from transformants, 2.9 kb from pTTv42, nothing from M181. Figure 19C depicts the expected signal of *bar*. 1.9 + 3.2 kb from transformants, 2.9 kb from pTTv42, nothing from M181.

[0050] Figure 20 graphically depicts normalized protease activity data from culture supernatants from each of the protease deletion supernatants and the parent strain M124. Protease activity was measured at pH 5.5 in first 5 strains and at pH 4.5 in the last three deletion strains. Protease activity is against green fluorescent casein. The six protease deletion strain has only 6% of the wild type parent strain and the 7 protease deletion strain protease activity was about 40% less than the 6 protease deletion strain activity.

[0051] Figure 21A depicts the results of an MAB02 zymogram with aminobenzamidine purified fractions from fermentation supernatants. Figure 21B depicts an SDS PAGE gel (7%) of aminobenzamidine purified fractions from fermentation supernatants.

[0052] Figure 22 depicts the results of an MAB02 zymogram assay with SBTI affinity purified fractions containing proteases. The major proteolytic activities appear white, where the protease has degraded the MAB02 antibody. Concentrated fraction 3 (cf3) and unconcentrated fractions 1-4 (fl-f4) were run in the zymogram gel.

[0053] Figure 23 depicts an SDS PAGE gel showing SBTI affinity purified fractions containing proteases. Concentrated fractions cf3 and cf4 are shown in the gel.

[0054] Figure 24 depicts an immunoblot showing the level of rituximab heavy chain degradation by SBTI purified proteases.

[0055] Figure 25 depicts an immunoblot showing the level of antibody degradation when incubated overnight with subtilisin containing *Pichia* supernatants. Figure 25A shows protease degradation of rituximab heavy chain. Figure 25B shows protease degradation of MAB01 heavy chain.

[0056] Figure 26 depicts Southern blot analysis showing the generation of the triple protease deletion strain M277. Figure 26A depicts the expected signal of *slpl* ORF: 6.5 kb from parents (M219, M228) only. Figure 26B depicts the expected signal of *slpl* 5'flank: 6.5 kb from parents, 3.3 kb from transformants, 4.4 kb from plasmid control pTTvl26. Figure 26C depicts the expected signal of *slpl* 3'flank: 6.5 kb from parents, 2.3 kb from transformants, 4.4 kb from plasmid control pTTvl26.

[0057] Figure 27 depicts an MAB02 zymogram assay showing the activity of protease deletion strain supernatants. White regions on the stained gel indicate an area of protease activity.

[0058] Figure 28 graphically depicts total protease activity of protease deletion culture supernatants compared to wild type M124 activity.

[0059] Figure 29 depicts Southern blots analysis showing the generation of the quadruple protease deletion strain M307. Figure 29A depicts the expected signal of *gapl* ORF: 4 kb from parent (*Mill* 2A = M306) only. Figure 29B depicts the expected signal of *gapl* 5'flank: 5.5 kb from parent, 3.4 kb from transformants, 4.1 kb from plasmid control pTTvl 17. Figure 29C depicts the expected signal of *gapl* 3'flank: 5.5 kb from parent, 3.1 kb from transformants, 4.1 kb from plasmid control pTTvl 17.

[0060] Figure 30 graphically depicts total protease activity in triple and quadruple deletion strains compared to wild type M124 strain.

[0061] Figure 31 graphically depicts protease activity over time between the M304 triple deletion strain and the M371 quadruple deletion strain.

[0062] Figure 32 depicts Southern blot analysis showing the generation of the quintuple protease deletion strain M369. Figure 32A depicts the expected signal of *gap2* ORF: 4.9 kb from parent (M307). Figure 32B depicts the expected signal of *gap2* 5'flank: 4.9 kb from parent, 2.3 kb from transformant, 2.3 kb from plasmid control pTTvl45. Figure 32C depicts the expected signal of *gap2* 3'flank: 4.9 kb from parent, 3.8 kb from transformants, 3.8 kb from plasmid control pTTvl45. Figure 32D depicts Southern blot analysis showing the generation of the *pyr4*- from the quintuple protease deletion strain M369, resulting in strain M381 (clone 14). The expected signal is *gap2* 5'flank: 1.5 kb from all strains, 4.1 kb from plasmid control pTTvl45. Figure 32E depicts Southern blot analysis showing the generation of the *pyr4*- from the quintuple protease deletion strain M369, resulting in strain M381 (clone 14). The expected signal is *gap2* 3'flank: 3.6 kb from M307, 2.7 kb from M369 + loopout clones, 3.8 kb from plasmid control pTTvl45.

[0063] Figure 33 graphically depicts the protease activity of day 5 supernatants taken from shake flask cultures done with the 4 protease deletion strain M307, the 5 protease deletion strain M369, and the 6 protease deletion transformants 10B, 44B, 97A, 97B, and 120A. Fluorescent casein was incubated with the diluted supernatants in citrate buffer pH 4.5 to detect protease activity.

[0064] Figure 34 depicts Southern blot analysis showing the generation of the 6-fold protease deletion strains M396 and M400. Figure 34A depicts the expected signal of *pep4* ORF: 6.3 kb from M307 and M369. Figure 34B depicts the expected signal of *pep4* ORF: 6.3 kb from M307 and M369, no signals from transformants. Figure 34C depicts the expected signal of *pep4* 5' flank: 6.3 kb from M307 and M369, 4.8 kb from transformants, 4.0 kb from pTTvl81. Figure 34D depicts the expected signal of *pep4* 3' flank: 6.3 kb from M307 and M369, 2.1 kb from transformants, 4.0 kb from pTTvl81. Figure 34E depicts Southern blot analysis showing the generation of *pyr4*- from 6-fold protease deletion strains M396. The expected signal of is *pep4* 3' flank: 6.3 kb from M307 and M369, 2.1 kb from repurified transformants, 4.9 kb from the loopout clones.

[0065] Figure 35 depicts an immunoblot showing the amount of rituximab heavy chain fragments created *in vitro* by supernatant proteases.

[0066] Figure 36 depicts an immunoblot showing degradation of heavy chain and light chain by supernatant samples from SBTI treated cultures and untreated controls. Figure 36A shows degradation of the heavy chain. Figure 36B shows the degradation of the light chain.

[0067] Figure 37 depicts an immunoblot showing the level of degradation of heavy chain and light chain by supernatant samples from cultures treated with chymostatin and pepstatin A, or from untreated control cultures. Figure 37A shows the degradation of the light chain. Figure 37B shows degradation of the heavy chain.

[0068] Figure 38 depicts the process of purifying antibodies from *T. reesei* culture supernatants.

[0069] Figure 39 depicts an immunoblot showing improved the stability of antibody heavy (HC) and light chain (LC) from *T. reesei* cells containing a deletion of the *pepl* protease. Three model antibodies were tested in large shake flask supernatant (*Apepl* and M124) and fermentation supernatant (pH 5.5; 28°C; 20 g/L spent grain extract, 60 g/L lactose).

[0070] Figure 40 depicts an immunoblot showing improved production of the rituximab (Rx) heavy chain from *T. reesei* cells containing a deletion of the *tspl* protease. Transformants 12-2A and 12-16A clearly show more heavy chain compared to the parent strain.

[0071] Figure 41 depicts an immunoblot showing reduced MAB01 heavy chain degradation after overnight incubation with supernatant from the triple protease deletion strain M277. After overnight incubation in day 5 culture supernatant, there was 2.5-fold more heavy chain found in the triple protease deletion supernatant compared to supernatant from control strain M124, which has no protease deletions. When incubated in the 7 day culture supernatant, there was 4-fold more heavy chain found in the triple protease deletion supernatant compared to supernatant from control strain M124.

[0072] Figure 42 depicts a degradation study of model proteins. Undiluted supernatant from the 6 protease deletion strain was used at pH 4.2 for spiking in pure model proteins (0.05 $\mu\text{g}/\mu\text{l}$). 50 mM sodium citrate pH 4.0 spiked with model proteins (0.05 $\mu\text{g}/\mu\text{l}$) is shown as a buffer control. The spiked supernatant and control were incubated for 20 hours at 37°C. 10 μl of each sample was loaded into 18% SDS PAGE gels. The hGH ran at 22 kD, the IFNa2b ran at 19.4 kD, and the IGF1 ran at 7.5 kD.

[0073] Figure 43 depicts stability testing of the MAB01 antibody heavy chain in supernatants from the 6 protease deletion strain. The MAB01 antibody was present in undiluted supernatant at 0.05 $\mu\text{g}/\mu\text{l}$. 10 μE of each sample was loaded to a 4-20% SDS PAGE gel. The heavy chain was stable after a 20 hour incubation at 37°C in supernatant from the 6 protease deletion strain at pH 4.2. The heavy chain was detected with anti-heavy chain IgG AP conjugated antibody (Sigma #A3188) diluted 1:30,000 in TBST. The full length heavy chain ran at 50 kD on the gel.

[0074] Figure 44 depicts day 4 samples of human growth hormone from 24 well cultures with and without inhibitors, and supplements. 12 μl of each supernatant was loaded. Primary antibody from Acris, catalog #AM00401PU-N mouse anti-hGH antibody (diluted to 2 $\mu\text{g}/\text{ml}$ in TBST) and BioRad (#170-6520) goat anti-mouse IgG AP conjugated secondary antibody diluted 1:10,000. The hGH standard (200 ng), Abeam catalog #ab51232. The full length hGH protein runs at 22 kD.

[0075] Figure 45 depicts a phylogeny of aspartic proteases of *T. reesei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium chrysogenum*, *Aspergillus oryzae*, *A. nidulans*, and *A. niger*. The alignment was created with Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) and the tree was calculated using average distance with BLOSUM62.

[0076] Figure 46 depicts a phylogeny of subtilisin proteases of *T. reesei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium chrysogenum*, *Aspergillus oryzae*, *A. nidulans*, and *A. niger*. The alignment was created with Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) and the tree was calculated using average distance

with BLOSUM62. "pyr" means pyrolysins, "prKsf3" means proteinase K, subfamily 3; prtA, prtK, prtJ, prtF, and prtBCI mean subfamilies as described in Bryant et al. (2009) BMC Evolutionary Biology 9:168, doi:10.1186/1471-2148-9-168, Figure 5 and additional file no. 8.

[0077] Figure 47 depicts a phylogeny of glutamic proteases of *T. reesei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium chrysogenum*, *Aspergillus oryzae*, *A. nidulans*, and *A. niger*. The alignment was created with Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) and the tree was calculated using average distance with BLOSUM62.

[0078] Figure 48 depicts a phylogeny of sedolisin proteases of *T. reesei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium chrysogenum*, *Aspergillus oryzae*, *A. nidulans*, and *A. niger*. The alignment was created with Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>) and the tree was calculated using average distance with BLOSUM62. As slp7 resembles sedolisin proteases, it is included in the tree. *Aspergillus fumigatus* sequences are included to aid the determination of the relationships between sedolisins. The abbreviations sedA/B/C/D/E in front of each protease are based on Reichard et al. (2006) APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Vol. 72, p. 1739-1748, Figure 4, from which BLAST search with *A. fumigatus* sedolisin the corresponding protease was retrieved..

[0079] Figure 49: **A:** Schematic drawings for the expression plasmids pTTv67 and pTTv99. The MABOI heavy chain is contained within in the pTTv67 vector and the light chain is contained within the pTTv99 vector. **B:** Schematic drawing for the expression vector pTTv223. The MABOI heavy and light chain is contained within the pTTv223 vector.

[0080] Figure 50: **A:** Western blot analysis MABOI light and heavy chain production in pH 5.2 in a fed batch fermentation of the MABOI production strain M507. The antibodies used were Sigma A3188 against the heavy chain (left blot) and Sigma A3813 against the light chain (right blot), both at 1:10,000 dilutions. Sample codes denote fermentation time in days. 0.1 µl of supernatant was loaded into each lane in both blots. **B:** Western blot analysis of MABOI light and heavy chain production in the fed batch fermentation of the MABOI production strain M507 at

pH 5.5. The antibodies used were Sigma A3188 against the heavy chain (blot to the left) and Sigma A3813 against the light chain (blot to the right), both at 1:10,000 dilutions. Sample codes denote fermentation time in days. 0.1 μl of supernatant was loaded into each lane in both blots.

[0081] Figure 51 . Western blot analysis MAB01 light and heavy chain production in strains M304 in the fed batch fermentation bio00503b at pH 5.5. The antibodies used were Sigma A3188 against the heavy chain and Sigma A3813 against the light chain. The day 8 from the M304 fermentation bio00477b was included as a control. Sample codes denote fermentation time in days. 0.1 μl of supernatant was loaded in both blots. The uppermost immunoblot is the heavy chain and lower immunoblot is the light chain.

[0082] Figure 52. The pTTv204 RNAi expression vector.

[0083] Figure 53: Immunoblot detecting MAB01 heavy chain production in strains expressing RNAi that knocks down *slp2* expression.

[0084] Figure 54 A depicts quantification of the IFN-a 2b expression level from the day 3 sample of M401 fermentation. 1 μl / 2 μl / 4 μl of supernatant were loaded to a 4-20% SDS PAGE gel. Immunoblotting was done with Abeam (#ab9386) anti-IFN-a 2b antibody diluted to 1 $\mu\text{g/ml}$ in TBST. The secondary antibody from Bio-rad (#170-6520) goat anti-mouse IgG AP conjugated secondary antibody diluted 1:5000 in TBST. The protein standards were loaded on the gel corresponding 50 ng, 100 ng and 200 ng of full length IFN-a 2b. Densitometric quantification was done with Totallab Quant TL100 software. For the quantification 2 μl sample was most representative. Full length IFN-a 2b control (100 ng) runs at 19.3 kD and carrier bound IFN-a 2b at 70 kDa

[0085] Figure 54 B depicts immunoblot analysis for day 3 - 6 samples of M577 and M652 fermentation cultures. 0.2 μl of growth supernatant was loaded to a 4-20% SDS PAGE gel. Immunoblotting was done with Abeam (#ab9386) anti-IFN-a 2b antibody diluted to 1 $\mu\text{g/ml}$ in TBST. The secondary antibody from Bio-rad (#170-6520) goat anti-mouse IgG AP conjugated

secondary antibody diluted 1:5000 in TBST. Full length IFN-a 2b control (100 ng) runs at 19.3 kD and carrier bound IFN-a 2b at 70 kDa

[0086] **Figure 55** depicts quantification of the IFN-a 2b expression level from the day 4 (M577 fermentation) and day 3 (M652 fermentation) samples. 0.05 μ l and 0.1 μ l of supernatant were loaded of each sample to a 4-20% SDS PAGE gel. Immunoblotting was done with Abeam (#ab9386) anti-IFN-a 2b antibody diluted to 1 μ g/ml in TBST. The secondary antibody from Bio-rad (#170-6520) goat anti-mouse IgG AP conjugated secondary antibody diluted 1:5000 in TBST. The protein standards were loaded on the gel corresponding 50 ng, 100 ng and 200 ng of full length IFN-a 2b. Densitometric quantification was done with Totallab Quant TL100 software. For the quantification 0,1 μ l samples were most representative. Full length IFN-a 2b control (100 ng) runs at 19.3 kD and carrier bound IFN-a 2b at 70 kDa

DETAILED DESCRIPTION

[0087] The present invention relates to improved methods of generating recombinant heterologous polypeptides in filamentous fungal cells that have reduced or no activity of at least three proteases. The present invention is based in part upon the surprising discovery that reducing the activity of a specific combination of endogenous proteases in filamentous fungal cells increases the expression and stability of a variety of recombinantly expressed heterologous proteins, such as immunoglobulins and growth factors. While others have created *Trichoderma* fungal cells with one or more proteases inactivated, they have not provided guidance as to which proteases are most relevant to increasing the expression and stability of specific types of proteins, such as mammalian proteins. For example, WO2011/075677 discloses certain proteases that can be knocked out in *Trichoderma* and even discloses *Trichoderma* fungal cells that are deficient in multiple proteases. However, WO2011/075677 does not provide any guidance regarding which of the proteases have an adverse impact on the expression and stability of mammalian proteins, such as immunoglobulins or growth factors, as no examples of expression of any mammalian proteins are described therein. Moreover, WO2011/075677 only discloses heterologous expression of a single fungal protein in each of three different fungal strains deficient in a single protease. Thus, one of skill in the art would likely read WO2011/075677 as teaching that

inactivating each single protease would be sufficient for heterologous protein production. Yoon et al (2009, Appl. Microbiol Biotechnol 82: 691-701, 2010: Appl. Microbiol Biotechnol DOI 10.1007/s00253-010-2937-0) reported the construction of quintuple and ten fold protease gene disruptants for heterologous protein production in *Aspergillus oryzae*. The 10 protease disruptant cells improve the production yield of chymosin by only 3.8 fold, despite the high number of disrupted protease genes. Van den Hombergh et al reported a triple protease gene disruptant of *Aspergillus niger*. While the data show a reduction in protease activity, there is no example of any mammalian protein production described herein.

[0088] Applicants have surprisingly shown that multiple proteases are relevant to reduction of total protease activity, increasing production of heterologous proteins and stabilizing the heterologous proteins after expression, in filamentous fungal cells, such as Trichoderma fungal cells. In particular, the inventors have identified proteases that are actually expressed in Trichoderma fungal cells (as opposed to merely being coded for in the genome) by purifying these proteases and determining which have activities that are most relevant in degrading heterologous proteins, such as mammalian proteins. Additionally, the inventors confirmed that deleting the genes responsible for the particular protease activities achieved a substantial reduction in total protease activity, which correlates to an increase in protein stabilization in terms of both quantity and quality of proteins produced in filamentous fungal cells containing such deletions, and resulted in an increase in the production of full length heterologous proteins in the cells. It was also found that Trichoderma fungal cells engineered to reduce the activity of at least three protease genes resulted in an unexpected, synergistic increase in the production of full length mammalian proteins, such as antibodies, therapeutic protein or antibody variants such as Fab or single domain antibodies. In other words, the amount of full length mammalian protein produced was greater than the sum of the amounts produced in Trichoderma fungal cells containing only one or two protease gene deletions. Thus, in contrast to WO2011/075677, the inventors have shown that production of intact heterologous proteins in filamentous fungal cells, such as Trichoderma fungal cells, can be achieved by reducing or eliminating the activity of at least three proteases in the cells.

[0089] Accordingly, certain aspects of the present disclosure provide filamentous fungal cells that produce increased levels of a heterologous protein by having reduced or no activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a heterologous polypeptide produced at a level of at least 2-fold higher than the production level of the polypeptide in a corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity. In other words, the desired increase in the level of the heterologous protein production is determinable by comparing the production level of the heterologous protein in a filamentous fungal cell having the reduced activity of at least three proteases, to that of a filamentous fungal cell which does not have such reduced activity, but is otherwise identical to the cell exhibiting the increased level.

[0090] Other aspects of the present disclosure provide methods of improving heterologous polypeptide stability, by: a) providing a filamentous fungal cell of the present disclosure having reduced or no activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a heterologous polypeptide; and b) culturing the cell such that the heterologous polypeptide is expressed, where the heterologous polypeptide has increased stability compared to a host cell not containing the mutations of the genes encoding the proteases.

[0091] Still other aspects of the present disclosure provide methods of making a heterologous polypeptide, by: a) providing a filamentous fungal cell of the present disclosure having reduced or no activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a heterologous polypeptide; b) culturing the host cell such that the heterologous polypeptide is expressed; and c) purifying the heterologous polypeptide.

[0092] Certain aspects of the present disclosure also provide *Trichoderma* fungal cells that produce increased levels of a mammalian polypeptide by having reduced or no activity of at least three proteases selected from *pep1*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pep11*, *pep12*, *tspl*, *slpl*, *slp2*, *gap1*, and *gap2*, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide produced at a level of at least 2-fold higher than the production level of the polypeptide in a corresponding parental *Trichoderma* fungal cell in which the proteases do not have the reduced activity. In other words, the desired increase in the level of the heterologous

protein production is determinable by comparing the production level of the heterologous protein in a *Trichoderma* fungal cell having the reduced activity of at least three proteases, to that of a *Trichoderma* fungal cell which does not have such reduced activity, but is otherwise identical to the cell exhibiting the increased level.

[0093] Other aspects of the present disclosure provide methods of improving mammalian polypeptide stability, by: a) providing a *Trichoderma* fungal cell of the present disclosure having reduced activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide; and b) culturing the cell such that the mammalian polypeptide is expressed, where the mammalian polypeptide has increased stability compared to a host cell not containing the mutations of the genes encoding the proteases.

[0094] Further aspects of the present disclosure provide methods of making a mammalian polypeptide, by: a) providing a *Trichoderma* fungal cell of the present disclosure having reduced activity of at least three protease, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide; b) culturing the host cell such that the mammalian polypeptide is expressed; and c) purifying the mammalian polypeptide.

Definitions

[0095] As used herein, an "immunoglobulin" refers to a multimeric protein containing a heavy chain and a light chain covalently coupled together and capable of specifically combining with antigen. Immunoglobulin molecules are a large family of molecules that include several types of molecules such as IgM, IgD, IgG, IgA, and IgE.

[0096] As used herein, an "antibody" refers to intact immunoglobulin molecules, as well as fragments thereof which are capable of binding an antigen. These include hybrid (chimeric) antibody molecules (see, e.g., Winter et al. *Nature* 349:293-99225, 1991; and U.S. Pat No. 4,816,567 226); F(ab')₂ and F(ab) fragments and Fv molecules; non-covalent heterodimers [227, 228]; single-chain Fv molecules (scFv) (see, e.g., Huston et al. *Proc. Natl. Acad. Sci. U.S.A.* 85:5897-83, 1988); dimeric and trimeric antibody fragment constructs; minibodies (see, e.g., Pack et al. *Biochem* 31, 1579-84, 1992; and Cumber et al. *J. Immunology* 149B, 120-26, 1992);

humanized antibody molecules (see e.g., Riechmann et al. *Nature* 332, 323-27, 1988; Verhoeyan et al. *Science* 239, 1534-36, 1988; and GB 2,276,169); and any functional fragments obtained from such molecules, as well as antibodies obtained through non-conventional processes such as phage display. Preferably, the antibodies are monoclonal antibodies. Methods of obtaining monoclonal antibodies are well known in the art.

[0097] As used herein, a "peptide" and a "polypeptide" are amino acid sequences including a plurality of consecutive polymerized amino acid residues. For purpose of this invention, typically, peptides are those molecules including up to 50 amino acid residues, and polypeptides include more than 50 amino acid residues. The peptide or polypeptide may include modified amino acid residues, naturally occurring amino acid residues not encoded by a codon, and non-naturally occurring amino acid residues. As used herein, "protein" may refer to a peptide or a polypeptide of any size.

Proteases of the Invention

[0098] The invention described herein relates to filamentous fungal cells, such as *Trichoderma* fungal cells, that produce increased levels of a heterologous polypeptide, such as a mammalian polypeptide, by having reduced or no detectable activity of at least three proteases found in the cells. Such proteases found in filamentous fungal cells that express a heterologous polypeptide normally catalyze significant degradation of the expressed recombinant polypeptides. Thus, by reducing or eliminating the activity of proteases in filamentous fungal cells that express a heterologous polypeptide, the stability of the expressed polypeptide is increased, resulting in an increased level of production of the polypeptide, and in some circumstances, improved quality of the produced polypeptide (e.g., full-length instead of degraded).

[0099] Proteases including, without limitation, aspartic proteases, trypsin-like serine proteases, subtilisin proteases, glutamic proteases, and sedolisin proteases. Such proteases may be identified and isolated from filamentous fungal cells and tested to determine whether reduction in their activity affects the production of a recombinant polypeptide from the filamentous fungal cell. Methods for identifying and isolating proteases are well known in the art, and include,

without limitation, affinity chromatography, zymogram assays, and gel electrophoresis. An identified protease may then be tested by deleting the gene encoding the identified protease from a filamentous fungal cell that expresses a recombinant polypeptide, such a heterologous or mammalian polypeptide, and determining whether the deletion results in a decrease in total protease activity of the cell, for example, to a level of 49% or less, or 31% or less, of the total protease activity of the corresponding parental filamentous fungal cell; and an increase in the level of production of the expressed recombinant polypeptide, for example two-fold higher than the production level in the corresponding parental filamentous fungal cell. Methods for deleting genes, measuring total protease activity, and measuring levels of produced protein are well known in the art and include the methods described herein. The "corresponding parental filamentous fungal cell" refers to the corresponding cell in which the proteases do not have reduced or eliminated activity.

Aspartic Proteases

[00100] Aspartic proteases are enzymes that use an aspartate residue for hydrolysis of the peptide bonds in polypeptides and proteins. Typically, aspartic proteases contain two highly-conserved aspartate residues in their active site which are optimally active at acidic pH. Aspartic proteases from eukaryotic organisms such as *Trichoderma* fungi include pepsins, cathepsins, and renins. Such aspartic proteases have a two-domain structure, which is thought to arise from an ancestral gene duplication. Consistent with such a duplication event, the overall fold of each domain is similar, though the sequences of the two domains have begun to diverge. Each domain contributes one of the catalytic aspartate residues. The active site is in a cleft formed by the two domains of the aspartic proteases. Eukaryotic aspartic proteases further include conserved disulfide bridges, which can assist in identification of the polypeptides as being aspartic acid proteases.

[00101] Nine aspartic proteases have been identified in *Trichoderma* fungal cells: *pep1* (tre74156); *pep2* (tre53961); *pep3* (tre121133); *pep4* (tre77579), *pep5* (tre81004), and *pep7* (tre58669), *pep8* (tre122076), *pep11* (tre121306) and *pep12* (tre1 19876).

Pepl

[00102] Examples of suitable *pepl* proteases include, without limitation, *Trichoderma reesei* *pepl* (SEQ ID NO: 1), *Hypocrea lixii* gill 1558498 (SEQ ID NO: 2), *Trichoderma asperellum* gil47027997 (SEQ ID NO: 3), *Trichoderma atroviride* jgilTriat21297887 (SEQ ID NO: 4), *Trichoderma virens* jgilTriviGv29_8_2181777 (SEQ ID NO: 5), *Aspergillus fumigatus* jgilTrire2lafm:Afu5gl3300 (SEQ ID NO: 6), *Aspergillus oryzae* gil94730408 (SEQ ID NO: 7), *Metarhizium anisopliae* gil322712783 (SEQ ID NO: 8), *Gibberella zeae* gil46126795 (SEQ ID NO: 9), *Fusarium venenatum* gill 84487 13 (SEQ ID NO: 10), *Fusarium oxysporum* gil342879173 (SEQ ID NO: 11), *Grosmannia clavigera* gil320591399 (SEQ ID NO: 12), *Verticillium albo-atrum* gil302422750 (SEQ ID NO: 13), *Chaetomium globosum* gilll6182964 (SEQ ID NO: 14), *Neurospora crassa* gil851 10723 (SEQ ID NO: 15), *Neurospora tetrasperma* gil336463990 (SEQ ID NO: 16), *Myceliophthora thermophila* gi367030924 (SEQ ID NO: 491), *Penicillium chrysogenum* gi255953325 (SEQ ID NO: 492), *Aspergillus niger* gi350639535 (SEQ ID NO: 493), *Aspergillus nidulans* gi67541436 (SEQ ID NO: 494), and homologs thereof.

[00103] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pepl* protease, has an amino acid sequence having 50% or more identity (*e.g.* 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 1-16, SEQ ID NOs:491-494. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 1-16, SEQ ID NOs:491-494.

[00104] In some embodiments, *pepl* is *T. reeseipepl*. The amino acid sequence encoded by *T. reeseipepl* is set forth in SEQ ID NO: 1. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (*e.g.* 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 1. In further embodiments, the protease has 100% identity to SEQ ID NO: 1.

Pep2

[00105] Examples of suitable *pep2* proteases include, without limitation, *Trichoderma reesei pep2* (SEQ ID NO: 182), *T atroviride jgi\Triat2\142040* (SEQ ID NO: 183), *Tvirens jgilTriviGv29_8_2153481* (SEQ ID NO: 184), *Cordyceps militaris CMO1 gil346326575* (SEQ ID NO: 185), *Neurospora crassa gi 85111370* (SEQ ID NO: 495), and homologs thereof.

[00106] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pep2* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 182-185, SEQ ID NO:495. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 182-185, SEQ ID NO:495.

[00107] In some embodiments, *pep2* is *T. reesei pep2*. The amino acid sequence encoded by *T. reesei pep2* is set forth in SEQ ID NO: 182. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 182. In further embodiments, the protease has 100% identity to SEQ ID NO: 182.

Pep3

[00108] Examples of suitable *pep3* proteases include, without limitation, *Trichoderma reesei pep3* (SEQ ID NO: 17), *T atroviride jgilTriat2* (SEQ ID NO: 18), *Tvirens, jgilTriviGv29_8_2* (SEQ ID NO: 19), *Hypocrea lixii gill 45583125* (SEQ ID NO: 20), *Trichoderma asperellum gil51860175* (SEQ ID NO: 21), *Aspergillus niger gil317025164* (SEQ ID NO: 22), *Aspergillus fumigatus gill59122534* (SEQ ID NO: 23), *Aspergillus niger gil34054572* (SEQ ID NO: 24), *Cordyceps militaris, gil346318620* (SEQ ID NO: 25), *Glomerella graminicola gil310800156* (SEQ ID NO: 26), *Fusarium oxysporum gil342871221* (SEQ ID NO: 27), *Grosmannia clavigera gil320591121* (SEQ ID NO: 28), *Botryotinia fuckeliana gill2002205* (SEQ ID NO: 29), *Thielavia terrestris gil346997107* (SEQ ID NO: 30), *Sclerotinia sclerotiorum gill56055954* (SEQ ID NO: 31), *Chaetomium globosum gill 16197829* (SEQ ID NO: 32), *Neurospora tetrasperma gil336472132* (SEQ ID NO: 33), *Neurospora crassa gil85102020* (SEQ ID NO: 34), *Neosartorya*

fischeri gill 19467426 (SEQ ID NO: 35), *Penicillium marneffei* gil212534792 (SEQ ID NO: 36), *M. thermophila* gi367025909 (SEQ ID NO: 496), *P. chrysogenum* gi255947264 (SEQ ID NO: 497), *A. oryzae* 391870123 (SEQ ID NO: 498), and homologs thereof.

[00109] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pep3* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 17-36, SEQ ID NOs:496-498. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 17-36, SEQ ID NOs:496-498.

[00110] In some embodiments, *pep3* is *T. reesei pep3*. The amino acid sequence encoded by *T. reesei pep3* is set forth in SEQ ID NO: 17. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 17. In further embodiments, the protease has 100% identity to SEQ ID NO: 17.

Pep4

[00111] Examples of suitable *pep4* proteases include, without limitation, *Trichoderma reesei pep4* (SEQ ID NO: 37), *Tvirens* jgilTriviGv29_8_2 (SEQ ID NO: 38), *Tatroviride* jgilTriat2 (SEQ ID NO: 39), *Trichoderma aureoviride* gill93735605 (SEQ ID NO: 40), *Aspergillus niger* gil 145232965 (SEQ ID NO: 41), *Aspergillus fumigatus* gil70999520 (SEQ ID NO: 42), *Aspergillus clavatus* gill21705756 (SEQ ID NO: 43), *Nectria haematococca* gil302899226 (SEQ ID NO: 44), *Glomerella graminicola* gil310796316 (SEQ ID NO: 45), *Cordyceps militaris* gil346322842 (SEQ ID NO: 46), *Gibberella zeae* gil46138535 (SEQ ID NO: 47), *Metarhizium anisopliae* gil322708430 (SEQ ID NO: 48), *Fusarium oxysporum* gil342882947 (SEQ ID NO: 49), *Metarhizium acridum* gil322700747 (SEQ ID NO: 50), *Verticillium dahliae*, gil346973691 (SEQ ID NO: 51), *Botryotinia fuckeliana* gill54309857 (SEQ ID NO: 52), *Chaetomium globosum* gill 16203505 (SEQ ID NO: 53), *Thielavia terrestris* gil347001590 (SEQ ID NO: 54), *Magnaporthe oryzae* gil39973863 (SEQ ID NO: 55), *Tuber melanosporum* gil296417651 (SEQ

ID NO: 56), *Neurospora crassa* gi185094599 (SEQ ID NO: 57), *M. thermophila* gi367031892 gi255947264 (SEQ ID NO: 499), *P. chrysogenum* gi255936729 gi255947264 (SEQ ID NO: 500), *A. oryzae* gi69770745 gi255947264 (SEQ ID NO: 501), *A. nidulans* gi67524891 gi255947264 (SEQ ID NO: 502), and homologs thereof.

[00112] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pep4* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 37-57, SEQ ID NOs:499-502. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 37-57, SEQ ID NOs:499-502.

[00113] In some embodiments, *pep4* is *T. reesei pep4*. The amino acid sequence encoded by *T. reesei pep4* is set forth in SEQ ID NO: 37. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 37. In further embodiments, the protease has 100% identity to SEQ ID NO: 37.

Pep5

[00114] Examples of suitable *pep5* genes include, without limitation, *Trichoderma reesei pep5* (SEQ ID NO: 58), *Tvirens* jgilTriviGv29_8_2 (SEQ ID NO: 59), *T atroviride* jgilTriat21277859 (SEQ ID NO: 60), *Metarhizium acridum* gi1322695806 (SEQ ID NO: 61), *Fusarium oxysporum* gill56071418 (SEQ ID NO: 62), *Cordyceps militaris* gi1346324830 (SEQ ID NO: 63), *Gibberella zeae* gi146124247 (SEQ ID NO: 64), *Verticillium dahliae* gi1346978752 (SEQ ID NO: 65), *M. thermophila* gi367019798 (SEQ ID NO: 503), and homologs thereof.

[00115] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pep5* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 58-65, SEQ ID NO:503. In some

embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 58-65, SEQ ID NO:503.

[00116] In some embodiments, *pep5* is *T. reesei pep5*. The amino acid sequence encoded by *T. reesei pep5* is set forth in SEQ ID NO: 58. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 58. In further embodiments, the protease has 100% identity to SEQ ID NO: 58.

Pep7

[00117] Examples of suitable *pep7* genes include, without limitation, *Trichoderma reesei pep7* (SEQ ID NO: 186), *Trichoderma atroviride* jgilTriat2 (SEQ ID NO: 187), *Trichoderma virens* jgilTriviGv29_8_2 (SEQ ID NO: 188), *Glomerella graminicola* gil310800487 (SEQ ID NO: 189), *Metarhizium acridum* gil322700577 (SEQ ID NO: 190), *Thielavia terrestris* gil347003264 (SEQ ID NO: 191), *Podospora anserine* gill71680938 (SEQ ID NO: 192), *Chaetomium thermophilum* gil340905460 (SEQ ID NO: 193), *Verticillium dahliae* gil346975960 (SEQ ID NO: 194), *Myceliophthora thermophila* gil347009870, gi367026634 (SEQ ID NO: 195), *Neurospora crassa* gil85090078 (SEQ ID NO: 196), *Magnaporthe oryzae* gil39948622 (SEQ ID NO: 197), *Chaetomium globosum* gill 16191517 (SEQ ID NO: 198), *Magnaporthe oryzae* gil39970765 (SEQ ID NO: 199), *A. nidulans* gi67522232 (SEQ ID NO: 504), *A. niger* gi350630464 (SEQ ID NO: 505), *A. oryzae* gi317138074 (SEQ ID NO: 506), and homologs thereof.

[00118] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pep7* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 186-199, SEQ ID NOs:504-506. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 186-199, SEQ ID NOs:504-506.

[00119] In some embodiments, *pep7* is *T. reesei pep7*. The amino acid sequence encoded by *T. reesei pep7* is set forth in SEQ ID NO: 186. In other embodiments, a protease of the present

disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 186. In further embodiments, the protease has 100% identity to SEQ ID NO: 186.

Pep8

[00120] Examples of suitable *pep8* genes include, without limitation, *Trichoderma reesei pep8* EGR48424 (SEQ ID NO: 507), *Trichoderma virens* EHK19238 (SEQ ID NO: 508), *Trichoderma atroviride* EHK40047 (SEQ ID NO: 509), *Neurospora tetrasperma* EG053367 (SEQ ID NO: 510), *Myceliophthora thermophila* XP_003658897 (SEQ ID NO: 511), *Neurospora crassa* XP_965343 (SEQ ID NO: 512), *Metarhizium anisopliae* EFZ03501 (SEQ ID NO: 513), *Thielavia terrestris* XP_003656869 (SEQ ID NO: 514), *Fusarium oxysporum* EGU79769 (SEQ ID NO: 515), and *Gibberella zeae* XP_381566 (SEQ ID NO: 516), *Magnaporthe oryzae* XP_003714540.1 (SEQ ID NO: 517), *P. chrysogenum* XP_002557331 (SEQ ID NO: 518), *A. oryzae* XP_001822899.1 (SEQ ID NO: 519), *A. nidulans* XP_664091.1 (SEQ ID NO: 520), *A. niger* EHA24387.1 (SEQ ID NO: 521), and homologs thereof.

[00121] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pep8* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 507-521. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 507-521.

[00122] In some embodiments, *pep8* is *T. reesei pep8*. The amino acid sequence encoded by *T. reesei pep8* is set forth in SEQ ID NO: 507. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 507. In further embodiments, the protease has 100% identity to SEQ ID NO: 507.

Pep11

[00123] Examples of suitable *pepll* genes include, without limitation, *Trichoderma reesei pepll* EGR49498 (SEQ ID NO: 522), *Trichoderma virens* EHK26120 (SEQ ID NO: 523), *Trichoderma atroviride* EHK41756 (SEQ ID NO: 524), *Fusarium pseudograminearum* EKJ74550 (SEQ ID NO: 525), *Metarhizium acridum* EFY91821 (SEQ ID NO: 526), and *Gibberella zeae* XP_384151 (SEQ ID NO: 527), *M. thermophila* XP_0036673.87.1 (SEQ ID NO: 528), *N. crassa* XP_960328.1 (SEQ ID NO: 529), and homologs thereof.

[00124] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pepll* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more} to an amino acid sequence selected from SEQ ID NOs: 522-529. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 522-529.

[00125] In some embodiments, *pepll* is *T. reesei pep8*. The amino acid sequence encoded by *T. reesei pepll* is set forth in SEQ ID NO: 522. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more} to SEQ ID NO: 522. In further embodiments, the protease has 100% identity to SEQ ID NO: 522.

Pepl2

[00126] Examples of suitable *pepl2* genes include, without limitation, *Trichoderma reesei pepl2* EGR52517 (SEQ ID NO: 530), *Trichoderma virens pepl2* EHK18859 (SEQ ID NO: 531), *Trichoderma atroviride pepl2* EHK45753 (SEQ ID NO: 532), *Fusarium pseudograminearum pepl2* EKJ73392 (SEQ ID NO: 533), *Gibberella zeae pepl2* XP_388759 (SEQ ID NO: 534), and *Metarhizium anisopliae pepl2* EFY95489 (SEQ ID NO: 535), *N. crassa* XP_964574.1 (SEQ ID NO: 536), *M. thermophila* XP_003659978.1 (SEQ ID NO: 537), and homologs thereof.

[00127] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *pepl2* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more} to an

amino acid sequence selected from SEQ ID NOs: 530-537. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 530-537.

[00128] In some embodiments, *pep8* is *T. reesei**pepl2*. The amino acid sequence encoded by *T. reesei**pepl2* is set forth in SEQ ID NO: 530. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 530. In further embodiments, the protease has 100% identity to SEQ ID NO: 530.

Trypsin-Like Serine Proteases

[00129] Trypsin-like serine proteases are enzymes with substrate specificity similar to that of trypsin. Trypsin-like serine proteases use a serine residue for hydrolysis of the peptide bonds in polypeptides and proteins. Typically, trypsin-like serine proteases cleave peptide bonds following a positively-charged amino acid residue. Trypsin-like serine proteases from eukaryotic organisms such as *Trichoderma* fungi include trypsin 1, trypsin 2, and mesotrypsin. Such trypsin-like serine proteases generally contain a catalytic triad of three amino acid residues (such as histidine, aspartate, and serine) that form a charge relay that serves to make the active site serine nucleophilic. Eukaryotic trypsin-like serine proteases further include an "oxyanion hole" formed by the backbone amide hydrogen atoms of glycine and serine, which can assist in identification of the polypeptides as being trypsin-like serine proteases.

[00130] One trypsin-like serine protease has been identified in *Trichoderma* fungal cells: *tspl* (tre73897). As discussed below, *tspl* has been demonstrated to have a significant impact on expression of recombinant polypeptides, such as immunoglobulins.

[00131] As discussed below in Example 3, serine proteases were purified from *Trichoderma* and shown to have multiple protease activities that degrade mammalian proteins. Of these activities, *tspl* was identified as a trypsin-like serine protease. The *tspl* protease gene was then deleted from *Trichoderma* fungal cells and it was demonstrated that deleting *tspl* achieved a significant reduction in total protease activity resulting in increased stabilization of mammalian proteins produced by the cells.

[00132] Examples of suitable *tspl* proteases include, without limitation, *Trichoderma reesei tspl* (SEQ ID NO: 66), *Trichoderma atroviride* jgilTriat21298187 (SEQ ID NO: 67), jgilTriviGv29_8_2 (SEQ ID NO: 68), *Hypocrea lixii* gill45583579 (SEQ ID NO: 69), *Hypocrea lixii* gil63025000 (SEQ ID NO: 70), *Sclerotinia sclerotiorum* gill56052735 (SEQ ID NO: 71), *Botryotinia fuckeliana* gil154314937 (SEQ ID NO: 72), *Phaeosphaeria nodorum* gill69605891 (SEQ ID NO: 73), *Leptosphaeria maculans* gil312219044 (SEQ ID NO: 74), *Verticillium dahliae* gil37992773 (SEQ ID NO: 75), *Cochliobolus carbonum* gill072114 (SEQ ID NO: 76), *Metarhizium acridum* gil322695345 (SEQ ID NO: 77), *Metarhizium anisopliae* gil4768909 (SEQ ID NO: 78), gil464963 (SEQ ID NO: 79), *Gibberella zeae* gil46139299 (SEQ ID NO: 80), *Metarhizium anisopliae* (SEQ ID NO: 81), *A. nidulans* gi67523821 (SEQ ID NO: 538) and homologs thereof.

[00133] Accordingly, in certain embodiments, a protease of the present disclosure, typically *tspl* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 66-81, SEQ ID NO:538. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 66-81, SEQ ID NO:538.

[00134] In some embodiments, *tspl* is *T. reesei tspl*. The amino acid sequence encoded by *T. reesei tspl* is set forth in SEQ ID NO: 66. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 66. In further embodiments, the protease has 100% identity to SEQ ID NO: 66.

Subtilisin Proteases

[00135] Subtilisin proteases are enzymes with substrate specificity similar to that of subtilisin. Subtilisin proteases use a serine residue for hydrolysis of the peptide bonds in polypeptides and proteins. Generally, subtilisin proteases are serine proteases that contain a catalytic triad of the three amino acids aspartate, histidine, and serine. The arrangement of these catalytic residues is

shared with the prototypical subtilisin from *Bacillus licheniformis*. Subtilisin proteases from eukaryotic organisms such as *Trichoderma* fungi include furin, MBTPS 1, and TPP2. Eukaryotic trypsin-like serine proteases further include an aspartic acid residue in the oxyanion hole. Subtilisin protease *slp7* resembles also sedolisin protease *tppl*.

[00136] Seven subtilisin proteases have been identified in *Trichoderma* fungal cells: *slpl* (tre51365); *slpl* (tre123244); *slp3* (tre123234); *slp5* (tre64719), *slp6* (tre121495), *slp7* (tre123865), and *slp8* (tre58698).

Slpl

[00137] Examples of suitable *slpl* proteases include, without limitation, *Trichoderma reesei slpl* (SEQ ID NO: 82), *Trichoderma atroviride* jgilTriat2 (SEQ ID NO: 83), *Trichoderma atroviride* jgilTriat2 (SEQ ID NO: 84), *Trichoderma virens* jgilTriviGv29_8_2 (SEQ ID NO: 85), *Hypocrea lixii* gil145583581 (SEQ ID NO: 86), *Metarhizium acridum* gil322694632 (SEQ ID NO: 87), *Fusarium oxysporum* gil342877080 (SEQ ID NO: 88), *Gibberella zeae* gil46139915 (SEQ ID NO: 89), *Epichloefestuca* gil170674476 (SEQ ID NO: 90), *Nectria haematococca* gil302893164 (SEQ ID NO: 91), *Sordaria macrospore* gil336266150 (SEQ ID NO: 92), *Glomerella graminicola* gil310797947 (SEQ ID NO: 93), *Neurospora tetrasperma* gil336469805 (SEQ ID NO: 94), *Neurospora crassa* gil85086707 (SEQ ID NO: 95), *Magnaporthe oryzae* gill45608997 (SEQ ID NO: 96), *Chaetomium globosum* gill16208730 (SEQ ID NO: 97), *M. thermophila* gi367029081 (SEQ ID NO: 539), and homologs thereof.

[00138] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *slpl* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 82-97, SEQ ID NO:539. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 82-97, SEQ ID NO:539.

[00139] In some embodiments, *slpl* is *T. reesei slpl*. The amino acid sequence encoded by *T. reesei slpl* is set forth in SEQ ID NO: 82. In other embodiments, a protease of the present

disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 82. In further embodiments, the protease has 100% identity to SEQ ID NO: 82.

Slp2

[00140] Examples of suitable *slp2* proteases include, without limitation, *Trichoderma reesei slp2* (SEQ ID NO: 98), *Tatroviride* jgilTriat2 (SEQ ID NO: 99), *Tvirens* jgilTriviGv29_8_2 (SEQ ID NO: 100), *Hypocrea lixii* gill5111226 (SEQ ID NO: 101), *Aspergillus fumigatus* gil70997972 (SEQ ID NO: 102), *Nectria haematococca* gil302915240 (SEQ ID NO: 103), *Gibberella zeae* gil46105128 (SEQ ID NO: 104), *Isaria farinose* gil68165000 (SEQ ID NO: 105), *Glomerella graminicola* gil310797854 (SEQ ID NO: 106), *Epichloefestuca* gill70674491 (SEQ ID NO: 107), *Metarhizium acridum* gil322697754 (SEQ ID NO: 108), *Acremonium* sp. F11177 gill47225254 (SEQ ID NO: 109), *Ophiostoma piliferum* gill5808807 (SEQ ID NO: 110), *Neurospora tetrasperma* gil336463649 (SEQ ID NO: 111), *Chaetomium thermophilum* gil340992600 (SEQ ID NO: 112), *Metarhizium flavoviride* gil254351265 (SEQ ID NO: 113), *Podospora anserine* gill71680111 (SEQ ID NO: 114), *Magnaporthe oryzae* gil39943180 (SEQ ID NO: 115), *Sclerotinia sclerotiorum* gill56058540 (SEQ ID NO: 116), *Talaromyces stipitatus* gil242790441 (SEQ ID NO: 117), *M. thermophila* gi367021472 (SEQ ID NO: 540), *A. niger* gil45237646 (SEQ ID NO: 541), *A. oryzae* gil69780712 (SEQ ID NO: 542), *P. chrysogenum* gi255955889 (SEQ ID NO: 543), *A. nidulans* gi259489544 (SEQ ID NO: 544), *N. crassa* gi85084841 (SEQ ID NO: 545), and homologs thereof.

[00141] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *slp2* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 98-117, SEQ ID NOs:540-545. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 98-117, SEQ ID NOs:540-545.

[00142] In some embodiments, *slp2* is *T. reesei slp2*. The amino acid sequence encoded by *T. reesei slp2* is set forth in SEQ ID NO: 98. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 98. In further embodiments, the protease has 100% identity to SEQ ID NO: 98.

Slp3

[00143] Examples of suitable *slp3* proteases include, without limitation, *Trichoderma reesei slp2* (SEQ ID NO: 166), *T. atroviride* jgilTriat2 (SEQ ID NO: 167), *T. virens* jgilTriviGv29_8_2 (SEQ ID NO: 168), *Hypocrea koningii* gill24295071 (SEQ ID NO: 169), *Purpureocillium lilacinum* gill30750164 (SEQ ID NO: 170), *Metarhizium anisopliae* gill6215677 (SEQ ID NO: 171), *Hirsutella rhossiliensis* gil90655148 (SEQ ID NO: 172), *Tolypocladium inflation* gill8542429 (SEQ ID NO: 173), *Metacordyceps chlamydosporia* gill9171215 (SEQ ID NO: 174), *Cordyceps militaris* gil346321368 (SEQ ID NO: 175), *Fusarium sp.* gil628051 (SEQ ID NO: 176), *Neurospora tetrasperma* gil336471881 (SEQ ID NO: 177), *Chaetomium globosum* gill 16197403 (SEQ ID NO: 178), *Neurospora crassa* gil85084841 (SEQ ID NO: 179), *Fusarium oxysporum* gil56201265 (SEQ ID NO: 180), *Gibberella zeae* gil461 14268 (SEQ ID NO: 181), *M. thermophila* gi367026259 (SEQ ID NO: 546), *A. nidulans* gi67538776 (SEQ ID NO: 547), *A. oryzae* gil69771349 (SEQ ID NO: 222), *A. niger* gi470729 (SEQ ID NO: 223), and homologs thereof.

[00144] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *slp3* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 166-181, SEQ ID NOs:546-547, SEQ ID NOs:222-223. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 166-181, SEQ ID NOs: 546-547, SEQ ID NOs:222-223.

[00145] In some embodiments, *slp3* is *T. reesei slp3*. The amino acid sequence encoded by *T. reesei slp3* is set forth in SEQ ID NO: 166. In other embodiments, a protease of the present

disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 166. In further embodiments, the protease has 100% identity to SEQ ID NO: 166.

Slp5

[00146] Examples of suitable *slp5* proteases include, without limitation, *Trichoderma reesei slp5* (SEQ ID NO: 200), *T. atroviride* jgilTriat2 (SEQ ID NO: 201), *T. virens* jgilTriviGv29_8_2 (SEQ ID NO: 202), *Hypocrea lixii* gil18161442 (SEQ ID NO: 203), *Fusarium oxysporum* gil342883549 (SEQ ID NO: 204), *Gibberella zeae* gil46135733 (SEQ ID NO: 205), *Glomerella graminicola* gil310796396 (SEQ ID NO: 206), *Nectria haematococca* gil302927954 (SEQ ID NO: 207), *Cordyceps militaris* gil346319783 (SEQ ID NO: 208), *Neurospora crassa* gil85094084 (SEQ ID NO: 209), *Neurospora tetrasperma* gil336467281 (SEQ ID NO: 210), *Verticillium dahliae* gil346971706 (SEQ ID NO: 211), *Thielavia terrestris* gil347001418 (SEQ ID NO: 212), *Magnaporthe oryzae* gil145605493 (SEQ ID NO: 213), *M. thermophila* gi367032200 (SEQ ID NO: 548), *P. chrysogenum* gi62816282 (SEQ ID NO: 549), and homologs thereof.

[00147] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *slp5* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 200-213, SEQ ID NOs:548-549. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 200-213, SEQ ID NOs:548-549.

[00148] In some embodiments, *slp5* is *T. reesei slp5*. The amino acid sequence encoded by *T. reesei slp5* is set forth in SEQ ID NO: 200. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 200. In further embodiments, the protease has 100% identity to SEQ ID NO: 200.

Slp6

[00149] Examples of suitable *slp6* proteases include, without limitation, *Trichoderma reesei slp6* (SEQ ID NO: 214), *T. atroviride* jgilTriat2 (SEQ ID NO: 215), *T. virens* jgilTriviGv29_8_2 (SEQ ID NO: 216), *Hypocrea virens* gil29421423 (SEQ ID NO: 217), *Hypocrea lixii* gil 145583 127 (SEQ ID NO: 218), *Trichoderma hamatum* gil30144643 (SEQ ID NO: 219), *Aspergillus fumigatus* gil2295 (SEQ ID NO: 220), *Aspergillus terreus* gill 15391 147 (SEQ ID NO: 221), *Aspergillus oryzae* gill69771349 (SEQ ID NO: 222), *Aspergillus niger* gil470729 (SEQ ID NO: 223), *Glomerella graminicola* gil310794714 (SEQ ID NO: 224), *Gibberella zeae* gi461 14946 (SEQ ID NO: 225), *Fusarium oxysporum* gil342873942 (SEQ ID NO: 226), *Nectria haematococca* gil302884541 (SEQ ID NO: 227), *Neosartorya fischeri* gill 19500190 (SEQ ID NO: 228), *Verticillium albo-atrum* gil302413 161 (SEQ ID NO: 229), *Glomerella graminicola* gil310790144 (SEQ ID NO: 230), *N. crassa* gi85090020 (SEQ ID NO: 550), and homologs thereof.

[00150] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *slp6* protease, has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to an amino acid sequence selected from SEQ ID NOs: 214-230, SEQ ID NO:550. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 214-230, SEQ ID NO:550.

[00151] In some embodiments, *slp6* is *T. reesei slp6*. The amino acid sequence encoded by *T. reesei slp6* is set forth in SEQ ID NO: 214. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 214. In further embodiments, the protease has 100% identity to SEQ ID NO: 214.

Slp7

[00152] Examples of suitable *slp7* proteases include, without limitation, *Trichoderma reesei slp7* (SEQ ID NO: 231), *T. atroviride* jgilTriat2 (SEQ ID NO: 232), *T. virens* jgilTriviGv29_8_2 (SEQ ID NO: 233), *Metarhizium anisopliae* gil322710320 (SEQ ID NO: 234), *Nectria*

haematococca gil302915000 (SEQ ID NO: 235), *Myceliophthora thermophila* gil347009020, gi367024935 (SEQ ID NO: 236), *Gibberella zeae* gil46137655 (SEQ ID NO: 237), *Thielavia terrestris* gil346996549 (SEQ ID NO: 238), *Magnaporthe oryzae* gill45610733 (SEQ ID NO: 239), *A. nidulans* gi67541991 (SEQ ID NO: 551), *P. chrysogenum* gi255933786 (SEQ ID NO: 552), *A. niger* gi317036543 (SEQ ID NO: 553), *A. oryzae* gil69782882 (SEQ ID NO: 554), *N. crassa* gi85109979 (SEQ ID NO: 555), and homologs thereof.

[00153] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *slp7* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 231-239, SEQ ID NOs:551-555. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 231-239, SEQ ID NOs:551-555.

[00154] In some embodiments, *slp7* is *T. reesei slp7*. The amino acid sequence encoded by *T. reesei slp7* is set forth in SEQ ID NO: 231. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 231. In further embodiments, the protease has 100% identity to SEQ ID NO: 231.

Slp8

[00155] Examples of suitable *slp8* proteases include, without limitation, *Trichoderma reesei slp8* (SEQ ID NO: 240), *T. atroviride* jgilTriat2H98568 (SEQ ID NO: 241), *T. virens* jgilTriviGv29_8_2133902 (SEQ ID NO: 242), and homologs thereof.

[00156] Accordingly, in certain embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 240-242. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 240-242.

[00157] In some embodiments, *slp8* is *T. reesei slp8*. The amino acid sequence encoded by *T. reesei slp8* is set forth in SEQ ID NO: 240. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 240. In further embodiments, the protease has 100% identity to SEQ ID NO: 240.

Glutamic Proteases

[00158] Glutamic proteases are enzymes that hydrolyze the peptide bonds in polypeptides and proteins. Glutamic proteases are insensitive to pepstatin A, and so are sometimes referred to as pepstatin insensitive acid proteases. While glutamic proteases were previously grouped with the aspartic proteases and often jointly referred to as acid proteases, it has been recently found that glutamic proteases have very different active site residues than aspartic proteases.

[00159] Two glutamic proteases have been identified in *Trichoderma* fungal cells: *gap1* (tre69555) and *gap2* (trel06661).

Gap1

[00160] Examples of suitable *gap1* proteases include, without limitation, *Trichoderma reesei gap1* (SEQ ID NO: 118), *T. atroviride* jgilTriat2l40863 (SEQ ID NO: 119), *T. virens* jgilTriviGv29_8_2l 192684 (SEQ ID NO: 120), *Aspergillus flavus* gil238499183 (SEQ ID NO: 121), *Aspergillus niger* gil45251555 (SEQ ID NO: 122), *Aspergillus terreus* gil15491521 (SEQ ID NO: 123), gil37154543 (SEQ ID NO: 124), gil48425531 (SEQ ID NO: 125), gil351873 (SEQ ID NO: 126), *Thielavia terrestris* gil346997245 (SEQ ID NO: 127), *Penicillium chrysogenum* gil255940586 (SEQ ID NO: 128), *M. thermophila* gi367026504 (SEQ ID NO: 574), *A. oryzae* gi317150886 (SEQ ID NO: 575), *N. crassa* gi85097968 (SEQ ID NO: 576), *A. niger* gil31056 (SEQ ID NO: 577), *P. chrysogenum* gi255930123 (SEQ ID NO: 578), *A. niger* gil45236956 (SEQ ID NO: 579), *A. oryzae* gil69772955 (SEQ ID NO: 580), *A. niger* gil45249222 (SEQ ID NO: 581), *A. nidulans* gi67525839 (SEQ ID NO: 582), *A. oryzae* gil69785367 (SEQ ID NO: 583), *P. chrysogenum* gi255955319 (SEQ ID NO: 584), *M. thermophila* gi367019352 (SEQ ID

NO: 585), *A. oryzae* gi391863974 (SEQ ID NO: 586), *M. thermophila* gi367024513 (SEQ ID NO: 587), and homologs thereof.

[00161] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *gap1* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 118-128, SEQ ID NOs:574-587. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 118-128, SEQ ID NOs:574-587.

[00162] In some embodiments, *gap1* is *T. reesei gap1*. The amino acid sequence encoded by *T. reesei gap1* is set forth in SEQ ID NO: 118. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 118. In further embodiments, the protease has 100% identity to SEQ ID NO: 118.

Gap2

[00163] Examples of suitable *gap2* proteases include, without limitation, *Trichoderma reesei gap2* (SEQ ID NO: 129), *T. atroviride* jgilTriat2l298116 (SEQ ID NO: 130), *T. virens* jgilTriviGv29_8_2l30331 (SEQ ID NO: 131), jgilTriviGv29_8_2l225131 (SEQ ID NO: 132), *Aspergillus flavus* gil238499183 (SEQ ID NO: 133), *Aspergillus niger* gill45251555 (SEQ ID NO: 134), *Aspergillus nidulans* gil67901056 (SEQ ID NO: 135), *Aspergillus clavatus* gill21711990 (SEQ ID NO: 136), *Aspergillus fumigatus* gil70986250 (SEQ ID NO: 137), *Penicillium marneffei* gil212534108 (SEQ ID NO: 138), *Talaromyces stipitatus* gil242789335 (SEQ ID NO: 139), *Grosmannia clavigera* gil320591529 (SEQ ID NO: 140), *Neosartorya fischeri* gill 19474281 (SEQ ID NO: 141), *Penicillium marneffei* gil212527274 (SEQ ID NO: 142), *Penicillium chrysogenum* gil255940586 (SEQ ID NO: 143), gill31056 (SEQ ID NO: 144), *M. thermophila* gi367030275 (SEQ ID NO: 588), and homologs thereof.

[00164] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *gap2* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%,

75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 129-144, SEQ ID NO:588. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 129-144, SEQ ID NO:588.

[00165] In some embodiments, *gap2* is *T. reesei gap2*. The amino acid sequence encoded by *T. reesei gap2* is set forth in SEQ ID NO: 129. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 129. In further embodiments, the protease has 100% identity to SEQ ID NO: 129.

Sedolisin Proteases

[00166] Sedolisin proteases are enzymes that use a serine residue for hydrolysis of the peptide bonds in polypeptides and proteins. Sedolisin proteases generally contain a unique catalytic triad of serine, glutamate, and aspartate. Sedolisin proteases also contain an aspartate residue in the oxyanion hole. Sedolisin proteases from eukaryotic organisms such as *Trichoderma* fungi include tripeptidyl peptidase.

[00167] Examples of suitable *tppl* proteases include, without limitation, *Trichoderma reesei tppl* (SEQ ID NO: 145), *T. atroviride* jgilTriat2H88756 (SEQ ID NO: 146), *T. virens* jgilTriviGv29_8_2l217176 (SEQ ID NO: 147), *Aspergillus fumigatus* gil70993168 (SEQ ID NO: 148), *Aspergillus oryzae* gill69776800 (SEQ ID NO: 149), *Aspergillus niger* gill45236399 (SEQ ID NO: 150), *Aspergillus clavatus* gill21708799 (SEQ ID NO: 151), *Aspergillus niger* gill45239871 (SEQ ID NO: 152), *Aspergillus clavatus* gill21714541 (SEQ ID NO: 153), *Aspergillus terreus* gill 15387645 (SEQ ID NO: 154), *Aspergillus fumigatus* gil70982015 (SEQ ID NO: 155), *Sclerotinia sclerotiorum* gill56045898 (SEQ ID NO: 156), *Botryotinia juckeliana* gill54321758 (SEQ ID NO: 157), *Neosartorya fischeri* gill 19499774 (SEQ ID NO: 158), *Talaromyces stipitatus* gil242798348 (SEQ ID NO: 159), *Penicillium marneffeii* gil212541546 (SEQ ID NO: 160), *Gibberella zeae* gil461 14460 (SEQ ID NO: 161), *Fusarium oxysporum* gil342890694 (SEQ ID NO: 162), *Grosmannia clavigera* gil320592937 (SEQ ID NO: 163),

Verticillium alboatrum gil302406186 (SEQ ID NO: 164), *Verticillium dahliae* gil346971444 (SEQ ID NO: 165), *A.fumigatus* CAE51075.1 (SEQ ID NO: 556), *A. oryzae* XP_001 820835.1 (SEQ ID NO: 557), *P. chrysogenum* XP_002564029.1 (SEQ ID NO: 558), *A. nidulans* XP_664805.1 (SEQ ID NO: 559), *P. chrysogenum* XP_002565814.1 (SEQ ID NO: 560), *M. thermophila* XP_003663689.1 (SEQ ID NO: 561), *N. crassa* XP_958412.1 (SEQ ID NO: 562), *A. niger* XP_001394118.1 (SEQ ID NO: 563), *A.fumigatus* CAE17674.1 (SEQ ID NO: 564), *A. niger* XP_00 1400873.1 (SEQ ID NO: 565), *A.fumigatus* CAE46473.1 (SEQ ID NO: 566), *A. oryzae* XP_002373530.1 (SEQ ID NO: 567), *A. nidulans* XP_660624.1 (SEQ ID NO: 568), *P. chrysogenum* XP_002562943.1 (SEQ ID NO: 569), *A.fumigatus* CAE17675.1 (SEQ ID NO: 570), *A.fumigatus* EAL86850.2 (SEQ ID NO: 571), *N. crassa* XP_961957.1 (SEQ ID NO: 572), *A. oryzae* BAB97387.1 (SEQ ID NO: 573), and homologs thereof.

[00168] Accordingly, in certain embodiments, a protease of the present disclosure, typically a *tppl* protease, has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more to an amino acid sequence selected from SEQ ID NOs: 145-165, SEQ ID NOs:556-573. In some embodiments, the protease has 100% identity to an amino acid sequence selected from SEQ ID NOs: 145-165, SEQ ID NOs:556-573.

[00169] In some embodiments, *tppl* is *T. reesei tppl*. The amino acid sequence encoded by *T. reesei tppl* is set forth in SEQ ID NO: 145. In other embodiments, a protease of the present disclosure has an amino acid sequence having 50% or more identity {e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 145. In further embodiments, the protease has 100% identity to SEQ ID NO: 145.

Homologous Proteases

[00170] Other embodiments of the present disclosure relate to reducing the activity of proteases that are homologous to the proteases of the present disclosure. "Homology" as used herein refers to sequence similarity between a reference sequence and at least a fragment of a second sequence. Homologs may be identified by any method known in the art, preferably, by

using the BLAST tool to compare a reference sequence to a single second sequence or fragment of a sequence or to a database of sequences. As described below, BLAST will compare sequences based upon percent identity and similarity.

[00171] The terms "identical" or percent "identity," in the context of two or more nucleic acid or amino acid sequences, refers to two or more sequences or subsequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 29% identity, optionally 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200, or more amino acids) in length.

[00172] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. When comparing two sequences for identity, it is not necessary that the sequences be contiguous, but any gap would carry with it a penalty that would reduce the overall percent identity. For blastn, the default parameters are Gap opening penalty=5 and Gap extension penalty=2. For blastp, the default parameters are Gap opening penalty=11 and Gap extension penalty=1.

[00173] A "comparison window," as used herein, includes reference to a segment of any one of the number of contiguous positions including, but not limited to from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a

reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981), by the homology alignment algorithm of Needleman and Wunsch (1970) *J Mol Biol* 48(3):443-453, by the search for similarity method of Pearson and Lipman (1988) *Proc Natl Acad Sci USA* 85(8):2444-2448, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection [see, e.g., Brent *et al.*, (2003) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (Ringbou Ed)].

[00174] Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.* (1997) *Nucleic Acids Res* 25(17):3389-3402 and Altschul *et al.* (1990) *J. Mol Biol* 215(3)-403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W , T , and X determine the sensitivity and speed of the alignment. The BLASTN program (for

nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix [see Henikoff and Henikoff, (1992) Proc Natl Acad Sci USA 89(22): 10915-10919] alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[00175] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, *e.g.*, Karlin and Altschul, (1993) Proc Natl Acad Sci USA 90(12):5873-5877). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

[00176] Other than percentage of sequence identity noted above, another indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.

[00177] As disclosed herein, proteases of the present disclosure may also include proteases that are conservatively modified variants of proteases encoded by the protease genes disclosed above. "Conservatively modified variants" as used herein include individual substitutions, deletions or additions to an encoded amino acid sequence which result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing

functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the disclosure. The following eight groups contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

[00178] Figures 45-48 depicts phylogenetic trees of aspartic, subtilisin, glutamic and sedolisin proteases of selected filamentous fungi.

Methods of Reducing the Activity of Proteases of the Invention

[00179] Further aspects of the present disclosure relate to reducing the activity of proteases found in filamentous fungal cells that express a heterologous polypeptide, such a mammalian polypeptide.

[00180] The activity of proteases found in filamentous fungal cells can be reduced by any method known to those of skill in the art.

[00181] In some embodiments reduced activity of proteases is achieved by reducing the expression of the protease, for example, by promoter modification or RNAi.

[00182] In other embodiments, reduced activity of proteases is achieved by modifying the gene encoding the protease. Examples of such modifications include, without limitation, a knock-out mutation, a truncation mutation, a point mutation, a missense mutation, a substitution mutation, a frameshift mutation, an insertion mutation, a duplication mutation, an amplification mutation, a translocation mutation, or an inversion mutation, and that results in a reduction in the corresponding protease activity. Methods of generating at least one mutation in a protease encoding gene of interest are well known in the art and include, without limitation, random mutagenesis and screening, site-directed mutagenesis, PCR mutagenesis, insertional mutagenesis, chemical mutagenesis, and irradiation.

[00183] In certain embodiments, a portion of the protease encoding gene is modified, such as the region encoding the catalytic domain, the coding region, or a control sequence required for expression of the coding region. Such a control sequence of the gene may be a promoter sequence or a functional part thereof, *i.e.*, a part that is sufficient for affecting expression of the gene. For example, a promoter sequence may be inactivated resulting in no expression or a weaker promoter may be substituted for the native promoter sequence to reduce expression of the coding sequence. Other control sequences for possible modification include, without limitation, a leader sequence, a propeptide sequence, a signal sequence, a transcription terminator, and a transcriptional activator.

[00184] Protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may also be modified by utilizing gene deletion techniques to eliminate or reduce expression of the gene. Gene deletion techniques enable the partial or complete removal of the gene thereby eliminating their expression. In such methods, deletion of the gene may be accomplished by homologous recombination using a plasmid that has been constructed to contiguously contain the 5' and 3' regions flanking the gene.

[00185] The protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may also be modified by introducing, substituting, and/or removing one or more nucleotides in the gene, or a control sequence thereof required for the transcription or translation of the gene. For example, nucleotides may be inserted or removed for the introduction of a stop codon, the removal of the start codon, or a frame-shift of the open reading frame. Such a modification may be accomplished by methods known in the art, including without limitation, site-directed mutagenesis and PCR generated mutagenesis (see, for example, Botstein and Shortle, 1985, *Science* 229: 4719; Lo et al., 1985, *Proceedings of the National Academy of Sciences USA* 81: 2285; Higuchi et al., 1988, *Nucleic Acids Research* 16: 7351; Shimada, 1996, *Meth. Mol. Biol.* 57: 157; Ho et al., 1989, *Gene* 77: 61; Horton et al., 1989, *Gene* 77: 61; and Sarkar and Sommer, 1990, *BioTechniques* 8: 404).

[00186] Additionally, protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may be modified by gene

disruption techniques by inserting into the gene a disruptive nucleic acid construct containing a nucleic acid fragment homologous to the gene that will create a duplication of the region of homology and incorporate construct DNA between the duplicated regions. Such a gene disruption can eliminate gene expression if the inserted construct separates the promoter of the gene from the coding region or interrupts the coding sequence such that a nonfunctional gene product results. A disrupting construct may be simply a selectable marker gene accompanied by 5' and 3' regions homologous to the gene. The selectable marker enables identification of transformants containing the disrupted gene.

[00187] Protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may also be modified by the process of gene conversion (see, for example, Iglesias and Trautner, 1983, *Molecular General Genetics* 189:5 73-76). For example, in the gene conversion a nucleotide sequence corresponding to the gene is mutagenized *in vitro* to produce a defective nucleotide sequence, which is then transformed into a *Trichoderma* strain to produce a defective gene. By homologous recombination, the defective nucleotide sequence replaces the endogenous gene. It may be desirable that the defective nucleotide sequence also contains a marker for selection of transformants containing the defective gene.

[00188] Protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may also be modified by established anti-sense techniques using a nucleotide sequence complementary to the nucleotide sequence of the gene (see, for example, Parish and Stoker, 1997, *FEMS Microbiology Letters* 154: 151-157). In particular, expression of the gene by filamentous fungal cells may be reduced or inactivated by introducing a nucleotide sequence complementary to the nucleotide sequence of the gene, which may be transcribed in the strain and is capable of hybridizing to the mRNA produced in the cells. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to the mRNA, the amount of protein translated is thus reduced or eliminated.

[00189] In addition, protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may also be modified by

established RNA interference (RNAi) techniques (see, for example, WO 2005/056772 and WO 2008/080017).

[00190] Protease encoding genes of the present disclosure that are present in filamentous fungal cells that express a recombinant polypeptide may also be modified by random or specific mutagenesis using methods well known in the art, including without limitation, chemical mutagenesis (see, for example, Hopwood, *The Isolation of Mutants in Methods in Microbiology* (J.R. Norris and D.W. Ribbons, eds.) pp. 363-433, Academic Press, New York, 25 1970).

Modification of the gene may be performed by subjecting filamentous fungal cells to mutagenesis and screening for mutant cells in which expression of the gene has been reduced or inactivated. The mutagenesis, which may be specific or random, may be performed, for example, by use of a suitable physical or chemical mutagenizing agent, use of a suitable oligonucleotide, subjecting the DNA sequence to PCR generated mutagenesis, or any combination thereof.

Examples of physical and chemical mutagenizing agents include, without limitation, ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N'-nitrosoguanidine (NTG) O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues. When such agents are used, the mutagenesis is typically performed by incubating the *Trichoderma* cells to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and then selecting for mutants exhibiting reduced or no expression of the gene.

[00191] In certain embodiments, the at least one mutation or modification in a protease encoding gene of the present disclosure results in a modified protease that has no detectable protease activity. In other embodiments, the at least one modification in a protease encoding gene of the present disclosure results in a modified protease that has at least 25% less, at least 50% less, at least 75% less, at least 90%, at least 95%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, at least 1,000%, or a higher percentage less protease activity compared to a corresponding non-modified protease.

[00192] In certain embodiments, for example, in a *Trichoderma* cell, the at least one mutation or modification in a protease encoding gene of the present disclosure results in a reduction of total protease activity to 49% or less, typically with a mutation in at least 2 distinct protease genes, or 31% or less, typically with a mutation in at least 3 distinct protease genes, or 13% or less, typically with a mutation in at least 4 distinct protease genes, or 10% or less, typically with a mutation in at least 5 distinct protease genes, or 6.3% or less, typically with a mutation in at least 6 distinct protease genes, or 5.5% or less, typically with a mutation in at least 7 distinct protease genes, of the total protease activity of the corresponding parental *Trichoderma* cell.

Heterologous Polypeptides of the Invention

[00193] The invention herein further relates to increasing the production of heterologous polypeptides in filamentous fungal cells that express such heterologous polypeptides by reducing the activity of proteases found in the cells.

[00194] As used herein a "heterologous polypeptide" refers to a polypeptide that is not naturally found in (i.e., endogenous) a filamentous fungal cell of the present disclosure, or that is expressed at an elevated level in a filamentous fungal cell as compared to the endogenous version of the polypeptide. In certain embodiments, the heterologous polypeptide is a mammalian polypeptide. In other embodiments, the heterologous polypeptide is a non-mammalian polypeptide.

Mammalian Polypeptides

[00195] Mammalian polypeptides of the present disclosure may be any mammalian polypeptide having a biological activity of interest. As used herein, a "mammalian polypeptide" is a polypeptide that is natively expressed in a mammal, a polypeptide that is derived from a polypeptide that is natively expressed in a mammal, or a fragment thereof. A mammalian polypeptide also includes peptides and oligopeptides that retain biological activity. Mammalian polypeptides of the present disclosure may also include two or more polypeptides that are combined to form the encoded product. Mammalian polypeptides of the present disclosure may further include fusion polypeptides, which contain a combination of partial or complete amino

acid sequences obtained from at least two different polypeptides. Mammalian polypeptides may also include naturally occurring allelic and engineered variations of any of the disclosed mammalian polypeptides and hybrid mammalian polypeptides.

[00196] The mammalian polypeptide may be a naturally glycosylated polypeptide or a naturally non-glycosylated polypeptide.

[00197] Examples of suitable mammalian polypeptides include, without limitation, immunoglobulins, antibodies, antigens, antimicrobial peptides, enzymes, growth factors, hormones, interferons, cytokines, interleukins, immunodilators, neurotransmitters, receptors, reporter proteins, structural proteins, and transcription factors.

[00198] Specific examples of suitable mammalian polypeptides include, without limitation, immunoglobulins, immunoglobulin heavy chains, immunoglobulin light chains, monoclonal antibodies, hybrid antibodies, F(ab')₂ antibody fragments, F(ab) antibody fragments, Fv molecules, single-chain Fv antibodies, dimeric antibody fragments, trimeric antibody fragments, functional antibody fragments, immunoadhesins, insulin-like growth factor 1, growth hormone, insulin, interferon alpha 2b, fibroblast growth factor 21, human serum albumin, camelid antibodies and/or antibody fragments, single domain antibodies, multimeric single domain antibodies, and erythropoietin.

[00199] Other examples of suitable mammalian proteins include, without limitation, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, a ligase, an aminopeptidase, an amylase, a carbohydrase, a carboxypeptidase, a catalase, a glycosyltransferase, a deoxyribonuclease, an esterase, a galactosidase, a betagalactosidase, a glucosidase, a glucuronidase, a glucuronoyl esterase, a haloperoxidase, an invertase, a lipase, an oxidase, a phospholipase, a proteolytic enzyme, a ribonuclease, a urokinase, an albumin, a collagen, a tropoelastin, and an elastin.

Non-mammalian Polypeptides

[00200] Non-mammalian polypeptides of the present disclosure may be any non-mammalian polypeptide having a biological activity of interest. As used herein, a "non-mammalian polypeptide" is a polypeptide that is natively expressed in a non-mammalian organism, such as a fungal cell, a polypeptide that is derived from a polypeptide that is natively expressed in a non-mammalian organism, or a fragment thereof. A non-mammalian polypeptide also includes peptides and oligopeptides that retain biological activity. Non-mammalian polypeptides of the present disclosure may also include two or more polypeptides that are combined to form the encoded product. Non-mammalian polypeptides of the present disclosure may further include fusion polypeptides, which contain a combination of partial or complete amino acid sequences obtained from at least two different polypeptides. Non-mammalian polypeptides may also include naturally occurring allelic and engineered variations of any of the disclosed non-mammalian polypeptides and hybrid non-mammalian polypeptides.

[00201] Examples of suitable non-mammalian polypeptides include, without limitation, aminopeptidases, amylases, carbohydrases, carboxypeptidases, catalases, cellulases, chitinases, cutinases, deoxyribonucleases, esterases, alpha-galactosidases, beta-galactosidases, glucoamylases, alpha-glucosidases, beta-glucosidases, invertases, laccases, lipases, mutanases, oxidases, pectinolytic enzymes, peroxidases, phospholipases, phytases, polyphenoloxidases, proteolytic enzymes, ribonucleases, transglutaminases and xylanases.

Heterologous Polypeptide Production

[00202] A heterologous polypeptide of interest is produced by filamentous fungal cells of the present disclosure containing at least three proteases having reduced activity by cultivating the cells in a nutrient medium for production of the heterologous polypeptide using methods known in the art. For example, the cells may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared

according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). The secreted polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it may be obtained from cell lysates.

[00203] A heterologous polypeptide of interest produced by a filamentous fungal cell of the present disclosure containing at least three proteases having reduced activity may be detected using methods known in the art that are specific for the heterologous polypeptide. These detection methods may include, without limitation, use of specific antibodies, high performance liquid chromatography, capillary chromatography, formation of an enzyme product, disappearance of an enzyme substrate, and SDS-PAGE. For example, an enzyme assay may be used to determine the activity of an enzyme. Procedures for determining enzyme activity are known in the art for many enzymes (see, for example, O. Schomburg and M. Salzmann (eds.), *Enzyme Handbook*, Springer-Verlag, New York, 1990).

[00204] The resulting heterologous polypeptide may be isolated by methods known in the art. For example, a heterologous polypeptide of interest may be isolated from the cultivation medium by conventional procedures including, without limitation, centrifugation, filtration, extraction, spray-drying, evaporation, and precipitation. The isolated heterologous polypeptide may then be further purified by a variety of procedures known in the art including, without limitation, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing (IEF), differential solubility (*e.g.*, ammonium sulfate precipitation), or extraction (see, for example, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Preparation of Polynucleotides Encoding Heterologous Polypeptides

[00205] Sequences of the heterologous polynucleotides of the present disclosure are prepared by any suitable method known in the art, including, without limitation, direct chemical synthesis or cloning. For direct chemical synthesis, formation of a polymer of nucleic acids typically involves sequential addition of 3'-blocked and 5'-blocked nucleotide monomers to the terminal 5'-hydroxyl group of a growing nucleotide chain, wherein each addition is effected by

nucleophilic attack of the terminal 5'-hydroxyl group of the growing chain on the 3'-position of the added monomer, which is typically a phosphorus derivative, such as a phosphotriester, phosphoramidite, or the like. Such methodology is known to those of ordinary skill in the art and is described in the pertinent texts and literature [e.g., in Matteucci *et al.*, (1980) *Tetrahedron Lett* 21:719-722; U.S. Pat. Nos. 4,500,707; 5,436,327; and 5,700,637]. In addition, the desired sequences may be isolated from natural sources by splitting DNA using appropriate restriction enzymes, separating the fragments using gel electrophoresis, and thereafter, recovering the desired nucleic acid sequence from the gel via techniques known to those of ordinary skill in the art, such as utilization of polymerase chain reactions (PCR; e.g., U.S. Pat. No. 4,683,195).

[00206] Each heterologous polynucleotide of the present disclosure can be incorporated into an expression vector. "Expression vector" or "vector" refers to a compound and/or composition that transduces, transforms, or infects a host cell, thereby causing the cell to express nucleic acids and/or proteins other than those native to the cell, or in a manner not native to the cell. An "expression vector" contains a sequence of nucleic acids (ordinarily RNA or DNA) to be expressed by the host cell. Optionally, the expression vector also includes materials to aid in achieving entry of the nucleic acid into the host cell, such as a virus, liposome, protein coating, or the like. The expression vectors contemplated for use in the present disclosure include those into which a nucleic acid sequence can be inserted, along with any preferred or required operational elements. Further, the expression vector must be one that can be transferred into a host cell and replicated therein. Preferred expression vectors are plasmids, particularly those with restriction sites that have been well documented and that contain the operational elements preferred or required for transcription of the nucleic acid sequence. Such plasmids, as well as other expression vectors, are well known in the art.

[00207] Incorporation of the individual polynucleotides may be accomplished through known methods that include, for example, the use of restriction enzymes (such as *Bam*HI, *Eco*RI, *Hha*I, *Xho*I, *Xma*I, and so forth) to cleave specific sites in the expression vector, e.g., plasmid. The restriction enzyme produces single stranded ends that may be annealed to a polynucleotide having, or synthesized to have, a terminus with a sequence complementary to the ends of the cleaved expression vector. Annealing is performed using an appropriate enzyme, e.g., DNA

ligase. As will be appreciated by those of ordinary skill in the art, both the expression vector and the desired polynucleotide are often cleaved with the same restriction enzyme, thereby assuring that the ends of the expression vector and the ends of the polynucleotide are complementary to each other. In addition, DNA linkers may be used to facilitate linking of nucleic acid sequences into an expression vector.

[00208] A series of individual polynucleotides can also be combined by utilizing methods that are known in the art (*e.g.*, U.S. Pat. No. 4,683,195).

[00209] For example, each of the desired polynucleotides can be initially generated in a separate PCR. Thereafter, specific primers are designed such that the ends of the PCR products contain complementary sequences. When the PCR products are mixed, denatured, and reannealed, the strands having the matching sequences at their 3' ends overlap and can act as primers for each other. Extension of this overlap by DNA polymerase produces a molecule in which the original sequences are "spliced" together. In this way, a series of individual polynucleotides may be "spliced" together and subsequently transduced into a host cell simultaneously. Thus, expression of each of the plurality of polynucleotides is affected.

[00210] Individual polynucleotides, or "spliced" polynucleotides, are then incorporated into an expression vector. The present disclosure is not limited with respect to the process by which the polynucleotide is incorporated into the expression vector. Those of ordinary skill in the art are familiar with the necessary steps for incorporating a polynucleotide into an expression vector. A typical expression vector contains the desired polynucleotide preceded by one or more regulatory regions, along with a ribosome binding site, *e.g.*, a nucleotide sequence that is 3-9 nucleotides in length and located 3-11 nucleotides upstream of the initiation codon in *E. coli*. See Shine and Dalgarno (1975) *Nature* 254(5495):34-38 and Steitz (1979) *Biological Regulation and Development* (ed. Goldberger, R. F.), 1:349-399 (Plenum, New York).

[00211] The term "operably linked" as used herein refers to a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of the DNA sequence or polynucleotide such that the control sequence directs the expression of a polypeptide.

[00212] Regulatory regions include, for example, those regions that contain a promoter and an operator. A promoter is operably linked to the desired polynucleotide, thereby initiating transcription of the polynucleotide via an RNA polymerase enzyme. An operator is a sequence of nucleic acids adjacent to the promoter, which contains a protein-binding domain where a repressor protein can bind. In the absence of a repressor protein, transcription initiates through the promoter. When present, the repressor protein specific to the protein-binding domain of the operator binds to the operator, thereby inhibiting transcription. In this way, control of transcription is accomplished, based upon the particular regulatory regions used and the presence or absence of the corresponding repressor protein. Examples include lactose promoters (Lac repressor protein changes conformation when contacted with lactose, thereby preventing the Lac repressor protein from binding to the operator) and tryptophan promoters (when complexed with tryptophan, TrpR repressor protein has a conformation that binds the operator; in the absence of tryptophan, the TrpR repressor protein has a conformation that does not bind to the operator). Another example is the *tac* promoter (see de Boer *et al.*, (1983) Proc Natl Acad Sci USA 80(1):21-25). As will be appreciated by those of ordinary skill in the art, these and other expression vectors may be used in the present disclosure, and the present disclosure is not limited in this respect.

[00213] Although any suitable expression vector may be used to incorporate the desired sequences, readily available expression vectors include, without limitation: plasmids, such as pSC101, pBR322, pBBR1MCS-3, pUR, pEX, pMR100, pCR4, pBAD24, pUC19, pRS426; and bacteriophages, such as M13 phage and λ phage. Of course, such expression vectors may only be suitable for particular host cells. One of ordinary skill in the art, however, can readily determine through routine experimentation whether any particular expression vector is suited for any given host cell. For example, the expression vector can be introduced into the host cell, which is then monitored for viability and expression of the sequences contained in the vector. In addition, reference may be made to the relevant texts and literature, which describe expression vectors and their suitability to any particular host cell.

[00214] Suitable expression vectors for the purposes of the invention, including the expression of the desired heterologous polypeptide, enzyme, and one or more catalytic domains described

herein, include expression vectors containing the polynucleotide encoding the desired heterologous polypeptide, enzyme, or catalytic domain(s) operably linked to a constitutive or an inducible promoter. Examples of particularly suitable promoters for operable linkage to such polynucleotides include promoters from the following genes: *gpdA*, *cbhl*, *Aspergillus oryzae* TACA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* glucoamylase (*glaA*), *Aspergillus awamori* *glaA*, *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Aspergillus oryzae* acetamidase, *Fusarium oxysporum* trypsin-like protease, fungal endo α -L-arabinase (*abnA*), fungal α -L-arabinofuranosidase A (*abfA*), fungal α -L-arabinofuranosidase B (*abfB*), fungal xylanase (*xlnA*), fungal phytase, fungal ATP-synthetase, fungal subunit 9 (*oliC*), fungal triose phosphate isomerase (*tpi*), fungal alcohol dehydrogenase (*adhA*), fungal α -amylase (*amy*), fungal amyloglucosidase (*glaA*), fungal acetamidase (*amdS*), fungal glyceraldehyde-3-phosphate dehydrogenase (*gpd*), yeast alcohol dehydrogenase, yeast lactase, yeast 3-phosphoglycerate kinase, yeast triosephosphate isomerase, bacterial α -amylase, bacterial Spo2, and SSO. Examples of such suitable expression vectors and promoters are also described in PCT/EP2011/070956, the entire contents of which is hereby incorporated by reference herein.

Pharmaceutical Compositions Containing Heterologous Polypeptides Produced by Filamentous Fungal Cells of the Invention

[00215] In another aspect, the present invention provides a composition, e.g., a pharmaceutical composition, containing one or more heterologous polypeptides of interest, such as mammalian polypeptides, produced by the filamentous fungal cells of the present disclosure having reduced activity of at least three proteases and further containing a recombinant polynucleotide encoding the heterologous polypeptide, formulated together with a pharmaceutically acceptable carrier. Pharmaceutical compositions of the invention also can be administered in combination therapy, i.e., combined with other agents. For example, the combination therapy can include a mammalian polypeptide of interest combined with at least one other therapeutic agent.

[00216] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., the mammalian polypeptide of interest, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

[00217] The pharmaceutical compositions of the invention may include one or more pharmaceutically acceptable salts. A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S.M., et al. (1977) *J. Pharm. Sci.* 66:1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chlorprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.

[00218] A pharmaceutical composition of the invention also may also include a pharmaceutically acceptable antioxidant. Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[00219] Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[00220] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of presence of microorganisms may be ensured both by sterilization procedures, and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[00221] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[00222] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars,

polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

[00223] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the certain methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[00224] The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.01 percent to about ninety-nine percent of active ingredient, preferably from about 0.1 percent to about 70 percent, most preferably from about 1 percent to about 30 percent of active ingredient in combination with a pharmaceutically acceptable carrier.

[00225] Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required

pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

[00226] For administration of a mammalian polypeptide of interest, in particular where the mammalian polypeptide is an antibody, the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example, dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg. An exemplary treatment regime entails administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months or once every three to 6 months. Certain dosage regimens for an antibody may include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, with the antibody being given using one of the following dosing schedules: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks.

[00227] Alternatively a mammalian polypeptide of interest can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the administered substance in the patient. In general, human antibodies show the longest half life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.

[00228] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present disclosure may be varied so as to obtain an amount of the active ingredient which is

effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[00229] A "therapeutically effective dosage" of an immunoglobulin of the present disclosure preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. For example, for the treatment of tumors, a "therapeutically effective dosage" preferably inhibits cell growth or tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. The ability of a compound to inhibit tumor growth can be evaluated in an animal model system predictive of efficacy in human tumors. Alternatively, this property of a composition can be evaluated by examining the ability of the compound to inhibit, such inhibition *in vitro* by assays known to the skilled practitioner. A therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.

[00230] A composition of the present disclosure can be administered via one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. Certain routes of administration for binding moieties of the invention include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical

administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.

[00231] Alternatively, a mammalian polypeptide according to the present disclosure can be administered via a nonparenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.

[00232] The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. (see, e.g., *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978).

[00233] Therapeutic compositions can be administered with medical devices known in the art. For example, in a certain embodiment, a therapeutic composition of the invention can be administered with a needleless hypodermic injection device, such as the devices disclosed in U.S. Patent Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; or 4,596,556. Examples of well-known implants and modules useful in the present invention include: U.S. Patent No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4,486,194, which discloses a therapeutic device for administering medicants through the skin; U.S. Patent No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system.

[00234] In certain embodiments, the use of mammalian polypeptides according to the present disclosure is for the treatment of any disease that may be treated with therapeutic antibodies.

Filamentous Fungal Cells of the Invention

[00235] The invention herein also relates to increasing the levels of production of heterologous polypeptides, such as mammalian polypeptides, in filamentous fungal cells by reducing or eliminating the activity of at least three proteases found in cells that express heterologous polypeptides, and that catalyze the degradation of the heterologous polypeptides. Reducing or eliminating the activity of proteases found in the filamentous fungal cells that express heterologous polypeptides increases the stability of the expressed recombinant polypeptides, which results in an increased level of production of the heterologous polypeptides. The activity of the proteases found in the filamentous fungal cells may be reduced, for example, by modifying the genes encoding the proteases.

[00236] "Filamentous fungal cells" include cells from all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK). Filamentous fungal cells are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

[00237] Any filamentous fungal cell may be used in the present disclosure so long as it remains viable after being transformed with a sequence of nucleic acids and/or being modified or mutated to decrease protease activity. Preferably, the filamentous fungal cell is not adversely affected by the transduction of the necessary nucleic acid sequences, the subsequent expression of the proteins (*e.g.*, mammalian proteins), or the resulting intermediates.

[00238] Examples of suitable filamentous fungal cells include, without limitation, cells from an *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*,

Penicillium, *Scytalidium*, *Thielavia*, *Tolypocladium*, or *Trichoderma* strain. In certain embodiments, the filamentous fungal cell is from a *Trichoderma* sp., *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Chrysosporium*, *Chrysosporium lucknowense*, *Filibasidium*, *Fusarium*, *Gibberella*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Myrothecium*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, or *Tolypocladium* strain.

[00239] *Aspergillus* fungal cells of the present disclosure may include, without limitation, *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus clavatus*, *Aspergillus flavus*, *Aspergillus joetidus*, *Aspergillus jumigatus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, or *Aspergillus terreus*.

[00240] *Neurospora* fungal cells of the present disclosure may include, without limitation, *Neurospora crassa*.

[00241] In certain embodiments, the filamentous fungal cell is not an *Aspergillus* cell.

[00242] In certain embodiments, the filamentous fungal cell is selected from the group consisting of *Trichoderma* (*T. reesei*), *Neurospora* (*N. crassa*), *Penicillium* (*P. chrysogenum*), *Aspergillus* (*A. nidulans*, *A. niger* and *A. oryzae*), *Myceliophthora* (*M. thermophila*) and *Chrysosporium* (*C. lucknowense*).

[00243] In certain embodiments, the filamentous fungal cell is a *Trichoderma* fungal cell. *Trichoderma* fungal cells of the present disclosure may be derived from a wild-type *Trichoderma* strain or a mutant thereof. Examples of suitable *Trichoderma* fungal cells include, without limitation, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, *Trichoderma atroviride*, *Trichoderma virens*, *Trichoderma viride*; and alternative sexual form thereof (*i.e.*, *Hypocrea*).

[00244] General methods to disrupt genes of and cultivate filamentous fungal cells are disclosed, for example, for *Penicillium*, in Kopke *et al.* (2010) Application of the *Saccharomyces cerevisiae* FLP/FRT recombination system in filamentous fungi for marker recycling and

construction of knockout strains devoid of heterologous genes. *Appl Environ Microbiol.* 76(14):4664-74. doi: 10.1128/AEM.00670-10, for *Aspergillus*, in Maruyama and Kitamoto (2011), Targeted Gene Disruption in Koji Mold *Aspergillus oryzae*, in James A. Williams (ed.), *Strain Engineering: Methods and Protocols, Methods in Molecular Biology*, vol. 765, DOI 10.1007/978-1-61779-197-0_27; for *Neurospora*, in Collopy et al. (2010) High-throughput construction of gene deletion cassettes for generation of *Neurospora crassa* knockout strains. *Methods Mol Biol.* 2010;638:33-40. doi: 10.1007/978-1-60761-611-5_3; and for *Myceliophthora* or *Chrysosporium* PCT/NL20 10/000045 and PCT/EP98/06496.

Filamentous Fungal Cell Components

[00245] Certain aspects of the present disclosure relate to filamentous fungal cells having reduced or no detectable activity of at least three proteases and having a recombinant polynucleotide encoding a heterologous polypeptide that is produced at increased levels, for example at least two-fold increased levels. Other aspects of the present disclosure relate to *Trichoderma* fungal cells that has reduced or no detectable protease activity of at least three proteases selected from *pep1*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pep11*, *pep12*, *tspl*, *slpl*, *slp2*, *slp7*, *gap1*, and *gap2*, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide produced at a level of at least 2-fold higher than the production level of the polypeptide in a corresponding parental *Trichoderma* fungal cell. In certain embodiments, the filamentous fungal cells or *Trichoderma* fungal cells have reduced or no activity of at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or more proteases.

Reduced expression of proteases

[00246] The reduced activity of the at least three proteases in filamentous fungal cells or *Trichoderma* fungal cells of the present disclosure can be the result of reduced or eliminated expression of the proteases. In some embodiments, the reduced or eliminated expression of the at least three proteases is the result of a modification to the catalytic domain, the coding region, or a control sequence required for expression of the coding region of the genes encoding each of the

proteases. In other embodiments, the reduced or eliminated expression of the proteases is the result of introducing, substituting, and/or removing one or more nucleotides in the genes, or a control sequence thereof required for the transcription or translation of the genes encoding each of the proteases.

[00247] In further embodiments, the reduced or eliminated expression of the proteases is the result of inserting into the genes encoding each of the proteases disruptive nucleic acid constructs each containing a nucleic acid fragment homologous to each of the genes that will create a duplication of the region of homology and incorporate construct DNA between the duplicated regions. In other embodiments, the reduced or eliminated expression of the proteases is the result of gene conversion of the genes encoding each of the proteases. In still other embodiments, the reduced or eliminated expression of the proteases is the result of by anti-sense polynucleotides or RNAi constructs that are specific for the each of the genes encoding each of the proteases. In one embodiment, an RNAi construct is specific for a gene encoding an aspartic protease such as a *pep-type* protease, a trypsin-like serine proteases such as a *tspl*, a glutamic protease such as a *gap-type* protease, a subtilisin protease such as a *sip-type* protease, or a sedolisin protease such as a *tppl* or a *slp7* protease. In one embodiment, an RNAi construct is specific for the gene encoding a *sip-type* protease. In one embodiment, an RNAi construct is specific for the gene encoding *slp2*, *slp3*, *slp5* or *slp6*. In one embodiment, an RNAi construct is specific for two or more proteases. In one embodiment, two or more proteases are any one of the *pep-type* proteases, any one of the trypsin-like serine proteases, any one of the *sip-type* proteases, any one of the *gap-type* proteases and/or any one of the sedolisin proteases. In one embodiment, two or more proteases are *slp2*, *slp3*, *slp5* and/or *slp6*. In one embodiment, RNAi construct comprises any one of nucleic acid sequences of Table 22.2.

[00248] In some embodiments, the genes encoding the proteases each contain a mutation that reduces or eliminates the corresponding protease activity. In other embodiments, the mutation reduces or eliminates the expression of each of the proteases. In further embodiments, the mutation is a knock-out mutation, a truncation mutation, a point mutation, a missense mutation, a substitution mutation, a frameshift mutation, an insertion mutation, a duplication mutation, an

amplification mutation, a translocation mutation, an inversion mutation that reduces or eliminates the corresponding protease activity.

[00249] In some embodiments, the mutation is a deletion of the protease encoding gene. In other embodiments, the mutation is a deletion of the portion of the protease encoding gene encoding the catalytic domain of the protease. In still other embodiments, the mutation is point mutation in the portion of the protease encoding gene encoding the catalytic domain of the protease.

Combinations of protease genes

[00250] The filamentous fungal cells or Trichoderma fungal cells of the present disclosure may contain at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more aspartic proteases, trypsin-like serine proteases, subtilisin proteases, and/or glutamic proteases. In certain embodiments, the proteases are encoded by *pep*-type protease genes, *gap*-type protease genes, or *sip*-type proteases genes. In some embodiments, the *pep*-type protease genes are selected from *pep1*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pep11*, and *pep12*. In other embodiments, the *gap*-type protease genes are selected from *gap1*, and *gap2*. In further embodiments, the *sip*-type proteases genes are selected from *slp1*, *slp2*, *slp3*, and *slp7*; or are selected from *slp1*, *slp2*, *slp3*, *slp5*, *slp6*, *slp7*, and *slp8*. In certain preferred embodiments, the *sip*-type proteases gene is *slp1*.

[00251] In other embodiments, the proteases are encoded by genes selected from *pep1*, *pep2*, *pep3*, *pep4*, *pep5*, *pep7*, *pep8*, *pep11*, *pep12*, *tspl*, *slp1*, *slp2*, *slp3*, *slp5*, *slp6*, *slp7*, *slp8*, *gap1*, *gap2*, and *tppl*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of at least three or at least four protease encoding genes selected from *pep1*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pep11*, *pep12*, *tspl*, *slp1*, *slp2*, *slp3*, *slp7*, *gap1*, and *gap2*. In certain embodiments, the filamentous fungal cell, for example a *Trichoderma* cell, has reduced or no expression levels of at least three protease encoding genes selected from *pep1*, *tspl*, and *slp1*. In other embodiments, the filamentous fungal cell, or *Trichoderma* cell, has reduced or no expression levels of at least three protease encoding genes selected from *gap1*, *slp1*

and pepl. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, and *gapl*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, and *pep4*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, and *slpl*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, and *slp3*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, and *pep3*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, and *pep2*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, *pep2*, and *pep5*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, *pep2*, and *pep5*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, *pep2*, *pep5*, and *tspl*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, *pep2*, *pep5*, *tspl*, and *slp7*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, *pep2*, *pep5*, *tspl*, *slp7*, and *slp8*. In some embodiments, the filamentous fungal cell, for example, a *Trichoderma* cell has reduced or no expression levels of protease encoding genes *slp2*, *pepl*, *gapl*, *pep4*, *slpl*, *slp3*, *pep3*, *pep2*, *pep5*, *tspl*, *slp7*, *slp8*, and *gap2*.

[00252] In certain embodiments, the filamentous fungal cell has at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more proteases with reduced protease activity, wherein the corresponding proteases with wild type activity each have an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the

amino acid sequences of SEQ ID NOs: 1-16; 17-36; 37-57; 58-65; 66-81; 82-97; 98-117; 118-128; 129-144; 166-181; 182-185; or SEQ ID NOs:491-588. In embodiments where the filamentous fungal cell is a *Trichoderma* fungal cell with reduced protease activity in one or more proteases, wherein the corresponding proteases with wild type activity each have an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequences of SEQ ID NOs: 1, 17, 37, 58, 66, 82, 98, 118, 129, 166, or 182; or SEQ ID NO:507, SEQ ID NO:522, or SEQ ID NO:530.

Heterologous polypeptides

[00253] The filamentous fungal cells or *Trichoderma* fungal cells of the present disclosure contain a recombinant polynucleotide encoding a heterologous polypeptide. In certain embodiments, the heterologous polypeptide is a mammalian polypeptide. In other embodiments, heterologous polypeptide is a non-mammalian polypeptide.

[00254] In embodiments where the filamentous fungal cell contains a recombinant polynucleotide encoding a mammalian polypeptide, the mammalian polypeptide can be a non-glycosylated mammalian polypeptide, a glycosylated mammalian polypeptide, or combinations thereof, including, without limitation, an immunoglobulin, an antibody, a growth factor, and an interferon. In some embodiments, the mammalian polypeptide is an immunoglobulin or antibody. In embodiments where the filamentous fungal cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody, the filamentous fungal cell, for example, a *Trichoderma* fungal cell may have reduced or no expression of at least three or at least four protease encoding genes selected from *pep1*, *pep3*, *pep4*, *pep8*, *pep11*, *pep12*, *tspl*, *slpl*, *slp2*, *slp7*, *gap1*, and *gap2*. In certain preferred embodiments, the cell, for example a *Trichoderma* fungal cell, contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced or no expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pep1*, *gap1*, *pep4*, *pep3*, *pep2*, *pep5*, and *gap2*. In certain preferred embodiments, the cell, for example a *Trichoderma* fungal cell, contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced or no expression of the protease encoding genes

pepl, *tspl*, *slpl*, and *gapl*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *pepl*, *tspl*, *slpl*, *gapl*, and *pep4*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, and *slp3*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, and *tspl*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, and *pepl*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pepl*, and *gapl*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pepl*, *gapl*, and *pep4*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pepl*, *gapl*, *pep4*, and *pep3*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pepl*, *gapl*, *pep4*, and *pep3*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pepl*, *gapl*, *pep4*, *pep3*, and *pep2*. In other embodiments, the cell contains a recombinant polynucleotide encoding an immunoglobulin or antibody and has reduced expression of the protease encoding genes *slpl*, *slp2*, *slp3*, *tspl*, *pepl*, *gapl*, *pep4*, *pep3*, *pep2*, and *pep5*.

[00255] In other embodiments, the filamentous fungal cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, or interleukin. In embodiments where the filamentous fungal cell, for example a *Trichoderma* fungal cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin, the filamentous fungal cell may have reduced or no expression of at least three or at least four protease encoding genes selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *gapl*, *gap2*, *slpl*, *slp2*, *slp7*, and *tspl*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or

interleukin and has reduced expression of the protease encoding genes *pepl*, *tspl*, *slpl*, *gapl*, and *gap2*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *slpl*, *slp2*, *pepl*, *gapl*, *pep4*, *slp7*, *pep2*, *pep3*, *pep5*, *tspl*, and *gap2*. In other embodiments, the cell, for example a *Trichoderma* fungal cell, contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, and *pep4*. In a further embodiment, the cell contains a recombinant polynucleotide encoding a growth factor, and has reduced expression of a *pep*-type protease genes are selected from *pepl*, *pep2*, *pep3*, *pep4*, and *pep5*. In certain preferred embodiments, the growth factor is IGF-1 or the interferon is interferon- α 2b. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, and *pep4*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, and *slp7*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, *slp7*, and *slp2*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, *slp7*, *slp2*, and *pep2*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, *slp7*, *slp2*, *pep2*, and *pep3*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, *slp7*, *slp2*, *pep2*, *pep3*, and *pep5*. In certain embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, *slp7*, *slp2*, *pep2*, *pep3*, *pep5*, and *slpl*. In certain

embodiments, the cell contains a recombinant polynucleotide encoding a growth factor, interferon, cytokine, human serum albumin, or interleukin and has reduced expression of the protease encoding genes *pepl*, *gapl*, *pep4*, *slp7*, *slp2*, *pep2*, *pep3*, *pep5*, *slpl*, and *tspl*.

[00256] In certain embodiments, the mammalian polypeptide is produced at a level that is at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 90-fold, at least 100-fold, or a greater fold higher than the production level of the polypeptide in a corresponding parental filamentous fungal cell without the reduced protease activity. In other embodiments, the mammalian polypeptide is produced in a full length version at a level higher than the production level of the full-length version of the polypeptide in a corresponding parental filamentous fungal cell.

[00257] In embodiments where the filamentous fungal cell contains a recombinant polynucleotide encoding a non-mammalian polypeptide, the non-mammalian polypeptide may be an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase or xylanase. In embodiments where the filamentous fungal cell contains a recombinant polynucleotide encoding a non-mammalian polypeptide, the filamentous fungal cell may have reduced or no detectable expression of at least three, at least four, at least five, or at least six protease encoding genes selected from *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, *pep8*, *pepl1*, *pepl2*, *tspl*, *slpl*, *slp2*, *slp3*, *gapl*, and *gap2*. In certain embodiments, the non-mammalian polypeptide is produced at a level that is at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 90-fold, at least 100-fold, or a greater fold higher than the production level of the polypeptide in a corresponding parental filamentous fungal cell. In other embodiments, the non-mammalian polypeptide is produced in a full length

version at a level higher than the production level of the full-length version of the polypeptide in a corresponding parental filamentous fungal cell.

Reduced activity of additional proteases

[00258] In some embodiments, the filamentous fungal cells or Trichoderma fungal cells of the present disclosure also have reduced activity of one or more additional proteases. In certain embodiments, the expression level of the one or more additional proteases is reduced. In certain preferred embodiments, genes encoding the one or more additional proteases each comprise a mutation that reduces the corresponding protease activity. The one or more additional protease encoding genes may be *pep7*, *tppl*, *gap2*, *slp3*, *slp5*, *slp6*, *slp7*, or *slp8*.

[00259] In certain embodiments, when the filamentous fungal cells is an *Aspergillus* cell, the total protease activity is reduced to 50% or less of the total protease activity in the corresponding parental *Aspergillus* cell in which the proteases do not have reduced activity.

[00260] In certain embodiments, total protease activity is reduced in the cell of the present disclosure, for example a Trichoderma cell, to 49% or less, 31% or less, 13% or less, 10% or less, 6.3% or less, or 5.5% or less, of the total protease activity in the corresponding parental filamentous fungal cell in which the proteases do not have reduced activity.

Additional recombinant modifications

[00261] In certain embodiments, the filamentous fungal cells or Trichoderma fungal cells of the present disclosure also have reduced activity of a dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase. Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase (EC 2.4.1.130) transfers an alpha-D-mannosyl residue from dolichyl-phosphate D-mannose into a membrane lipid-linked oligosaccharide. Typically, the dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase enzyme is encoded by an *alg3* gene. Thus, in certain embodiments, the filamentous fungal cell has reduced activity of ALG3, which is the activity encoded by the *alg3* gene. In some embodiments, the *alg3* gene contains a mutation

that reduces the corresponding ALG3 activity. In certain embodiments, the *alg3* gene is deleted from the filamentous fungal cell.

[00262] In other embodiments, the filamentous fungal cells or Trichoderma fungal cells of the present disclosure further contain a polynucleotide encoding an α -1,2-mannosidase. The polynucleotide encoding the α -1,2-mannosidase may be endogenous in the host cell, or it may be heterologous to the host cell. These polynucleotides are especially useful for a filamentous fungal cell expressing high-mannose glycans transferred from the Golgi to the ER without effective exo- α -2-mannosidase cleavage. The α -1,2-mannosidase may be a mannosidase I type enzyme belonging to the glycoside hydrolase family 47 (cazy.org/GH47_all.html). In certain embodiments the α -1,2-mannosidase is an enzyme listed at cazy.org/GH47_characterized.html. In particular, the α -1,2-mannosidase may be an ER-type enzyme that cleaves glycoproteins such as enzymes in the subfamily of ER α -mannosidase I EC 3.2.1.13 enzymes. Examples of such enzymes include human α -2-mannosidase IB (AAC26169), a combination of mammalian ER mannosidases, or a filamentous fungal enzyme such as α -1,2-mannosidase (MDS1) (*T. reesei* AAF34579; Maras M et al J Biotech. 77, 2000, 255). For ER/Golgi expression the catalytic domain of the mannosidase is typically fused with a targeting peptide, such as HDEL, KDEL, or part of an ER or early Golgi protein, or expressed with an endogenous ER targeting structures of an animal or plant mannosidase I enzyme, see, for example, Callewaert *et al.* 2001 Use of HDEL-tagged *Trichoderma reesei* mannosyl oligosaccharide 1,2- α -D-mannosidase for N-glycan engineering in *Pichia pastoris*. FEBS Lett 503: 173-178.

[00263] In further embodiments, the filamentous fungal cells or Trichoderma fungal cells of the present disclosure also contain an N-acetylglucosaminyltransferase I catalytic domain and an N-acetylglucosaminyltransferase II catalytic domain. Such catalytic domains are useful for expressing complex N-glycans in non-mammalian cells. N-acetylglucosaminyltransferase I (GlcNAc-TI; GnTI; EC 2.4.1.101) catalyzes the reaction $\text{UDP-N-acetyl-D-glucosamine} + 3\text{-(}\alpha\text{-D-mannosyl)-}\beta\text{-D-mannosyl-R} \rightleftharpoons \text{UDP} + 3\text{-(2-(N-acetyl-}\beta\text{-D-glucosaminy)-}\alpha\text{-D-mannosyl)-}\beta\text{-D-mannosyl-R}$, where R represents the remainder of the N-linked oligosaccharide in the glycan acceptor. An N-acetylglucosaminyltransferase I catalytic domain is any portion of an N-acetylglucosaminyltransferase I enzyme that is capable of catalyzing this

reaction. N-acetylglucosaminyltransferase II (GlcNAc-TII; GnTII; EC 2.4.1.143) catalyzes the reaction $\text{UDP-N-acetyl-D-glucosamine} + 6\text{-(}\alpha\text{-D-mannosyl)-}\beta\text{-D-mannosyl-R} \rightleftharpoons \text{UDP} + 6\text{-(2-(N-acetyl-}\beta\text{-D-glucosaminyl)-}\alpha\text{-D-mannosyl)-}\beta\text{-D-mannosyl-R}$, where R represents the remainder of the N-linked oligosaccharide in the glycan acceptor. An N-acetylglucosaminyltransferase II catalytic domain is any portion of an N-acetylglucosaminyltransferase II enzyme that is capable of catalyzing this reaction. Examples of suitable N-acetylglucosaminyltransferase I catalytic domains and an N-acetylglucosaminyltransferase II catalytic domains can be found in International Patent Application No. PCT/EP2011/070956. The N-acetylglucosaminyltransferase I catalytic domain and N-acetylglucosaminyltransferase II catalytic domain can be encoded by a single polynucleotide. In certain embodiments, the single polynucleotide encodes a fusion protein containing the N-acetylglucosaminyltransferase I catalytic domain and the N-acetylglucosaminyltransferase II catalytic domain. Alternatively, the N-acetylglucosaminyltransferase I catalytic domain can be encoded by a first polynucleotide and the N-acetylglucosaminyltransferase II catalytic domain can be encoded by a second polynucleotide.

[00264] In embodiments where, the filamentous fungal cell or Trichoderma fungal cell contains an N-acetylglucosaminyltransferase I catalytic domain and an N-acetylglucosaminyltransferase II catalytic domain, the cell can also contain a polynucleotide encoding a mannosidase II. Mannosidase II enzymes are capable of cleaving Man5 structures of GlcNAcMan5 to generate GlcNAcMan3, and if combined with action of a catalytic domain of GnTII, to generate GO; and further, with action of a catalytic domain of a galactosyltransferase, to generate G1 and G2. In certain embodiments mannosidase II-type enzymes belong to glycoside hydrolase family 38 (cazy.org/GH38_all.html). Examples of such enzymes include human enzyme AAC50302, *D. melanogaster* enzyme (Van den Elsen J.M. et al (2001) EMBO J. 20: 3008-3017), those with the 3D structure according to PDB-reference 1HTY, and others referenced with the catalytic domain in PDB. For ER/Golgi expression, the catalytic domain of the mannosidase is typically fused with an N-terminal targeting peptide, for example using targeting peptides listed in the International Patent Application No. PCT/EP2011/070956 or of

SEQ ID NOs 589-594. After transformation with the catalytic domain of a mannosidase II-type mannosidase, a strain effectively producing GlcNAc₂Man₃, GlcNAc₁Man₃ or GO is selected.

[00265] In certain embodiments that may be combined with the preceding embodiments, the filamentous fungal cell further contains a polynucleotide encoding a UDP-GlcNAc transporter.

[00266] In certain embodiments that may be combined with the preceding embodiments, the filamentous fungal cell further contains a polynucleotide encoding a β -1,4-galactosyltransferase. Generally, β -1,4-galactosyl transferases belong to the CAZy glycosyltransferase family 7 (cazy.org/GT7_all.html). Examples of useful β 4GalT enzymes include p4GalT1, e.g. bovine *Bos taurus* enzyme AAA30534.1 (Shaper N.L. et al Proc. Natl. Acad. Sci. U.S.A. 83 (6), 1573-1577 (1986)), human enzyme (Guo S. et al. Glycobiology 2001, 11:813-20), and *Mus musculus* enzyme AAA37297 (Shaper, N.L. et al. 1998 J. Biol. Chem. 263 (21), 10420-10428). In certain embodiments of the invention where the filamentous fungal cell contains a polynucleotide encoding a galactosyltransferase, the filamentous fungal cell also contains a polynucleotide encoding a UDP-Gal 4 epimerase and/or UDP-Gal transporter. In certain embodiments of the invention where the filamentous fungal cell contains a polynucleotide encoding a galactosyltransferase, lactose may be used as the carbon source instead of glucose when culturing the host cell. The culture medium may be between pH 4.5 and 7.0 or between 5.0 and 6.5. In certain embodiments of the invention where the filamentous fungal cell contains a polynucleotide encoding a galactosyltransferase and, optionally, a polynucleotide encoding a UDP-Gal 4 epimerase and/or UDP-Gal transporter, a divalent cation such as Mn²⁺, Ca²⁺ or Mg²⁺ may be added to the cell culture medium.

[00267] In certain embodiments that may be combined with the preceding embodiments, the level of activity of α -1,6-mannosyltransferase in the host cell is reduced compared to the level of activity in a wild-type host cell. In certain embodiments, the filamentous fungal has a reduced level of expression of an *och1* gene compared to the level of expression in a wild-type filamentous fungal cell.

[00268] Another aspect includes methods of producing a Man₃GlcNAc₂ N-glycan [i.e. Mana₃(Manoc₆)Man₃₄GlcNAc₃₄GlcNAc] in a filamentous fungal cell including the steps of providing a filamentous fungal cell with a recombinant polynucleotide encoding a heterologous polypeptide and a reduced level of activity of an alg3 mannosyltransferase compared to the level of activity in a wild-type filamentous fungal cell and culturing the filamentous fungal cell to produce a Man₃GlcNAc₂ glycan, where the Man₃GlcNAc₂ glycan constitute at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the neutral N-glycans secreted by the filamentous fungal cell. In certain embodiment, Man₃GlcNAc₂ N-glycan represents at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the total N-glycans of the heterologous polypeptide.

[00269] Another aspect includes methods of producing a complex N-glycan (i.e an N-glycan comprising a terminal GlcNAc₂Man₃ structure), for example GlcNAc₂Man₃GlcNAc₂ {i.e. GO, i.e. GlcNAcP₂Man₃(GlcNAc₃₂Man₆)Man₃₄GlcNAc₃₄GlcNAc} glycan in a filamentous fungal cell including the steps of providing a filamentous fungal cell with a recombinant polynucleotide encoding a heterologous polypeptide, a reduced level of activity of an alg3 mannosyltransferase compared to the level of activity in a wild-type filamentous fungal cell and comprising further a polynucleotide encoding an N-acetylglucosaminyltransferase I catalytic domain and a polynucleotide encoding an N-acetylglucosaminyltransferase II catalytic domain and culturing the filamentous fungal cell to produce the complex N-glycan, for example GlcNAc₂Man₃GlcNAc₂ glycan, where the GlcNAc₂Man₃GlcNAc₂ glycan constitutes at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the neutral N-glycans secreted by the filamentous fungal cell. In certain embodiments, the complex N-glycan, for example GlcNAc₂Man₃GlcNAc₂ glycan, represents at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the total N-glycans of the polypeptide. In certain embodiments, said complex N-glycans are GlcNAcMan₃ and/or GlcNAc₂Man₃.

[00270] Another aspect includes methods of producing a G1 or G2 N-glycan or mixture thereof, for example GalGlcNAc2Man3GlcNAc2 {i.e. G1, i.e. Gaip4GlcNAcp2Mana3(GlcNAcp2Mana6)Manp4GlcNAcp4GlcNAc } or GlcNAcP2Mana3(Gaip4GlcNAcP2Mana6)ManP4GlcNAcP4GlcNAc } and/or Gal2GlcNAc2Man3GlcNAc2 {i.e. G2, i.e. Gaip4GlcNAcp2Mana3(Gaip4GlcNAcP2Mana6)ManP4GlcNAcP4GlcNAc} glycan in a filamentous fungal cell including the steps of providing a filamentous fungal cell with a recombinant polynucleotide encoding a heterologous polypeptide and a reduced level of activity of an alg3 mannosyltransferase compared to the level of activity in a wild-type filamentous fungal cell and comprising further a polynucleotide encoding an N-acetylglucosaminyltransferase I catalytic domain, a polynucleotide encoding an N-acetylglucosaminyltransferase II catalytic domain, and a polynucleotide encoding a GalT catalytic domain and culturing the filamentous fungal cell to produce the G1 or G2 N-glycan or mixture thereof, where G1 glycan constitutes at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the neutral N-glycans secreted by the filamentous fungal cell, or where the G2 glycan constitutes at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the neutral N-glycans secreted by the filamentous fungal cell. In certain embodiment, G1 glycan constitutes at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the total N-glycans of the polypeptide. In certain embodiment, G2 glycan constitutes at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the total N-glycans of the polypeptide.

[00271] In certain embodiments, the method of producing a complex N-glycan will generate a mixture of different glycans. The complex N-glycan or Man3GlcNAc2 may constitute at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), or at least 90% or more of such a glycan mixture. In certain embodiments, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), or at least 90% or more of the N-glycans of the polypeptide consists of such a

glycan mixture. In certain embodiments, the method of producing a complex and G1 and/or G2 N-glycan will generate a mixture of different glycans. The complex N-glycan, Man3GlcNAc2, G1 and/or G2 may constitute at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), or at least 90% or more of such a glycan mixture. In certain embodiments, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), or at least 90% or more of of the N-glycans of the polypeptide consists of such a glycan mixture.

[00272] In certain embodiments, methods of producing a hybrid N-glycan are desirable. As used herein, the term "hybrid" means a glycan containing both unsubstituted terminal mannose residues (as are present in high-mannose glycans) and substituted mannose residues with an N-acetylglucosamine linkage, for example GlcNAcP2Man3[Man3(Mana6)Mana6]ManP4GlcNAcP4GlcNAc. In such embodiments, a Man5 {i.e. Man3[Man3(Mana6) Mana6]ManP4GlcNAcP4GlcNAc} expressing filamentous fungal cell such as *T. reesei* strain is transformed with a recombinant polynucleotide encoding a heterologous polypeptide and a polynucleotide encoding an N-acetylglucosaminyltransferase I catalytic domain and the filamentous fungal cell is cultured to produce the hybrid N-glycan where the hybrid N-glycan constitutes at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the neutral N-glycans secreted by the filamentous fungal cell. In certain embodiment, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% (mol %) of the N-glycans of the polypeptide consists of a hybrid N-glycan.

[00273] The Man3GlcNAc2, complex, hybrid, G1, and G2 N-glycan may be attached to a molecule selected from an amino acid, a peptide, and a polypeptide. In certain embodiments, the Man3GlcNAc2, complex, hybrid, G1, and G2 N-glycan is attached to a heterologous polypeptide. In certain embodiments, the heterologous polypeptide is a glycosylated protein. In certain embodiment, the glycosylated polypeptide is a mammalian polypeptide. In certain embodiments, mammalian polypeptide is an antibody or its antigen-binding fragment.

[00274] In certain embodiments, glycosyltransferases, or example, GnTI, GnTII, or GalT or glycosylhydrolases, for example, α -1,2-mannosidase or mannosidase II, include a targeting peptide linked to the catalytic domains. The term "linked" as used herein means that two polymers of amino acid residues in the case of a polypeptide or two polymers of nucleotides in the case of a polynucleotide are either coupled directly adjacent to each other or are within the same polypeptide or polynucleotide but are separated by intervening amino acid residues or nucleotides. A "targeting peptide", as used herein, refers to any number of consecutive amino acid residues of the recombinant protein that are capable of localizing the recombinant protein to the endoplasmic reticulum (ER) or Golgi apparatus (Golgi) within the filamentous fungal cell. The targeting peptide may be N-terminal or C-terminal to the catalytic domains. In certain embodiments, the targeting peptide is N-terminal to the catalytic domains. In certain embodiments, the targeting peptide provides direct binding to the ER or Golgi membrane. Components of the targeting peptide may come from any enzyme that normally resides in the ER or Golgi apparatus. Such enzymes include mannosidases, mannosyltransferases, glycosyltransferases, Type 2 Golgi proteins, and MNN2, MNN4, MNN6, MNN9, MNN10, MNS1, KRE2, VAN1, and OCH1 enzymes. Suitable targeting peptides are described in the International Patent Application No. PCT/EP2011/070956. In one embodiment, the targeting peptide of GnTI or GnTII is human GnTII enzyme. In other embodiments, targeting peptide is derived from *Trichoderma Kre2*, *Kre2*-like, *Ochl*, *Anpl*, and *Vanl*. In one embodiment, the targeting peptide is selected from the group of SEQ ID NOs: 589-594.

Uses of the Filamentous Fungal Cells of the Invention

[00275] The invention herein further relates to methods of using any of the filamentous fungal cells of the present disclosure, such as *Trichoderma* fungal cells, that have reduced or no protease activity of at least three proteases and that contain a recombinant polynucleotide encoding a heterologous polypeptide, such as a mammalian polypeptide, that is produced at increased levels, for improving heterologous polypeptide stability and for making a heterologous polypeptide. Methods of measuring protein stability and for making a heterologous polypeptide are well known, and include, without limitation, all the methods and techniques described in the present disclosure.

[00276] Accordingly, certain embodiments of the present disclosure relate to methods of improving heterologous polypeptide stability, by: a) providing a filamentous fungal cell of the present disclosure having reduced or no activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a heterologous polypeptide; and b) culturing the cell such that the heterologous polypeptide is expressed, where the heterologous polypeptide has increased stability compared to a host cell not containing the mutations of the genes encoding the proteases. Other embodiments of the present disclosure relate to methods of improving mammalian polypeptide stability, by: a) providing a Trichoderma fungal cell of the present disclosure having reduced or no activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide; and b) culturing the cell such that the mammalian polypeptide is expressed, where the mammalian polypeptide has increased stability compared to a host cell not containing the mutations of the genes encoding the proteases. The filamentous fungal cell or Trichoderma fungal cell may be any cell described in the section entitled "Filamentous Fungal Cells of the Invention". Methods of measuring polypeptide stability and for culturing filamentous fungal and Trichoderma fungal cells are well known in the art, and include, without limitation, all the methods and techniques described in the present disclosure.

[00277] In certain embodiments, the stability of the heterologous polypeptide or mammalian polypeptide is increased by at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 90-fold, at least 100-fold, or a greater fold higher compared to a heterologous polypeptide or mammalian polypeptide expressed in a corresponding parental filamentous fungal or Trichoderma fungal cell.

[00278] Other embodiments of the present disclosure relate to methods of making a heterologous polypeptide, by: a) providing a filamentous fungal cell of the present disclosure having reduced or no activity of at least three proteases, where the cell further contains a recombinant polynucleotide encoding a heterologous polypeptide; b) culturing the host cell such that the heterologous polypeptide is expressed; and c) purifying the heterologous polypeptide.

Further embodiments of the present disclosure relate to methods of making a mammalian polypeptide, by: a) providing a Trichoderma fungal cell of the present disclosure having reduced or no activity of at least three protease, where the cell further contains a recombinant polynucleotide encoding a mammalian polypeptide; b) culturing the host cell such that the mammalian polypeptide is expressed; and c) purifying the mammalian polypeptide. The filamentous fungal cell or Trichoderma fungal cell may be any cell described in the section entitled "Filamentous Fungal Cells of the Invention". Methods of culturing filamentous fungal and Trichoderma fungal cells and purifying polypeptides are well known in the art, and include, without limitation, all the methods and techniques described in the present disclosure.

[00279] In certain embodiments, the filamentous fungal cell or Trichoderma fungal cell is cultured at a pH range selected from pH 3.5 to 7; pH 3.5 to 6.5; pH 4 to 6; pH 4.3 to 5.7; pH 4.4 to 5.6; and pH 4.5 to 5.5. In certain embodiments, to produce an antibody the filamentous fungal cell or Trichoderma fungal cell is cultured at a pH range selected from 4.7 to 6.5; pH 4.8 to 6.0; pH 4.9 to 5.9; and pH 5.0 to 5.8.

[00280] In some embodiments, the heterologous polypeptide is a mammalian polypeptide. In other embodiments, the heterologous polypeptide is a non-mammalian polypeptide.

[00281] In certain embodiments, the mammalian polypeptide is selected from an immunoglobulin, immunoglobulin heavy chain, an immunoglobulin light chain, a monoclonal antibody, a hybrid antibody, an F(ab')₂ antibody fragment, an F(ab) antibody fragment, an Fv molecule, a single-chain Fv antibody, a dimeric antibody fragment, a trimeric antibody fragment, a functional antibody fragment, a single domain antibody, multimeric single domain antibodies, an immunoadhesin, insulin-like growth factor 1, a growth hormone, insulin, and erythropoietin. In other embodiments, the mammalian protein is an immunoglobulin or insulin-like growth factor 1. In yet other embodiments, the mammalian protein is an antibody. In further embodiments, the yield of the mammalian polypeptide is at least 0.5, at least 1, at least 2, at least 3, at least 4, or at least 5 grams per liter. In certain embodiments, the mammalian polypeptide is an antibody, optionally, IgG1, IgG2, IgG3, or IgG4. In further embodiments, the yield of the antibody is at least 0.5, at least 1, at least 2, at least 3, at least 4, or at least 5 grams per liter. In still other

embodiments, the mammalian polypeptide is a growth factor or a cytokine. In further embodiments, the yield of the growth factor or cytokine is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 1.5, at least 2, at least 3, at least 4, or at least 5 grams per liter. In further embodiments, the mammalian polypeptide is an antibody, and the antibody contains at least 70 %, at least 80 %, at least 90 %, at least 95 %, or at least 98 % of a natural antibody C-terminus and N-terminus without additional amino acid residues. In other embodiments, the mammalian polypeptide is an antibody, and the antibody contains at least 70 %, at least 80 %, at least 90 %, at least 95 %, or at least 98 % of a natural antibody C-terminus and N-terminus that do not lack any C-terminal or N-terminal amino acid residues

[00282] In certain embodiments where the mammalian polypeptide is purified from cell culture, the culture containing the mammalian polypeptide contains polypeptide fragments that make up a mass percentage that is less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% of the mass of the produced polypeptides. In certain preferred embodiments, the mammalian polypeptide is an antibody, and the polypeptide fragments are heavy chain fragments and/or light chain fragments. In other embodiments, where the mammalian polypeptide is an antibody and the antibody purified from cell culture, the culture containing the antibody contains free heavy chains and/or free light chains that make up a mass percentage that is less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% of the mass of the produced antibody. Methods of determining the mass percentage of polypeptide fragments are well known in the art and include, measuring signal intensity from an SDS-gel.

[00283] In further embodiments, the non-mammalian polypeptide is selected from an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

[00284] In certain embodiments of any of the disclosed methods, the method includes the further step of providing one or more, two or more, three or more, four or more, or five or more

protease inhibitors. In certain embodiments, the protease inhibitors are peptides that are co-expressed with the mammalian polypeptide. In other embodiments, the inhibitors inhibit at least two, at least three, or at least four proteases from a protease family selected from aspartic proteases, trypsin-like serine proteases, subtilisin proteases, and glutamic proteases.

[00285] In certain embodiments of any of the disclosed methods, the filamentous fungal cell or Trichoderma fungal cell also contains a carrier protein. As used herein, a "carrier protein" is a portion of a protein that is endogenous to and highly secreted by a filamentous fungal cell or Trichoderma fungal cell. Suitable carrier proteins include, without limitation, those of *T. reesei* mannanase I (Man5A, or MANI), *T. reesei* cellobiohydrolase II (Cel6A, or CBHII) (see, e.g., Paloheimo et al Appl. Environ. Microbiol. 2003 December; 69(12): 7073-7082) or *T. reesei* cellobiohydrolase I (CBHI). In some embodiments, the carrier protein is CBH1. In other embodiments, the carrier protein is a truncated *T. reesei* CBHI protein that includes the CBHI core region and part of the CBHI linker region. In some embodiments, a carrier such as a cellobiohydrolase or its fragment is fused to an antibody light chain and/or an antibody heavy chain. In some embodiments, a carrier such as a cellobiohydrolase or its fragment is fused to insulin-like growth factor 1, growth hormone, insulin, interferon alpha 2b, fibroblast growth factor 21, or human serum albumin. In some embodiments, a carrier-antibody fusion polypeptide comprises a Kex2 cleavage site. In certain embodiments, Kex2, or other carrier cleaving enzyme, is endogenous to a filamentous fungal cell. In certain embodiments, carrier cleaving protease is heterologous to the filamentous fungal cell, for example, another Kex2 protein derived from yeast or a TEV protease. In certain embodiments, carrier cleaving enzyme is overexpressed.

[00286] It is to be understood that, while the invention has been described in conjunction with the certain specific embodiments thereof, the foregoing description is intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

[00287] The invention having been described, the following examples are offered to illustrate the subject invention by way of illustration, not by way of limitation.

EXAMPLES

Example 1 — IDENTIFICATION OF ASPARTIC PROTEASES IN TRICHODERMA REESEI

[00288] This example demonstrates the ability of aspartic proteases from *Trichoderma reesei* (*T. reesei*) culture supernatants to degrade antibody heavy chains and light chains.

Aspartic Protease Purification

[00289] It was found that protease activity in *T. reesei* supernatants could be inhibited with the aspartic protease inhibitor pepstatin A. Therefore, pepstatin A (Sigma #P2032) was attached to agarose beads via a diaminodipropylamine linker, and was used as an affinity resin for purification. The *T. reesei* fed batch fermentation supernatant (15 ml) was used to batch bind proteases to the resin in 35 ml of buffer containing 50 mM sodium acetate, 0.2 M NaCl, pH 3.0. The column was washed with the same binding buffer and bound protein was removed with elution buffer (50 mM Tris-HCL, 1 M NaCl, pH 8.5). Fractions of 0.5 ml were collected. In total 42 µg of protease was purified. The peak fraction contained 0.04 µg/µl protein. 30 µl of each fraction was mixed with 6 µl of Laemmli sample buffer containing β-mercaptoethanol. The samples were heated at 95°C for 5 minutes before being loaded into a 4-15% PAGE gel (BioRad mini-protean TGX precast gel) along with a broad range prestained molecular weight marker (BioRad). The gel was run in SDS PAGE running buffer for 30 minutes at 100 V, and then stained with GelCode (Thermo Scientific) blue stain.

[00290] A 42 kD doublet band was purified in the pepstatin A affinity column (Fig. 1), and was excised from the SDS PAGE gel and subjected to in-gel trypsin digestion with sequencing grade modified trypsin (Promega #V5111). The resulting peptides were then extracted from the gel and purified by C18 ZipTip (Millipore #ZTC18M096). The purified peptides were analyzed by LC-MS/MS on a QSTAR Pulsar, ESI-hybrid quadrupole-TOF (AB Sciex).

[00291] This analysis resulted in the identification of 4 aspartic proteases that have very similar molecular weights. The identified proteases included: *pep1* (Tre74156; 42.7 kD, 42% sequence coverage), *pep2* (Tre53961; 42.4 kD, 15% sequence coverage), *pep3* (Tre121133; 49

kD, 6% sequence coverage), and *pep5* (Tre81004; 45 kD, 9% sequence coverage). These aspartic proteases ran at a similar molecular weight in the PAGE gel. Their amino acid sequence similarity is between 51%-64%.

[00292] Protein (0.8 µg) from the peak fraction (F3) was then incubated with IgG (50 µg/ml) in sodium citrate buffer (50 mM, pH 5.5) at 37°C for 20 hours (Fig. 2). The protein was incubated either in the presence or absence of 10 µM pepstatin A. The antibody mixture was combined with Laemmli sample buffer and heated at 95°C for 5 minutes. These samples were then loaded into a 4-15% PAGE gel (BioRad mini-protean TGX precast gel) along with a broad range prestained molecular weight marker (BioRad). The gel was run in SDS PAGE running buffer for 30 minutes at 100 V. The IgG was not reduced before being run on the gel. Full size IgG runs just above the 200 kDa marker. As can be seen in the nonreducing gel in Figure 2, the aspartic proteases were able to produce mild degradation of the IgG. Moreover, IgG degradation was inhibited by pepstatin A. The aspartic protease activity was more limited at pH 5.5 than at acidic pHs, where they had maximal activity.

Analysis of *pepl* Deletion

[00293] The aspartic protease *pepl* protease was then tested to determine its abundance in *T. reesei*. This was performed by purifying aspartic proteases from supernatant samples derived from the *pepl* deletion strain M182. The M182 *pepl* deletion strain also produces the rituximab antibody.

[00294] The M181 *pepl* deletion strain made in the base strain M124 was grown in large shake flask cultures along with M124 control flasks. The cultures were grown in 300 ml of TrMM with 4 g/L lactose, 2 g/L spent grain extract, and 100 mM PIPPS, pH 5.5. Three different model antibodies were incubated (0.05 µg/µl final concentration) in the shake flask culture supernatants (diluted 2 mg/ml in sodium citrate buffer pH 5.5) of the *pepl* deletion strain and its parental strain M124, and as a comparison in a fermentation culture supernatant of the parental strain. Supernatant samples (30 µl) from day 5 cultures containing antibody were loaded into a 4-15% SDS PAGE gel and transferred to nitrocellulose for immunoblotting with an anti-heavy

chain AP conjugated antibody (Sigma #A3188) or anti-light chain antibody AP conjugate (Sigma #A3813) diluted 1:30,000 in TBST. When incubated with antibody overnight for 18 hours, the *Apepl* supernatant degraded less of the heavy chain protein as compared to the M124 control strain or fermentation supernatant (pH 5,5; 28°C; 20 g/L spent grain extract, 60 g/L lactose) (Fig. 39). The heavy chain was more susceptible to degradation as compared to the light chain. The biggest stabilization effect was evident for rituximab and MAB01 heavy chains. In the heavy chain, two distinct degradation products can be seen -48 kD and -38 kD (Fig. 39). There was only a slight improvement in the stability of light chain protein in the *Apepl* supernatant as compared to controls (Figure 39).

Generation of pep1 deletion plasmid

[00295] The first deletion construct for *pepl* (TreID74156), was designed to enable removal of the selection marker from the *Trichoderma reesei* genome after successful integration and thereby recycling of the selection marker for subsequent protease gene deletions. In this approach, the recycling of the marker, i.e. removal of *pyr4* gene from the deletion construct, resembles so called blaster cassettes developed for yeasts (Hartl, L. and Seiboth, B., 2005, Curr Genet 48:204-211; and Alani, E. et al., 1987, Genetics 116:541-545). Similar blaster cassettes have also been developed for filamentous fungi including *Hypocrea jecorina* (anamorph: *T. reesei*) (Hartl, L. and Seiboth, B., 2005, Curr Genet 48:204-211).

[00296] The TreID number refers to the identification number of a particular protease gene from the Joint Genome Institute *Trichoderma reesei* v2.0 genome database. Primers for construction of deletion plasmids were designed either "by eye" or using Primer3 software (Primer3 website, Rozen and Skaletsky (2000) *Bioinformatics Methods and Protocols: Methods in Molecular Biology*. Humana Press, Totowa, NJ, pp 365-386).

[00297] The principle of the blaster cassette using *pyr4* as the marker gene is as follows: *pyr4*, encoding orotidine-5' -monophosphate (OMP) decarboxylase of *T. reesei* (Smith, J.L., et al., 1991, Current Genetics 19:27-33) is needed for uridine synthesis. Strains deficient for OMP decarboxylase activity are unable to grow on minimal medium without uridine supplementation

(i.e. are uridine auxotrophs). The utilisation of 5-fluoroorotic acid (5-FOA) in generation of mutant strains lacking OMP decarboxylase activity (*pyr4⁻* strains) is based on the conversion of 5-FOA to a toxic intermediate 5-fluoro-UMP by OMP decarboxylase. Therefore, cells which have a mutated *pyr4* gene are resistant to 5-FOA, but in addition are also auxotrophic for uridine. The 5-FOA resistance can in principle result also from a mutation in another gene (*pyr2*, orotate phosphoribosyltransferase), and therefore the spontaneous mutants obtained with this selection need to be verified for the *pyr4⁻* genotype by complementing the mutant with the *pyr4* gene. Once mutated, the *pyr4* gene can be used as an auxotrophic selection marker in *T. reesei*. In our blaster cassette *pyr4* is followed by a 308 bp direct repeat of *pyr4* 5' untranslated region (5'UTR) and surrounded by 5' and 3' flanking regions of the gene to be deleted. Integration of the deletion cassette is selected via the *pyr4* function. Removal of the *pyr4* marker is then forced in the presence of 5-FOA by recombination between the two homologous regions (direct repeat of 5'UTR) resulting in looping out of the selection marker and enabling the utilisation of the same blaster cassette (*pyr4* loopout) in successive rounds of gene deletions. After looping out only the 308 bp sequence of 5'UTR remains in the locus.

[00298] Thus, the *pyr4* selection marker and the 5' direct repeat fragment (308 bp of *pyr4* 5'UTR) were produced by PCR using plasmid pARO502 (containing a genomic copy of *T. reesei pyr4*) as a template. PCR amplification was performed with Phusion polymerase and either HF buffer or GC buffer, or with Dynazyme EXT polymerase. The reaction conditions varied based on the fragment being amplified. Both fragments contained 40 bp overlapping sequences needed to clone the plasmid with the loopout cassette using homologous recombination in yeast (see below). To enable possible additional cloning steps, an *AscI* digestion site was placed between the *pyr4* marker and the 5' direct repeat and *NotI* sites to surround the complete blaster cassette.

[00299] 1066 bp of 5' flanking region and 1037 bp of 3' flanking region were selected as the basis of the *pepl* deletion plasmid. Fragments were produced by PCR. Products were separated with agarose gel electrophoresis and correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. Template DNA used in the amplification of the flanking regions was from the *T. reesei* wild type strain QM6a (ATCC13631).

[00300] For the yeast homologous recombination system used in cloning, overlapping sequences for the vector and the selection marker were placed to the appropriate PCR-primers. To enable marker switch in the construct, *NotI* restriction sites were introduced between the flanking regions and the selection marker. *PmeI* restriction sites were placed between the vector and the flanking regions for removal of vector sequence prior to transformation into *T. reesei*. Vector backbone pRS426 was digested with restriction enzymes (*EcoRI* and *XhoI*). The restriction fragments were then separated with agarose gel electrophoresis, and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods.

[00301] To construct the deletion plasmid, the vector backbone and the appropriate marker and flanking region fragments were transformed into *Saccharomyces cerevisiae* (strain H3488/FY834). The yeast transformation protocol was based on the method for homologous yeast recombination described in the *Neurospora* knockouts workshop material of Colot and Collopy, (Dartmouth *Neurospora* genome protocols website), and the Gietz laboratory protocol (University of Manitoba, Gietz laboratory website). The plasmid DNA from the yeast transformants was rescued by transformation into *Escherichia coli*. A few clones were cultivated, plasmid DNA was isolated and digested to screen for correct recombination using standard laboratory methods. A few clones with correct insert sizes were sequenced and stored.

[00302] The first deletion plasmid for *pepl* (plasmid pTTv41, Table 1.1) used another selection marker, *bar*, a synthetic construct carrying a phosphinothricin N-acetyltransferase of *Streptomyces* ssp (GenBank ID: AF013602.1, Sweigard et al, 1997, Fungal Genet Newsl 44:52-53). The flanking region and marker fragments were produced by PCR and assembled to a plasmid using the yeast recombination method described above. To clone the second *pepl* deletion plasmid (pTTv71, Table 1.1), the *bar* marker was removed from the deletion plasmid pTTv41 with *NotI* digestion and replaced by the *pyr4* blaster cassette described above using the yeast homologous recombination system. These deletion plasmids for *pepl* (pTTv41 and pTTv71) result in 1874 bp deletion in the *pepl* locus and cover the complete coding sequence of PEPL

Table 1.1: Primers for generating *pepl* deletion plasmids.

Deletion plasmid pTTv41 for <i>pepl</i> (TreID74156), vector backbone pRS426	
Primer	Sequence
5flankfw	GTAACGCCAGGGTTTTCCCAGTCACGACGGTTTAAACGTATTGCGATGAGCAGC AGA (SEQ ID NO: 243)
5flankrev	ATCCACTTAACGTTACTGAAATCTGGTCTCCTAACCCACCAAG (SEQ ID NO: 244)
3flankfw	CTCCTTCAATATCATCTTCTGTCTGTGAAATGAGGTCCTTCC (SEQ ID NO: 245)
3flankrev	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACCAAACGCAGCAGAAAC CATA (SEQ ID NO: 246)
PTfwd	GATTCAGTAACGTTAAGTGGATGCGGCCGCGACAGAAGATGATATTGAAG (SEQ ID NO: 247)
PTrev	GACAGAAGATGATATTGAAGGAGGCGGCCGCTTAAGTGGATCCCGGTGAC (SEQ ID NO: 248)
Deletion plasmid pTTv71 for <i>pepl</i> (TreID74156), vector backbone pTTv41	
Primer	Sequence
T3 15_pyr4_for	GGTGGGTTAGGAGACCAGATTTTCAGTAACGTTAAGTGGATGCGGCCGCCTAGC ATCGACTACTGCTGC (SEQ ID NO: 249)
T3 16_pyr4_rev	GCAGCAGTAGTCGATGCTAGGCGCGCCATGCAAAGATACACATCAA (SEQ ID NO: 250)
T3 17_pyr4_loop_for	TTGATGTGTATCTTTGCATGGCGCGCCTAGCATCGACTACTGCTGC (SEQ ID NO: 251)
T3 18_pyr4_loop_rev	AGGGACCTCATTTACAGACAGAAGATGATATTGAAGGAGGCGGCCGCGGCTG ATGAGGCTGAGAGAG (SEQ ID NO: 252)

*Generation of *pepl* deletion strains M1 81 and M1 95*

[00303] To enable recycling of the selection marker and allow rapid deletion of subsequent protease genes, *pepl* was deleted from M127 (*pyr4*⁻ mutant of the basic strain M124) using the *pyr4* blaster cassette described above. To remove the vector sequence, plasmid pTTv71 (*Apepl* - *pyr4*) was digested with *PmeI* and the correct fragment was purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *pepl* deletion cassette was used to transform strain M127. Preparation of protoplasts and transformation for *pyr4* selection were carried out essentially according to methods in Penttila et al. (1987, *Gene* 61:155-164) and Gruber et al (1990, *Curr. Genet.* 18:71-76).

[00304] 200 clones were picked as selective streaks. 24 transformants growing fast as selective streaks were screened by PCR using the primers listed in Table 1.2 for the correct integration using standard laboratory methods. Seven putative disruptants were purified to single cell clones.

Deletion of *pepl* was verified by Southern analyses from these clones (Fig. 3A) using standard laboratory methods. DNA for Southern analyses was extracted with Easy-DNA kit for genomic DNA isolation (Invitrogen). Southern analyses were essentially performed according to the protocol for homologous hybridizations in Sambrook et al. (1989, Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press) using radioactive labeling (³²P), HexaLabel Plus, or DecaLabel Plus kits (Fermentas). Southern digestion schemes were designed using either Sci Ed Central for Windows 95 (Clone Manager 5 for Windows 95) or Geneious Pro 5.3.6 software, (Geneious website). Southern analyses also verified that four of the clones were single integrants (Figs. 3B and 3C). Three clones indicated multiple or inaccurate integration of the deletion cassette and were discarded. Two pure clones were designated with strain numbers M1 81 (9-20A-1) and M195 (9-35A-1).

Generation of rituximab producing pepl deletion strain M1 82

[00305] To remove vector sequence, plasmid pTTv41 (*Apepl-bar*) was digested with *PmeI* and the correct fragment was purified from agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *pepl* deletion cassette was used to transform strain M169 (expressing harmonized rituximab antibody). Preparation of protoplasts and transformation were carried out according to methods described in Penttila et al (1987) and Avalos et al. (1989).

[00306] Approximately 100 clones were picked as selective streaks. 24 transformants growing fast as selective streaks were screened by PCR (using the primers listed in Table 1.2) for the correct integration using standard laboratory methods. Eight putative disruptants were purified to single cell clones. Deletion of *pepl* was verified by Southern analyses from five clones (Fig. 4A) using standard laboratory methods described above for M181 and M195. Southern analyses also verified that four of the clones were single integrants (Figs. 4B and 4C). One clone indicated multiple or inaccurate integration of the deletion cassette and was discarded. One pure clone (11-1A) was designated with strain number M1 82.

Table 1.2: Primers for screening integration of *pepl* deletion constructs.

For screening integration of pTTv41	
Primer	Sequence

<u>T075_74156_5int</u>	<u>TCGCTGTAACGAACTTCTGT (SEQ ID NO: 253)</u>
<u>T032_Bar_loppu_for</u>	<u>CATTGTTGACCTCCACTAGC (SEQ ID NO: 254)</u>
<u>T076_74156_3int</u>	<u>GCTGCTGATCGGACATTTTT (SEQ ID NO: 255)</u>
<u>T031_Bar_alku_rev2</u>	<u>GTTTCTGGCAGCTGGACT (SEQ ID NO: 256)</u>

For screening integration of pTTv71

Primer	Sequence
<u>T075_74156_5int</u>	<u>TCGCTGTAACGAACTTCTGT (SEQ ID NO: 257)</u>
<u>T027_Pyr4_orf_start_rev</u>	<u>TGCGTCGCCGTCTCGCTCCT (SEQ ID NO: 258)</u>

For screening deletion of *pepl* ORF

Primer	Sequence
<u>T077_74156_5orf_pcr</u>	<u>CGACGATCTACAGCCATCTG (SEQ ID NO: 259)</u>
<u>T078_74156_3orf_pcr</u>	<u>ACCCAAAGCGTCCTTCATTA (SEQ ID NO: 260)</u>

*Analysis of rituximab producing *pepl* deletion strain M182*

[00307] The M182 strain was grown in *Trichoderma* minimal medium (TrMM) supplemented with 20 g/l spent grain extract, 60 g/l lactose, and 8.1 g/l casamino acids at pH 5.5 and 28°C. Seven microgram of aspartic protease was recovered from 15 ml of supernatant. When the purified fractions were run on a 4-15% SDS PAGE gel (BioRad mini-protean TGX precast gel), the 42 kD molecular weight band previously seen in the parent strain had disappeared (Fig. 5). Only a faint band around 40 kD could be seen. The 40 kD band may correspond to minor aspartic proteases. A second purification was done from a cultivation supernatant where *pepl* was present. The M169 strain produced rituximab and did not contain a *pepl* protease deletion. The strain was grown in *Trichoderma* minimal medium supplemented with 20 g/l spent grain extract, 60 g/l lactose, and 8.1 g/l casamino acids at pH 5.5 and 28°C. 17 µg of aspartic protease were purified from 15 ml of supernatant, and showed a 42 kD band on the SDS PAGE gel (Fig. 5). According to this analysis, approximately 10 µg of *pepl* protease is produced per 15 ml of culture supernatant. That is about 60% of the total aspartic protease and only about 0.04% of total protein content in the supernatant. This data demonstrates that *pepl* is the most abundant aspartic protease in *T. reesei*.

Analysis of other aspartic proteases

[00308] Deletion of *pep2* showed only a slight improvement in antibody heavy chain production and reduced total protease activity (Figs. 6 and 7).

[00309] Therefore, *pep3* and *pep5* were the next important proteases to be deleted especially in a *pep1ltspllspl* triple deletion strain, as they still contribute up to half of the remaining protease activity in a triple deletion strain supernatant.

Generation of pep2 deletion plasmid

[00310] The pTTv96 deletion plasmid for the aspartic protease *pep2* (TreID0053961) was constructed essentially as described for the pTTv41 *pep1* deletion plasmid above. 920 bp of 5' flanking region and 1081 bp of 3' flanking region were selected as the basis of the *pep2* deletion plasmid. Flanking region fragments were produced by PCR using the primers listed in Table 1.3. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template DNA used in the PCR of the flanking regions was from the *T. reesei* wild type strain QM6a. The *bar* cassette was obtained from pTTv41 with *NotI* digestion. The vector backbone was *EcoRI/XhoI* digested pRS426 as for pTTv41 above. The plasmid was constructed using the yeast homologous recombination method described for pTTv41 above. This deletion plasmid for *pep2* (pTTv96) results in a 1437 bp deletion in the *pep2* locus and covers the complete coding sequence of PEP2.

Table 1.3: Primers for generating *pep2* deletion plasmid.

Primer	Sequence
5'flank fw_vector	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACTTCAGTTGTGGCA TCTCAGC (SEQ ID NO: 261)
5'flank rev_marker cassette promoter	GCCAAGCCCAAAAAGTGCTCCTTCAATATCATCTTCTGTGCGGCCGCGG GAAGCAAGTTTCGAAGTG (SEQ ID NO: 262)
3'flank fw_marker cassette end	CCCGTCACCGAGATCTGATCCGTCACCGGGATCCACTTAAGCGGCCGCA ATGGATGAGGTGTGGCTTC (SEQ ID NO: 263)
3'flank rev_vector	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACTCCTCACCGAAG AGCAAGTC (SEQ ID NO: 264)

Generation of rituximab producing pep2 deletion strain M455

[00311] To remove vector sequence, plasmid pTTv96 (*Apep2-bar*) was digested with *PmeI* and the correct fragment was purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 6 µg of the *pep2* deletion cassette was used to transform strain M169 (expressing harmonized rituximab antibody). Preparation of protoplasts and transformation were carried out as described for M182 above using *bar* selection.

[00312] Over 200 clones were picked as selective streaks. 29 transformants grew well as second streaks. The best 10 transformants growing fast as selective streaks were screened for the correct integration by PCR, using the primers listed in Table 1.4, using standard laboratory methods. The deletion cassette was integrated properly in 9 of the 10 clones analyzed. The open reading frame was deleted in 9 of the 10 transformants analyzed by PCR. Five disruptants were purified to single cell clones. One pure transformant (206A) was designated with strain number M455.

Table 1.4: Primers for screening integration of *pep2* deletion constructs.

For screening integration of pTTv96	
Primer	Sequence
5'flank fw_vector	GTAACGCCAGGGTTTTCCCAGTCACGACGGTTTAAACTTCAGTTGTGGCA TCTCAGC (SEQ ID NO: 265)
T032_Bar_loppu_for	CATGTGTGACCTCCACTAGC (SEQ ID NO: 266)
T030_Bar_alku_rev	CGTCACCGAGATCTGATCC (SEQ ID NO: 267)
3'flank rev_vector	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACTCCTCACCGAAG AGCAAGTC (SEQ ID NO: 268)
For screening deletion of <i>pep2</i> ORF	
Primer	Sequence
T601_pep2 fwd	GACGTGGTACGACAACATCG (SEQ ID NO: 269)
T623_pep2 rev	TATCAAGGTACCGGGGACAG (SEQ ID NO: 270)

Analysis of rituximab producing pep2 deletion strain

[00313] The M455 strain, 4 other *pep2* deletion transformants, and the parental rituximab production strain M169 were grown in shake flask cultures in *Trichoderma* minimal medium (TrMM) supplemented with 20 g/l spent grain extract, 40 g/l lactose, 100 mM PIPPS, and 8.1 g/l casamino acids at pH 5.5 and 28°C. To analyze the effect on rituximab production, 30 µl of

supernatant from the day 5 culture samples was subjected to immunoblotting. The heavy chain was detected with the anti-heavy chain AP conjugated antibody (Sigma #A3188) diluted 1:10,000 in TBST. The light chain was detected with the anti-kappa light chain AP conjugated antibody (Sigma #A3813). A slight improvement in heavy chain production was seen in transformant 206A (Fig. 6). The heavy chain was fragmented, but the full length and the 38 kD fragment were slightly improved over the parental strain. Additionally, total protease activity was measured with succinylated casein (QuantiCleave protease assay kit, Pierce #23263) according to the manufacturer's protocol. Transformant 206A/M455 showed the biggest decrease in protease activity compared to the parent strain M169 activity (Fig. 7). The total protease activity in the supernatant was reduced by 10% for M455.

Analysis of Pichia-expressed aspartic proteases

[00314] The *T. reesei* aspartic proteases *pep3* (tre21 133) and *pep7* (tre58669) expressed from *Pichia* were also tested *in vitro*, by measuring the degradation of the MAB01 antibody and IGF-1. Degradation of MAB01 and IGF-1 by *pep3* and *pep7* was analyzed by immunoblotting. The aspartic proteases were produced in *Pichia* supernatants. *Pichia* supernatants were diluted to 1x concentration, and then mixed with 50 mM sodium citrate buffer, pH 5.5. MAB01 was added to each reaction so that the final concentration would be 0.05 $\mu\text{g}/\mu\text{l}$. IGF-1 was added to each reaction so that the final concentration would be 0.30 $\mu\text{g}/\mu\text{l}$. Ten microliters of each reaction mixture was then sampled and added to 3 μl of Laemmli sample buffer with β -mercaptoethanol. The samples were heated at 95°C for 5 minutes before being loaded into a 4-15% PAGE gel (BioRad mini-protean TGX precast gel) along with an all blue precision plus prestained molecular weight marker (BioRad). The PAGE gel was run for 30 minutes at 200V. The proteins in the gel were then electrotransferred into a nitrocellulose filter at 100V for 1 hour. The protein containing nitrocellulose filter was then blocked with 5% milk powder in Tris buffered saline with 0.1% tween (TBST) for 1 hour shaking at room temperature. The blocked membranes were then probed with antibody. The MAB01 containing membranes were probed with an anti-IgG heavy chain antibody AP conjugate (Sigma #A3188) diluted 1:30,000 in TBST. The IGF-1 samples were analyzed using a primary anti-IGF-1 antibody (1:2000 in TBST) and anti-IgG AP conjugated secondary antibody (1:5000 in TBST). All antibody incubations were done for 1 hour

at room temperature on a shaker. The membranes were then washed with 3 changes of TBST for 20 minutes each on the shaker. The membranes were developed with the BCIP/NBT alkaline phosphatase substrate (Promega #S3771) for up to 5 minutes. As shown in Figure 8, the *pep3* protease had low MABOI degrading activity at pH 5.5 after overnight incubation at 37°C, but the activity was higher at pH 4.5. The *pep7* protease only had minimal antibody degrading activity at pH 4.5.

Isolation of Additional Aspartic Proteases Using SIP Peptide

[00315] Several additional aspartic proteases were isolated from the *T. reesei* M277 triple protease deletion strain (*pepl*, *tspl*, *slpl*). The M277 strain does not express heterologous proteins. The M277 deletion strain was generated as described in Example 4 below. The strain was grown in *Trichoderma* minimal medium supplemented with 20 g/l spent grain extract, 60 g/l lactose, and 9 g/l casamino acids at pH 5.5 and 28°C. The aspartic proteases were isolated by affinity purification using the SIP peptide (Ac-Phe-Lys-Phe-(AHPPA)-Leu-Arg-NH₂) (Kataoka Y. et al. 2005 FEBS Letters 579, pp 2991-2994). The SIP peptide was conjugated to NHS activated agarose resin (Pierce #26196) using the protocol provided by the manufacturer. The SIP affinity resin was used to purify proteases. Fermentation supernatant (15 ml) from the *T. reesei* M277 strain was then used to batch bind proteases to the resin in 35 ml buffer containing 50 mM sodium acetate, 0.2 M NaCl, pH 3.0 (from fermentation conditions pH 5.5; 28°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose). The column was washed with the same binding buffer and bound protein removed with elution buffer (50 mM Tris-HCL, 1 M NaCl, pH 8.5). Fractions of 0.5 ml were then collected.

[00316] 30 µl of each purified fraction was then run on a 4-15% SDS PAGE gel (BioRad mini-protean TGX precast gel) and stained overnight with GelCode blue (Thermo Scientific). The SDS PAGE gel showed predominate bands around 42 kDa and a faint band around 25 kD (Fig. 9). The bands from the gel were then cut and subjected to in-gel trypsin digestion with sequencing grade modified trypsin (Promega #V5111). The resulting peptides were extracted from the gel and purified by C18 ZipTip (Millipore #ZTC18M096). The purified peptides were analyzed by LC-MS/MS on a QSTAR Pulsar, ESI-hybrid quadrupole-TOF (AB Sciex). This

analysis revealed that PEP2, PEP3, PEP4, and PEP5 were present in the sample along with GAP1 and SLP2. It is believed that the faint band around 25 kD corresponds to the glutamic protease GAP1.

[00317] The SIP purified proteases were then tested for their ability to degrade the MAB01 antibody heavy chain. The purified SIP proteases were incubated overnight with MAB01 at a final concentration of 0.05 $\mu\text{g}/\mu\text{l}$ in sodium citrate buffer at 37°C. The samples were incubated at pH 4.0 and pH 5.5 and both in the presence and absence of an SIP inhibitor peptide. The reactions were sampled after. The collected samples were analyzed by immunoblotting with an anti-IgG heavy chain antibody AP conjugate (Sigma A3188) diluted 1:30,000 in TBST. The results of the immunoblot showed that the proteases had high protease activity against the MAB01 heavy chain when incubated at pH 4.0, and reduced activity at pH 5.5 (Fig. 10). Additionally, both aspartic and glutamic protease activities were inhibited by incubation with the SIP peptide (Fig. 10).

Analysis of SIP-purified aspartic proteases

[00318] Protease activity was then tested against casein both in the presence and absence of protease inhibitors. Protease activity against casein was tested using the EnzChek protease assay kit (Molecular probes #E6638, green fluorescent casein substrate). The working stock solution was prepared by diluting the stock to 10 $\mu\text{g}/\text{ml}$ in 50 mM sodium citrate, pH 5.5. The purified protease fractions (10 μl) were diluted with 40 μl of sodium citrate, pH 5.5. 100 μl of the diluted substrate was combined with the diluted protease fractions in a 96 well sample plate. The plate was then covered and kept at 37°C for one to three hours. Fluorescence readings were taken at one, two, and three hours with a Varioskan fluorescent plate reader (Thermo Scientific) using 485 nm excitation and 530 nm emission.

[00319] The SIP inhibitor peptide, pepstatin A, LIP peptide, SBTI, and chymostatin were used as inhibitors. The SIP inhibitor peptide inhibited both aspartic and glutamic proteases; pepstatin A inhibited only aspartic proteases; LIP peptide only inhibited glutamic protease; SBTI was able to inhibit SLP2 and PEP4, and chymostatin inhibited SLP2. SIP, LIP, and pepstatin A were used

at a concentration of 60 μM , and SBTI was used at a concentration of 200 $\mu\text{g/ml}$. To differentiate between the aspartic and glutamic proteases, pepstatin A was used as inhibitors, as it does not inhibit glutamic proteases.

[00320] When casein digestion was studied, a large portion of the SIP protease activity was inhibited by pepstatin A (Fig. 11). The results from casein degradation studies suggested that a large part of the activity at pH 5.5 in the purified fractions comes from aspartic proteases. The LIP peptide, which is the GAP1 propeptide, inhibited the protease activity slightly less compared to SIP inhibitor. The SBTI and chymostatin were able to inhibit the SLP2 protease in the purified sample.

[00321] These results support the conclusion that there are 4 aspartic proteases present in the SIP fraction (PEP2, PEP3, PEP4, and PEP5).

EXAMPLE 2 - IDENTIFICATION OF GLUTAMIC PROTEASES

[00322] This example demonstrates the ability of glutamic proteases from *Trichoderma reesei* (*T. reesei*) culture supernatants to degrade antibody heavy chains and light chains.

Analysis of *gapl* Deletion

[00323] It has been previously determined that there are four glutamic protease sequences in the *T. reesei* genome. The most abundant glutamic protease is *gapl* (tre69555), as determined by transcriptional profiling. Accordingly, the *gapl* protease was purified from *T. reesei* supernatant from SIP peptide affinity chromatography, as described Example 1.

[00324] A *gapl* deletion was then generated using the *T. reesei* MAB01 antibody production strain M244 (*Apepl*).

*Generation of *gapl* deletion plasmid*

[00325] The deletion pTTv1 17 plasmid for the glutamic protease *gapl* (TreID69555) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1. 1000 bp of 5' flanking region and 1100 bp of 3' flanking region were selected as the basis of the *gapl*

deletion plasmid. Flanking region fragments were produced by PCR using the primers listed in Table 2.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template DNA used in the PCR of the flanking regions was from the *T. reesei* wild type strain QM6a. The *pyr4* blaster cassette was obtained from pTTv71 with *NotI* digestion. The vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *gapl* (pTTv17) resulted in a 1037 bp deletion in the *gapl* locus and covers the complete coding sequence of GAPI.

Table 2.1: Primers for generating *gapl* deletion plasmid.

Deletion plasmid pTTv17 <i>tor gapl</i> (TreID69555), vector backbone pRS426	
Primer	Sequence
JJ-045 primer	GATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAAC ACTCATGAGGGACTATGG (SEQ ID NO: 271)
JJ-046 primer	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCGGCCG CCAAGAAGAGGCAGAGGGTAAT (SEQ ID NO: 272)
JJ-047 primer	CAACCAGCCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGGCCG CTATACATACTGATGATACA (SEQ ID NO: 273)
JJ-048 primer	TGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCGTTTAAA CGCCCATGTATGGACTCTAC (SEQ ID NO: 274)

Generation of MABOI producing ApeplAgapl double deletion strain M296

[00326] To generate the MABOI antibody producing strain for the second protease deletions, the *pepl* deletion strain M181 (Example 1) was transformed with MABOI light and heavy chain constructs (pTTv98+pTTv67) using hygromycin and acetamide in selection. This MABOI strain with the *pepl* deletion was designated with number M244. The removal of the *pyr4* blaster cassette from *pepl* locus was carried out essentially as described in Example 3 below for M195 (in generation of double protease deletion strain M219). This *pyr4*- strain was designated with number M285 and used as the parent for the subsequent protease deletion.

[00327] To remove vector sequence, plasmid pTTv17 (*Agapl-pyr4*) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit

(Qiagen). Approximately 5 µg of the *gapl* deletion cassette was used to transform strain M285 (*pyr4*⁻ of MABOI antibody strain M244, based on *Apepl* strain M181). Preparation of protoplasts and transformation were carried out using *pyr4* selection essentially as described for the *pepl* deletion strains M181 and M195 in Example 1.

[00328] Colonies from the transformation plates were picked as selective streaks. Clones growing fast as selective streaks were screened by PCR using the primers listed in Table 2.2 for the correct integration using standard laboratory methods. Putative disruptants were purified to single cell clones.

Table 2.2: Primers for screening *gapl* integration and strain purity.

For screening integration of pTTvll7	
Primer	Sequence
T052_gapl_5screen_F	CTCAGAAAGGTTGTAGTTGTGA (SEQ ID NO: 275)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 276)
T053_gapl_3screen_R	GATGTTGTGTTTTTCAGTCTGCA (SEQ ID NO: 277)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 278)
For screening deletion of gap/ ORF	
T109_gapl_ORF_F	ATGTTTCATCGCTGGCGTCG (SEQ ID NO: 279)
T110_gapl_ORF_R	CTAAACGTAAGAGCAGGTCAA (SEQ ID NO: 280)

Analysis of MABOI producing ApeplAgapl double deletion strain

[00329] The double deletion strain (*ApeplAgapl*) was grown in a 2 litre shake flask culture containing 300 ml of *Trichoderma* minimal medium supplemented with 40 g/l lactose, 20 g/l spent grain extract, and 9 g/l casamino acids and buffered to pH 5.5 with 100 mM PIPPS. The *Agapl* strain was then tested for MABOI heavy chain and light chain production (Fig. 12). The *Agapl* strain was compared to strains having deletions in each of *slp1*, *slp2*, and *slp3*. The *Apepl* strain M244 was used as a control. Samples were from day 7 large shake flask cultures. Samples were analyzed via immunoblotting with anti-IgG heavy chain (Sigma #A3188) or anti-light chain (Sigma #A3812) antibody AP conjugate (Fig. 12). The *gapl* deletion resulted in a 2-fold improvement in heavy chain production and a 1.6-fold improvement in light chain production as compared to the M244 control strain (Fig. 13).

Analysis of *gap2* Deletion

[00330] Based upon transcriptional profiling data generated from the M194 *Trichoderma reesei* strain, the second most abundant glutamic protease was identified as *gap2* (tre106661). Thus, the *gap2* protease was also deleted from the M244 (*Apepl*) strain using the pTTV145 deletion construct.

Generation of gap2 deletion plasmid

[00331] The pTTV145deletion plasmid for the glutamic protease *gap2* (TreID106661) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1. 1021 bp of 5' flanking region and 1010 bp of 3' flanking region were selected as the basis of the *gap2* deletion plasmid. In this plasmid the direct repeat fragment of the *pyr4* blaster cassette was changed from *pyr4* 5'UTR to 320 bp direct repeat from the end of *gap2* 5' flanking region and no *AscI* site was added between the *pyr4* and the 5' direct repeat. This type of blaster cassette should not leave any additional sequence to the locus of the deleted gene after excision. Fragments were produced by PCR using the primers listed in Table 2.3. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template DNA used in the PCR of the flanking regions was the *T. reesei* wild type strain QM6a. The *pyr4* marker gene was obtained from pHH05 with *NotI* digestion. The vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *gap2* (pTTv145) results in a 944 bp deletion in the *gap2* locus and covers the complete coding sequence of GAP2.

Table 2.3: Primers for generating *gap2* deletion plasmid.

Deletion plasmid pTTv145 for <i>gap2</i> (TreID106661), vector backbone pRS426	
Primer	Sequence
T101_gap2_5flank_F_pRS426	GATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGGTT TAAACGCTACTACGCGAGCAAGTG (SEQ ID NO: 281)
T102_gap2_5flank_R_pyr4	GGAAGTGTGCGCGATTGGGAGAATTCGTGCGATCGCGGCGGC CGCCGGATGAAGATGTGCAGTTG (SEQ ID NO: 282)
T103gap2-loop_F_pyr4	AGGGAACATATCACCTCGGGCATTTCATTTGGTAGGCGGC CGCTAAGATATCTCAAGCTTATGCG (SEQ ID NO: 283)

T104gap2-loop_R	CGGATGAAGATGTGCAGTTG (SEQ ID NO: 284)
T105gap2_3flank_F_loop	TGTCTCACTTCCACCCATCTCAACTGCACATCTTCATCCGAGCA ACAACATGAGGTTTCGAA (SEQ ID NO: 285)
T106_gap2_3ilank_R_pRS426	CCTATGTTGTGTGGAATTGTGAGCGGATAACAATTTACAGTTT AAACACAACGCATGTCCAGCTTTTG (SEQ ID NO: 286)

Generation of MABOI producing ApeplAgap2 double deletion strains M360

[00332] To generate the MABOI antibody producing strain for the second protease deletions, the *pepl* deletion strain M181 (Example 1) was transformed with MABOI light and heavy chain constructs (pTTv98+pTTv67) using hygromycin and acetamide in selection. The removal of the *pyr4* blaster cassette from *pepl* locus was carried out essentially as described in Example 3 below for M195 (in generation of double protease deletion strain M219). This *pyr4*⁻ strain was designated with number M285 and used as the parent for the subsequent protease deletion.

[00333] To remove vector sequence, plasmid pTTv145 (*Agap2-pyr4*) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *gap2* deletion cassette was used to transform strain M285 (*pyr4*⁻ of MABOI antibody strain M244, based on *Apepl* strain M181). Preparation of protoplasts and transformation were carried out using *pyr4* selection essentially as described for the strains M181 and M195 in Example 1.

[00334] Colonies from the transformation plates were picked as selective streaks. Clones growing fast as selective streaks were screened by PCR using the primers listed in Table 2.4 for the correct integration using standard laboratory methods. Putative disruptants were purified to single cell clones.

Table 2.4: Primers for screening *gap2* integration and strain purity.

For screening integration of pTTv145	
Primer	Sequence
T048_gap2_5screen_F	GCTTGGCATCACGGAAGCT (SEQ ID NO: 287)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 288)
T049_gap2_3 screen_R	TTGACAAGAAAGGTCCGTTG (SEQ ID NO: 289)
T028_Pyr4_ilank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 290)

For screening deletion *otgap2* ORF

T107_gap2_ORF_F	ATGGATGCTATCCGAGCCAG (SEQ ID NO: 291)
T108_gap2_ORF_R	CTATTCATACTCAACAGTCACA (SEQ ID NO: 292)

Analysis of MABOI producing ApeplAgap2 double deletion strain

[00335] Several deletion transformants were produced. The culture supernatants from these transformants were run on a 4-15% SDS PAGE gel and then the MABOI antibody heavy chain was analyzed by immunoblotting with an anti-heavy chain AP conjugated antibody (Sigma #A3188), and the light chain was detected with an anti-light chain AP conjugated antibody (Sigma #A3812). The results of the immunoblot show that deleting *gap2* resulted in a several fold increase in MABOI heavy and light chain production (Fig.14).

Analysis of *Pichia* a-expressed *gap2*

[00336] *Pichia* supernatants containing *Trichoderma reesei gap2* were also studied *in vitro*. The *gap2* containing supernatant and MABOI antibody were diluted into sodium citrate buffers adjusted to pH 4.0, 4.5, 5.0, and 5.5, and incubated for 20 hours at 37°C. Samples were taken at 0 minutes and after 20 hours. MABOI heavy chain production was analyzed by immunoblotting using an anti-IgG heavy chain (Sigma #A3188) antibody AP conjugate. The results of the immunoblot show that *gap2* had maximal proteolytic activity against heavy chain MABOI at pH 4.0 (Fig. 15). While the *gap2* protease activity was low at pH 5.5 (Fig. 15), over 4 days it was able to demonstrate significant activity on the heavy chain. The *gap2* protease produced degradation products around 25 kD, indicating that it has proteolytic activity in the heavy chain hinge region.

Example 3 - IDENTIFICATION OF SERINE PROTEASES

[00337] This example demonstrates the ability of serine proteases from *Trichoderma reesei* (*T. reesei*) to degrade antibody heavy chains and light chains.

Serine Protease Purification

[00338] Serine proteases comprise a major family of proteases that have been identified as antibody degrading enzymes. Accordingly, serine proteases were purified from *Trichoderma* supernatant. The serine proteases were first affinity purified from fermentation culture supernatants with a p-aminobenzamidine sepharose 4 fast flow resin (GE healthcare # 17-5123-10). 15 ml of the fermentation culture supernatant was batch bound to the resin in 35 ml of binding buffer (0.05 M Tris-HCL, 0.5 M NaCl, pH 7.4). After packing and washing the column with the same binding buffer, the column was eluted with 0.05 M glycine, pH 3.0. The fractions were then neutralized with 1M Tris HCL, pH 8.8.

[00339] In total 1.7 mg of protein was purified from the affinity column. When the peak fractions were run on a 4-15% SDS-PAGE gel, several major bands (~10 kD, 53 kD, 39 kD, 29 kD) and many more minor bands were seen. The peak fraction protein mixture (F4) was then tested for protease activity by incubating a sample of the F4 with human IgG1 in sodium citrate buffer (50 mM, pH 5.5) at 37°C for 20 hours. The samples were incubated both in the presence and absence of the serine protease inhibitor PMSF (5 mM). The incubated samples were then analyzed by immunoblotting with an anti-IgG heavy chain AP conjugate antibody (Sigma #A3188) and an anti-IgG light chain AP conjugate antibody (Sigma #A3812) diluted 1:30,000 in TBST. The results of the immunoblot showed that the F4 purified protein fraction thoroughly degraded the IgG (Fig. 16). Additionally, treatment with PMSF was able to inhibit most of the degradation, indicating that the protease activity in the F4 fraction that was responsible for the IgG degradation was predominantly serine protease activity.

[00340] In order to identify which proteins in the purified fractions exhibited protease activity, the peak fractions were run on an IgG (0.5 mg/ml MAB02) SDS PAGE zymogram gel (12%). The purified fractions and unpurified supernatant samples were run on the zymogram gel under denaturing conditions. After running the gel, the proteins in the gel were renatured by incubating the gel in 1% triton X-100 to remove the SDS. The zymogram gel was then allowed to incubate overnight in reaction buffer (50 mM sodium citrate, pH 5.5) so that the proteases could degrade IgG in the gel. The gel was then stained with GelCode blue to reveal the extent of IgG staining. Active proteases produced a clear band with no staining (Fig. 17).

[00341] There were two clear bands visible on the IgG gel zymogram at around 29 kD and 65 kD. However, the band at 29 kD was much more predominant suggesting it may be responsible for most of the serine protease activity in the sample. These bands were the only two visible ones in the unpurified supernatant sample, and were more pronounced in the purified fractions (Fig. 17). When the protease sample was pre-treated with PMSF, a known serine protease inhibitor, the clear white bands appeared grey or were not visible, indicating that the bands correspond to serine protease enzymes (Fig. 17).

Identification of the 29 kD Serine Protease TSP1

[00342] From a matched SDS PAGE gel without MAB02, the 29 kD band was cut from the gel and subjected to in-gel trypsin digestion with sequencing grade modified trypsin (Promega #V51 11). In the purified fractions, the 29 kD band was seen as a distinct protein band. This distinct band was then isolated. The resulting peptides were extracted from the gel and purified by CI8 ZipTip (Millipore #ZTC18M096). The purified peptides were analyzed by LC-MS/MS on a QSTAR Pulsar, ESI-hybrid quadrupole-TOF (AB Sciex). The resulting mass analysis clearly identified the 29 kD band as the trypsin-like serine protease TSP1 (tre73897, 35% sequence coverage).

Analysis of *tspl* deletion

[00343] The gene encoding TSP1 (*tspi*) was then deleted from the rituximab antibody production strain M169 to create M183 (*Atspl*). Shake flask cultures were made with M169 and the *tspl* deletion strain transformants to measure the effect on rituximab expression. The cultures were grown in 300 ml of TrMM with 4 g/L lactose, 2 g/L spent grain extract, and 100 mM PIPPS, pH 5.5. Supernatant samples (30 μ l) from day 5 were loaded into a 4-15% SDS PAGE gel and transferred to nitrocellulose for immunoblotting with an anti-heavy chain AP conjugated antibody (Sigma #A3188) diluted 1:10,000 in TBST. Two *tspl* deletion strain transformants showed a clear increase in rituximab heavy chain expression compared to the parent control strain (Fig. 40).

[00344] The deletion construct for the first protease gene, *pepl* (TreID74156), was designed as described above in Example 1.

*Generation of *tspl* deletion plasmids*

[00345] The deletion plasmids for the alkaline trypsin-like serine protease *tspl* (TreID71322/TreID73897, Dienes et al, 2007, Enz Microb Tech 40:1087-1094) were constructed essentially as described for the *pepl* deletion plasmids in Example 1. 953 bp of 5' flanking region and 926 bp of 3' flanking region were selected as the basis of the *tspl* deletion plasmids. As for *pepl*, the first deletion plasmid for *tspl* (pTTv42) used *bar* as the selection marker. The flanking region fragments were produced by PCR using the primers listed in Table 3.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template DNA used in the PCR of the flanking regions was from the *T. reesei* wild type strain QM6a. The *bar* marker was obtained from pTTv41 (Example 1) with *NotI* digestion. The vector backbone was *EcoRVXhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1.

[00346] To clone the second *tspl* deletion plasmid (pTTv72), the *bar* marker was removed from the deletion plasmid pTTv42 with *Noil* digestion. The *pyr4* blaster cassette was obtained from pTTv71 (Example 1) with *Noil* digestion, ligated to *Noil* cut pTTv42 and transformed into *E. coli* using standard laboratory methods. A few transformants were cultivated, plasmid DNA isolated and digested to screen for correct ligation and orientation of the *pyr4* blaster cassette using standard methods. One clone with correct insert size and orientation was sequenced and stored. These deletion plasmids for *tspl* (pTTv42 and pTTv72) result in a 1252 bp deletion in the *tspl* locus and cover the complete coding sequence of TSPL.

Table 3.1: Primers for generating *tspl* deletion plasmids.

Deletion plasmid pTTv42 for <i>tspl</i> (TreID71322/TreID73897), vector backbone pRS426	
Primer	Sequence
T303_71322_5f	GTAACGCCAGGGTTTTCCCAGTCACGACGGTTTAAACTGCTGTTGCTG TTTGTTGATG (SEQ ID NO: 293)

T304_71322_5r_pt	CCCGTCACCGAGATCTGATCCGTCACCGGGATCCACTTAAGCGGCCGC CTGTGGTGAGATCTCCAGACG (SEQ ID NO: 294)
T305_71322_3f_pt	GCCAAGCCCAAAAAGTGCTCCTTCAATATCATCTTCTGTGCGCGGCCGC ACTGTGCCCAACAATAAGCAG (SEQ ID NO: 295)
T306_71322_3r	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACCCAAGGCGCT GGCTGTTA (SEQ ID NO: 296)
Deletion plasmid pTTv72 for <i>tspl</i> (TreID71322/TreID73897), vector backbone pTTv42	
Primer	Sequence
no new primers, pTTv42 digested with NotI and ligated with <i>pyr4</i> -loopout fragment from pTTv71	

*Generation of *pepltspl* double deletion strain M219*

[00347] To reuse *pyr4* as the selection marker, removal of the *pyr4* blaster cassette from the *pepl* deletion strain M195 was carried out. Spores were spread onto minimal medium plates containing 20 g/l glucose, 2 g/l proteose peptone, 1 ml/l Triton X-100, 5 mM uridine and 1.5 g/l 5-FOA, pH 4.8. 5-FOA resistant colonies were picked after 5-7 days to 0.9% NaCl, suspended thoroughly by vortexing and filtrated through a cotton-filled pipette tip. To purify clones to single cell clones, filtrates were spread again onto plates described above. Purified clones were sporulated on plates containing 39 g/l potato dextrose agarose. These clones were tested for uridine auxotrophy by plating spores onto minimal medium plates (20 g/l glucose, 1 ml/l Triton X-100) where no growth was observed, indicating that the selected clones were *pyr4*⁻. All clones were further tested by PCR (using the primers listed in Table 3.2) for the removal of the blaster cassette and were shown to be correct. The clone (9-35A-1A-a) used to generate the double protease deletion strain (M219) was designated with strain number M196 (*Apepl*, *pyr4*⁻).

[00348] To remove vector sequence, plasmid pTTv72 (*Atspl-pyr4*) was digested with *PmeI* and the correct fragment was purified from an agarose gel using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *tspl* deletion cassette was used to transform M196 (*Apepl*, *pyr4*⁻). Preparation of protoplasts and transformation were carried out using *pyr4* selection essentially as described for the *pepl* deletion strains M181 and M195 in Example 1.

[00349] Over 100 colonies were picked and 48 were screened by PCR using the primers listed in Table 3.2 for the correct integration of the deletion cassette and also for the deletion of the *tspl*

ORF using standard laboratory methods. Four putative *Atspl* clones were purified to single cell clones. Deletion of *tspl* was verified by Southern analyses from these clones (Fig. 18A) using standard laboratory methods described in Example 1 for M181 and M195. Southern analyses also indicated that only four transformants (two parallel clones from two transformants, clones 16-5AA, 16-5BA, 16-1 1AA, 16-1 1BA, Figs. 18B and 18C) were single integrants. The other clones were determined to carry additional copies somewhere else in the genome and were discarded. To exclude that the faint signal seen in Figure 18 for the *tspl* ORF in transformants would originate from *tspl* gene, the deletion of *tspl* ORF was confirmed by PCR using the primers in Table 3.2. No signal for *tspl* ORF was obtained. The clone (16-5AA) used in removal of the *pyr4* blaster cassette (and to generate the triple deletion strain M277) was designated with strain number M219 (*Apepl Atspl*).

Generation of MABOI producing Apepl Atspl double deletion strains M252

[00350] To remove vector sequence, plasmid pTTv42 (*Atspl-bar*) was digested with *PmeI* and the correct fragment purified from agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *tspl* deletion cassette was used to transform strain M181 (*Apepl*, Example 1). Preparation of protoplasts and transformation were carried out using *bar* selection essentially as described for the *pepl* deletion strain M182 in Example 1.

[00351] Colonies growing on transformation plates were picked as selective streaks. Clones growing fast as selective streaks were screened by PCR using the primers listed in Table 3.2 for the correct integration using standard laboratory methods. Putative disruptants were purified to single cell clones. Deletion of *tspl* was verified by Southern analyses from these clones (Fig. 19A) using standard laboratory methods described in Example 1 for M181 and M195. All clones were also verified to be single integrants (Figs. 19B and 19C). One double protease deletion clone (13-172D) was designated with number M194.

Table 3.2: Primers for screening removal of *otpyr4* blaster cassette and for screening *tspl* integration and strain purity.**For screening removal *otpyr4* blaster cassette from M195**

T083_74156_5a_seq	GATCGACAAAGGTTCCAGCG (SEQ ID NO: 297)
T084_74156_3a_seq	AATTGTATCATTCGAGGCT (SEQ ID NO: 298)

For screening integration of pTTv42

Primer	Sequence
T307_71322_5int	CTGTTTGGCCCTCGAAACT (SEQ ID NO: 299)
T032_Bar_loppu_for	CATGTTGACCTCCACTAGC (SEQ ID NO: 300)
T308_71322_3int	TTCGCCATCCAAATTTCTTC (SEQ ID NO: 301)
T031_Bar_alku_rev2	GTTTCTGGCAGCTGGACT (SEQ ID NO: 302)

For screening integration of pTTv72

Primer	Sequence
T307_71322_5int	CTGTTTGGCCCTCGAAACT (SEQ ID NO: 303)
T027_Pyr4_orf_start_rev	TGCGTCGCCGTCTCGTCCT (SEQ ID NO: 304)
T308_71322_3int	TTCGCCATCCAAATTTCTTC (SEQ ID NO: 305)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 306)

For screening deletion of *tsp*/ORF

T309_71322_5orfpcr	CCCAAGTCGTCTCAGCTCTC (SEQ ID NO: 307)
T310_71322_3orfpcr	TCGAAGGCTTCAGTGAGGTA (SEQ ID NO: 308)

[00352] The double protease deletion strain M194 was used to generate the MABOI antibody expressing strains M247 and M252 below. Construction of strain M247 was carried out by transforming M194 with MABOI heavy and light chain constructs (pTTvl01 + pTTvl02). Strain M252 was constructed by transforming M194 with MABOI heavy and light chain constructs (pTTv99 + pTTv67). Both transformations were based on hygromycin and acetamide selection.

Analysis of MABOI producing ApeplAtspl double deletion strain M252

[00353] The MABOI antibody producing double deletion strain (*ApeplAtspl*) was shown to produce 261 mg/1 antibody, with 43% full length antibody, when grown in a fermentor. The protease activity of the strain was then tested by growing the strain in *Trichoderma* minimal medium supplemented with 20 g/1 spent grain extract, 60 g/1 lactose, and 9 g/1 casamino acids at pH 5.5 and 22°C. The total protease activity against casein in this strain was determined to be 2.0-fold less than the wild type M124 strain (Fig. 20).

Identification of the 65 kD Serine Protease SLP1

[00354] The protease producing the activity around 65 kD was more difficult to identify due to its low expression level and proximity in size to several highly expressed proteins. The highly expressed proteins were previously identified to be CBHI, CBHII, CIP2, and xylanase 4. Improvements were made to better separate the 65 kD protease from the highly expressed proteins. The improvements included using a lower gel percentage (7%) SDS PAGE gel for zymogram and standard SDS PAGE gels to run the samples a longer time so that the 54 kD molecular weight marker was at the bottom of the gels. Additionally, fermentation supernatant from a *T. reesei* rituximab antibody transformant was also used to purify the serine proteases. The rituximab antibody transformant is strain M169, which produces rituximab and lacks protease deletions. The strain was grown in *Trichoderma* minimal medium supplemented with 20 g/l spent grain extract and 60 g/l lactose at pH 5.5 and 28°C. The CBHI produced in this culture lacks the cellulose binding domain; therefore it is around 10 kD smaller. However, M169 did not show a distinct band corresponding to the 65 kD protease (Fig. 21). Thus, the general region was cut and subjected to in-gel trypsin digestion with sequencing grade modified trypsin (Promega #V5111). The resulting peptides were extracted from the gel and purified by C18 ZipTip (Millipore #ZTC18M096). The purified peptides were analyzed by LC-MS/MS on a QSTAR Pulsar, ESI-hybrid quadrupole-TOF (AB Sciex).

[00355] The peptide analysis showed that the second highest scoring protein was the protease tre51365. The top scoring protein was xylanase4, which was a contaminant in the sample. The tre51365 subtilisin protease, now called SLP1, was found in 3 independent samples from three separate purifications. In the best scoring sample, 6 peptides were found and sequenced by LC-MS/MS. The sequence coverage was 8%, since the native protease gene codes for 882 amino acids that compose a 93 kD protease. In gelatin zymography, a weak band at -90 kD could be seen along with smearing down to 65 kD suggesting that the SLP1 protease itself undergoes proteolysis but retains much of its activity.

Generation of sip1 deletion plasmid

[00356] The gene encoding SLP1 (*slpl*) was then deleted in the MAB01 antibody production strain M244 (*Apepl*).

[00357] The deletion plasmid for the subtilisin-like protease *slpl* (TreID51365) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1. 1094 bp of 5' flanking regions and 1247 bp of 3' flanking region were selected as the basis of the *slpl* deletion plasmid. Fragments were produced by PCR using the primers listed in Table 3.3. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template used in the PCR of the flanking regions was from the *T. reesei* wild type strain QM6a. The *pyr4* blaster cassette was obtained from pTTv71 (Example 1) with *NotI* digestion. The vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *slpl* (pTTv126) results in 2951 bp deletion in the *slpl* locus and covers the complete coding sequence of SLPL.

Table 3.3: Primers for generating *slpl* deletion plasmid.

Deletion plasmid pTTv126 for <i>slpl</i> (TreID51365), vector backbone pRS426	
Primer	Sequence
5flankfw_vect	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACATCTCGGAGT GATGCTTCCT (SEQ ID NO: 309)
slpl_5flankrev_pyr4Pro m	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCGGCC GCATCAGACGAAACCAGACGAG (SEQ ID NO: 310)
slp1_3flankfw_pyr4Term	CAACCAGCCGAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGGCCG CGCGAATCGAGTTGATGATTC (SEQ ID NO: 311)
3flankrev_vect	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACCTGGTTGGGA TCTGACCACT (SEQ ID NO: 312)

Generation of MAB01 producing ApeplAspl deletion strain M298 and M299

[00358] To generate the MAB01 antibody producing strain for the second protease deletions, the *pepl* deletion strain M181 (in Example 1) was transformed with MAB01 light and heavy chain constructs (pTTv98+pTTv67) using hygromycin and acetamide in selection. The removal of the *pyr4* blaster cassette from *pepl* locus was carried out essentially as described for M195

above (in generation of double protease deletion strain M219). This *pyr4*- strain was designated with number M285 and used as the parent for the subsequent protease deletion.

[00359] To remove vector sequence, plasmid pTTv126 (*Aslpl-pyr4*) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *slpl* deletion cassette was used to transform M285 (*pyr4*⁻ of MAB01 antibody strain M244, based on *Apepl* strain M181). Preparation of protoplasts and transformation were carried out using *pyr4* selection essentially as described for the *pepl* deletion strains M181 and M195 in Example 1.

[00360] Colonies growing on transformation plates were picked as selective streaks. Clones growing fast as selective streaks were screened by PCR using the primers listed in Table 3.4 for the correct integration using standard laboratory methods. Putative disruptants were purified to single cell clones.

Table 3.4: Primers for screening *slpl* integration and strain purity.

For screening integration of pTTv126	
Primer	Sequence
T079_slpl_scrn_5forw	GCAGACAAACAGAGCAACGA (SEQ ID NO: 313)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 314)
T080_slpl_scrn_3rev	TAGAGGGTGTCGATGGAAGC (SEQ ID NO: 315)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 316)
For screening deletion of slp/ORF	
T081_slpl_orf_fw	GGTCTCTTCTTTGCCAGCAC (SEQ ID NO: 317)
T082_slpl_orf_rev	TGTCGCTGAACTGAATTTGC (SEQ ID NO: 318)

Analysis of MAB01 producing ApeplAslpl double deletion strain M298/M299

[00361] Deletion of *slpl* in the M244 strain showed an expected improvement in heavy and light chain production (Figs. 12 and 13). The *slpl* deletion strain (*ApeplAslpl*) was grown in a 2 litre shake flask culture containing 300 ml of *Trichoderma* minimal medium supplemented with 40 g/l lactose, 20 g/l spent grain extract, and 9 g/l casamino acids and buffered to pH 5.5 with 100 mM PIPPS. As described in Example 2 above, the culture supernatants were run on a 4-15%

PAGE gel and immunoblotted to detect the MAB01 heavy and light chain. The heavy chain was produced at levels that were 2.8-fold higher than the production levels of the M244 parent strain (Fig. 13). The light chain was produced at levels that were 1.8-fold higher than the production levels of the M244 parent strain (Fig. 13).

Identification of Additional Serine Proteases

[00362] Additional antibody degrading serine proteases were identified using other affinity ligands. The soybean trypsin inhibitor (SBTI) effectively stabilizes the antibody heavy and light chain. Therefore, it is able to inhibit proteases that are responsible for cleaving the antibody. Thus, in order to identify these proteases, affinity purification was performed with SBTI coupled to agarose (Sigma #T0637).

[00363] The *T. reesei* strain M44 was used to identify the proteases. The M44 strain is a wild type strain with no heterologous protein expression. The M44 strain was grown in *Trichoderma* minimal medium supplemented with 20 g/l spent grain extract and 60 g/l lactose at pH 5.5 and 28°C. A 20 ml sample of M44 culture supernatant from a 217 hour sample was incubated with the SBTI-agarose affinity resin (1 ml) in 30 ml of binding buffer (50 mM Tris, 0.5 M NaCl, pH 7.5) (pH 5.5; 28°C; 20 g/L spent grain extract, 60 g/L lactose). The supernatant binding buffer mixture was combined in a 50 ml conical tube and agitated at room temperature for 1 hour. The mixture was then added to a glass column and washed with 200 ml of binding buffer. 50 ml of high salt buffer (1 M NaCl) was next used to further remove nonspecific interactions. Finally, the column was washed again with 100 ml of the original binding/wash buffer. The column was then eluted with 0.8 M benzamidine HCl in 50 mM Tris, pH 5.0. The fractions were collected in 0.5 ml volumes and subjected to a protein assay using BioRad Bradford reagent with bovine immunoglobulin as a standard.

[00364] From all the fractions collected, 190 µg of protein was purified from the SBTI affinity column. The peak fraction was washed in a vivaspin ultrafiltration spin filter (Sartorius-stedim) with 10 kD molecular weight cutoff to remove the benzamidine inhibitor and concentrate the fraction. The concentrated fractions (cf3 and cf4) and nonconcentrated fractions (fl-f4) were

loaded on an MAB02 zymogram gel (as described above) and on a regular SDS PAGE gel for analysis. The results of the zymogram show that there are two visible proteolytic activities (Fig. 22). The most predominant band was visible around 40 kD and a fainter band was visible around 26 kD (Fig. 22). In the zymogram gel, darker staining protein bands flanked the white zymogram activity band. Comparing this to concentrated fractions loaded on an SDS PAGE gel, these doublet bands could be seen around 38 kD (Fig. 23). The PAGE gel was a 4-15% gradient gel and the zymogram gel was 12%, so the relative sizes can be slightly different. On the PAGE gel, a protein band could clearly be seen in the area of 26 kD, which corresponded to the size of the second fainter zymogram activity.

[00365] To further analyze the proteolytic activity of the purified protease of cf3, the fraction was tested for its ability to degrade the rituximab antibody heavy chain. A 5 μ l sample of cf3 was incubated in sodium citrate buffer pH 5.5 with 0.05 μ g/ml rituximab. The incubated samples were then analyzed by immunoblotting using an anti-human IgG heavy chain-specific AP conjugated antibody (Sigma #A3188) diluted 1:30,000 in TBST. The results of the immunoblot show that the proteases immediately degraded the rituximab antibody heavy chain. The full length rituximab heavy chain runs at just over 50 kD, while the initial degradation product was around 45 kD (Fig. 24). Additionally, incubation overnight generated an additional product of 38 kD (Fig. 24).

[00366] The proteases responsible for the zymogram activities were identified after LC-MS/MS peptide sequencing. Protein containing gel sections were cut out of the SDS PAGE gel shown in Figure 23 and subjected to in-gel trypsin digestion with sequencing grade modified trypsin (Promega #V5111). The resulting peptides were extracted from the gel and purified by C18 ZipTip (Millipore #ZTC18M096). The purified peptides were analyzed by LC-MS/MS on a QSTAR Pulsar, ESI-hybrid quadrupole-TOF (AB Sciex).

[00367] The top scoring protease hit was the subtilisin like protease, *slp2* (trsl 23244). Two peptides from *slp2* were found and sequenced, covering 6% of the entire sequence length. The full length *slp2* protease is 58 kD, but it is usual that the active protease can be smaller in size.

[00368] There were also other proteases found in adjacent regions. Analysis of the lower 26 kD region identified the trypsin serine-like protease *tspl* (tre73897). This corresponded to the faint zymogram activity observed. As described above, this protease was identified via aminobenzamidine affinity purification.

[00369] In addition, the whole SBTI affinity purified fraction was trypsin digested in solution to determine the entire protease content of the sample. Other identified proteases included the tre123865 protease *slp7* (60 kD); the tre77579 protease *pep4* (42 kD); and the tre58698 protease *slp8* (41 kD).

[00370] The *Trichoderma reesei* subtilisin proteases *slp5*, *slp6*, and *slp7* were overproduced in *Pichia* supernatants for investigation of their activity against the antibody rituximab and MABOI heavy chains (Fig. 25). The rituximan mock supernatant was compared to supernatants containing *slp5* and *slp6* (Fig. 25A). The MABOI mock supernatant was compared to supernatants containing *slp7* (Fig. 25B). Rituximab and MABOI were added to the protease-containing *Pichia* supernatants and incubated overnight at 37°C. Samples were taken and analyzed by immunoblotting with an anti-heavy chain AP conjugated antibody. This analysis revealed that the *slp6* protease showed heavy degradation activity on the rituximab heavy chain and light degradation of the MABOI, compared to the mock control supernatants (Fig. 25).

Generation of slp2 and sip3 deletion plasmids

[00371] Based on the above results, the *slp2* and *slp3* protease genes were each deleted from the MABOI antibody producing strain M244.

[00372] The deletion plasmids for the subtilisin-like proteases *slp2* (TreID 123244) and *slp3* (TreID 123234) were constructed essentially as described for *pep1* deletion plasmid pTTv41 in Example 1. 1000 bp of 5' and 1100 bp of 3' flanking regions were selected as the basis of the *slp2* deletion plasmid. For *slp3*, 1000 bp of 5' and 1100 bp of 3' flanking regions were selected. Fragments were produced by PCR using the primers listed in Table 3.5. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template used in the PCR of

the flanking regions was from the *T. reesei* wild type strain QM6a. The *pyr4* blaster cassette was obtained from pTTv71 (Example 1) with *NotI* digestion. The vector backbone was *EcoRVXhoI* digested pRS426 as in Example 1. The plasmids were constructed using the yeast homologous recombination method described in Example 1. The deletion plasmid for *slp2* (pTTvll5) results in a 2114 bp deletion in the *slp2* locus and covers the complete coding sequence of SLP2. The deletion plasmid for *slp3* (pTTvll6) results in a 1597 bp deletion in the *slp3* locus and covers the complete coding sequence of SLP3.

Table 3.5: Primers used for plasmids.

Deletion plasmid pTTvll5 for <i>slp2</i> (TreID123244), vector backbone pRS426	
Primer	Sequence
JJ-037 primer	GATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAA CGCAGTCTATCCCATCCCTG (SEQ ID NO: 319)
JJ-038 primer	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCGGCC GCGCGGATGATGAAGGAAGAAG (SEQ ID NO: 320)
JJ-039 primer	CAACCAGCCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGGCCG CAACAGCTGTTTCGCACGCGTG (SEQ ID NO: 321)
JJ-040 primer	TGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCGTTTAAA CGGCTGGGCATTGGGGCCG (SEQ ID NO: 322)
Deletion plasmid pTTvll6 for <i>slp3</i> (TreID123234), vector backbone pRS426	
Primer	Sequence
JJ-041 primer	GATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAA CAAACAAGGCACAAAGGCCTG (SEQ ID NO: 323)
JJ-042 primer	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCGGCC GCATCCAAGGATGAGGAGAAC (SEQ ID NO: 324)
JJ-043 primer	CAACCAGCCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGGCCG CACCTAATGGTTTCTTCGTTTTTC (SEQ ID NO: 325)
JJ-044 primer	TGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCGTTTAAA CCGGTCCGAAGGGTGTTTTGG (SEQ ID NO: 326)

Generation of MAB01 producing ApeplAslp2 and ApeplAslp3 deletion strains M292 and M295

[00373] To generate the MAB01 antibody producing strain for the second protease deletions, the *pepl* deletion strain M181 (in Example 1) was transformed with MAB01 light and heavy chain constructs (pTTv98+pTTv67) using hygromycin and acetamide in selection. The removal of the *pyr4* blaster cassette from *pepl* locus was carried out essentially as described for M195

above (in generation of double protease deletion strain M219). This *pyr4*- strain was designated with number M285 and used as the parent for the subsequent protease deletions.

[00374] To remove vector sequence, plasmids pTTv1 15 (*Aslp2-pyr4*) and pTTv1 16 (*Aslp3-pyr4*) were digested with *PmeI* and the correct fragments purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of either deletion cassette was used to transform M285 (*pyr4*⁻ of MAB01 antibody strain M244, based on *Apepl* strain M181) separately. Preparation of protoplasts and transformation were carried out using *pyr4* selection essentially as described for the *pepl* deletion strains M181 and M195 in Example 1.

[00375] Colonies growing on transformation plates were picked as selective streaks. Clones growing fast as selective streaks were screened by PCR using the primers listed in Table 3.6 for the correct integration using standard laboratory methods. Putative disruptants were purified to single cell clones. No pure clones were obtained even after repeated purification steps.

Table 3.6: Primers for screening *slp2* (pTTvll5) and *slp3* (pTTvll6) integration and strain purity.

For screening integration of pTTvll5

Primer	Sequence
T054_slp2_5screen_F	GATGCACCGCTGCGGCC (SEQ ID NO: 327)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 328)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 329)
T055_slp2_3screen_R	GGCGTTGCTCCCCATGCG (SEQ ID NO: 330)

For screening deletion of *slp2* ORF

T111_slp2_ORF_F	ATGCGGTCCGTTGTCGCC (SEQ ID NO: 331)
T112_slp2_ORF_R	TTACTCGGAGAGCTCAGAGA (SEQ ID NO: 332)

For screening integration of pTTvll6

Primer	Sequence
T056_slp3_5screen_F	GTGAATGGGTGGCAACATGA (SEQ ID NO: 333)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 334)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 335)
T057_slp3_3 screen_R	CATCAAGTTGACCACCATTGT (SEQ ID NO: 336)

For screening deletion of *slp3* ORF

T113_slp3_ORF_F	ATGCGGTGTCGTCCTCC (SEQ ID NO: 337)
T114_slp3_ORF_R	TTAACCGGAAGGGTTGCCGT (SEQ ID NO: 338)

Analysis of MABOI producing ApeplAslp2 and ApeplAslp3 double deletion strains M292 and M295

[00376] The M292 strain (*Apepl Aslp2*) and M295 strain (*ApeplAslp3*) were grown along with their sister transformants in a 2 liter shake flask culture containing 300 ml of *Trichoderma* minimal medium supplemented with 40 g/l lactose, 20 g/l spent grain extract, and 9 g/l casamino acids and buffered to pH 5.5 with 100 mM PIPPS. The culture supernatants were run on a 4-15% SDS PAGE gel and immunoblot analysis was performed to detect the MABOI heavy chain and light chain. The results show that both deletions improved MABOI stability (Figs. 12 and 13). The *Aslp2* deletion improved MABOI heavy chain expression in shake flask culture by about 2.4-fold on day 7, as compared to the parent M244 strain (Fig. 13). The *Aslp3* improved MABOI heavy chain expression in large shake flasks by about 1.5-fold and MABOI light chain expression by about 1.7-fold as compared to the M244 parent strain (Fig. 13). Moreover, when compared to *Aslp3* and *Agapl*, *Aslp2* showed the highest fold increased in MABOI heavy chain expression relative to MABOI heavy chain expression in the M244 parent strain (Fig. 13).

[00377] When *slp2* was deleted from the M306 multiple deletion strain (*Apepl Atspl Aslpl*), deletion of *slp2* resulted in a reduction in sporulation and slower growth as compared to the parent strain.

Example 4 — TRICHODERMA MULTIPLE PROTEASE DELETION STRAINS

[00378] This example demonstrates increased antibody production and stability from *Trichoderma reesei* (*T. reesei*) strains containing multiple deletions of the protease genes identified above in Examples 1-3.

Generation of Triple Deletion Strain *Apepl Atspl Aslpl*

[00379] A *T. reesei* strain having a triple deletion *Apepl Atspl Aslpl* was generated and tested for improvement in antibody production. The strain was also used for further rounds of protease deletions.

Generation of triple protease deletion strain M277

[00380] To generate a marker-free triple protease deletion strain, the looping out of the *pyr4* marker was applied to strain M219 essentially as described above for looping out *pyr4* from the single protease deletion strain *Apepl*. Three consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells. Final clones were verified for the looping out of *pyr4* by PCR (using the primers listed in Table 3.1); no specific signals were seen with primers annealing with the looped out part of the *pyr4*. The looping out was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. The clone used to generate the triple protease deletion strain was designated with strain number M228 (*Apepl Atspl, pyr4⁻*).

[00381] The deletion plasmid pTTv126 for the third protease gene, subtilisin-like protease *slpl* (TreID51365) is described above (Table 3.3). This deletion plasmid results in 2951 bp deletion in the *slpl* locus and covers the complete coding sequence of SLPL

[00382] To remove vector sequence, plasmid pTTv126 (*Aslpl-pyr4* loopout) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *slpl* deletion cassette was used to transform M228 (*Apepl Atspl, pyr4⁻*) above. Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00383] 200 clones were picked as first streaks. 48 of these streaks were screened by PCR using the primers listed in Table 4.1 for the correct integration using standard laboratory methods. Five putative triple protease disruptants (*Apepl Atspl Aslpl*) were purified to single cell clones. Deletion of *slpl* was verified by Southern analyses of the five clones (Fig. 26A). Southern analyses were performed as described in Example 1. Southern analyses also verified that three of the clones were single integrants (Figs. 26B and 26C). The two other clones were shown to carry additional copies somewhere else in the genome and were discarded. The clone used in removal of the *pyr4* blaster cassette (and to generate the quadruple protease deletion strain M307 below) was designated with strain number M277 (*Apepl Atspl Aslpl*).

Table 4.1: Primers for screening removal of *pyr4* blaster cassette and for screening *slpl* integration and strain purity.**For screening removal *otpyr4* blaster cassette from M219**

Primer	Sequence
T307_71322_5int	CTGTTTGGCCCTCGAAACT (SEQ ID NO: 339)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 340)
T308_71322_3int	TTCGCCATCCAAATTTCTTC (SEQ ID NO: 341)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 342)

For screening integration of pTTv126

Primer	Sequence
T079_slpl_scrn_5forw	GCAGACAAACAGAGCAACGA (SEQ ID NO: 343)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 344)
T080_slpl_scrn_3rev	TAGAGGGTGTGCATGGAAGC (SEQ ID NO: 345)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 346)

For screening deletion of *slplORF*

T081_slpl_orf_fw	GGTCTCTTCTTTGCCAGCAC (SEQ ID NO: 347)
T082_slpl_orf_rev	TGTCGCTGAACTGAATTTGC (SEQ ID NO: 348)

Generation of MABOI producing triple protease deletion strain M304

[00384] To generate the MABOI antibody producing strain for the third protease deletion, the *pepltspl* double protease deletion strain M194 (Example 3) was transformed with MABOI light and heavy chain constructs (pTTv99+pTTv67) using hygromycin and acetamide in selection. This MABOI strain with *pepl/tspl double* deletion was designated with number M252. Removal of the *pyr4* blaster cassette from *pepl* locus was carried out essentially as described in Example 3 for M195 (in generation of double protease deletion strain M219). This *pyr4*⁻ strain was designated with number M284 and used as the parent for the subsequent protease deletion.

[00385] The third protease deletion to M284 was obtained by using *slpl* deletion construct pTTv128. This construct contains a native KEX2 overexpression cassette targeted to the *slpl* locus. Transformation was carried out essentially according to the protocol described in Example 1 for the strains M181 and M195 using *pyr4* selection. The resulting strain is the MABOI producing triple protease deletion strain M304.

Analysis of MAB01 producing Triple Protease Deletion Strain M304

[00386] The triple protease deletion (*ApeplAtsplAslpl*) MAB01 antibody producing strain M304 was shown to produce the MAB01 antibody at yields of up to 3.5 g/L in culture (pH 5.5; 28-→22°C; 60 g/L spent grain, 30 g/L glucose, 60 g/L lactose + lactose feed), and product quality up to 84% of full length IgG (see Example 6 below). The protease activity of the strain was also tested by growing the strain in *Trichoderma* minimal medium supplemented with 60 g/l solid spent grain, 30 g/l glucose, and 60 g/l lactose at pH 5.5. The culture was grown up at 30°C and then shifted to 22°C for the production phase. The fedbatch cultivation was done with a lactose feed. The total protease activity against casein in this strain was determined to be about 3.2-fold less compared to the wild type strain M124 (Fig. 20).

Comparison of Single, Double, and Triple Deletion Strains

[00387] The relative protease activity of culture supernatants from the single protease deletion (*Apepl*) strain M181 (see Example 1), the double protease deletion (*ApeplAtspl*) strain M219 (see Example 3), and the triple protease deletion (*ApeplAtsplAslpl*) strain M277 were compared. These deletion strains were compared to the wild type strain M124. The three protease deletion strains were grown in 2 liter shake flasks with 300 ml TrMM containing 40g/l lactose, 20 g/l spent grain extract, and 100 mM PIPPS at pH 5.5. Samples were taken on days 3, 5, 7, and 10. Day 7 culture supernatant samples from M124, M181, M219, and M277 were each diluted 1:2 in sodium citrate buffer (50 mM, pH 5.5) and 30 µl were loaded on a 12% zymogram SDS PAGE gel containing MAB02. The SDS PAGE gel was run at 100V for 45 minutes. The gel was then incubated in 2.5% Triton X-100 for one hour, before being washed several times with the reaction buffer (50 mM sodium citrate, pH 5.5). The zymogram gel was then left overnight shaking in the reaction buffer. The next morning the gel was stained with GelCode Blue staining reagent. Regions where the MAB02 antibody has been degraded showed up as white spots on the blue stained gel.

[00388] Two protease activities were seen in the control M124 and the M181 *Apepl* samples (Fig. 27). The most predominate activity was seen between 65-90 kD, which corresponds to *slpl*.

A fainter activity was seen around 28 kD, which corresponds to *tspl*. As was expected, the M219 *ApeplAtspl* strain did not produce a zymogram band at 28 kD. Likewise, the M277 *ApeplAtsplAslpl* strain did not produce either zymogram activity. The active size of *slpl* appears to be variable, since it was still active when it was cleaved down to 65 kD even though its mature size is 90 kD. The size variation can be seen in Figure 27.

[00389] The total protease activity against succinylated casein from supernatant cultures of the M181, M219, and M277 deletion strains was also measured from day 3, day 5, and day 7 samples. The supernatants were first diluted to 2 mg/ml total protein in 50 mM sodium citrate, pH 5.5 before being assayed. 50 μ l of diluted supernatant was loaded into a 96 well plate and 50 μ l of succinylated casein was added to begin the reaction. A background control with buffer instead of casein was used for each sample. After the addition of casein the protease reaction was allowed to proceed for 1 hour at 37°C. To develop the reaction 50 μ l of TNBSA reagent was added to every well and the plate incubated for 16 hours at 37°C. The absorbance at 450 nm was measured for the whole plate. The nonspecific background signal is subtracted from specific protease activity measurement. As shown in Figure 28, the supernatant samples from the three protease deletion strains contained less protease activity than the M124 wild type strain.

[00390] The supernatant from the M277 and M124 cultures (day 5 and 7) was diluted to 6 mg/ml in 50 mM sodium citrate buffer. To these diluted supernatants the MABOI antibody was spiked in to a final concentration of 0.05 μ g/ μ l. These reactions were incubated at 37°C overnight. The reactions were sampled at zero time, 1 hour, and over overnight incubation. The 20 μ l samples were loaded into a 4-15% SDS PAGE gel and run at 200 volts for 40 minutes. The gel was transferred at 100 volts for 1 hour to nitrocellulose for immunoblotting. The membrane was blocked with 5% milk in TBST for one hour. The heavy chain of MABOI was detected with an anti-heavy chain AP conjugated antibody (Sigma #A3188) diluted 1:30,000 in TBST. After washing the membrane with TBST, the blot was developed with AP substrate (Promega). Comparing the overnight incubated samples it was clearly evident that the heavy chain degraded more in the M124 strain supernatant. The M124 contains no protease deletions. With 3 protease deletions, the M277 strain produced MABOI heavy chain that was significantly stable. On day 5,

there was 2.5-fold more heavy chain in the M277 supernatant after overnight incubation. With the day 7 supernatant, there was 4-fold more heavy chain visible (Fig. 41).

Quadruple Deletion Strain M307

[00391] The M307 strain having a quadruple deletion *Apepl Atspl Aslpl Agapl* was generated and used for further rounds of protease deletions.

Generation of quadruple protease deletion strain M307

[00392] To generate a marker-free quadruple protease deletion strain, removal of the *pyr4* blaster cassette was applied to strain M277 essentially as described in Example 3 for removal of the *pyr4* blaster cassette from the single protease deletion strain M195 (*Apepl*). Three consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells. Final clones were verified for the removal of the blaster cassette by PCR using the primers listed in Table 4.2 with standard laboratory methods. No specific signals were seen with primers annealing with the removed part of the *pyr4*. Removal was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. The clone used to generate the quadruple protease deletion strain was designated with strain number M306 (*Apepl Atspl Aslpl, pyr4⁻*).

[00393] The deletion plasmid pTTv1 17 for the fourth protease gene, glutamic protease *gapl* (TreID69555) is described in Example 2 (Table 2.1). This deletion plasmid results in a 1037 bp deletion in the *gapl* locus and covers the complete coding sequence of GAPI.

[00394] To remove vector sequence, plasmid pTTv1 17 (*Agapl-pyr4*) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *gapl* deletion cassette was used to transform M306 (*Apepl Atspl Aslpl, pyr4⁻*) above. Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00395] 150 clones were picked as first streaks. 48 of these streaks were screened by PCR using the primers listed in Table 4.2 for the correct integration using standard laboratory methods. Eight putative quadruple protease disruptants (*ApeplAtsplAslplAgapl*) were purified to single cell clones. Deletion of *gapl* was verified by Southern analyses of the eight clones (Fig. 29A). Southern analyses were performed as described in Example 1. Southern analyses also verified that three of the clones were single integrants (Figs. 29B and 29C). The five other clones were shown to carry additional copies somewhere else in the genome and were discarded. The clone used in removal of the *pyr4* blaster cassette (and to generate the quintuple protease deletion strain M369 below) was designated with strain number M307 (*ApeplAtsplAslplAgapl*).

Table 4.2: Primers for screening removal of *pyr4* blaster cassette and for screening *gapl* integration and strain purity.

For screening removal of <i>pyr4</i> blaster cassette from M277	
Primer	Sequence
T079_slpl_scrn_5forw	GCAGACAAACAGAGCAACGA (SEQ ID NO: 349)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 350)
T080_slpl_scrn_3rev	TAGAGGGTGTTCGATGGAAGC (SEQ ID NO: 351)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 352)
For screening integration of pTTvll7	
Primer	Sequence
T052_gapl_5screen_F	CTCAGAAAGTTGTAGTTGTGA (SEQ ID NO: 353)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 354)
T053_gapl_3screen_R	GATGTTGTGTTTTTCAGTCTGCA (SEQ ID NO: 355)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 356)
For screening deletion of <i>gapl</i> ORF	
T109_gapl_ORF_F	ATGTTTCATCGCTGGCGTCG (SEQ ID NO: 357)
T110_gapl_ORF_R	CTAAACGTAAGAGCAGGTCAA (SEQ ID NO: 358)

Generation of MAB01 producing quadruple protease deletion strain M371

[00396] To generate quadruple protease deletion strain with MAB01 antibody production, removal of the *pyr4* blaster cassette from *slpl* locus from strain M304 was carried out essentially as described in Example 3 for M195 (in generation of double protease deletion strain M219).

This *pyr4⁻* strain was designated with number M317 and used as the parent for the subsequent protease deletion.

[00397] The fourth protease deletion to M317 was obtained by using *gapl* deletion construct pTTv1 17 above. Transformation was carried out essentially according to the protocol described in Example 1 for the strains M181 and M195 using *pyr4* selection. The resulting strain is the MAB01 producing quadruple protease deletion strain M371.

Analysis of quadruple protease deletion strain

[00398] The total protease activity of culture supernatant from the quadruple deletion strain M307 was then measured and compared with culture supernatants from the triple deletion strain M277 and the wild type strain M124. Each strain was grown in 2 liter shake flasks with 300 ml TrMM containing 40 g/l lactose, 20 g/l spent grain extract, and 100 mM PIPPS at pH 5.5. Day 7 supernatant samples were taken for total protease assay. The total protein concentrations of the supernatants were measured using the BCA assay with bovine immunoglobulin as the standard. The supernatants were diluted serially 1:2 in sodium citrate buffer at pH 5.5. The diluted supernatants were added to fluorescently labeled casein substrate and incubated at 37°C. The fluorescence was measured after 1 hour at 485 nm excitation and 530 nm emission. The results showed that rate of protease activity of the triple deletion strain M277 was 3 times less than the wild type strain M124 and the quadruple deletion strain M307 was 8 times less than the wild type strain M124 (Fig. 30).

[00399] Additionally, Figure 20 summarises the total protease activity against casein from the M188 single deletion strain, the M219 double deletion strain, the M277 triple deletion strain, and the M307 quadruple deletion strain as compared to the wild type M124 strain. The *pepl* single deletion reduced the protease activity by 1.7-fold, the *pepl/tspl* double deletion reduced the protease activity by 2-fold, the *pepl/tspl/slpl* triple deletion reduced the protease activity by 3.2-fold, and the *pepl/tspl/slpl/gapl* quadruple deletion reduced the protease activity by 7.8-fold compared to the wild type M124 strain (Fig. 20).

[00400] The MAB01 antibody producing strain M371 contains a quadruple deletion *Apepl Atspl Aslpl Agapl*. The strain was grown in the fermentor and compared to the triple deletion MAB01 producing strain under the same conditions. The batch cultivation was performed with the M371 strain that produced MAB01 and was with *pepl*, *tspl*, *slpl*, and *gapl* protease deletions and *kex2* overexpression. The strain was grown in *Trichoderma* minimal medium supplemented with 40 g/1 solid spent grain, 40 g/1 glucose, and 40 g/1 lactose at pH 5.5. The culture was grown up at 30°C and then shifted to 22°C for the production phase. The batch cultivation was performed with the M304 strain that produced MAB01 and was with *pepl*, *tspl*, and *slpl* protease deletions and *kex2* overexpression. The strain was grown in *Trichoderma* minimal medium supplemented with 40 g/1 solid spent grain, 40 g/1 glucose, and 40 g/1 lactose at pH 5.5. The culture was grown up at 30°C and then shifted to 22°C for the production phase.

[00401] The full length antibody yield calculated was 20% higher in the *gapl* deletion strain from the day 6 sample. Under the same conditions, the quadruple deletion strain produced 1.9 g/L (897 mg/L full length antibody) and the triple deletions strain produced 1.3 g/L (731 mg/L full length antibody). From the fermentor supernatants, the total protease activity against casein was measured. The supernatant samples were diluted in sodium citrate buffer pH 5.5 so that the total protein concentration was 0.15 mg/ml for all samples. To this diluted supernatant 10 µg/ml BODIPY casein was added to begin the protease assay. Samples from each day of the cultivation were compared between the two different strains. The results show that there was up to 30% less total protease activity in the *gapl* deletion strain on day 5 (Fig. 31). On day 6, the protease activity was 20% lower, which correlates to the 20% improvement in antibody yield on that day.

Quintuple Deletion Strain

[00402] The M369 strain having a quintuple deletion *Apepl Atspl Aslpl Agapl Agap2* was generated and used for further rounds of protease deletions.

Generation of quintuple protease deletion strain M369

[00403] To generate a marker-free quintuple protease deletion strain, removal of the *pyr4* blaster cassette was applied to strain M307 essentially as described in Example 3 for removal of

the *pyr4* blaster cassette from the single protease deletion strain M195 (*Apepl*). Three consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells. Final clones were verified for the removal of the blaster cassette by PCR using the primers listed in Table 4.3 with standard laboratory methods. No specific signals were seen with primers annealing with the removed part of the *pyr4* blaster cassette. Removal was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. The clone used to generate the quintuple protease deletion strain was designated with strain number M321 (*Apepl Atspl ΔsIpl Agapl, pyr4⁻*).

[00404] The deletion plasmid pTTv145 for the fifth protease gene, glutamic protease *gap2* (TreID106661) is described in Example 2 (Table 2.3). This deletion plasmid results in a 944 bp deletion in the *gap2* locus and covers the complete coding sequence of GAP2.

[00405] To remove vector sequence, plasmid pTTv145 (*Agap2-pyr4* loopout) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 μg of the *gap2* deletion cassette was used to transform M321 (*Apepl Atspl Aslpl Agapl, pyr4⁻*) above. Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00406] 100 clones were picked as first streaks. All 20 growing streaks were screened by PCR using the primers listed in Table 4.3 for the correct integration using standard laboratory methods. 10 putative quintuple protease disruptants (*Apepl Atspl Aslpl Agapl Agap2*) were purified to single cell clones and rescreened by PCR. Only one purified clone was negative for the *gap2* ORF. The *gap2* deletion was verified by Southern analyses of the clone (Fig. 32A). Southern analyses were performed as described in Example 1. Southern analyses also indicated the clone carries an additional copy of the deletion cassette somewhere else in the genome or has some internal rearrangements in that locus (Figs. 32B and 32C). Since this was the only quintuple protease deletion clone obtained it was selected for further use (Figs. 32D and 32E). Clone 14 was the clone used for removal of the *pyr4* blaster cassette, and to generate the 6-fold protease

deletion strains M396 and M400 below (Fig. 32E). This clone was designated with strain number M369 (*Apepl Atspl Aslpl Agapl Agap2*).

Table 4.3: Primers for screening removal of *pyr4* blaster cassette and for screening *gap2* integration and strain purity.

For screening removal of <i>pyr4</i> blaster cassette from M307	
Primer	Sequence
T052_gap1_5screen_F	CTCAGAAAGGTTGTAGTTGTGA (SEQ ID NO: 359)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 360)
T053_gap1_3screen_R	GATGTTGTGTTTTCAGTCTGCA (SEQ ID NO: 361)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 362)
For screening integration of pTTv145	
Primer	Sequence
T048_gap2_5screen_F	GCTTGGCATCACGGAAGCT (SEQ ID NO: 363)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 364)
T049_gap2_3 screen_R	TTGACAAGAAAGGTCCGGTTG (SEQ ID NO: 365)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 366)
For screening deletion <i>oigap2</i> ORF	
T107_gap2_ORF_F	ATGGATGCTATCCGAGCCAG (SEQ ID NO: 367)
T108_gap2_ORF_R	CTATTCATACTCAACAGTCACA (SEQ ID NO: 368)

Analysis of quintuple protease deletion strain

[00407] Protease activity from the M369 strain was measured against its parent strain M307. The *gap2* protease deletion resulted in 23% less protease activity against casein (Fig. 33).

6-Fold Deletion Strain

[00408] The 6-fold protease deletion strain having deletions *Apepl Atspl Aslpl Agapl Agap2Apep4* was generated and used for further rounds of protease deletions.

Generation of pep4 deletion plasmids

[00409] The deletion plasmid pTTv181 for the sixth protease gene, aspartic protease *pep4* (TreID77579) was constructed essentially as described for the *Apepl* plasmid pTTv71 in

Example 1. 959 bp of 5' flanking region and 992 bp of 3' flanking region were selected as the basis of the *pep4* deletion plasmid. As for *pepl*, the first deletion plasmid for *pep4* (pTTv43, Table 4.4) carried another selection marker, *bar*, which was replaced with the *pyr4* blaster cassette. The blaster cassette was obtained from pTTv71 with *NotI* digestion, ligated to *NotI* cut pTTv43, and then transformed into *E. coli* using standard methods. A few transformants were cultivated, plasmid DNA isolated and digested to screen for correct ligation and orientation of the *pyr4* blaster cassette using standard laboratory methods. One clone with correct insert size and orientation was sequenced and stored (pTTv73, Table 4.4). The blaster cassette was changed slightly once more: the direct repeat fragment used in removal of *pyr4* was changed from 308 bp of *pyr4* 5'UTR to 300 bp direct repeat from the end of *pep4* 5' flanking region (as in pTTv145, *gap2-pep4*). This was made by removing the existing *pyr4* blaster cassette from pTTv73 with *NotI* digestion. The *pyr4* gene was amplified by PCR using pTTv73 as a template using the primers in Table 4.4. For the yeast homologous recombination system used in cloning, overlapping sequences for the vector were placed to the appropriate PCR-primers. To enable marker switch in the construct, *NoiI* restriction sites were introduced on both sides of the *pyr4* selection marker and for additional cloning steps an *AscI* site was introduced between the *pep4* 5'direct repeat and 3' flank. This type of blaster cassette should not leave any additional sequence to the locus of the deleted gene after excision. The 300 bp *pep4* 5'direct repeat was amplified by PCR using the *T. reesei* wild type strain QM6a as a template. Products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. A few of the clones obtained from the recombination were cultivated, and plasmid DNA was isolated and digested to screen for correct recombination using standard methods. These deletion plasmids for *pep4* (pTTv43, pTTv73 and pTTv181, Table 4.4) result in a 1413 bp deletion in the *pep4* locus and cover the complete coding sequence of PEP4.

Table 4.4: Primers for generating *pep4* deletion plasmids.

Deletion plasmid pTTv43 for <i>pep4</i> (TreID77579), vector backbone pRS426	
Primer	Sequence
T298_77579_5f	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACTCAGGTC AACCACCGAGGAC (SEQ ID NO: 369)

T299_77579_5r_pt	CCCGTCACCGAGATCTGATCCGTCACCGGGATCCACTTAAGCGG CCGCTGAATGGGATGGTTCGATTG (SEQ ID NO: 370)
T300_77579_3f_pt	GCCAAGCCCCAAAAAGTGCTCCTTCAATATCATCTTCTGTGCGCGG CCGCAGGTAGACGCTTTGCGAGTG (SEQ ID NO: 371)
T301_77579_3r	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACTGAACT GACGCGGACTGA (SEQ ID NO: 372)

Deletion plasmid pTTv73 for *pep4* (TreID77579), vector backbone pTTv43

Primer	Sequence
no new primers, pTTv43 digested with NotI and ligated with <i>pyr4</i> -loopout fragment from pTTv71	

Deletion plasmid pTTv181 for *pep4* (TreID77579), vector backbone pTTv73

Primer	Sequence
T209_ <i>pyr4</i> _f_rec <i>pep4</i> _5f	AAGTTCCTTCCTCTGGCAGCAATCGAACCATCCATTTCAGCGG CCGCCTAGCATCGACTACTGCTGC (SEQ ID NO: 373)
T210_ <i>pyr4</i> _r	CATGCAAAGATACACATCAA (SEQ ID NO: 374)
T211_ <i>pep4</i> _loop_f_rec <i>pyr4</i>	TGATTGTACCCAGCTGCGATTGATGTGTATCTTTGCATGGCGG CCGCTCAATGTTGACTGCCCCAGG (SEQ ID NO: 375)
T212_ <i>pep4</i> _loop_r_rec <i>pep4</i> _3 f	GCACTTCTTAGATACACACACTCGCAAAGCGTCTACCTGGCG CGCCTGAATGGGATGGTTCGATTG (SEQ ID NO: 376)

Generation of 6-fold protease deletion strains M396 and M400

[00410] To generate a marker-free 6-fold protease deletion strain, removal of the *pyr4* marker was applied to strain M369 essentially as described in Example 3 for removal of *pyr4* blaster cassette from the strain M195 (*Apepl*). Three consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells. Final clones were verified by PCR using the primers listed in Table 4.5 with standard laboratory methods. Signal corresponding to successful removal of the blaster cassette was obtained for all clones. Removal was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. Southern analyses of six putative *pyr4*⁻ clones verified the removal of the blaster cassette for three clones. In addition, the Southern analyses revealed that these three clones have lost the extra signals seen for the *gap2* flanks in parent M369. Therefore these clones should have the expected genomic organisation in the *gap2* locus. The clone used to generate the 6-fold protease deletion strain was designated with strain number M381 (*Apepl Atspl Aslpl Agapl Agap2, pyr4*⁻).

[00411] To remove vector sequence, plasmid pTTv181 (*Apep4-pyr4* loopout) was digested with *PmeI* and the correct fragment purified from an agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the *pep4* deletion cassette was used to transform M381 (*Apepl Atspl Aslpl Agapl Agap2, pyr4⁻*). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00412] Over 200 transformants were picked as first streaks. 32 growing streaks were screened by PCR (using the primers listed in Table 4.5) for correct integration. Seven clones gave the expected signals and were purified to single cell clones and rescreened by PCR using the primers listed in Table 4.5. Deletion of *pep4* was verified by Southern analyses from five clones (Figs. 34A and 34B) using standard laboratory methods described in Example 3 for M181 and M195. Southern analyses also indicated that all transformants (Figs. 34C and 34D) were single integrants. To exclude that the faint signal seen in the PCR screening for the *pep4* ORF in transformants would originate from *pep4* gene, three clones were purified further via single cell steps and reanalysed by Southern hybridisations and PCR. No signal for *pep4* ORF was obtained from either analysis indicating strain purity. Clone 25-120A used for removal of the *pyr4* blaster cassette (and in generation of the 7-fold protease deletion strain) was designated with strain number M396 and the repurified clone 25-120A-a with strain number M400.

Table 4.5: Primers for screening removal of *pyr4* blaster cassette from M369 and for screening *pep4* integration and strain purity.

For screening removal of <i>pyr4</i> blaster cassette from M369	
Primer	Sequence
T222_gap2_5f_f2	GGCAGGTCGCAGAGCAAGACA (SEQ ID NO: 377)
T049_gap2_3 screen_R	TTGACAAGAAAGGTCCGGTTG (SEQ ID NO: 378)
For screening integration of pTTv181	
Primer	Sequence
T302_77579_5int	GATTCATCACAGGGGCAGTC (SEQ ID NO: 379)
T027_Pyr4_orf_start_rev	TGCGTCGCCGTCTCGCTCCT (SEQ ID NO: 380)
T415_77579_3screen	ACGCCGTTGCTGAGCCTTG (SEQ ID NO: 381)
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTCCA (SEQ ID NO: 382)

For screening deletion of *pep4* ORF

T416_77579_probeF	GAGCCCATCATCAACACCTC (SEQ ID NO: 383)
T417_77579_probeR	TGCCAAGGTCGTAGACGGA (SEQ ID NO: 384)

Analysis of Protease activity in the 4-, 5-, and 6-Fold Protease Deletion Strains

[00413] The quadruple protease deletion strain M307, the quintuple protease deletion strain M369, and the 6-fold protease deletion strain transformants were cultivated in shake flask cultures. Supernatant samples taken from large shake flask cultures grown in TrMM with 20 g/L spent grain and 40 g/L lactose buffered with 100 mM PIPPS at pH 4.8. The pH was -4.25 on day 5. The 6 protease deletion transformants tested were not the final strain, so there was some variation due to the purity of the spores. These were some of the best transformants, but further spore purification was done subsequently. The day 5 supernatants were diluted 1:3 in 50 mM sodium citrate buffer pH 4.5. To this diluted supernatant BODIPY casein FL (10 µg/ml) was added and incubated together at 37°C for 4 hours. To protease activity assay was conducted as described in the manufacture's protocol (enzCheck protease assay kit #E6638, Molecular Probes). The protease activity results can be seen in Figure 33.

[00414] There was a small reduction in protease activity when the quintuple protease deletion strain M369 was grown under acidic conditions. The deletion of *gap2* in the strain provided a 23% reduction in protease activity against casein. In the 6-fold protease deletion strains the aspartic protease *pep4* was deleted in the 5 transformants studied. The best transformant showed a 35% reduction compared to its parent strain M369.

Generation of 7-Fold Deletion Strain

[00415] The 7-fold protease deletion strain having deletions *Apepl Atspl Aslpl Agapl Agap2Apep4Apep3* was generated and used for further rounds of protease deletions.

Generation of pep3 deletion plasmids

[00416] The first deletion plasmid pTTv188 for the seventh protease gene, aspartic protease *pep3* (TreID121 133) was constructed essentially as described for *Apepl* plasmid pTTv41 in Example 1. 1215 bp of 5' flanking region and 1082 bp of 3' flanking region were selected as the basis of the *pep3* deletion plasmid. As for *gap2* (pTTv145) and *pep4* (pTTv181) deletion plasmids above, in this plasmid the direct repeat fragment is a 300 bp stretch from the end of *pep3* 5' flanking region. Fragments were produced by PCR using the primers listed in Table 4.6. As for pTTv181 (*Apep4-pyr4*) above, to enable marker switch in the construct, *NotI* restriction sites were introduced on both sides of the *pyr4* selection marker and for additional cloning steps an *AscI* site was introduced between the *pep3* 5'direct repeat and 3' flank. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. Template used in the PCR of the flanking regions was the *T. reesei* wild type strain QM6a. The *pyr4* marker gene was obtained from pTTv181 with *NotI* digestion. The vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1.

[00417] The second deletion plasmid for the aspartic protease *pep3* (TreID121 133), pTTv192, was constructed using the plasmid pTTv188 above as the backbone. This second plasmid carries a native KEX2 (TreID123156) overexpression cassette and uses acetamidase (*AmdS*) gene from *Aspergillus nidulans* as the selection marker. The *pyr4* blaster cassette was removed from pTTv188 with *NotI-AscI* double digestion. The fragments for *cDNAI* promoter (template: pTHN3 plasmid DNA), native *kex2* (template: *T. reesei* QM6a genomic DNA), *trpC* terminator (template: pHH02 plasmid DNA) and *AmdS* marker (template: pHH01 plasmid DNA) were produced by PCR using the primers listed in Table 4.6. As for pTTv188 above, to enable marker switch in the construct, *Noil* restriction sites were introduced on both sides of the *AmdS* selection marker. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. The plasmid was constructed using the yeast homologous recombination method described in Example 1.

[00418] The third deletion plasmid for the aspartic protease *pep3* (TreID121133), pTTv205, was constructed using the plasmid pTTv192 above as the backbone. The *AmdS* marker was removed from pTTv192 with *NotI* digestion. Fragments for a new *pyr4* blaster cassette (located after the KEX2 overexpression cassette) were produced by PCR using the primers listed in Table 4.6. In this blaster cassette, the direct repeat is a 300 bp stretch from the beginning of the *pep3* 3' flanking region and located before the *pyr4* gene. As for pTTv192 above, to enable marker switch in the construct, *NoiI* restriction sites were introduced on both sides of the *pyr4* blaster cassette. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with gel extraction kit (Qiagen) using standard laboratory methods. The plasmid was constructed using the yeast homologous recombination method described in Example 1.

[00419] These deletion plasmids for *pep3* (pTTv188, pTTv192 and pTTv205, Table 4.6) result in a 2590 bp deletion in the *pep3* locus and cover the complete coding sequence of PEP3.

Table 4.6: Primers for generating *pep3* deletion plasmids.

Deletion plasmid pTTv188 for <i>pep3</i> (TreID121133), vector backbone pRS426	
Primer	Sequence
T346_peg3_5f_for	GGTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACGTCGA GCCCCCTGGACACCT (SEQ ID NO: 385)
T347_peg3_5f_rev	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCG GCCGCCATCGCCGTCGCGGACATGA (SEQ ID NO: 386)
T348_peg3_loop_for	TGATTGTACCCCAGCTGCGATTGATGTGTATCTTTGCATGGCGG CCGCTCGACGTTGTATCTGCACTC (SEQ ID NO: 387)
T349_peg3_loop_rev	GTACGTTCTGATTGCCAACTACGGACCAGACCAGGGCTCCGGC GCGCCCATCGCCGTCGCGGACATGA (SEQ ID NO: 388)
T350_peg3_3f_for	GGAGCCCTGGTCTGGTCCGT (SEQ ID NO: 389)
T351_peg3_3f_rev	AGCGGATAACAATTTACACAGGAAACAGCGTTTAAACACGCG CTCAACATGCCCA (SEQ ID NO: 390)
Deletion plasmid pTTv192 for <i>pep3</i> (TreID121133), vector backbone pTTv188	
Primer	Sequence
T389_cDNApromoter_peg3flank	GCTGGCCGCTGGGAATAGCGTCATGTCCGCGACGGCGATGGAA TTCGGTCTGAAGGACGT (SEQ ID NO: 391)
T138_cDNAI_Rev	GTTGAGAGAAGTTGTTGGATTG (SEQ ID NO: 392)
T139_123561For_cDNAI	AACCAAAGACTTTTTGATCAATCCAACAACCTCTCTCAACATGA AGATTTCTCGATCCTTG (SEQ ID NO: 393)
123561Rev	TCAGCGCCGTAACCTCTGC (SEQ ID NO: 394)

trpCtermFor_123561	TGATGGTGATGAGGCGGAAAAGCAGAGGTTACGGCGCTGAGGA TCCACTTAACGTTACTGA (SEQ ID NO: 395)
T390_trpCtermR_AmdS	TCTCTCAAAGGAAGAATCCCTTCAGGGTTGCGTTTCCAGTGCGG CCGCTCTCCTTCTAGAAAAGAAGGATTA (SEQ ID NO: 396)
T391_AmdS_endR	ACTGGAAACGCAACCCTGAA (SEQ ID NO: 397)
T390_trpCtermR_AmdS	TCTGATTGCCAACTACGGACCAGACCAGGGCTCCGGCGCGGCG GCCGCTAGATCTACG (SEQ ID NO: 398)
Deletion plasmid pTTv205 for <i>pep3</i> (TreID121133), vector backbone pTTv192	
Primer	Sequence
T428_peg3_3ilankDR_F- trpCterm	GTACACTTGTTTTAGAGGTAATCCTTCTTTCTAGAAGGAGAGCGG CCGCGGAGCCCTGGTCTGGTCC (SEQ ID NO: 399)
T429_peg3_3ilankDR_R-pyr4	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGAAG CTGACGGGCGTCAACG (SEQ ID NO: 400)
T094_pyr4_F	TAGCATCGACTACTGCTGC (SEQ ID NO: 401)
T430_pyr4_R-peg3_3ilank	GTACGTTCTGATTGCCAACTACGGACCAGACCAGGGCTCCGCG GCCGCCATGCAAAGATACACATCAATC (SEQ ID NO: 402)

Generation of 7-fold protease deletion strains

[00420] To generate a marker-free 7-fold protease deletion strain, removal of the *pyr4* marker was applied to the 6-fold deletion strain M396 essentially as described in Example 3 for removal of the *pyr4* blaster cassette from the strain M195 (*Apepl*). Four consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells.

[00421] Final clones were verified by PCR using the primers listed in Table 4.7 with standard laboratory methods. Signal corresponding to successful removal of the blaster cassette was obtained. Removal of the blaster cassette was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. Southern analyses of four putative *pyr4*⁻ clones verified the removal of the blaster cassette for all clones (Fig. 34E). The clone (25-120A-62) used to generate the 7-fold protease deletion strain was designated with strain number M402 (*Apepl Atspl Aslpl Agapl Agap2Apep4, pyr4*⁻).

[00422] Two parallel transformations were carried out; one with the deletion construct from pTTv188 (standard *pep3* deletion) and the other with pTTv205 (KEX2 overexpression included). To remove vector sequence, plasmids pTTv188 and pTTv205 were digested with *PmeI* and the

correct fragments purified from agarose gel using QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of either deletion cassette was used to transform M402 (*Apepl Atspl Aslpl Agapl Agap2Apep4, pyr4⁻*). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00423] Transformants were picked as first streaks. Growing streaks were screened by PCR (using the primers listed in Table 4.7) for correct integration. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 4.7.

[00424] Deletion of *pep3* was verified by Southern analyses from selected clones using methods described in Example 1. Chosen clones were used for removal of the *pyr4* blaster cassette, and in generation of the 8-fold protease deletion strains (Fig. 34E).

Table 4.7: Primers for screening removal of *pyr4* blaster cassette from M396 and for screening *pep3* integration and strain purity.

For screening removal of *pyr4* blaster cassette from M396

Primer	Sequence
T302_77579_5int	GATTCATCACAGGGGCAGTC (SEQ ID NO: 403)
T214_pep4_3f_seq_rl	CCGCTCTCAAACCTGCCCAA (SEQ ID NO: 404)

For screening integration of pTTv188

Primer	Sequence
T625_pep3_5int_new	ACGTGAAGTTGCCCATCAA (SEQ ID NO: 405)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 406)
T626_pep3_3int_new	GACCAATGGCTTCACGAAGT (SEQ ID NO: 407)
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTCCA (SEQ ID NO: 408)

For screening integration of pTTv205

Primer	Sequence
T625_pep3_5int_new	ACGTGAAGTTGCCCATCAA (SEQ ID NO: 409)
T140_cDNA lpromoter_seqRl	TAACTTGTACGCTCTCAGTTCGAG (SEQ ID NO: 410)
T626_pep3_3int_new	GACCAATGGCTTCACGAAGT (SEQ ID NO: 411)
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTCCA (SEQ ID NO: 412)

For screening deletion of *pep3* ORF

Primer	Sequence
T352_pep3_orf_f or	CAGCAGCACCGCATCCACCA (SEQ ID NO:413)

T353_pep3_orf_rev	GCCGAATCGCTGGTTGCCCT (SEQ ID NO: 414)
T753_pep3_orf_for2	ATGGAAGCCATCCTCCAGG (SEQ ID NO: 415)
T754_pep3_orf_rev2	TGGATCATGTTGGCGACG (SEQ ID NO: 416)
T855_pep3_orf_f3	GTAAGACGCCCCGTCTC (SEQ ID NO: 417)

Generation of 8-Fold Deletion Strain

[00425] The 8-fold protease deletion strain having deletions *Apep1 Atspl Aslpl Agapl Agap2Apep4Apep3Apep5* is generated.

Generation of pep5 deletion plasmid

[00426] The first deletion plasmid for the eighth protease gene, aspartic protease *pep5* (TreID81004) was constructed essentially as described for the *Apep1* plasmid pTTv41 in Example 1, but an additional second selection marker cassette (*bar*, Example 1) was placed after the *pyr4* gene creating a deletion plasmid with a double selection marker blaster cassette. The double marker system enables a) utilisation of e.g. *bar* (or *hph*, a cassette for hygromycin resistance) as the initial resistance marker and faster selection; b) transformation of *pyr4*⁺ strains (without the need to generate *pyr4*⁻ prior to transformation); and c) removal of both markers from the transformants using 5-fluoroorotic acid (like in removal of standard *pyr4* blaster cassette) and simultaneous mutagenization of the endogenous *pyr4* resulting in marker-free, *pyr4*⁻ strain.

[00427] The second deletion plasmid for the aspartic protease *pep5* (TreID81004), pTTv229, was constructed using the plasmid pTTv202 above as the backbone. The *pyr4-bar* double marker was removed from pTTv202 with *NotI* digestion. The *pyr4* marker gene was obtained from pTTv181 with *NotI* digestion. Cloning of the plasmid pTTv229 was done with standard ligation using T4 DNA ligase at room temperature. Part of the ligation mixture was transformed into *E. coli* with electroporation. A few clones were cultivated, plasmid DNA was isolated and digested to screen for correct ligation using standard laboratory methods. Correct ligation and orientation of the marker was further verified by sequencing. These deletion plasmids for *pep5* (pTTv202 and pTTv229, Table 4.8) result in a 1687 bp deletion in the *pep5* locus and cover the complete coding sequence of PEP5.

[00428] 1348 bp of 5' flanking region and 1164 bp of 3' flanking region were selected as the basis of the *pep5* deletion plasmid. A 300 bp stretch from the end of *pep5* 5' flank was used as the direct repeat fragment. These fragments as well as the second selection marker cassette, *bar* (Example 1), were amplified by PCR using the primers listed in Table 4.8. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. To enable removal of the complete double marker cassette, *NotI* restriction sites were introduced on both sides of the double marker cassette, and an *AsiSI* site between the two selection markers. An *AscI* site was introduced between the *pep5* 5' direct repeat and 3' flank. Vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The *pyr4* selection marker was obtained from pTTv181 (*Apep4-pyr* above) with *NotI* digestion. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *pep5* (pTTv202, Table 4.8) results in a 1687 bp deletion in the *pep5* locus and covers the complete coding sequence of PEP5.

Table 4.8: Primers for generating *pep5* deletion plasmid.

Deletion plasmid pTTv202 for <i>pep5</i> (TreID81004), vector backbone pRS426	
Primer	Sequence
T372_5f_for	GGTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACGGAGG CTGCGACACCGTCTG (SEQ ID NO: 418)
T373_5f_rev	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCG GCCGCCCGCCTGAAACGACCTCCC (SEQ ID NO: 419)
T376_5DR_for	CCCGTCACCGAGATCTGATCCGTCACCGGGATCCACTTAAGCGG CCGCGAGAGAGAAACAAAACAGTG (SEQ ID NO: 420)
T377_5DR_rev	ACATTCCGACCGTTTACTGATCCAAGCCGTGCAACCGACTGGCG CGCCCCGGCCTGAAACGACCTCCC (SEQ ID NO: 421)
T378_3f_for	AGTCGGTTGCACGGCTTGGGA (SEQ ID NO: 422)
T379_3f_rev	AGCGGATAACAATTTACACAGGAAACAGCGTTTAAACGAGAC GGACGCCTGCACCAC (SEQ ID NO: 423)
T374_bar_recpyr4_fbr2	TGATTGTACCCAGCTGCGATTGATGTGTATCTTGCATGGCGA TCGCGACAGAAGATGATATTGAAG (SEQ ID NO: 424)
T375_bar_rev	TTAAGTGGATCCCGGTGACG (SEQ ID NO: 425)
Deletion plasmid pTTv229 for <i>pep5</i> (TreID81004), vector backbone pTTv202	
Primer	Sequence
no new primers, pTTv202 digested with <i>NotI</i> and ligated with <i>pyr4</i> fragment from pTTv181	

Generation of 8-fold protease deletion strain

[00429] To generate a marker-free 8-fold protease deletion strain, removal of the *pyr4* marker was applied to the 7-fold deletion strain M486 (34-14A-a, pTTv205 in M402) essentially as described in Example 3 for removal of the *pyr4* blaster cassette from the strain M195 (*Apepl*).

Four consecutive

5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells.

[00430] Final clones were verified by PCR using the primers listed in Table 4.9 with standard laboratory methods. Signal corresponding to successful removal of the blaster cassette was obtained for majority of the clones. Removal of the blaster cassette was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. Southern analyses of putative *pyr4*⁻ clones verified the removal of the blaster cassette.

[00431] To remove vector sequence, plasmid pTTv229 was digested with *PmeI* + *XbaI* and the correct fragment purified from an agarose gel using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform a clone of 8-fold protease deletion strain (*Apepl Atspl Aslpl Agapl Agap2Apep4Apep3, pyr4*⁻). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00432] Transformants were picked as first streaks. Growing streaks are screened by PCR (using the primers listed in Table 4.9) for correct integration. Clones giving the expected signals are purified to single cell clones and rescreened by PCR using the primers listed in Table 4.9. Deletion of *pep5* is verified by Southern analyses from selected clones using methods described in Example 1.

Table 4.9: Primers for screening removal of *pyr4* blaster cassette from 7-fold strain and for screening *pep5* integration and strain purity.

For screening removal of <i>pyr4</i> blaster cassette from M486 and strain purity	
Primer	Sequence
T047_trpC_term_end_F	CCTATGAGTCGTTTACCCAGA (SEQ ID NO: 426)
T854_pep3_3f_r2	TGGCCGAGTCTATGCGTA (SEQ ID NO: 427)
T488_pyr4_5utr_rev	GGAGTTGCTTTAATGTCCGGG (SEQ ID NO: 428)
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTTCCA (SEQ ID NO: 429)
T855_pep3_orf_f3	GTAAGACGCCCCGTCTC (SEQ ID NO: 430)
T754_pep3_orf_rev2	TGGATCATGTTGGCGACG (SEQ ID NO: 431)
For screening integration of pTTv229	
Primer	Sequence
T627_pep5_5int_new	GTCGAAGATGTCCTCGAGAT (SEQ ID NO: 432)
T488_pyr4_5utr_rev	GGAGTTGCTTTAATGTCCGGG (SEQ ID NO: 433)
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTTCCA (SEQ ID NO: 434)
T628_pep5_3int_new	TAGTCCATGCCGAAGTGC (SEQ ID NO: 435)
For screening deletion of <i>pep5</i> ORF	
Primer	Sequence
T418_pep5_orf_for	CCGGACCTGCACCGCAAGTT (SEQ ID NO: 436)
T419_pep5_orf_rev	AGGGCAATGTGCCCCAGCAC (SEQ ID NO: 437)
T859_pep5_orf_f2	GACCTGCACCGCAAGTT (SEQ ID NO: 438)
T860_pep5_orf_f3	GTCGAGCGTCTGATATTCAC (SEQ ID NO: 439)
T861_pep5_orf_r2	GACGGAGACCTCCCACA (SEQ ID NO: 440)

Example 5 —IMPROVED ANTIBODY PRODUCTION WITH PROTEASE INHIBITORS

[00433] This example demonstrates the ability of protease inhibitors to increase full length antibody production in *Trichoderma reesei* production strains.

[00434] Based on the knowledge that the heavy chain is cleaved by tryptic and chymotryptic proteases, inhibitors of these two enzyme classes were tested against antibody degradation both *in vitro* and in culture experiments utilizing an antibody producing *T. reesei* strain. The inhibitors soybean trypsin inhibitor (SBTI) and chymostatin were tested, as they have been previously shown in *in vitro* experiments to stabilize antibody heavy chains.

In vitro Inhibitor Treatment

[00435] Chymostatin and SBTI were analyzed *in vitro* with culture supernatant. Supernatant from a fed batch fermentor culture was diluted to 6 mg/ml with sodium citrate buffer pH 5.5 (pH 5.5; 28°C; 20 g/L spent grain extract, 60 g/L lactose). The fedbatch cultivation was performed with the *T. reesei* wild type strain M44, which does not contain heterologous protein expression. The strain was grown in *Trichoderma* minimal medium supplemented with 20 g/l spent grain extract and 60 g/l lactose at pH 5.5 and 28°C.

[00436] To this diluted supernatant 0.05 µg/µl of rituximab, 100 µM chymostatin, 1 mg/ml SBTI, or a combination of both inhibitors was added in a total volume of 50 µl and sampled at 0, 1, and 19 hours to assess the early and late degradation of the rituximab antibody heavy chain. The resulting heavy chain products were analyzed by immunoblot using anti-heavy chain AP conjugated antibody (Sigma #A3188) diluted 1:30,000 in TBST (Fig. 35). The initial degradation products generated from the heavy chain were approximately 42 kDa and 38 kDa, which were seen in the untreated control lane at 1 hour (Fig. 35). Additional fragments were generated after 19 hours, the two major products remained. Chymostatin treatment inhibited the initial production of the 42 kDa fragment, while SBTI treatment inhibited the 38 kDa fragment from forming (Fig. 35). Combining the two compounds inhibited about 96% of the initial heavy chain degradation and about 75% of the degradation after 19 hours (Fig. 35). These results demonstrate that the two inhibitors were able to effectively stabilize the rituximab antibody heavy chain.

Treatment of *T. reesei* Cultures with Inhibitors

[00437] The effectiveness of the inhibitors was also tested with the rituximab antibody producing strain, which contains a VALEKR linker sequence and the *pepl* deletion. This strain was grown in triplicate, in small flasks both in presence or absence of chymostatin, SBTI, or pepstatin A. The small shake flasks contained 50 ml of TrMM plus lactose (40 g/l), spent grain extract (20 g/l), and buffer with 100 mM PIPPS at pH 5.5. The SBTI inhibitor was added to the culture at final concentrations of either 100 µg/ml or 500 µg/ml. Chymostatin was used at 100

μM , and pepstatin A was used at 10 μM . Each of the three inhibitors was added to the cultures daily on day 2, 3, 4, and 5.

[00438] Growth of the cultures was followed daily by pH from day 2 until day 7. For the cultures grown with SBTI there were no significant differences in the pH of the cultures compared to the untreated controls. In the PIPPS buffered cultures, the pH decreased from an initial pH of 5.5 down to a pH of 4.8 after day 6. With chymostatin and pepstatin A the cultures were monitored up to day 7. On day 7 the average pH for the control bottles was 4.6, while the average pH for chymostatin treated cultures was 4.9, and the average pH of pepstatin A treated cultures was 5.0. Thus, for the cultures treated with chymostatin and pepstatin A there was a small reduction in growth.

[00439] Culture supernatant samples (30 μl) were also collected on days 3, 4, and 5 for analysis of antibody production. The analysis was performed by immunoblots using an anti-IgG heavy chain antibody AP conjugate (Sigma #A3188) and an anti-light chain antibody AP conjugate (Sigma #A3812). Each antibody was diluted 1:30,000 in TBST. The full length rituximab heavy chain is about 51 kD, the rituximab light chain CHBI fusion is about 100 kD, and the free rituximab light chain is about 28 kD.

[00440] Results of immunoblot analysis of culture supernatant samples treated with SBTI are shown in Figure 36. On all days sampled there was more full length rituximab heavy chain and more 38 kD degradation product present in the SBTI treated cultures than in untreated cultures. On day 5 rituximab heavy chain production was several fold higher in the SBTI treated cultures than in untreated cultures (Fig. 36A). Thus, the use of SBTI had a positive effect on improving rituximab heavy chain production. There was also a minor improvement in overall rituximab light chain production, particularly with the carrier bound light chain (Fig. 36B).

[00441] Results of immunoblot analysis of culture supernatant samples treated with chymostatin and pepstatin A are shown in Figure 37. Chymostatin treated cultures showed similar results as those seen with SBTI (Fig. 37). The rituximab heavy chain was stabilized on day 5 (Fig. 37B). When compared to the untreated control cultures, chymostatin increased the

amount of full length rituximab heavy chain produced, although there the major degradation product at 38 kD was still seen.

[00442] Overall, it appears that SBTI treatment was more effective in promoting higher protein production than chymostatin treatment. However, chymostatin treatment produced a higher full length rituximab heavy chain to fragment ratio. As seen in Figure 37B, the third chymostatin culture sample showed approximately 90% full length rituximab heavy chain compared to 10% heavy chain fragment. Thus, the combination of SBTI and chymostatin treatment would be very beneficial to achieving higher antibody production yields.

Example 6 - T. REESEI ANTIBODY PRODUCTION

[00443] This example quantifies the amount of antibodies produced in the *T. reesei* protease deletion strains described above in Examples 1-4.

Antibody Purification

[00444] Culture supernatants from each of the *T. reesei* protease deletion strains listed in Table 6.1 were filtered through 0.45 μm syringe filter and adjusted to the composition of binding buffer by adding 1/50 volume of 1 M sodium phosphate, pH 7, prior to purification. The affinity column was connected to an ÄKTA Purifier, and the purification was performed according to the manufacturer's instructions. The following chromatography conditions were used: flow rate, 1 ml/min; detection 280 nm; injection loop, 5 ml; buffer A, 20 mM sodium phosphate, pH 7; buffer B, 0.1 M glycine-HCl, pH 2.7. Isocratic run with buffer A was conducted until the start of the elution, which was carried out with 5 ml of buffer B. The column was equilibrated at least with 5 ml of buffer A prior to each analysis. 1 ml of culture supernatant was injected for quantitative runs. 0.5 ml fractions were collected into tubes containing 40 μl of 0.5 M Tris, pH 9, during the elution step. Antibody was eluted sharply in two fractions, which were pooled into one sample of 1 ml. From the samples with the highest peak areas among each sample series (fermentation), one run with 5-10 ml injection volume was performed to obtain more concentrated sample for gel filtration analysis.

[00445] For quantification, a series of dilutions was prepared of antibody standard and run in 1 ml volume in HiTrap Protein G column similarly to the samples analyzed. A standard curve (10-500 µg) was established of the peak areas measured at 280 nm and used for the quantification of the MAB01 or rituximab antibodies isolated from the culture supernatants. The quality of the purified samples was checked by SDS-PAGE.

Gel Filtration Profiles of Prot G Purified Samples

[00446] A 250 µl sample of each purified MAB01 and rituximab antibody was run in Tris-buffered saline (25 mM Tris, 140 mM NaCl, and 3 mM KCl, pH7.4) in a Superdex 200 10/300 GL gel filtration column (Amersham Biosciences) connected to an ÄKTA Purifier HPLC system. The flow rate was 0.75 ml/min and absorbance was measured at 280 nm. Fractions (0.75 ml) were collected during the whole run. The fractions showing only one peak were concentrated and characterized on a standard SDS-PAGE gel (Fig. 38). The percentage of each peak eluted was calculated by dividing the peak area with the total area of the sample measured at 280 nm.

[00447] The antibody purification process is shown in Figure 38.

Antibody Quantification

[00448] The amounts of antibodies produced by the *T. reesei* protease deletion strains are summarized in Table 6.1.

Table 6.1: Summary of quantity and quality of antibodies produced by crude fermentor supernatant cultures from *T. reesei* strains described in Examples.

Heterologous protein	Aprotease	Culture	Total amount of niAb (mg/L)	Total amount of full length mAb (mg/L)	Notes/Conditions
MAB02	none	shake flask	3	n/a	
Rituximab	none	shake flask	9	n/a	
Rituximab	none	fermentation	21	n/a	strain M187; pH 5,5; 28°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose

Heterologous protein	Aprotease	Culture	Total amount of mAb (mg/L)	Total amount of full length mAb (mg/L)	Notes/Conditions
Rituximab	none	shake flask	3	n/a	strain M189
MAB01	pepl	fermentation	160	3	pH 4,8; 28°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose
Rituximab	pepl	fermentation	152 237	66 n/a	pH 5,2; 22°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose and pH 5,2; 30->22°C; 40 g/L spent grain, 60 g/L glucose
MAB01	pepl, tspl	fermentation	67	n/a	pH 5,2; 22°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose
MAB01	pepl	fermentation	205	n/a	strain M244; pH 5,5; 28->22°C; 9 g/L casaminoacids; 20 g/L spent grain extract, 60 g/L lactose + Chymostatin+SBTI; Carrier free LC.
MAB01	pepl tspl	fermentation	261	<130	strain M247; pH 5,5; 22°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose
MAB01	pepl slp2	fermentation	202 221	60 67	strain M292; pH 5,5; 30->22°C; 20 g/L spent grain extract, 60 g/L lactose or pH 5,5; 30->22°C; 40 g/L spent grain, 30 g/L glucose
MAB01	pepl slp3	fermentation	93	n/a	strain M295; pH 5,5; 22°C; 9 g/L casaminoacids; 20 g/L spent grain extract, 60 g/L lactose
MAB01	pepl gapl	fermentation	107	n/a	pH 5,5; 22°C; 9 g/L casaminoacids; 20 g/L spent grain extract, 60

Heterologous protein	Aprotease	Culture	Total amount of mAb (mg/L)	Total amount of full length mAb (nig/L)	Notes/Conditions
					g/L lactose
MAB01	pepl spl	fermentation	136	19	strain M298; pH 5,5; 28->22°C; 9 g/L casaminoacids; 20 g/L spent grain extract, 60 g/L lactose
MAB01	pepl spl	fermentation	94	n/a	strain M299; pH 5,5; 22°C; 9 g/L casaminoacids; 20 g/L spent grain extract, 60 g/L lactose
MAB01	pepl tspl spl	fermentation	2159 3500 1200 1344	1471 2500 822 731	strain M304; pH 5,5; 30->22°C; 40 g/L spent grain, 40 g/L glucose, 40 g/L lactose or pH 5,5; 28->22°C; 60 g/L spent grain, 30 g/L glucose, 60 g/L lactose + lactose feed or pH 5,5; 30->22°C; 50 g/L spent grain, 30 g/L glucose or pH 5,5; 30->22°C; 40 g/L spent grain, 40 g/L glucose, 40 g/L lactose
MAB01	pepl tspl spl gapl	fermentation	1965	897	strain M371; pH 5,5; 30->22°C; 40 g/L spent grain, 40 g/L glucose, 40 g/L lactose

[00449] In Table 6.1, the total amount of antibody (mAb) is the amount of protein that was purified from the culture supernatant. After protein purification, the antibody was run in size exclusion chromatography to measure the amount of full length assembled antibody. This amount was then referred to as "Full mAb."

[00450] As shown in Table 6.1, the M304 triple deletion strain (*Apepl Atspl Aslpl*) achieved an antibody yield of 3500 mg/L total IgG, with 2500 mg/L being correctly assembled into full

length MAB01 antibody. This corresponds to 71% of full length antibody. The improvement in the percentage of full length antibody was a result of the *slpl* deletion. In contrast to the M304 strain, the M247 double deletion strain (*ApeplAtspl*) achieved a 43% production yield of full length antibody (pH 5.5; 22°C; 9 g/l casaminoacids; 20 g/L spent grain extract, 60 g/L lactose). Thus, it can directly be seen that the addition of the *Aslpl* deletion increases the product quality significantly (by 25%).

Antibody quality improvement in M507 MAB01 production strain

[00451] Two MAB01 production strains were produced, M304 in a 3 protease deletion background and M507 in a 7 protease deletion background. The M304 strain was constructed with separate cassettes for the heavy and light chain (Figure 49). The heavy chain was integrated into the *cbhl* locus and the light chain into the *egll* locus. The M507 strain was made by integrating a tandem cassette containing both the heavy and light chain into the CBHI locus (Figure 49). MAB01 tandem vector orients the heavy and light chains in opposite directions. The light chain uses the NVISKR cleavage site and the heavy chain uses the DGETVVKR cleavage site. The M304 strain has 3 proteases *pepl*, *tspl*, and *slpl* deleted. The M507 has 7 proteases *pepl*, *tspl*, *slpl*, *gapl*, *gap2*, *pep4*, *pep3* deleted. Both strains overexpress *kex2* protease.

[00452] The MAB01 bidirectional tandem vector pTTv223 was transformed to the seven-fold protease deletion strain M486 with *kex2* overexpression using standard protoplast transformation. Transformants were selected on acetamide-triton plates and first streaks were PCR screened for the 5' and 3' integration of the AmdS marker to the *cbhl* locus. Double positive transformants were purified through single spore cultivations and spore stocks were generated on PD plates supplemented with ampicillin.

[00453] The M304 and M507 strains were cultivated in fermentors with 30 g/l glucose, 60 g/l spent grain, 60 g/l lactose with lactose feed at 28°C and shifted to 22°C later in the culture. The M507 strain was cultivated at pH 5.2 (cultivation bio00541b) and pH 5.5 (cultivation bio00543b). The M304 strain was grown at pH 5.5 (cultivation bio00503b). The M304 fermentation

bio00477b sample was included as a control in the bio00503b immunoblot. The bio00477b cultivation was done with the same medium and conditions as described for bio00503b.

[00454] The M507 strain was cultivated at both pH 5.2 and pH 5.5 to study the effect of the pH on antibody production. Supernatant samples from the pH 5.2 fermentation were analyzed by Western blot and shown in Figure 50A and samples from the pH 5.5 fermentation shown in Figure 50B. The antibody produced looked rather similar in both M507 cultivations. There was somewhat more light chain in the pH 5.2 conditions. In both cultivations there were heavy chain fragments. The M304 strain was cultivated at pH 5.5 and the results can be seen in Figure 51. The amount of full length heavy chain produced drops off after day 7 in the M304 strain. The amount of heavy chain goes down after day 9 in the M507 strain. The other difference between the strains was the amount of light chain produced. The M304 produced significantly more.

[00455] Protein G purified immunoglobulin concentrations from the three fermentation runs can be seen in Table 6.2. The highest total antibody concentration for the M304 strain was 3.1 g/l on day 9. The highest concentrations for the M507 strain were at day 10, 3.0 g/l at pH 5.2 and 2.8 g/l at pH 5.5. After size exclusion chromatography the amount of full-length antibody was calculated for each sample (Table 6.3). The highest full-sized antibody amount was 2.0 g/l for both M507 fermentations at day 8 (pH 5.2) and day 9 (pH 5.5). The M304 produced a similar 2.0 g/l level of full-length antibody on day 8.

Table 6.2: Total antibody concentration determined after protein G purification from culture samples

Total Ab	M304	M507	M507
	bio00503b	bio00541b	bio00543b
	pH 5.5	pH 5.2	pH 5.5
Day	mg/L	mg/L	mg/L
5	2300	1200	1164
6	2800	1427	1454
7	3000	2211	2116
8	3000	2745	2455
9	3100	2721	2709
10	2100	2995	2808

11		2702	2164
----	--	------	------

[00456] The difference between the M304 and M507 strains becomes obvious when considering the percentage of full-length antibody produced over the time course of the cultivations. The percentage of full-length antibody was higher with the M507 compared to the strain M304. The M507 strain grown at pH 5.5 produced the highest quality antibody, up to 78% being full-length on day 7. The M304 reached 68% on day 6, but then the product quality decreases compared to M507. The M507 product was 73% full-length until day 9.

Table 6.3: The concentration of full-length antibody was calculated after size exclusion chromatography

Full sized Ab	M304	M507	M507
	bio00503b	bio00541b	bio00543b
	pH 5.5	pH 5.2	pH 5.5
Day	mg/L	mg/L	mg/L
6	1900	1062	1074
7	2000	1557	1645
8	2000	1998	1859
9	1700	1924	1988
10	900	1871	1806

Table 6.4: Percentage of full-length antibody produced over the time course of the cultivations.

Full sized %	M304	M507	M507
	bio00503b	bio00541b	bio00543b
	pH 5.5	pH 5.2	pH 5.5
Day	%	%	%
6	68	74	74
7	67	70	78
8	60	73	76
9	56	71	73
10	44	62	64

Protease activity measurements

[00457] The protease activity in the supernatant was compared between the M304 and M507 strains grown under the same conditions. The Triab62 and Triab67 cultivations were grown at pH 5.5 in 30 g/l glucose, 60 g/l lactose, 20 g/l whole spent grain, 20 g/l spent grain extract with lactose feed at 28°C and shifted to 22°C later in the culture.

[00458] The protein concentrations were determined from all supernatant samples from day 2-7. All the supernatants were diluted in sodium citrate buffer pH 5.5, so that all the samples had a total protein concentration of 0.625 mg/ml. 100 µl of all the diluted supernatants were added into a black 96 well plate, using 3 replicate wells per sample. 100 µl of casein FL diluted stock (10 µg/ml) made in sodium citrate buffer pH 5.5 was added to each supernatant containing well. The plates were incubated covered in plastic bag at 37°C. The fluorescence from the wells was measured after 2, 3, and 4 hours. The readings were done on the Varioskan fluorescent plate reader using 485 nm excitation and 530 nm emission.

[00459] The protease activity in supernatant from the 7-fold protease deletion strain M507 was 2- to 2.5- times lower than M304 (3 protease deletions), see Table 6.5. The acidic proteases deleted (*gap1*, *gap2*, *pep4*, *pep3*) contribute to this improvement. The general protease activity in the 7-fold deletion strain is noticeably lower with the casein substrate. This data generally correlates to the results seen with percentage full length antibody. Lower protease activity leads to higher quality antibody.

Table 6.5: Protease activity in fermentation supernatant from pH 5.5 cultures. Casein was used as the substrate for the measurements.

	M304	M507
	Triab62	Triab67
Day	pH 5.5	pH 5.5
1	1,4	1,3
2	8,5	1,8
3	67,4	4,1
4	98,8	38,8
5	102,3	48,3

6	83,3	54,6
7	103,1	54,5
8	109,8	55,3
9	120,9	61,1
10	134,9	70,0
11	148,0	76,2

Example 7 — PRODUCTION OF NON-ANTIBODY PROTEINS

[00460] The protease stability of the model proteins IGF1, hGH, and IFNa2b were analyzed by spiking them into supernatant from the 6-fold protease deletion strain (*ApeplAtsplAslplAgaplAgap2Apep4*) M400. The supernatant was collected from a large shake flask culture CAH15. The undiluted supernatant from the shake flask cultivation CAH15 was incubated with the purified model proteins with and without pepstatin A (50 μ M) and SBTI (0.2 mg/ml) inhibitors for 20 hours at 37°C. The 5 day culture supernatant pH was around 4.2. The reaction containing 0.05 μ g/ μ l of model protein was sampled after 20 hours. 50 mM sodium citrate pH 4.0 spiked with model proteins (0.05 μ g/ μ l) was used as a buffer control.

[00461] From each reaction 10 μ l was loaded into an 18% SDS PAGE gel and run for 30 minutes at 200 V. The proteins in the gel were then transferred to nitrocellulose for immunoblotting. The nitrocellulose membrane was blocked for 1 hour at room temperature with 5% milk in TBST buffer. The individual blots were probed with their specific primary antibody to detect the appropriate model protein for 1 hour at room temperature on a shaker. The mouse anti-IGF1 antibody (R&D systems #mab291) was used at 2 μ g/ml diluted in TBST. The mouse anti-rhGH antibody (Abeam #ab51232) was used at 2 μ g/ml diluted in TBST. The mouse anti-IFNa2b antibody (Abeam #ab9386) was used at 1 μ g/ml diluted in TBST. After briefly washing the blot membranes with TBST, the secondary antibody was added for 1 hour at room temperature shaking. The secondary goat anti-mouse AP conjugated antibody (Biorad #170-6520) was diluted 1:10,000 in TBST.

[00462] When incubated overnight in supernatant, full length proteins were observed for hGH, IFNa2b, and IGF1, although the majority appeared to be degraded (Fig. 42). There was a

predominate degradation product for human growth hormone and IFNa2b around 15 kD. However, these 3 model proteins were remarkably stabilized after treating the supernatant with the aspartic protease inhibitor pepstatin A. This inhibitor blocked the key proteases responsible for the majority of the protease activity. The SBTI provided only a small benefit for product stability. Although the pH optimum for SBTI is higher than used in the experiment (pH 4.2 vs. optimal pH 8.0) and thus the binding of these inhibitors to their target proteases may not be most efficient.

[00463] Pepstatin A effectively inhibits aspartic proteases. It is known from affinity purification studies with pepstatin A that the remaining aspartic proteases in the supernatant are *pep2*, *pep3*, and *pep5*. Therefore, if the remaining 2 or 3 aspartic proteases were deleted the supernatant will be almost free of aspartic protease activity. For production of these model proteins, the aspartic proteases *pep2*, *pep3*, and *pep5* would be considered major proteases.

[00464] This same spiking experiment as was done with MAB01 to investigate its stability in the 6 protease deletion supernatant with and without inhibitors (Fig. 43). Samples were taken as described above and immunoblotted with an anti-heavy chain AP conjugated antibody (Sigma #A3188). After 20 hours incubation, there was no significant heavy chain degradation. There was no obvious benefit having used inhibitors. The antibody was stable in this pH 4.2 supernatant. The production of MAB01 under more acidic conditions, such as pH 4.5 would likely improve the production yield or at least decrease the amount of heavy chain cleavage that would occur.

[00465] To evaluate what inhibitors would best stabilize production of hGH, 24 well cultures of these strains were performed. The M369 human growth hormone strain (*ApeplAtsplAslplAgaplAgap2*) was grown along with single components or with combinations of the following: trypsin and subtilisin inhibitor SBTI, the acidic protease inhibitor peptide SIP, the acidic protease inhibitor peptide LIP, the aspartic protease inhibitor pepstatin A free peptide, pepstatin A immobilized to agarose beads, the trypsin and subtilisin inhibitor BBI from lima bean, the subtilisin inhibitor chymostatin, and BSA. Three independent wells were chosen for control wells where no inhibitors or supplements were added. These two strains were grown in 3 ml of TrMM with diammonium citrate without ammonium sulfate, 100 mM PIPPS, 20 g/L spent

grain extract, 40 g/L lactose adjusted to pH 4.5. The 24 well plates were shaken at 800 rpm, 85% humidity, and 28°C. The cultures were grown for 6 days and covered with an air permeable membrane.

[00466] Inhibitors were added first on day 1 and then daily beginning on day 3. 100 μ l samples were taken from the culture wells beginning on day 3. The mycelium was spun down for 5 minutes at 13k and the supernatant collected. From the culture supernatant 12 μ l was loaded in a 4-20% SDS PAGE gel and immunoblotting made on nitrocellulose with mouse anti-hGH antibody (2 μ g/ml) and goat anti-mouse IgG AP conjugated secondary antibody diluted 1:10,000 in TBST.

[00467] On day 4, the human growth hormone could still be seen in the culture supernatant in all the 3 control lanes (Fig. 44). Two of the control lanes show a faint band and one control lane shows a light band. The effect of the inhibitors and supplements was immediately observed. The inhibitor/supplements that had a big effect are highlighted in red and those with the best effect are starred. Pepstatin A had a negative effect on the growth hormone production. When used at 5 or 20 μ M, production of the hGH seemed to be absent. It appears to have some toxic effect on the production. Only when the pepstatin was immobilized onto agarose beads was this effect negated. One of the best treatments was pepstatin A beads plus 0.2 mg/ml SBTI (see the third star on the blot in Figure 44). With only SBTI (0.2 mg/ml) there was improved production, but there was a large degradation band present at 18 kD that appears to be produced by the action of aspartic proteases. As expected, this degradation product was reduced by the addition of pepstatin A beads or the SIP peptide inhibitor. The SIP peptide was beneficial even when used alone at 20 or 50 μ M. There was a noticeable increase in hGH amount when the SIP peptide was used, but the biggest improvement occurred when used in combination with SBTI or BSA. When chymostatin 5 μ M and 25 μ M were used it also improved the amount of full length product observed. Supplementing the culture with BSA (0.25%) alone aids production, but did not prevent the large degradation product from forming.

[00468] Estimating the expression levels relative to the 200 ng control sample, the control wells produced between 3-6 mg/L of hGH, the BSA (0.25%)/SIP (50 μ M)/8BTI (0.2 mg/ml)

treatment produced 24.5 mg/L, the SIP (50 µM)/8BTI (0.2 mg/ml) treatment produced 26.6 mg/L, and the pepstatin A beads/SBTI (0.2 mg/ml) addition yielded 24.5 mg/L of hGH. Therefore, using a combination of inhibitors and additives worked best increasing the production levels by at least 4-fold. The critical parameter was to include an aspartic protease inhibitor into the mix.

Example 8 — GENERATION OF PEP7 DEFICIENT *T. REESEI*

[00469] The deletion plasmid for the aspartic protease *pep7* (TreID58669) is constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1. 1062 bp of 5' flanking regions and 1121 bp of 3' flanking region are selected as the basis of the *pep7* deletion plasmid. Fragments are produced by PCR using the primers listed in Table 8.1. The products are separated with agarose gel electrophoresis and the correct fragments are isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. Template to be used in the PCR of the flanking regions is from the *T. reesei* wild type strain QM6a. The *pyr4* blaster cassette is obtained from pTTv71 (Example 1) with *NotI* digestion. The vector backbone is *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid is constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *pep7* results in deletion in the *pep7* locus and covers the complete coding sequence of PEP7

Table 8.1: Primers for generating *pep7* deletion plasmids.

Deletion plasmid for <i>pep7</i> (TreID58669), vector backbone pRS426	
Primer	Sequence
5flankfw_pRS426	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACCATAAACTTGCGCAGTC GAA (SEQ ID NO: 441)
5flankrev_pyr4	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCGCCGCCTTCT AGGATGGAGCGCTTG (SEQ ID NO: 442)
3flankfw_pyr4	CAACCAGCCGCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGGCCGAGACGG CTTCTTCCAAAACA (SEQ ID NO: 443)
3flankrev_pRS426	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACCCCGAGGGAGGCTATTC TAC (SEQ ID NO: 444)
For screening integration of <i>pep7</i> deletion cassette	
Primer	Sequence
scrn_5forw	CTTTCCAAGCGTTTGAGTCC (SEQ ID NO: 445)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 446)

<u>scm_3rev</u>	<u>GCGTGTTTTATCCTGGTGCT (SEQ ID NO: 447)</u>
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 448)
For screening deletion of pep7 ORF	
<u>orf_fw</u>	<u>CACCTCCGTCGATGAGTTTT (SEQ ID NO: 449)</u>
orf_rev	AGAAGAAGGTGGTGGTGGTG (SEQ ID NO: 450)

Example 9 — GENERATION OF SLP5 DEFICIENT *T. REESEI*

[00470] The deletion plasmid for the aspartic protease *slp5* (TreID64719) is constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1. 1044 bp of 5' flanking regions and 1003 bp of 3' flanking region are selected as the basis of the *slp5* deletion plasmid. Fragments are produced by PCR using the primers listed in Table 9.1. The products are separated with agarose gel electrophoresis and the correct fragments are isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. Template to be used in the PCR of the flanking regions is from the *T. reesei* wild type strain QM6a. The *pyr4* blaster cassette is obtained from pTTv71 (Example 1) with *NotI* digestion. The vector backbone is *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid is constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *slp5* results in deletion in the *slp5* locus and covers the complete coding sequence of SLP5.

Table 9.1: Primers for generating *slp5* deletion plasmids.

Deletion plasmid for <i>slp5</i> (TreID64719), vector backbone pRS426	
Primer	Sequence
5flankfw_pRS426	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACGTTTGAGCATTCTCCCAAGC (SEQ ID NO: 451)
5flankrev_pyr4	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCCGGCCGCCCA TTTTGAAGAAGATGC (SEQ ID NO: 452)
3flankfw_pyr4	CAACCAGCCGAGCCTCAGCCTCTCTCAGCCTCATCAGCCGGCCGCATGCTCCTCGTCATTAAGC (SEQ ID NO: 453)
3flankrev_pRS426	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACACAACACCTTCTCCGACACC (SEQ ID NO: 454)
For screening integration of <i>slp5</i> deletion cassette	
Primer	Sequence
scm_5forw	ATGCCCAAGTTTCGTACCTG (SEQ ID NO: 455)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 456)

<u>scm_3rev</u>	<u>GGCGCATTGAGAAGAAGAAC (SEQ ID NO: 457)</u>
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 458)
For screening deletion of <i>slp5</i> ORF	
<u>orf_fw</u>	<u>CACTTGATGAACGCTGGCTA (SEQ ID NO: 459)</u>
<u>orf_rev</u>	<u>CGTAATGGCGTTGTTGACAG (SEQ ID NO: 460)</u>

Example 10 - GENERATION OF SLP6 DEFICIENT *T. REESEI*

[00471] The deletion plasmid for the aspartic protease *slp6* (TreID121495) is constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1. 1192 bp of 5' flanking regions and 1114 bp of 3' flanking region are selected as the basis of the *slp6* deletion plasmid. Fragments are produced by PCR using the primers listed in Table 10.1. The products are separated with agarose gel electrophoresis and the correct fragments are isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. Template to be used in the PCR of the flanking regions is from the *T. reesei* wild type strain QM6a. The *pyr4* blaster cassette is obtained from pTTv71 (Example 1) with *NotI* digestion. The vector backbone is *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid is constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *slp6* results in deletion in the *slp6* locus and covers the complete coding sequence of SLP6.

Table 10.1: Primers for generating *slp6* deletion plasmids.

Deletion plasmid for <i>slp6</i> (TreID121495), vector backbone pRS426	
Primer	Sequence
5flankfw_pRS426	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACGAGGCAGCCAAAAAGT GAAG (SEQ ID NO: 461)
5flankrev_pyr4	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCGGCCGCTGAAA GAAGGCAGGACCAGT (SEQ ID NO: 462)
3flankfw_pyr4	CAACCAGCCGAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGGCCCAAGAGG CTCGGACAAAGACA (SEQ ID NO: 463)
3flankrev_pRS426	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACGATCGTGGTGCACGAG ACTA (SEQ ID NO: 464)
For screening integration of <i>slp6</i> deletion cassette	
Primer	Sequence
scm_5forw	GCACTGCGTTGCCTTTCTAT (SEQ ID NO: 465)
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA (SEQ ID NO: 466)

<u>scrn_3rev</u>	<u>GAAAGCATGGCTCGTTTCTC (SEQ ID NO: 467)</u>
<u>T028_Pyr4_flank_rev</u>	<u>CATCCTCAAGGCCTCAGAC (SEQ ID NO: 468)</u>
For screening deletion of <i>slp6</i> ORF	
<u>orf_fw</u>	<u>ACCCGGCTCAACTAGCTACA (SEQ ID NO: 469)</u>
<u>orf_rev</u>	<u>AGCTGGCCTTTCGTTACAGA (SEQ ID NO: 470)</u>

Example 11 — GENERATION OF SLP7 DEFICIENT T. REESEI

Generation of *slp7* Deletion Plasmid

[00472] The deletion plasmid pTTv269 for the serine protease *slp7* (trel23865) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1, except that the marker used for selection was *pyr4-hgh* from pTTv194.

[00473] 949 bp of 5' flanking region and 1025 bp of 3' flanking region were selected as the basis of the *slp7* deletion plasmid pTTv269. These fragments were amplified by PCR using the primers listed in Table 11.1. Template used in the PCR of the flanking regions was from the *T. reesei* wild type strain QM6a. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4-hgh* cassette was obtained from pTTv194 (*Apep4-pyr4-hgh*) with *NotI* digestion. To enable removal of the marker cassette, *NotI* restriction sites were introduced on both sides of the cassette. Vector backbone was *EcoKVXhol* digested pRS426 as in Example 1. The plasmid pTTv269 was constructed with the 5' flank, 3' flank, *pyr4-hgh* marker, and vector backbone using the yeast homologous recombination method described in Example 1. This deletion plasmid for *slp7* (pTTv269, Table 11.1) results in a 2019 bp deletion in the *slp7* locus and covers the complete coding sequence of SLP7.

Table 11.1: Primers for generating *slp7* deletion plasmids.

Deletion plasmid pTTv269 (*Lslp7-pyr4-hgh*), vector backbone pRS426

Primer	Sequence
T1088_slp7_5flkfw_vector	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACTCCCATA TGCCTCTTGAAGG
T1089_slp7_5flkrev_pyr4Prom	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCG GCCGCTTGCAGCAAGATGTCGTTT (SEQ ID NO: 472)
T1090_slp7_3flkfw_pyr4loop	CAACCAGCCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGG CCGCTGGGTGATAAGCTTGGGTTT
T1091_slp7_3flkrev_vector	GCGGATAACAATTTTACACAGGAAACAGCGTTTAAACATCATGA TGACCCATCGACA

Example 12 - GENERATION OF SLP8 DEFICIENT T. REESEIGeneration of slp8 Deletion Plasmid

[00474] The deletion plasmid pTTv330 for subtilisin-like protease *slp8* (tre58698) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1, except that the marker used for selection was a double marker *pyr4-hph*.

[00475] 975 bp of 5' flanking region and 1038 bp of 3' flanking region were selected as the basis of the *slp8* deletion plasmid. A 298 bp stretch from the end of *slp8* 5' flank was used as the direct repeat fragment. These fragments were amplified by PCR using the primers listed in Table 12.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4-hph* cassette was obtained from pTTv210 (*Asepl-pyr4-hph*) with *NotI* digestion. To enable removal of the complete double marker cassette, *NoiI* restriction sites were introduced on both sides of the double marker cassette. *AscI* site was introduced between the *slp8* 5'direct repeat and 3' flank. Vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *slp8* (pTTv330, Table 12.1) results in a 1433 bp deletion in the *slp8* locus and cover the complete coding sequence of SLP8.

Table 12.1: Primers for generating *slp8* deletion plasmid.**Deletion plasmid pTTv330 (*Aslp8-pyr4-hph*), vector backbone pRS426**

Primer	Sequence
--------	----------

T1203_slp8_5f_f	GATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACG GTTTAAACATCGTGCTTGGGCTATTCTG
T1204_slp8_5f_r	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAG GCGGCCGCGGAAAGACGCCAGAAAGAAA
T1205_slp8_5dr_f	GTACACTTGTTTAGAGGTAATCCTTCTTTCTAGAAGGAGA GCGGCCGCGCTCGATGTGGATGATACT
T1206_slp8_5dr_r	ATCTATACTGTCTGCACCAAAAAGTACAACAACGCAAA CCGGGCGCGCCGAAAGACGCCAGAAAGAAA
T1207_slp8_3f_f	CGGTTTGC GTTGT TACTT
T1208_slp8_3f_r	TGGAATTGTGAGCGGATAACAATTCACACAGGAAACAGC GTTTAAACACAACCCAACGTTCTCTCGT

Example 13 - PROTEASE HOMOLOGS

[00476] *T. reesei* *pepl*, *pep2*, *pep3*, *pep4*, *pep5*, and *pep7*; *tspl*; *slpl*, *slp2*, *slp3*, *slp5*, *slp6*, *slp7*, and *slp8*; *gap1* and *gap2*; and *tppl* homologs were identified from other organisms.

[00477] BLAST searches were conducted using the National Center for Biotechnology Information (NCBI) non-redundant amino acid database using the *Trichoderma reesei* protease amino acid sequences as queries. Alternatively, FASTA searches were conducted with the UniProt Knowledgebase of European Bioinformatics Institute (EBI). *Trichoderma virens* and *Trichoderma atroviride* BLAST searches were conducted using the DOE Joint Genome Institute's web site (*Trichoderma virens* Gv29-8 v2.0 and *Trichoderma atroviride* v2.0, respectively). Sequence hits from the BLAST searches were aligned using the ClustalW2 alignment tool provided by EBI. Phylogenetic trees were also generated using the sequence alignments.

[00478] Figure 45 depicts a phylogenetic tree of aspartic proteases of selected filamentous fungi.

[00479] Figure 46 depicts a phylogenetic tree of subtilisin proteases of selected filamentous fungi.

[00480] Figure 47 depicts a phylogenetic tree of glutamic proteases of selected filamentous fungi.

[00481] Figure 48 depicts a phylogenetic tree of sedolisin proteases of selected filamentous fungi.

Example 14 - GENERATION OF 9-FOLD PROTEASE DELETION STRAINS

Generation of 9-fold Protease Deletion Strain Having Deletions

Apep1Atsp1Aslp1Agap1Agap2Apep4Apep3Apep5Apep2

Generation of new pep2 deletion plasmids

[00482] The first deletion plasmid, pTTv213, for the aspartic protease *pep2* (tre0053961) was constructed essentially as described for the *Apep1* plasmid pTTv41 in Example 1, but an additional second selection marker cassette carrying hygromycin phosphotransferase gene (*hph*), was placed after the *pyr4* gene creating a deletion plasmid with a double selection marker blaster cassette. The double marker system enables a) utilisation of e.g. *hph* as the initial resistance marker and faster selection; b) transformation of *pyr4+* strains (without the need to generate *pyr4-* prior to transformation); and c) removal of both markers from the transformants using 5-fluoroorotic acid (like in removal of standard *pyr4* blaster cassette) and simultaneous mutagenization of the endogenous *pyr4* resulting in marker-free, *pyr4-* strain. In addition to the double marker, the first deletion plasmid contained also an overexpression cassette for native KEX2 (tre123561; promoter *cDNA1*, terminator *cbh2*).

[00483] The second deletion plasmid for the aspartic protease *pep2* (tre0053961), pTTv232, was constructed using the plasmid pTTv213 above as the backbone. The *kex2* overexpression cassette (*pcDNA1-kex2-tcbh2*) was removed from pTTv213 with *AscI* digestion. Cloning of the plasmid pTTv232 was done with standard ligation (self-ligation) using T4 DNA ligase at room temperature. Part of the ligation mixture was transformed into *E. coli* with electroporation. A few clones were cultivated, plasmid DNA was isolated and digested to screen for correct ligation using standard laboratory methods. Correct ligation was further verified by sequencing.

[00484] The third deletion plasmid for the aspartic protease *pep2* (tre0053961), pTTv246, was constructed using the plasmid pTTv232 above as the backbone. The *pyr4-hph* double marker was removed from pTTv232 with *NotI* digestion. The *pyr4* marker gene was obtained from pTTv181 (*Apep4-pyr4* above) with *NotI* digestion. Cloning of the plasmid pTTv246 was done with standard ligation using T4 DNA ligase at room temperature. Part of the ligation mixture was transformed into *E. coli* with electroporation. A few clones were cultivated, plasmid DNA was isolated and digested to screen for correct ligation using standard laboratory methods. Correct ligation and orientation of the marker was further verified by sequencing.

[00485] 1000 bp of 5' flanking region and 1020 bp of 3' flanking region were selected as the basis of the *pep2* deletion plasmids. A 300 bp stretch from the end of *pep2* 5' flank was used as the direct repeat fragment. These fragments as well as the second selection marker cassette (*hph*), *cDNAI* promoter, native *kex2* gene and *cbh2* terminator were amplified by PCR using the primers listed in Table 14.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4* selection marker was obtained from pTTv181 (*Apep4-pyr4* above) with *NotI* digestion. To enable removal of the complete double marker cassette in pTTv213, *Noil* restriction sites were introduced on both sides of the double marker cassette, and a *SwaI* site between the two selection markers. *AscI* sites were introduced on both sides of the *kex2* overexpression cassette (between *pep2* 5'direct repeat and 3' flank). Vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid pTTv213 was constructed using the yeast homologous recombination method described in Example 1. These deletion plasmids for *pep2* (pTTv213, pTTv232 and pTTv246, Table 14.1) result in a 1580 bp deletion in the *pep2* locus and cover the complete coding sequence of PEP2.

Table 14.1: Primers for generating *pep2* deletion plasmids.

Deletion plasmid pTTv213, vector backbone pRS426	
Primer	Sequence
T431_pep2-5flankF-pRS426	GATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGGTTT AAACCGGTTGTCCATTTTCATCCTTC
T629_pep2_5f_rev_pyr4	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGGCG GCCGCGGGGAAGCAAGTTTTCGAAGT
T630_pep2_5DR_for_trpC	GTACACTGTTTTAGAGGTAATCCTTCTTTCTAGAAGGAGAGCGG CCGCTCCACGCTCTTGCCAC

T631_pep2_5DR_rev_cDNA1	GTCATTAAGTCCATCATTCCACGTCCTTCAGACCGAATTCGGCGC GCCGGGGAAGCAAGTTTCGAAGT
T632_pep2_3f_for_tcbh2	ATGATGCCTTTGCAGAAATGGCTTGCTCGCTGACTGATACGGCG CGCCTATCGCGAAAGTAGCCAATA
T633_pep2_3f_rev	AGCGGATAACAATTTACACAGGAAACAGCGTTTAAACCATCCT TTTCCTCACCACGA
T491_hph_recpyr4_fOr3	TGATTGTACCCAGCTGCGATTGATGTGTATCTTTGCATGATTA AATTCCTTAGCTCTGTACAGT
T492_hph_rev2	GCGGCCGCTCTCCTTCTAGAAAGAAGGA
T495_cDNA1_for	GAATTCGGTCTGAAGGACGT
T138_cDNA1_Rev	GTTGAGAGAAGTTGTTGGATTG
T139_123561For_cDNA1	AACCAAAGACTTTTTGATCAATCCAACAACCTCTCTCAACATGA AGATTTCCTCGATCCTTG
T516_123561Rev	TCAGCGCCGTAACCTCTGC
T496_tcbh2_for	TGATGGTGATGAGGCGGAAAAGCAGAGGTTACGGCGCTGAGGC TTTCGTGACCGGGCTTC
T497_tcbh2_rev	GTATCAGTCAGCGAGCAAGC

Deletion plasmid pTTv232

Primer	Sequence
no new primers, pTTv213 digested with <i>Ascl</i> (to remove <i>kex2</i> overexpression cassette) and self-ligated	

Deletion plasmid pTTv246

Primer	Sequence
no new primers, pTTv232 digested with <i>NotI</i> and ligated with <i>pyr4/NotI</i> -fragment from pTTv181	

Generation of 9-fold protease deletion strain with pep2 (tre53961); M574

[00486] To generate a marker-free 9-fold protease deletion strain, removal of the *pyr4* marker was applied to the 8-fold deletion strain M504 (38-48A, pTTv229 in M496) essentially as described in Example 3 for removal of the *pyr4* blaster cassette from the strain M195 (*Apepl*). Consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells.

[00487] Final clones were verified by PCR using the primers listed in Table 14.2 with standard laboratory methods. Signal corresponding to successful removal of the blaster cassette was obtained for majority of the clones. Removal of the blaster cassette was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. Resulting strain used in generation of 9-fold protease deletion strain was designated with strain number M521.

[00488] To remove vector sequence, plasmid pTTv246 (*Apep2-pyr4*) was digested with *MssI* and the correct fragment purified from an agarose gel using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform a clone of 8-fold protease deletion strain M521 (*Apep1 Atspl Aslpl Agap1 Agap2Apep4Apep3Apep5, pyr4-*). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00489] Transformants were picked as first streaks. Growing streaks were screened by PCR (using the primers listed in Table 14.2) for correct integration. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 14.2. Deletion of *pep2* was verified by Southern analyses from selected clones (data not shown) using methods described in Example 1. Clone 41-45G was designated with strain number M574.

Table 14.2: Primers for screening removal of *pyr4* blaster cassette from 8-fold protease deletion strain and for screening p^{Y_v246}/*Apep2-pyr4* integration and strain purity.

For screening removal *otpyr4* blaster cassette from M504 and strain purity

Primer	Sequence
T858_pep5_5f_f3	GGAATCGTCACCAAGGAG
T755_pep5_3f_rev3	CTTCTGGTGACATTCCGAC
T627_pep5_5int_new	GTCGAAGATGTCCTCGAGAT
T488_pyr4_5utr_rev	GGAGTTGCTTTAATGTCGGG
T860_pep5_orf_f3	GTCGAGCGTCTGATATTCAC
T861_pep5_orf_r2	GACGGAGACCTCCCACA

For screening integration of pTTv246 (*Apep2-pyr4*)

Primer	Sequence
T596_pep2 fwd 5'flank screen	CCTCTGCGTTGAGCAACATA
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTCCA
T600_pep2 rev 3'flank screen	CGAAAGCGTGGAGTCTTCTC

For screening deletion of *pep2* (tre53961) ORF

Primer	Sequence
T601_pep2 fwd	GACGTGGTACGACAACATCG
T623_pep2 rev	TATCAAGGTACCGGGGACAG
T1077_pep2_orf_probef2	AACAAAGCCTTCACAGGCC
T1078_pep2_orf_prober2	TGAGGCTCCTTCCAACCTTTT

Generation of 9-fold Protease Deletion Strain Having DeletionsApep1Atsp1Aslp1Agap1Agap2Apep4Apep3Apep5Apep12*Generation of pep12 deletion plasmids*

[00490] The first deletion plasmid, pTTv209, for the aspartic protease *pepl2* (trel 19876) was constructed essentially as described for the *Apepl* plasmid pTTv41 in Example 1, but an additional second selection marker cassette, a synthetic construct carrying a phosphinothricin N-acetyltransferase gene (*bar*) of *Streptomyces* ssp., was placed after the *pyr4* gene creating a deletion plasmid with a double selection marker blaster cassette. The double marker system enables a) utilisation of e.g. *bar* as the initial resistance marker and faster selection; b) transformation of *pyr4*⁺ strains (without the need to generate *pyr4*⁻ prior to transformation); and c) removal of both markers from the transformants using 5-fluoroorotic acid (like in removal of standard *pyr4* blaster cassette) and simultaneous mutagenization of the endogenous *pyr4* resulting in marker-free, *pyr4*⁻ strain.

[00491] The second deletion plasmid for the aspartic protease *pepl2* (trel 19876), pTTv245, was constructed using the plasmid pTTv209 above as the backbone. The *pyr4-bar* double marker was removed from pTTv209 with *NotI* digestion. The new *pyr4* marker gene was obtained from pTTv181 (*Apep4-pyr4* above) with *NotI* digestion. Cloning of the plasmid pTTv245 was done with standard ligation using T4 DNA ligase at room temperature. Part of the ligation mixture was transformed into *E. coli* with electroporation. A few clones were cultivated, plasmid DNA was isolated and digested to screen for correct ligation using standard laboratory methods. Correct ligation and orientation of the marker was further verified by sequencing.

[00492] 1019 bp of 5' flanking region and 895 bp of 3' flanking region were selected as the basis of the *pepl2* deletion plasmids. A 300 bp stretch from the end of *pepl2* 5' flank was used as the direct repeat fragment. These fragments were amplified by PCR using the primers listed in Table 14.3. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The double marker (*pyr4-bar*) was digested from pTTv202 (*Apep5-pyr4-bar*) with

NotI. To enable removal of the complete double marker cassette, *NotI* restriction sites were introduced on both sides of the double marker cassette. *AscI* site was introduced between the *pepl2* 5' direct repeat and 3' flank. Vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid pTTv209 was constructed using the yeast homologous recombination method described in Example 1. These deletion plasmids for *pepl2* (pTTv209 and pTTv245, Table 14.3) result in a 2198 bp deletion in the *pepl2* locus and cover the complete coding sequence of PEP12.

Table 14.3: Primers for generating *pepl2* deletion plasmids.

Deletion plasmid pTTv209 (<i>Apepl2-pyr4-bar</i>), vector backbone pRS426	
Primer	Sequence
T477_ <i>pepl2</i> _5f_for	GGTAACGCCAGGGTTTTCCCAGTCACGACGGTTTAAAC CGACAGCACGTTGTGTGCTCC
T478_ <i>pepl2</i> _5f_rev	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTA GGCGGCCGCTGGAGACCCAGCAGCCAGCA
T479_ <i>pepl2</i> _DR_for	CCCGTCACCGAGATCTGATCCGTCACCGGGATCCACTTAA GCGGCCGCTCAGAGGGAGGCTGCCCAAC
T480_ <i>pepl2</i> _DR_rev	GAGACTCGAACAAAGACATCTTTGCGACCTCGTCCAC GGCGGCGCGCCTGGAGACCCAGCAGCCAGCA
T481_ <i>pepl2</i> _3f_for	GCCGTGGACGAGGTCGCAAA
T482_ <i>pepl2</i> _3f_rev	AGCGGATAACAATTTACACAGGAAACAGCGTTTAAAC CCCTGCGCCCTCTTCTGCAC
Deletion plasmid pTTv245 (<i>Apepl2-pyr4</i>)	
Primer	Sequence
no new primers, pTTv209 digested with <i>NotI</i> and ligated with <i>pyr4</i> fragment from pTTv181	

*Generation of 9-fold protease deletion strain with *pepl2* (trel 19876); M575*

[00493] To generate a marker-free 9-fold protease deletion strain, removal of the *pyr4* marker was applied to the 8-fold deletion strain M504 (38-48A, pTTv229 in M496) essentially as described in Example 3 for removal of the *pyr4* blaster cassette from the strain M195 (*Apepl*). Consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells.

[00494] Final clones were verified by PCR using the primers listed in Table 14.4 with standard laboratory methods. Signal corresponding to successful removal of the blaster cassette was

obtained for majority of the clones. Removal of the blaster cassette was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. Resulting strain used in generation of 8-fold protease deletion strain was designated with strain number M521.

[00495] To remove vector sequence, plasmid pTTv245 (*Apepl2-pyr4*) was digested with *MssI* and the correct fragment purified from an agarose gel using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform a clone of 8-fold protease deletion strain M521 (*ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5, pyr4-*). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00496] Transformants were picked as first streaks. Growing streaks were screened by PCR (using the primers listed in Table 14.4) for correct integration. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 14.4. Deletion of *pepl2* was verified by Southern analyses from selected clones (Data not shown) using methods described in Example 1. Clone 42-45B was designated with strain number M575.

Table 14.4: Primers for screening removal of *pyr4* blaster cassette from 8-fold protease deletion strain and for screening pTTv245/*Apepl2-pyr4* integration and strain purity.

For screening removal <i>otpyr4</i> blaster cassette from M504 and strain purity	
Primer	Sequence
T858_pep5_5f_f3	GGAATCGTCACCAAGGAG
T755_pep5_3f_rev3	CTTCTGGTGACATTCCGAC
T627_pep5_5int_new	GTCGAAGATGTCCTCGAGAT
T488_pyr4_5utr_rev	GGAGTTGCTTTAATGTCGGG
T860_pep5_orf_f3	GTCGAGCGTCTGATATTCAC
T861_pep5_orf_r2	GACGGAGACCTCCCACA
For screening integration of pTTv245 (<i>bpepl2-pyr4</i>)	
Primer	Sequence
T517_pepl2_5int	AGCAGTCCACCTGCTCAAAA
T026_Pyr4_orf_5rev2	CCATGAGCTTGAACAGGTAA
T061_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTTCCA
T518_pepl2_3int	GATTCACACCAATGAGTCGG
For screening deletion of <i>pepl2</i> (trel 19876) ORF	

T486_pep12_orf_probef	CCCCGACTTTGCCCCGTCAC
T487_pep12_orf_prober	TCGTCAGAGTCGTCGCCCGT
T1057_pep12_orf_probef2	GCGCAGCTAATGTCCTCTGT
T1058_pep12_orf_prober2	TTGTTGAGCCAGAGTCGAGA

Example 15 - Generation of 10-fold protease deletion strain

Generation of 10-fold Protease Deletion Strain Having Deletions

Apep1AtsplAsplAgap1Agap2Apep4Apep3Apep5Apep2Apep11

Generation of pep11 deletion plasmid

[00497] The deletion plasmid pTTv312 for the aspartic protease *pep11* (tre121306) was constructed essentially as described for *pep1* deletion plasmid pTTv41 in Example 1.

[00498] 956 bp of 5' flanking region and 943 bp of 3' flanking region were selected as the basis of the *pep11* deletion plasmid. A 307 bp stretch from the end of *pep11* 5' flank was used as the direct repeat fragment. These fragments were amplified by PCR using the primers listed in Table 15.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4* cassette was obtained from pTTv181 (*Apep4-pyr4* above) with *NotI* digestion. To enable removal of the marker cassette, *NoiI* restriction sites were introduced on both sides of the cassette. *AscI* site was introduced between the *pep11* 5' direct repeat and 3' flank. Vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *pep11* (pTTv312, Table 15.1) results in 2624 bp deletion in the *pep11* locus and covers the complete coding sequence of PEP1 1.

Table 15.1: Primers for generating *pep11* deletion plasmids.

Deletion plasmid pTTv312 (*&pep11-pyr4*), vector backbone pRS426

Primer	Sequence
T1009_pep11_5flkw_vector	GTAACGCCAGGGTTTTCCCAGTCACGACGGTTTAAAC ATGAGCGTGATCGACAAGTG

T1010_pepl 1_5flkrev_pyr4Prom	GCGCTGGCAACGAGAGCAGAGCAGAGCAGTAGTCGATGCTAG GCGGCCGCCCTCTGAGGTCGAGATGGAG
T1144_pepl 1_5dr_for	TGATTGTACCCCAGCTGCGATTGATGTGTATCTTTGCAT GGCGGCCGCACGACTAATATCCACTGCCG
T1145_pepl 1_5dr_rev	AACCAAAGTGTACAATGCTCATCTCGTATTCACATGCAAA GGCGCGCCCTCTGAGGTCGAGATGGAG
T1146_pepl 1_3f_for	TTTGCATGTGAATACGAGATGA
T1012_pepl 1_3flkrev_vector	GCGGATAACAATTCACACAGGAAACAGCGTTTAAAC TGCTCGATCCTACTCCAAGG

Generation of 10-fold protease deletion strain with pepl1 (trel21306); M658

[00499] To generate a marker-free 10-fold protease deletion strain, removal of the *pyr4* marker was applied to the 9-fold deletion strain M574 (41-45G, pTTv246 in M521) essentially as described in Example 3 for removal of the *pyr4* blaster cassette from the strain M195 (*Apepl1*). Consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells.

[00500] Final clones were verified by PCR using the primers listed in Table 15.2 with standard laboratory methods. Signal corresponding to successful removal of the blaster cassette was obtained for majority of the clones. Removal of the blaster cassette was further verified by plating the clones onto minimal medium plates with or without 5 mM uridine. No growth was observed on the plates without uridine supplementation. Resulting strain used in generation of 10-fold protease deletion strain was designated with strain number M597.

[00501] To remove vector sequence, plasmid pTTv312 (*Apepl1-pyr4*) was digested with *MssI* and the correct fragment purified from an agarose gel using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform a clone of 9-fold protease deletion strain M597 (*Apepl1Atspl1Aslpl1Agapl1Agap2Apep4Apep3Apep5Apep2, pyr4-*). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using *pyr4* selection.

[00502] Transformants were picked as first streaks. Growing streaks were screened by PCR (using the primers listed in Table 15.2) for correct integration. Clones giving the expected signals

were purified to single cell clones and rescreened by PCR using the primers listed in Table 15.2. Deletion of *pepll* was verified by Southern analyses from selected clones (data not shown) using methods described in Example 1. Clone 47-62B was designated with strain number M632. An additional single cell purification step was applied to strain M632 to obtain 10-fold protease deletion strain M658.

Table 15.2: Primers for screening removal of *pyr4* blaster cassette from 9-fold protease deletion strain and for screening *pTTv312*/*pepll-pyr4* integration and strain purity.

For screening removal of *pyr4* blaster cassette from M574 and strain purity

Primer	Sequence
T1162_pep2_5f_f2	CTGTAAAGGCAGCATCGG
T1163_pep2_3f_r2	TCAGAACGGCTTCAATCATT
T1162_pep2_5f_f2	CTGTAAAGGCAGCATCGG
T488_pyr4_5utr_rev	GGAGTTGCTTTAATGTCTGGG
T601_pep2 fwd	GACGTGGTACGACAACATCG
T623_pep2 rev	TATCAAGGTACCGGGGACAG

For screening integration of pTTv312 (*Apepll-pyr4*)

Primer	Sequence
T1013_pepl_1_screen_5flk_fwd	TTACGACTCGATCCCTGTCC
T488_pyr4_5utr_rev	GGAGTTGCTTTAATGTCTGGG
T06_1_pyr4_orf_screen_2F	TTAGGCGACCTCTTTTTCCA
T1016_pepl_1_screen_3flk_rev	GCCGCTAGGATCGTGATAAG

For screening deletion of *pepll* ORF

Primer	Sequence
T1017_pepl_1_orf_fwd	GTGTCCCAGGACGACAACCTT
T1018_pep11_orf_rev	TGAAGGTTGCAGTGATCTCG

Example 16 - GENERATION OF TPPI DELETION PLASMID

[00503] The deletion plasmid pTTv331 for tripeptidyl peptidase *tppl* (tre82623) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1, except that the marker used for selection was a double marker *pyr4-hph*.

[00504] 1245 bp of 5' flanking region and 1025 bp of 3' flanking region were selected as the basis of the *tppl* deletion plasmid. A 311 bp stretch from the end of *tppl* 5' flank was used as the direct repeat fragment. These fragments were amplified by PCR using the primers listed in Table

16.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4-hph* cassette was obtained from pTTv210 (*Asepl-pyr4-hph*) with *NoI* digestion. To enable removal of the complete double marker cassette, *NoI* restriction sites were introduced on both sides of the double marker cassette. *AscI* site was introduced between the *tppl* 5' direct repeat and 3' flank. Vector backbone was *EcoRVXhoI* digested pRS426 as in Example 1. The plasmid was constructed using the yeast homologous recombination method described in Example 1. This deletion plasmid for *tppl* (pTTv331, Table 16.1) results in 2152 bp deletion in the *tppl* locus and covers the complete coding sequence of TPP1.

Table 16.1: Primers for generating *tppl* deletion plasmid.

Deletion plasmid pTTv331 (<i>Atpp1-pyr4-hph</i>), vector backbone pRS426	
Primer	Sequence
T311_82623_5for	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAAC CGCATTACGAATGCACAAAG
T1190_tppl_5f_rev2	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTA GGCGGCCGCCCATGTCAGCTCAGACCAAT
T1191_tppl_5dr_for	GTACACTTGTTTTAGAGGTAATCCTTCTTTCTAGAAGGAGA GCGGCCGCAGGCCCTGGACTGCTAGTTT
T1192_tppl_5dr_rev	CGAGCCATCCGCCGCGGCCCTATATTCCACCCGAGTCCT CGGCGCGCCCCATGTCAGCTCAGACCAAT
T1193_tppl_3f_for2	GAGGACTCGGGTGGGAATATAGG
T314_82623_3rev	GCGGATAACAATTTACACAGGAAACAGCGTTTAAAC TTGGTCTTGAATGAAAGGTGTG

Example 17 - GENERATION OF PEP8 DELETION PLASMIDS

[00505] Another deletion plasmid pTTv319 for aspartic protease *pep8* (tr122076) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1.

[00506] The second deletion plasmid for the aspartic protease *pep8* (tr122076), pTTv328, was constructed using the plasmid pTTv319 above as the backbone. The *pyr4* marker was removed from pTTv319 with *NoI* digestion. The *pyr4-hph* cassette was obtained from pTTv210 (*Asepl-pyr4-hph*) with *NoI* digestion. Cloning of the plasmid pTTv328 was done with standard ligation using T4 DNA ligase at room temperature. Part of the ligation mixture was transformed

into *E. coli* with electroporation. A few clones were cultivated, plasmid DNA was isolated and digested to screen for correct ligation using standard laboratory methods. Correct ligation and orientation of the marker was further verified by sequencing.

[00507] 1095 bp of 5' flanking region and 988 bp of 3' flanking region were selected as the basis of the *pep8* deletion plasmids. A 324 bp stretch from the end of *pep8* 5' flank was used as the direct repeat fragment. These fragments were amplified by PCR using the primers listed in Table 17.1. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4* selection marker used in pTTv319 was obtained from pTTv181 (*Apep4-pyr4* above) with *NotI* digestion. To enable removal of the *pyr4* marker cassette, *NotI* restriction sites were introduced on both sides of the cassette. *AscI* site was introduced between the *pep8* 5' direct repeat and 3' flank. Vector backbone was *EcoRVXhoI* digested pRS426 as in Example 1. The plasmid pTTv319 was constructed using the yeast homologous recombination method described in Example 1. These deletion plasmids for *pep8* (pTTv319 and pTTv328, Table 17.1) result in a 1543 bp deletion in the *pep8* locus and cover the complete coding sequence of PEP8.

Table 17.1: Primers for generating *pep8* deletion plasmid.

Deletion plasmid pTTv319 (<i>Apep8-pyr4</i>), vector backbone pRS426	
Primer	Sequence
T 1019_pep8_5flkw_ vector	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAAC AGGTTTGGGTGTGAGATCG
T 1020_pep8_5flkrev_pyr4Prom	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTA GGCGGCCGCGCGCAAAGCTACTGGGCTAT
T 1167_pep8_5DR_for	TGATTGTACCCAGCTGCGATTGATGTGTATCTTTGCAT GGCGGCCGCTCTGCTCTGCTCTGTTCTGC
T 1168_pep8_5DR_rev	AAAGTTCGTCAAAGAGCACTCATAGGGCTGAGAAAA GCCAGGCGCGCCGCGCAAAGCTACTGGGCTAT
T 1169_pep8_3f_for2	TGGCTTTTCTCAGCCCTATG
T1022_pep8_3flkrev_vector	GCGGATAACAATTCACACAGGAAACAGCGTTTAAAC CAATGTGTGCCTGTTTTTCG
Deletion plasmid pTTv328 (<i>Apep8-pyr4-hph</i>)	
Primer	Sequence
no new primers, pTTv319 digested with <i>NotI</i> and ligated with <i>pyr4-hph</i> fragment from pTTv210	

[00508] The third deletion plasmid pTTv266 for aspartic protease *pep8* (trel 22076) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1, except that the marker used for selection was *pyr4-hgh* from pTTv194.

[00509] 1095 bp of 5' flanking region and 988 bp of 3' flanking region were selected as the basis of the *pep8* deletion plasmid pTTv266. These fragments were amplified by PCR using the primers listed in Table 17.2. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4-hgh* selection marker used in pTTv266 was obtained from pTTv194 (*Apep4-pyr-hgh* above) with *NotI* digestion. To enable removal of the *pyr4-hgh* marker cassette, *NotI* restriction sites were introduced on both sides of the cassette. Vector backbone was *EcoRVXhoI* digested pRS426 as in Example 1. The plasmid pTTv266 was constructed with the 5' flank, 3' flank, *pyr4-hgh* marker, and vector backbone using the yeast homologous recombination method described in Example 1. The deletion plasmids for *pep8* (pTTv266, Table 17.2) result in a 1543 bp deletion in the *pep8* locus and cover the complete coding sequence of PEP8.

Table 17.2: Primers for generating *pep8* deletion plasmid.

Deletion plasmid pTTv266 (<i>Apep8-pyr4-hgh</i>), vector backbone pRS426	
Primer	Sequence
T1019_peg8_5flkfw_vector	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAACAGGTTT GGTTGTGAGATCG
T1020_peg8_5flkrev_pyr4Prom	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAGG CGGCCGCGCGCAAAGCTACTGGGCTAT
T1021_peg8_3flkfw_pyr41oop	CAACCAGCCGCGCCTCAGCCTCTCTCAGCCTCATCAGCCGC GGCCGCTGGCTTTTCTCAGCCCTATG
T1022_peg8_3flkrev_vector	GCGGATAACAATTTACACAGGAAACAGCGTTTAAACCAATG TGTGCCTGTTTTTCG

Example 18 - GENERATION OF PROTEASE DELETIONS IN THE INTERFERON PRODUCING STRAINS

Generation of IFN-a 2b Producing 5-fold Protease Deletion Strain

[00510] To generate the IFN-a 2b producing strain for the five fold protease deletion strain, the *ApeplAtsplAslplAgaplAgap2* five fold protease deletion strain M369 was transformed with IFN-a 2b expression cassette (pTTv173) using hygromycin in selection. This IFN-a 2b strain with *ApeplAtsplAslplAgaplAgap2* five fold protease deletions was designated with number M401.

Analysis of IFN-a 2b producing 5-Fold Protease Deletion Strain M401

[00511] To study the expression level of IFN-a 2b, the 5-fold protease deletion (*ApeplAtsplAslplAgaplAgap2*) IFN-a 2b producing strain M401 was cultured in culture conditions pH 4,5; 28->22°C; 30 g/l glucose, 60 g/l lactose, 20 g/l whole spent grain, and 20 g/l spent grain extract. To analyze the expression level of IFN-a 2b, day 3 culture sample was subjected to quantitative immunoblotting (Fig. 54A). The samples were analysed by comparison to IFN-a 2b standard curve and the densitometric quantification was done with Totallab Quant TL100 software. Immunoblotting was done with Abeam (#ab9386) anti-IFN-a 2b antibody diluted to 1 µg/ml in TBST. The secondary antibody from Bio-rad (#170-6520) goat anti-mouse IgG AP conjugated secondary antibody diluted 1:5000 in TBST. The protein standards were loaded to the gel corresponding 50 ng, 100 ng, 200 ng and 400 ng of IFN-a 2b. The analysis showed that M401 produced IFN-a 2b at yields of up to 51.9 mg/l and 52% of the product was cleaved from the carrier molecule.

Generation of IFN-a 2b producing 8-fold protease deletion strain M577

[00512] To generate the IFN-a 2b producing strain for the eight fold protease deletion strain, the *ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5* eight fold protease deletion strain M504 was transformed with IFN-a 2b expression cassette (pTTv254) using acetamide in selection. This IFN-a 2b strain with *ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5* eight fold protease deletions was designated with number M577.

Analysis of IFN-a 2b producing 8-Fold Protease Deletion Strain M577

[00513] To study the expression level of IFN-a 2b, the 8-fold protease deletion (*ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5*) IFN-a 2b producing strain M577 was cultured in the conditions pH 4,5; 28->22°C; 2% yeast extract, 4% cellulose, 8% cellobiose and 4% sorbose. To study the expression of IFN-a 2b, M577 fermentation samples were subjected to immunoblotting (Fig. 54B). To analyse the expression level of IFN-a 2b, day 4 culture sample was subjected to quantitative immunoblotting (Fig. 55). The sample was analysed by comparison to IFN-a 2b standard curve and the densitometric quantification was done with TotalLab Quant TL100 software. Immunoblotting was done with Abeam (#ab9386) anti-IFN-a 2b antibody diluted to 1 µg/ml in TBST. The secondary antibody from Bio-rad (#170-6520) goat anti-mouse IgG AP conjugated secondary antibody diluted 1:5000 in TBST. The protein standards were loaded to the gel corresponding 50 ng, 100 ng and 200 ng of IFN-a 2b. The analysis showed that M577 produced IFN-a 2b at yields of up to 1780 mg/l and 66.5% of the product was cleaved from the carrier molecule. The 8-fold protease deletion strain M577 produced 34 times more IFN-a 2b than 5-fold protease deletion strain M401.

Generation of IFN-a 2b producing 9-fold Protease Deletion Strain M652

[00514] To generate the IFN-a 2b producing strain for the nine fold protease deletion strain, the *ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5Apep2* nine fold protease deletion strain M574 was transformed with IFN-a 2b expression cassette (pTTv173) using hygromycin in selection. This IFN-a 2b strain with *ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5Apep2* nine fold protease deletions was designated with number M652.

Analysis of IFN-a 2b producing 9-Fold Protease Deletion Strain M652

[00515] To study the expression level of IFN-a 2b, the 8-fold protease deletion (*ApeplAtsplAslplAgaplAgap2Apep4Apep3Apep5Apep2*) IFN-a 2b producing strain M652 was cultured in the conditions pH 4,5; 28->22°C; 2% yeast extract, 4% cellulose, 8% cellobiose and 4% sorbose. To study the expression of IFN-a 2b, M652 fermentation samples were subjected to immunoblotting (Fig. 54B). To analyse the expression level of IFN-a 2b, day 3 culture sample was subjected to quantitative immunoblotting (Fig. 55). The sample was analysed by comparison

to IFN- α 2b standard curve and the densitometric quantification was done with Totallab Quant TL100 software. Immunoblotting was done with Abeam (#ab9386) anti-IFN- α 2b antibody diluted to 1 μ g/ml in TBST. The secondary antibody from Bio-rad (#170-6520) goat anti-mouse IgG AP conjugated secondary antibody diluted 1:5000 in TBST. The protein standards were loaded on the gel corresponding 50 ng, 100 ng and 200 ng of IFN- α 2b. The analysis showed that M652 produced IFN- α 2b at yields of up to 1928 mg/1 and 85% of the product was cleaved from the carrier molecule. The 9-fold protease deletion strain M652 produced slightly more than 8-fold protease deletion M577 and 37 times more IFN- α 2b than 5-fold protease deletion strain M401.

Generation of 9-fold protease deletion strain M670 with pep8 (trel22076) deleted from the interferon production strain M577

[00516] To remove the deletion cassette, plasmid pTTv266 (*Apep8-pyr4-hgh*) was digested with *PmeI* and the correct fragment was purified using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 μ g of the deletion cassette was used to transform the 8-fold protease deletion strain M577 (*Apepl Atspl Aslpl Agapl Agap2Apep4Apep3Apep5*). The M577 strain produces interferon alpha 2b. Preparation of protoplasts and transformation were carried out essentially as described in Example 1 using hygromycin selection.

[00517] Transformants were picked and streaked on selection plates. Growing streaks were screened by PCR (using the primers listed in Table 18.1) for correct integration. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 18.1. Clone 82-9 was designated with strain number M670.

Table 18.1: Primers for screening pTTv266/*Apep8-pyr4-hgh* integration and strain purity.

For screening integration of pTTv266 (*Apep8-pyr4-hgh*)

Primer	Sequence
T1023_pep8_screen_5flk_fwd	TTTATCCGCTTCCACGACAC
T1084_screen_5flk_pyr_rev	TCTTGAGCACGACAATCGAC
T1015_screen_3flk_hygro_f wd	GCATGGTTGCCTAGTGAATG
T1024_pep8_screen_3flk_rev	CGATGGTGAAGTCAATGTGG

For screening deletion *oipep8* ORF

T1025_pep8_orf_fwd	GGCGATTACTTCCAGGACAA
T1026_pep8_orf_rev	CAATGGCAATCTGGTTGTTG

*Generation of *pepll* deletion plasmid*

[00518] The deletion plasmid pTTv268 for the aspartic protease *pepll* (trel21306) was constructed essentially as described for *pepl* deletion plasmid pTTv41 in Example 1, except that the marker used for selection was *pyr4-hgh* from pTTv194.

[00519] 956 bp of 5' flanking region and 957 bp of 3' flanking region were selected as the basis of the *pepll* deletion plasmid pTTv268. These fragments were amplified by PCR using the primers listed in Table 18.2. The products were separated with agarose gel electrophoresis and the correct fragments were isolated from the gel with a gel extraction kit (Qiagen) using standard laboratory methods. The *pyr4-hgh* cassette was obtained from pTTv194 (*Apep4-pyr-hgh*) with *NotI* digestion. To enable removal of the marker cassette, *Noil* restriction sites were introduced on both sides of the cassette. Vector backbone was *EcoRI/XhoI* digested pRS426 as in Example 1. The plasmid was constructed. The plasmid pTTv268 was constructed with the 5' flank, 3' flank, *pyr4-hgh* marker, and vector backbone using the yeast homologous recombination method described in Example 1. This deletion plasmid for *pepll* (pTTv268, Table 18.2) results in a deletion in the *pepll* locus and covers the complete coding sequence of PEP1 1.

Table 18.2: Primers for generating *pepll* deletion plasmids.

Deletion plasmid pTTv268 (<i>bpepll-pyr4-hgh</i>), vector backbone pRS426	
Primer	Sequence
T1009_pepl_1_5flkfw_vector	GTAACGCCAGGGTTTTCCAGTCACGACGGTTTAAAC ATGAGCGTGATCGACAAGTG
T1010_pepl_1_5flkrev_pyr4Prom	GCGCTGGCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAG GCGGCCGCCCTCTGAGGTCGAGATGGAG
T1011_pepl_1_3flkfw_pyr4loop	CAACCAGCCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGCGG CCGCTTTGCATGTGAATACGAGATGA
T1012_pepl_1_3flkrev_vector	GCGGATAACAATTTACACAGGAAACAGCGTTTAAAC TGCTCGATCCTACTCCAAGG

*Generation of 9-fold protease deletion strain M672 with *pepll* (trel21306) deleted from the interferon production strain M577*

[00520] To remove the deletion cassette, plasmid pTTv268 (*Apepl1-pyr4-hgh*) was digested with *PmeI* and the correct fragment was purified using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform the 8-fold protease deletion strain M577 (*Apepl1Atspl1Aslpl1Agapl1Agap2Apep4Apep3Apep5*). The M577 strain produces interferon alpha 2b. Preparation of protoplasts and transformation were carried out essentially as described in Example 1 using hygromycin selection.

[00521] Transformants were picked and streaked on selection plates. Growing streaks were screened by PCR (using the primers listed in Table 18.3) for correct integration. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 18.3. Clone 33-9 was designated with strain number M672.

Table 18.3: Primers for screening pTTv268/*Apepl1-pyr4-hgh* integration and strain purity.

For screening integration of pTTv268 (<i>Apepl1-pyr4-hgh</i>)	
Primer	Sequence
T1013_pepl1_screen_5flk_fwd	TTACGACTCGATCCCTGTCC
T1084_screen_5flk_pyr_rev	TCTTGAGCACGACAATCGAC
T1015_screen_3flk_hygro_fwd	GCATGGTTGCCTAGTGAATG
T1016_pepl1_screen_3flk_rev	GCCGCTAGGATCGTGATAAG
For screening deletion of <i>pepl1</i> ORF	
T1017_pepl1_orf_fwd	GTGTCCCAGGACGACAACCT
T1018_pepl1_orf_rev	TGAAGGTTGCAGTGATCTCG

*Generation of 9-fold protease deletion strain M673 with *slp7* (*trel23865*) deleted from the interferon production strain M577*

[00522] To remove the deletion cassette, plasmid pTTv269 (*Aslp7-pyr4-hgh*) was digested with *PmeI* and the correct fragment was purified using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform the 8-fold protease deletion strain M577 (*Apepl1Atspl1Aslpl1Agapl1Agap2Apep4Apep3Apep5*). The M577 strain produces interferon alpha 2b. Preparation of protoplasts and transformation were carried out essentially as described in Example 1 using hygromycin selection.

[00523] Transformants were picked and streaked on selection plates. Growing streaks were screened by PCR (using the primers listed in Table 18.4) for correct integration. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 18.4. Clone 5-64 was designated with strain number M673.

Table 18.4: Primers for screening pTTv269/*slp7-pyr4-hgh* integration and strain purity.

For screening integration of pTTv269 (*Aslp7-pyr4-hgh*)

Primer	Sequence
T1092_slp7_screen_5flk_fwd	TTGGTTTGAACAGCTGCAAG
T1084_screen_5flk_pyr_rev	TCTTGAGCACGACAATCGAC
T1015_screen_3flk_hygro_f wd	GCATGGTTGCCTAGTGAATG
T1093_slp7_screen_3flk_rev	ATGGTCAGCCAGAACCTGAC

For screening deletion of *slp7* ORF

T1094_slp7_orf_fwd	TCTTGAGCCGTTTCTCGAAT
T1095_slp7_orf_rev	CCGCTCTTAGATCGATGGTC

Example 19 - GENERATION OF G OPRODUCING STRAINS M627 AND M629

[00524] Vectors pTTgl56 and pTTgl73 were constructed by adding the double selection marker cassette (Hygromycin resistance marker gene (*hph*) between *pkil* promoter and *cbh2* terminator in addition to *pyr4* expression cassette) to intermediate vectors pTTgl45 and pTTgl46. Intermediates were constructed by yeast recombination cloning, marker cassettes were added by conventional cloning by NotI digestion and ligation.

[00525] The generation strategy of fragments for intermediate vectors is presented on Table 19.1 below. Primers used for fragment generation are listed on Table 19.2 below. Once the fragments for pTTgl45 and pTTgl46 were constructed according to plan on Table 19.1, they were electroporated to yeast *Saccharomyces cerevisiae* FY834 for plasmid assembly by homologous recombination. Yeast cells were plated to SC-ura for 2-3 days cultivation in +30°C. Colonies were then pooled from the plates and plasmid pool was purified with Phenol/Chloroform extraction method. Plasmid pool was transformed to competent *E. coli* cells by electroporation. Electroporated cells were plated to LB+amp selection plates, cultivated

+37°C over night and colonies were screened by PCR. Positive colonies were then streaked to fresh plates as pure cultures, single colonies were cultured in liquid LB+amp media and potential intermediate vectors pTTg145 and pTTg146 were purified according to standard protocols. Plasmids were analyzed by restriction analysis and sequences were verified by sequencing.

[00526] Marker cassette was then added to vectors by conventional *NotI* digestion from pTTg163 and ligation into *NotI* linearized intermediates pTTg145 and pTTg146.

Table 19.1: Construction strategy of intermediate vectors pTTg145-pTTg149. The pTTv141 and pTTv11 are described in International Patent Application No. PCT/EP2011/070956. The plasmids pTTg124 and pTTv225 were used for construction of fragments specified in table below.

Vector code	Fragment 1	Fragment 2	Fragment 3	Fragment 4
pTTg145 (intermediate for pTTg156)	pTTv141 cut with <i>NotI</i>	PCR product from pTTg124 template GP364, GP334 >pCDNA promoter sequence and overlap to <i>GnTI</i>	pTTv11 cut with <i>SacII/NdeI</i>	PCR product from pTTv11 template GP342, GP358
pTTg146 (intermediate for pTTg173)	pTTv141 cut with <i>NotI</i>	PCR product from pTTv225 template GP395, GP334 >pCDNA promoter sequence with <i>Kre2</i> leader and overlap to <i>GnTI</i>	PCR product from pTTv11 template GP340, GP336	n/a

Table 19.2: Primers used for construction of intermediate vectors pTT145-pTTg149.

Code	Sequence 5' > 3'
GP364	TCTCCACTCGACCTGCAGGCATGCGCGATCGCGCGGCCGAATTCGGTCTGAAGGACGTGG
GP334	TGGCGCCCCACAGCACAAAGCCCTGCAGACTGCTTCTTCAGCATGTTGAGAGAAGTTGTTGG
GP395	CATCTCCACTCGACCTGCAGGCATGCGCGATCGCGCGGCCGAATTCGGTCTGAAGGACGTGG
GP340	GGGGATGCCCTGTCGAGCCAGCGGGGAGGGTGCCACCGCCGCCCTCCCGCCCAGCCG
GP336	GAAGGTGGTTTTTGCCTGTATAAGCCAGCCATCCGGCATACTGCCCGCGGCCGCCCTGCAGTGCAGGATCTGC
GP342	TGGCGCCCCACCGACGTGGGAGGGCTATGATCCCAGCTGGAATTAGCATATGATTAATTAAGG
GP358	GGTTTTTGCCTGTATAAGCCAGCCATCCGGCATACTGCCCGCGGCCGAGTGCAGGATCTGC

[00527] *Trichoderma reesei* MAB01 expression strain M507 with 7-fold protease deletion was transformed with the *Pmel* fragments of pTTgl56 and pTTgl73 targeted to *alg3* locus. Variable amount of transformants (100-170 depending on the construct) were picked onto selective plates. On the basis of PCR screening with Phire Plant Direct PCR kit (Finnzymes F-130), clones with positive results concerning 5'- and 3'-integration were selected for single spore platings and re-screening for integration and *alg3* deletion (5 clones from pTTgl56 transformation, 3 clones from pTTgl73 transformation). Primers used for screening are listed on Table 19.3 below.

[00528] PCR-screened strains were finally subjected to shake flask cultivation and glycan analysis. Final strains were named as M629 (pTTgl73 transformant) and M627 (pTTgl56 transformant).

Table 19.3: Primers used for screening *alg3* integration in M507 pTTgl56 and pTTgl73.

Code	Description	Sequence 5' – 3'
GP488	<i>alg3</i> 5' integration screen Forward outside the flank	GATGTTGCGCCTGGGTTGAC
GP495	<i>alg3</i> 5' integration screen Reverse from pGPDA	CTTCTTATTGATTTGAGCC
GP490	<i>alg3</i> 3' integration screen Reverse outside the flank	GATTGTCATGGTGTACGTGA
GP497	<i>alg3</i> 3' integration screen Forward from <i>cbhII</i> terminator	GAGCCGCATCGCATAG
GP491	<i>alg3</i> orf, forward (1492 bp product)	GCGTCACTCATCAAACTGC
GP492	<i>alg3</i> orf, reverse (1492 bp product)	CTTCGGCTTCGATGTTTCA

WSG Fermentation of Strains M627 and M629 and Glycan Analysis

[00529] *T. reesei* strains M627 and M629 were fermented in 4% WSG, 2% glucose, 4% cellobiose, 6% lactose, pH 5.5, and sampling was performed at days 3-6. The antibody titers are shown in Table 19.4.

[00530] For N-glycan analysis MAB01 was purified from culture supernatants using Protein G HP MultiTrap 96-well filter plate (GE Healthcare) according to manufacturer's instructions. The antibody concentrations were determined via UV absorbance against MAB01 standard curve.

[00531] N-glycans were released from EtOH precipitated and SDS denatured antibody using PNGase F (ProZyme Inc.) in 20 mM sodium phosphate buffer, pH 7.3, in overnight reaction at +37°C. The released N-glycans were purified with Hypersep C-18 and Hypersep Hypercarb (Thermo Scientific) and analysed with MALDI-TOF MS. The results are shown in Table 19.6. In the strains M627 and M629 GO levels ranged between 24.3% to 41.7%, no GO was seen in the strain M507.

WSG Cultivation in Shake Flasks of Strains M627 and M629 and Glycan Analysis

[00532] *T. reesei* strains M627 and M629 were cultivated in shake flasks in TrMM, 4% lactose, 2% SGE, 100 mM PIPPS, pH 5.5, at +28°C. Sampling was performed at day 5.

[00533] For N-glycan analysis MAB01 was purified from culture supernatants using Protein G HP MultiTrap 96-well filter plate (GE Healthcare) according to manufacturer's instructions. The antibody concentrations in Protein G eluents were determined via UV absorbance against MAB01 standard curve (Table 19.5). Titers in culture medium were not measured.

[00534] N-glycan release was performed as above, the results are shown in Table 19.7. GO levels were 21.1 and 56.9 % for M627 and M629, respectively.

Table 19.4: Antibody titers in fermentation culture supernatants of strains M627 and M629 fermented in WSG medium.

Strain	Titer (g/l)			
	day 3	day 4	day 5	day 6
M627	0.294	0.580	0.813	0.818
M629	0.292	0.538	0.755	0.821

Table 19.5: Antibody concentrations in Protein G eluents of strains M627 and M629 cultivated in WSG medium in shake flasks.

Strain	Titer (g/l) in Prot G eluent
	day 5
M507	0.303
M627	0.105
M629	0.103

Table 19.6: Relative proportions of neutral N-glycans from purified antibody from strains M627 and M629 fermented in WSG medium. Sampling at days 3-6.

Composition	Short	m\z	M627				M629			
			d3	d4	d5	d6	d3	d4	d5	d6
			%	%	%	%	%	%	%	%
Hex3HexNAc2	Man3	933.31	3.7	7.9	10.6	11.5	2.6	6.6	11.5	12.2
Hex4HexNAc2	Man4	1095.37	2.1	1.9	2.2	1.9	1.6	1.8	2.1	2.2
Hex3HexNAc3	GnMan3	1136.40	0.0	0.3	0.1	0.0	0.0	0.2	0.4	0.1
Hex5HexNAc2	Man5	1257.42	1.4	1.7	1.3	1.4	1.5	1.3	1.3	1.0
Hex3HexNAc4	G0	1339.48	31.7	32.6	28.3	25.0	41.7	40.0	42.9	24.3
Hex6HexNAc2	Hex6	1419.48	60.0	55.5	57.2	60.0	51.6	49.9	41.3	59.8
Hex7HexNAc2	Hex7	1581.53	1.1	0.3	0.3	0.2	0.9	0.3	0.4	0.4
Hex8HexNAc2	Hex8	1743.58	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 19.7: Relative proportions of neutral N-glycans from purified antibody, at day 5, from strains M627 and M629 cultivated in WSG medium in shake flasks.

Composition	Short	m\z	M627	M629
			%	%
Hex3HexNAc2	Man3	933.31	47.9	7.2
Hex4HexNAc2	Man4	1095.37	2.5	2.0
Hex3HexNAc3	GnMan3	1136.40	0.0	0.8
Hex5HexNAc2	Man5	1257.42	0.0	1.4
Hex3HexNAc4	G0	1339.48	21.1	56.9
Hex6HexNAc2	Hex6	1419.48	28.4	31.4
Hex7HexNAc2	Hex7	1581.53	0.0	0.4
Hex8HexNAc2	Hex8	1743.58	0.0	0.0

Example 20 — GENERATION OF GLCNACMAN5 PRODUCING STRAINS WITH DIFFERENT PROMOTERS

[00535] Vectors for GnTI with different promoters are described in Table 20. 1. The vectors were targeted into *egl2* locus of *T.reesei*.

Table 20.1: Description of Human GnTI vectors with different promoters.

pTTg153	pcDNA1-Kre2-GnTI to Egl2
pTTg167	pcbh1-Kre2-GnTI to Egl2
pTTg168	pgpdA-Kre2-GnTI to Egl2
pTTg170	pgpdA-GnTI to Egl2
pTTg171	pcbh1-Kre2-GnTI to Egl2 (inactive GnTI)

Materials and methods

[00536] The generation strategy of fragments for vectors of Table 20.1 is presented in Table 20.2 and the primers used for fragment generation are listed on Table 20.3. Fragments were amplified by PCR and products were purified from the agarose gel. Digested pTTg152 vector was purified from the gel. All PCR amplifications were made with high-fidelity Phusion polymerase (Finnzymes). Fragments for pTTg153-pTTg171 were electroporated to yeast *Saccharomyces cerevisiae* FY834 for plasmid assembly by homologous recombination. Yeast cells were plated to SC-ura for 2-3 days cultivation in +30°C. Colonies were then pooled from the plates and plasmid pool was purified with Phenol/Chloroform extraction method as routinely. Plasmid pool was transformed to competent *E. coli* cells by electroporation. Electroporated cells were plated to LB+amp selection plates, cultivated +37°C over night and colonies were screened by PCR. Positive colonies were then streaked to fresh plates as pure cultures, single colonies were cultured in liquid LB+amp media and potential vectors pTTg153-pTTg171 were purified according to standard protocols. Plasmids were analyzed by restriction analysis and sequences were verified by sequencing.

Table 20.2: Construction strategy of the vectors. Vectors pTTv225, pTTv77, pTTg91 were used for construction of fragments specified on below. Vectors pTTvllO, pTTvl41, pTTvll, and pTTvl3 are described in the International Patent Application No. PCT/EP2011/070956.

Vector code	Fragment 1	Fragment 2	Fragment 3	Fragment 4
pTTg1 53	PCR product from pTTv225 template GP346, GP471	PCR product from pTTv1 1 template GP472, GP345	PCR product from pTTv77 template GP348, GP349 >egl2 3' flank fragment sequence	pTTv77 cut with ClaI and FseI
pTTg1 67	PCR product from pTTv1 10 template GP337, GP338	PCR product from pTTv225 template GP335, GP402 >cDNA1 promoter - Kre2 targeting signal fragment amplification	PCR product from pTTv1 1 template GP472, GP345	pTTg1 52 cut with FseI and AseI
pTTg1 68	PCR product from pTTv1 4 1 template GP343, GP347	PCR product from pTTv225 template GP335, GP402	PCR product from pTTv1 1 template GP472, GP345	pTTg1 52 cut with FseI and AseI
pTTg1 70	PCR product from pTTv1 3 template GP343, GP399	pTTg1 52 cut with FseI and Sail	n/a	n/a
pTTg1 71	PCR product from pTTv1 10 template GP400, GP401	PCR product from pTTv225 template GP335, GP402	PCR product from pTTg91 template GP403, GP404 Inactive Gntl fragment amplification	pTTg1 52 cut with FseI and Sail

Table 2 d.3: Primers used for construction of vectors OF Table 20.2

Code	Sequence 5' > 3'
GP335	ATGGCGTCAACAAATGCGCGCTATGT
GP337	ATTCACACTCTCAGAATAAATTCATCGCCAATTTGACAGGCCGGCCATTCTCACGGT GAATGTAGGCC TTTTGTA
GP338	TTAGTAGATAGCGCACATAGCGCGCATTGTTGACGCCATGCGGTTGACTATTGGG TTTCTGTGCCTCAAAAGAT
GP343	CACACTCTCAGAATAAATTCATCGCCAATTTGACAGGCCGGCCGCTTGTATCTCT ACACACAGGCTCAA
GP345	CTGCAGTGCAGGATCTG CATATATG
GP346	TTATTCACACTCTCAGAATAAATTCATCGCCAATTTGACAGGCCGGCCACTAGTGGT CTGAAGGACGTGG
GP347	TTAGTAGATAGCGCACATAGCGCGCATTGTTGACGCCATCTGATGTCTGCTCAAG CGGGGTA
GP348	AGGACCTTAATTAATCATATATGCAGATCCTGCACTGCAGGCCGGCCGCTCTGA GCTGAATGCAGAAGC
GP349	CTTGACCTCGGAGAAAGTTACCCTCCTTTTGTGACACACGATCGATTTCCAACAGAT GGAAAGAAGAAAGG
GP399	AATACCGCCGCACTGGCCGTAGTGAGACTGGGTAGGTCGACTAATTCAGCTGGG ATCATA
GP400	CACACTCTCAGAATAAATTCATCGCCAATTTGACAGGCCGGCCAATTCTCACGGTG AATGTA
GP401	TTAGTAGATAGCGCACATAGCGCGCATTGTTGACGCCATGCGGTTGACTATTGGG TT

GP402	TTCGAGGGCCGGGAGCGATGCCGA
GP403	GGCTTCAACGACCTCGTCGGCATCGCTCCCGGCCCTCGAAACGCGCCCAGCACCT GGCA
GP404	ATACCGCCGCACTGGCCGTAGTGAGACTGGGTAGGTGCGACTAATTCCAGCTAGGA TCATA
GP471	AGAATACCGGATTACTGATCCGGAGAATACTTTGTAAATAGCGGCCGCGGCTGATG AGGCTGAGAGAGG
GP472	CAACGACCTCGTCGGCATCGCTCCCGGCCCTCGAATGAACGGGGATGCCCTGTCTG AGC

[00537] *Trichoderma reesei* MAB01 expression strain M507 with 7-fold protease deletion was transformed with the *Pmel* fragments of vectors pTTgl53-pTTgl71 targeted to *egl2* locus. Variable amount of transformants were picked onto selective plates. On the basis of PCR screening with Phire Plant Direct PCR kit (Finnzymes F-130), clones with positive results concerning 5'- and 3'-integration were selected for single spore platings and re-screening for integration and *egl2* deletion. PCR-screened strains were finally subjected to shake flask cultivation and glycan analysis.

Shakeflask cultures of strain M507 transformed with GnTI and promoter constructs

[00538] Strain M507 transformed with vectors of Tables 20.1 and 20.2 were cultivated in shake flasks in TrMM, 4% lactose, 2% SGE, 100 mM PIPPS, pH5.5, at +28°C and sampling was performed at day 5. An inactive GnTI construct was tested to determine possible effects of GlcNAcMan5 glycans to growth of *T. reesei*.

[00539] For N-glycan analysis MAB01 was purified, concentrations were determined and N-glycans analysed with MALDI-TOF MS as described above. N-glycan analysis of MAB01 showed that GnMan5 levels ranged from 8 to 79.2 % of the total glycans (Tables 20.4 and 20.5A and B). The inactive GnTI produced wild type glycosylation as expected.

Table 20.4: GnTI constructs and antibody concentrations. Strain numbers for selected clones are given in parentheses in "Clones" column.

Focus/vector	Clones	Antibody titer g/L in ProtG eluent
pTTgl67	33-6A	0.15
	33-6B (M704)	0.14
pTTgl68	34-6A	0.53
	34-45A (M706)	0.51
pTTgl70	1A	0.55
	2A (M710)	0.73
pTTgl71	2A	0.7
	6A (M712)	0.55
pTTgl53	11A	1.03
	23A (M702)	0.99
M507		0.68

Tables 20.5A and B: Relative proportions of neutral N-glycans of MAB01, at day 5.

Table A			1A	2A (pTTg170)	34-6A	34-45A	33-6A	33-6B
Composition	Short	m/z	%	%	%	%	%	%
Hex3HexNAc2	Man3	933.31	0.0	0.0	0.0	0.0	0.0	0.0
Hex4HexNAc2	Man4	1095.37	0.0	0.0	0.0	0.0	0.0	0.0
Hex5HexNAc2	Man5	1257.42	85.0	74.3	24.5	19.6	5.0	5.8
Hex3HexNAc4	GO	1339.48	0.0	0.0	0.0	0.0	0.0	0.0
Hex6HexNAc2	Man6	1419.48	5.7	5.5	13.4	10.3	5.9	7.2
Hex5HexNAc3	GnMan5	1460.50	2.5	10.8	42.9	56.7	79.2	77.9
Hex7HexNAc2	Man7	1581.53	3.7	5.2	11.0	8.0	5.6	5.1
Hex8HexNAc2	Man8	1743.58	2.2	2.8	6.0	4.3	4.4	4.0
Hex9HexNAc2	Man9	1905.63	0.9	1.4	2.0	1.1	0.0	0.0
Hex10HexNAc2	Man10	2067.69	0.0	0.0	0.2	0.1	0.0	0.0

Table B			2A (pTT _g 171)	6A	11A	23A
Composition	Short	m/z	%	%	%	%
Hex3HexNAc2	Man3	933.31	0.0	0.0	0.0	1.6
Hex4HexNAc2	Man4	1095.37	0.0	0.0	0.0	0.0
Hex5HexNAc2	Man5	1257.42	85.7	89.5	71.8	70.1
Hex3HexNAc4	GO	1339.48	0.0	0.0	0.0	0.0
Hex6HexNAc2	Man6	1419.48	6.1	4.3	10.5	7.2
Hex5HexNAc3	GnMan5	1460.50	0.0	0.0	8.0	12.2

Hex7HexNAc2	Man7	1581.53	4.8	3.6	6.4	5.5
Hex8HexNAc2	Man8	1743.58	2.8	1.9	2.6	2.4
Hex9HexNAc2	Man9	1905.63	0.6	0.7	0.7	1.0
Hex10HexNAc2	Man10	2067.69	0.0	0.0	0.0	0.0

Fermenter cultures of strain M507 transformed with GnTI constructs

[00540] The *T. reesei* strains M702, M704, M706, M710, M712, M716 and M507 were fermented in 4% WSG, 2% Glc, 4% cellobiose, 6% lactose, pH 5.5, and sampling was performed at days 3-6. The antibody titers are shown in Table 20.6. N-glycans were detached and analysed as above described using PNGase F.

[00541] N-glycan analysis of MABO1 showed that GnMan5 levels ranged from 1.8 to 68.5 % of the total glycans (Tables 20.7 A, B and C). The inactive GnTI produced wild type glycosylation as expected as did the control strain M507.

Table 20.6: Antibody concentrations of MABO1.

Strain	Titer g/l			
	d3	d4	d5	d6
M702	1,23	1,72	2,14	2,34
M704	0,299	0,399	0,415	0,479
M706	0,293	1,04	1,65	2,04
M710	0,951	1,09	1,32	1,69
M712	1,34	1,93	2,34	2,4
M716	0,16	0,519	1,11	1,69
M507	1,04	1,81	2,24	2,3

Table 20.7 A, B and C: Relative proportions of neutral N-glycans on MABOI, at day 3, 4, 5 and 6.

Table A			M702				M704				M706			
			d3	d4	d5	d6	d3	d4	d5	d6	d3	d4	d5	d6
Composition	Short	m\z	%	%	%	%	%	%	%	%	%	%	%	%
Hex4HexNAc2	Man4	1095,4	0,0	0,5	0,4	0,0	0,0	0,0	0,0	0,0	0,3	0,0	0,5	0,5
Hex5HexNAc2	Man5	1257,4	36,0	46,8	55,7	72,1	9,7	12,9	16,1	20,3	21,6	45,5	63,3	70,5
Hex6HexNAc2	Man6	1419,5	11,5	12,1	9,8	6,2	9,2	7,2	5,6	10,1	13,0	8,6	7,8	5,5
Hex5HexNAc3	GnMan5	1460,5	40,5	29,7	25,1	14,8	67,5	68,5	64,9	51,9	45,7	39,2	22,2	17,1
Hex7HexNAc2	Man7	1581,5	7,6	6,8	5,3	4,6	8,4	6,8	6,9	9,1	11,9	4,1	3,5	3,3
Hex8HexNAc2	Man8	1743,6	3,7	3,2	2,8	2,2	4,2	3,7	5,2	5,1	5,8	2,1	2,0	2,2
Hex9HexNAc2	Man9	1905,6	0,8	0,8	0,7	0,0	1,0	0,8	1,1	3,4	1,5	0,5	0,4	0,4
Hex10HexNAc2	Man10	2067,7	0,0	0,1	0,1	0,0	0,0	0,0	0,2	0,0	0,3	0,0	0,2	0,3

Table B			M710				M712			
			d3	d4	d5	d6	d3	d4	d5	d6
Composition	Short	m\z	%	%	%	%	%	%	%	%
Hex4HexNAc2	Man4	1095,4	0,4	0,3	0,4	0,0	0,0	0,0	0,3	0,0
Hex5HexNAc2	Man5	1257,4	72,0	72,6	78,5	84,2	76,7	85,0	85,6	89,8
Hex6HexNAc2	Man6	1419,5	13,9	13,4	11,0	6,3	12,4	8,4	7,6	4,2
Hex5HexNAc3	GnMan5	1460,5	2,5	3,3	2,1	3,5	0,0	0,0	0,0	0,0
Hex7HexNAc2	Man7	1581,5	7,5	6,8	5,0	3,6	7,4	4,4	4,1	3,3
Hex8HexNAc2	Man8	1743,6	3,3	2,9	2,6	1,8	2,7	2,1	1,9	2,1
Hex9HexNAc2	Man9	1905,6	0,5	0,6	0,4	0,5	0,7	0,0	0,4	0,6
Hex10HexNAc2	Man10	2067,7	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0

Table C			M716				M507			
			d3	d4	d5	d6	d3	d4	d5	d6
Composition	Short	m\z	%	%	%	%	%	%	%	%
Hex4HexNAc2	Man4	1095,4	0,0	0,0	0,3	0,4	0,0	0,4	0,0	0,0
Hex5HexNAc2	Man5	1257,4	62,1	73,8	84,8	85,5	70,7	79,5	87,3	89,6
Hex6HexNAc2	Man6	1419,5	14,9	10,0	7,2	7,8	17,2	12,5	8,1	5,4
Hex5HexNAc3	GnMan5	1460,5	4,3	4,2	1,8	1,9	0,0	0,0	0,0	0,0
Hex7HexNAc2	Man7	1581,5	12,8	8,0	4,2	3,0	8,8	5,0	3,5	2,6
Hex8HexNAc2	Man8	1743,6	5,1	3,4	1,5	1,2	2,8	2,1	1,1	1,9
Hex9HexNAc2	Man9	1905,6	0,8	0,6	0,4	0,3	0,5	0,5	0,0	0,4
Hex10HexNAc2	Man10	2067,7	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0

Example 21 - GENERATION OF GLCNACMAN 5 PRODUCING STRAINS WITH DIFFERENT TARGETING PEPTIDES

Generation of Plasmids

[00542] Plasmids used in generating GNT1 strains with different Golgi targeting peptides (pTTv274, pTTv275, pTTv276, pTTv278, pTTv279, pTTv280) were all based on the common parental plasmid pTTv265 which contains human GNT1 (P26572) with a 38 amino acid N-terminal truncation. Pedigree of pTTv265 is summarised in Table 21.1.

Table 21.1: Pedigree of Golgi targeting peptide plasmids pTTv274, pTTv275, pTTv276, pTTv278, pTTv279, pTTv280. Golgi targeting peptides were added to pTTv265 generating the aforementioned plasmids.

<u>plasmid</u>	<u>content</u>
pTTv77	egl2 5' and 3' flanks, cbhl promoter, pyr4 loopout marker, pRS426 backbone
pTTv256	promoter change to pTTv77: cbhl to gpdA
pTTv264	selection marker change to pTTv256: pyr4 loopout to hygromycin
pTTv265	human GNT1 (del38 aa) added to pTTv264

Stepwise Description of Generation of Plasmids

[00543] Plasmid pTTv77 contains *egl2* (trel20312) 5' and 3'flanking regions for targeted integration to *T. reesei* genome and *cbhl* promoter for gene expression. Integration of plasmid pTTv77 to genome results in 2456 bp deletion in *egl2* locus. 1020 bp and 1024 bp regions from *egl2* locus were amplified for 5' and 3'flanks. 2176 bp from *cbhl* locus was amplified for promoter fragment. Template used in the PCR reactions was genomic DNA of *T. reesei*. Primer used in PCR reactions are shown in Table 21.2. Selection marker *pyr4* blaster cassette was a *NotI* fragment from pTTv71 described above and vector backbone was *EcoRI/XhoI* digested pRS426 described above. All fragments were purified using standard laboratory methods and plasmid was cloned by yeast recombination method as described in Examples. After plasmid rescue to *E. coli* a few clones were verified for correct recombination. Stored clone was verified by sequencing.

Table 21.2: Primers used in cloning pTTv77.

Primer name	Primer sequence
T575_egl2_5'flank_F	GATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACG GTTTAAACTCCAAAGTTCCTGTCTTCTCC
T576_egl2_5'flank_R	TGTCAAATTGGCGATGAATTTAT
T577_egl2-cbh 1_prom+term_F	TTATTCACACTCTCAGAATAAATTCATCGCCAATTTGACA GGCCGGCCGGGTAGGAATTGCACTCAAG
T572_cbh1_prom+term_R	GCAACGAGAGCAGAGCAGCAGTAGTCGATGCTAG GCGGCCGCGCCGCTCATCGTCTTGACAGCAATGC
T578_egl2_3'flank_F	ACCAGCCGCAGCCTCAGCCTCTCTCAGCCTCATCAGCCGC GCGGCCGCCACTCTGAGCTGAATGCAGA
T579_egl2_3'flank_R	CCTATGTTGTGTGGAATTGTGAGCGGATAACAATTTTACA GTTTAAACGCGCTGCCTCCACGATGT

[00544] Plasmid pTTv256 is based on plasmid pTTvW. In plasmid pTTv256 promoter *cbhl* was changed to *gpdA*. To clone pTTv256, plasmid pTTvW was digested with *FseVIPaI* to release *cbhl* promoter. New promoter, *A. nidulans gpdA* was released from a plasmid with *FseI/PacI* digestion. Fragment purification and cloning were performed using standard laboratory methods. A few clones were verified for correct ligation. Stored clone was verified by sequencing.

[00545] Plasmid pTTv264 is based on plasmid pTTv256. In pTTv264 selection marker was changed from *pyr4* blaster cassette to *hygR* selection marker. To clone pTTv264, plasmid pTTv256 was digested with *NotI* to release *pyr4* blaster cassette. Marker *hygR* was amplified by PCR using modified pRLMex30 as a template with primers shown in Table 21.3. All fragments were purified using standard laboratory methods and plasmid was cloned by yeast recombination method described in Examples. After plasmid rescue to *E. coli* a few clones were verified for correct recombination and stored clone was verified by sequencing.

Table 21.3: Primers used in cloning pTTv264.

Primer name	Primer sequence
T974-Cbh 1t+NotI+PKI promoter 5'end	GACCAACTTGTCCGTTGCGAGGCCAACTTGCATTGCTGT CAAGACGATGAGCGGCCGCATAACGGTGAGACTAGCGGC
T942_pTTv256_3' end+NotI+tcbh2_rev	ATACAAACGTTGGCGAGGCTTCTGCATTGAGCTCAGAGTG GCGGCCGCGTGCTGCGGAATCATTATCATCTG

[00546] Plasmid pTTv265 is based on plasmid pTTv264 described above. In pTTv265 human GNT1 with N-terminal truncation of 114 nucleic acids (38 amino acids) was added under *gpdA* promoter. To clone pTTv265, plasmid pTTv264 was linearized with *PadI*. Human GNT1 was amplified by PCR from synthetic plasmid pTTv1 carrying full-length human GNT1 gene (P26572, pTTv1 is also described in the International Patent Application No. PCT/EP2011/070956). Primers used in amplification are shown in Table 21.4. All fragments were purified using standard laboratory methods. Plasmid was cloned by yeast recombination method described above. After plasmid rescue to *E. coli* a few clones were verified for correct recombination and stored clone was verified by sequencing.

Table 21.4: Primers used in cloning pTTv265.

Primer name	Primer sequence
T943_G PDAp+TC+Pacl+GNT1_F	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACATCA TCTTAATTAATCAGTCAGCGCTCTCGATGCC
T944_Cbh 1t(pTTv256)+Swal+GNT1_R	CCAATACCGCCGCACTGGCCGTAGTGAGACTGGGTAG GTCATTTAAATCTAATTCAGCTGGGATCATAG

[00547] The human N-terminal 38 amino acid truncated GnTI amino acid sequence in the plasmid pTTv1 for constructing pTTv265.

[00548] SVSALDGD PASLTRE VIRLAQD AEVELERQRGLLQQIGD ALSQRGRVPTAAP
PAQPRVPVTPAPAVIPILVIACDRSTVRRCLDKLLHYRPSAELFPIIVSQDCGHEETAQAIA
SYGSAVTHIRQPDLSIAVPPDHRKFQGYK IARHYRWALGQVFRQFRFPAAVVVEDDL
EVAPDFFEYFRATYPLLKADPSLWCVSAWNDNGKEQMVDASRPELLYRTDFFPGLGWL
LLAELWAELEPKWPKAFWDDWMRRPEQRQGRACIRPEISRTMTFGRKGVSHGQFFDQH
LKFIKLNQQFVHFTQLDLSYLQREAYDRDFLARVYGAPQLQVEKVRTNDRKELGEVRV
QYTGRDSFKAFKALGVMDL KSGVPRAGYRGIVTFQFRGRRVHLAPPPTWEGYDPSW
N

[00549] Plasmids pTTv274, pTTv275, pTTv276, pTTv278, pTTv279 and pTTv280 were all based on plasmid pTTv265 described above. In these plasmids different Golgi targeting peptides were added to precede the N-terminally truncated human GNTI gene. To clone these plasmids,

pTTv265 was linearized with *Pad*. Different Golgi targeting peptides were amplified by PCR using primers shown in Table 21.5A. Template DNA for GNT2 (pTTv274) was synthetic plasmid carrying codon harmonised human GNT2 gene from the International Patent Application No. PCT/EP201 1/070956). Template for other Golgi targeting peptides (pTTv276, pTTv278, pTTv279, pTTv280) was *T. reesei* genomic DNA. KRE2 (pTTv275) was produced by PCR using annealing primers in Table 21.5A. All fragments were purified using standard laboratory methods and plasmids were cloned by yeast recombination method as described Examples. After plasmid rescue to *E. coli* a few clones from each cloning were verified for correct recombination and stored clones were verified by sequencing.

Table 21.5A: Primers used to produce Golgi targeting peptides in pTTv274, pTTv275, pTTv276, pTTv278, pTTv279 and pTTv280.

Plasmid	Primer	Primer sequence
pTTV274	T945_GNT2-gts-f	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACAT CATCATGCGCTTCCGAATCTACAAG
	T946_GNT2-gts-r	GGGTGAGGCTGGCGGGGTCGCCATCGAGAGCGCTG ACTGAGGGGTGATCCCCTCCCCTG
pTTv275	T 1117_KRE2-gts-cds-F	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACAT CATCATGGCGTCAACAAATGCGCGCTATGTGCGCTAT CTACTAATCGCCTTCTTACAATCC
	T 1118_KRE2-gts-cds-mid-F	TACTAATCGCCTTCTTACAATCCTCGTCTTCTACTTTG TCTCCAATTCAAAGTATGAGGGCGTCGATCTCAACAA GGGCACCTT
	T 1119_KRE2-gts-cds-R	GGGTGAGGCTGGCGGGGTCGCCATCGAGAGCGCTGA CTGACTTTGGTGTCTGCTTGGTCAATCCGGAGCTGTG AAGGTGCCCTTGTTGAGATCGACGC
	T 1120_gpdAp 3prim-F	GCAGCTTGACTAACAGCTAC
	T 1121_GNT1 5end-R	GGGTGAGGCTGGCGGGGTC
pTTv276	T949_KRE2-like-gts-f	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACAT CATCATGGCCATTGCCCGGCCGGT
	T950_KRE2-like-gts-r	GGGTGAGGCTGGCGGGGTCGCCATCGAGAGCGCTG ACTGAGCCCGTGGCTATCAAGAAGAAGAC
pTTv278	T953_Och1 -gts-f	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACAT CATCATGTTGAATCCACGCCGCG
	T954_Och1 -gts-r	GGGTGAGGCTGGCGGGGTCGCCATCGAGAGCGCTG ACTGAGGACGTCGAGGCCGATTCCG
pTTv279	T955_Anp1 -gts-f	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACAT CATCATGATGCCACGGCATCACTC
	T956_Anp1 -gts-r	GGGTGAGGCTGGCGGGGTCGCCATCGAGAGCGCTG ACTGATTCGAGCTTCAGGTCATCGT
pTTv280	T957_Van1 -gts-f	GCAGCTTGACTAACAGCTACCCCGCTTGAGCAGACAT CATCATGCTGCTCCCAAGGGCG

T958_Van1 -gts-r	GGGTGAGGCTGGCGGGGTCGCCATCGAGAGCGCTG ACTGACTCAGATGCCGAAGTGGACAC
------------------	---

Table 21.5B: Amino acid sequence of targeting peptides in plasmids of Table 21.5A.

Plasmid	Protein	TrelD	Amino acid sequence
pTTv274	human GNT2	-	MRFRIYKRKVL I LTLVVAACG FVLWSSNG RQR KNEALAPPLLD AEPARGAGG RGG DHP (SEQ ID NO:589)
pTTv275	KRE2	2 1576	MASTNARYVRYLLIAFFTI LVFYFVSNSKYEGV DLNKGFTTAPDSTKTTPK (SEQ ID NO:590)
pTTv276	KRE2-like	6921 1	MAIARPVRALGGLAAI LWCFFLYQLLRPSSSY NSPG DRYINFERDPNLDPTG (SEQ ID NO:591)
pTTv278	Och1	65646	MLNPRRALIAAAFI LTVFFLISRSHNSESASTS (SEQ ID NO:592)
pTTv279	Anp1	82551	MMP RHHSSG FSNGYPRADTFEISPHRFQPR TLPPH RKRKRTAI RVGIAVVVILVVLVW FGQPR SVASLISLG ILSGYDDLKLE (SEQ ID NO:593)
pTTv280	Van 1	8 12 11	MLLPKGG LDWRSARAQI PPTRALWNAVTRTR FILLVGITGL ILLLWRGVSTSASE (SEQ ID NO:594)

Generation of Strains with Different Golgi Targeting Peptides For GNT1

[00550] Fragments for transformations were released from plasmids pTTv274 (GNT2), pTTv275 (KRE2), pTTv276 (KRE2-like), pTTv278 (OCH1), pTTv279 (ANP1) and pTTv280 (VANI) (Tables 21.5A and 21.5B) with *Pmel*. All fragments were transformed individually to MAB01 expressing strain M507 and protoplast transformations were carried out essentially as described in Examples for hygromycin selection.

[00551] Well growing clones on selective streaks were screened for the 5' and 3' integration into the *egl2* locus. Double integration-positive clones were additionally screened for the loss of the *egl2* ORF. The clones giving the desired results were purified through single spore platings, and the single spore-derived clones were verified by PCR to be pure integration strains. Resulting strains are listed in Table 21.6 below.

Table 21.6: Summary of the GnTI Golgi targeting peptide strains.

Strain	Plasmid	Targeting peptide	TreID
M607	pTTv274	Human GNT2	-
M685	pTTv275	Kre2	21576
M610	pTTv276	Kre2-like	6921 1
M615	pTTv278	Och1	65646
M620	pTTv279	Anp1	82551
M622	pTTv280	Van1	8121 1

[00552] Fermentation of strains M507, M607, M610, M615, M620, M622, and M685 and glycan analysis

[00553] The *T. reesei* strains M507, M607, M610, M615, M620, M622, and M685 were fermented in 4% whole spent grain, 2% glucose, 4% cellobiose, 6% lactose, pH 5.5, and sampling was performed at days 3-6. The antibody titers are shown in Table 21.7. N-glycans were detached and analysed as above described using PNGase F.

[00554] N-glycan analysis of MAB01 showed that GnMan5 levels ranged from 4 to 66 % of the total glycans (Table 21.8 A, B and C). The control strain M507 showed wild type glycosylation as expected.

Table 21.7: Antibody concentrations from strains with human GnTI with different targeting peptides.

Strain	Titer g/l			
	d3	d4	d5	d6
M507	0,882	1,54	1,94	2,09
M607	0,536	1,45	2,22	2,28
M610	0,352	1,04	1,87	2,19
M615	0,554	1,15	1,76	1,9
M620	0,559	1,24	1,95	2,21
M622	0,697	1,36	1,8	2,04
M685	0,388	1,05	1,94	2,44

Table 21.8 A, B and C: Relative proportions of neutral N-glycans of MABOI, at day 3, 4, 5 and 6, from strains with human GnTI with different targeting peptides.

Table A			M507				M607				M610			
			d3	d4	d5	d6	d3	d4	d5	d6	d3	d4	d5	d6
Composition	Short	m/z	%	%	%	%	%	%	%	%	%	%	%	%
Hex4HexNAc2	Man4	1095,4	0,3	0,0	0,0	0,0	0,0	0,2	0,0	0,0	0,0	0,0	0,0	0,2
Hex5HexNAc2	Man5	1257,4	79,3	89,4	88,4	93,6	11,5	24,7	37,0	42,8	29,4	44,5	68,8	74,3
Hex4HexNAc3	GnMan4	1298,5	0,0	0,0	0,0	0,0	0,2	0,2	0,0	0,0	0,0	0,0	0,0	0,0
Hex6HexNAc2	Man6	1419,5	12,3	7,0	7,0	3,9	8,8	7,4	4,0	2,5	7,0	6,3	6,2	2,9
Hex5HexNAc3	GnMan5	1460,5	0,0	0,0	0,0	0,0	66,1	59,4	56,0	49,6	52,5	44,0	21,1	18,9
Hex7HexNAc2	Man7	1581,5	6,3	2,6	3,2	1,9	8,6	4,8	1,9	3,5	7,3	3,7	2,7	2,7
Hex6HexNAc3	GnMan6	1622,6	0,0	0,0	0,0	0,0	1,8	0,7	0,0	0,0	1,0	0,4	0,0	0,0
Hex8HexNAc2	Man8	1743,6	1,6	1,0	1,2	0,7	2,8	2,2	0,9	1,2	2,1	1,1	1,1	0,8
Hex9HexNAc2	Man9	1905,6	0,3	0,0	0,3	0,0	0,3	0,2	0,2	0,4	0,7	0,0	0,1	0,2
Hex10HexNAc2	Man10	2067,7	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0

Table B			M615				M620			
			d3	d4	d5	d6	d3	d4	d5	d6
Composition	Short	m/z	%	%	%	%	%	%	%	%
Hex4HexNAc2	Man4	1095,4	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,2
Hex5HexNAc2	Man5	1257,4	21,7	36,4	54,1	51,5	22,0	35,5	50,8	63,9
Hex4HexNAc3	GnMan4	1298,5	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Hex6HexNAc2	Man6	1419,5	10,7	7,7	6,3	4,2	10,5	6,6	5,5	4,3
Hex5HexNAc3	GnMan5	1460,5	57,0	50,1	36,5	38,8	57,3	53,0	40,5	28,0
Hex7HexNAc2	Man7	1581,5	7,4	3,9	2,0	3,6	7,2	3,3	2,3	2,4
Hex6HexNAc3	GnMan6	1622,6	0,8	0,3	0,0	0,3	1,2	0,4	0,0	0,0
Hex8HexNAc2	Man8	1743,6	2,4	1,4	1,0	1,3	1,6	1,1	0,9	1,1
Hex9HexNAc2	Man9	1905,6	0,0	0,2	0,0	0,4	0,3	0,2	0,0	0,1
Hex10HexNAc2	Man10	2067,7	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0

Table C			M622				M685			
			d3	d4	d5	d6	d3	d4	d5	d6
Composition	Short	m/z	%	%	%	%	%	%	%	%
Hex4HexNAc2	Man4	1095,4	0,0	0,0	0,0	0,2	0,0	0,0	0,0	0,0
Hex5HexNAc2	Man5	1257,4	63,8	77,9	85,6	85,0	29,7	43,1	70,3	78,3
Hex4HexNAc3	GnMan4	1298,5	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Hex6HexNAc2	Man6	1419,5	15,0	9,1	7,3	4,9	6,5	6,5	5,2	3,8
Hex5HexNAc3	GnMan5	1460,5	6,4	7,8	4,1	4,9	56,3	44,9	21,7	14,7
Hex7HexNAc2	Man7	1581,5	10,7	4,0	2,3	3,5	4,8	3,7	2,0	2,1
Hex6HexNAc3	GnMan6	1622,6	0,5	0,0	0,0	0,0	0,9	0,3	0,0	0,0
Hex8HexNAc2	Man8	1743,6	3,3	1,1	0,6	1,2	1,9	1,2	0,7	1,1
Hex9HexNAc2	Man9	1905,6	0,3	0,2	0,0	0,2	0,0	0,2	0,0	0,0
Hex10HexNAc2	Man10	2067,7	0,0	0,0	0,0	0,1	0,0	0,0	0,0	0,0

Example 22 - SILENCING OF SLP GENES VIA RNAI AND DELETION OF SLP2

[00555] Three silencing constructs were constructed for knocking down the expression of *slp2* (tre123244). These RNAi constructs contain a *gpdA* promoter, targeted integration to the *pep2* (tre53961) protease locus, and a *pyr4* loop-out marker with 3' *pep2* direct repeat. Two short 19 bp target sequences and a large 448 bp sequence were inserted into this vector to create pTTv217, pTTv218, and pTTv263, respectively. These vectors were designed to knockdown the expression of *slp2* and reduce its protease activity. The RNAi vectors were transformed into the *pyr4*-version of the MAB01 production strain M507. The pTTv204 vector is shown in Figure 52.

[00556] The pTTv204 RNAi expression vector was linearized with the AsiSI restriction enzyme. The primers T846 and T847 were annealed together and integrated via yeast recombination into the pTTv204 vector. The primers are shown in Table 22.1. The 19 base pair target sequence is contained in the resulting pTTv217 vector. The primers T848 and T849 were annealed together and integrated into the linearized pTTv204 vector to create the pTTv218 RNAi vector. This vector contains a 19 base pair target sequence. The primers are shown in Table 22.1. The target sequences are shown in Table 22.2.

[00557] The pTTv263 vector was made in two pieces and integrated into the pTTv204 vector. The primers T965 and T967 were used to amplify a 506 base pair sense fragment including the 58 base pair intron sequence in the *slp2* gene. The pTTv204 vector was opened with the AsiSI restriction enzyme and the 506 sense fragment was integrated into the vector via yeast recombination. The primers T1006 and T1007 were used to amplify an antisense fragment of 448 base pair. The antisense fragment was digested with FseI and AsclI restriction enzymes. The vector including the sense fragment was also digested with FseI and AsclI. The vector and antisense fragment were ligated together to create the vector pTTv263. The primers are listed in Table 22.1. The target sequence is shown in Table 22.2.

[00558] The pTTv217, pTTv218, pTTv263 RNAi vectors were digested with PmeI to release the expression cassette. The fragments were separated with agarose gel electrophoresis and the correct fragments were isolated with a gel extraction kit (Qiagen) using standard laboratory

methods. Approximately 5 µg of the expression cassette was used to transform the MAB01 antibody expression strain M507 (pyr4- version). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using pyr4 selection.

[00559] The short target sequence in the pTTv217 vector was designed to specifically affect only *slp2*. The pTTv218 target sequence was homologous to *slp3*, *slp5*, and *slp6*. The large 448 bp target sequence in pTTv263 vector was meant to affect several subtilisins. The target sequences in these vectors are listed in Table 22.2. The resulting knockdown strains M665, M666, and M667 were cultivated in small scale cultures.

[00560] Several pTTv217, pTTv218, and pTTv263 transformants were grown in 24 well cultures to compare their MAB01 production against the control strain M507. The strains were grown in TrMM with diammonium citrate without ammonium sulfate, 100 mM PIPPS, 2% spent grain extract, 4% lactose at pH 5.5. Duplicate wells were used for each transformant. Samples from the 24 well cultures taken on day 6 were used for immunoblotting. The supernatant was diluted with sodium citrate buffer pH 5.5, so that 0.5 µl of each supernatant could be loaded into the 4-15% Criterion gel. Mixed with LSB+BME and heated at 95°C for 5 minutes. The proteins were transferred to nitrocellulose with the Criterion blotter at 100 volts for 30 minutes. The nitrocellulose membrane was blocked with 5% milk in TBST for 1 hour. The heavy chain was detected with anti-heavy chain AP conjugate antibody (Sigma #A3188) diluted 1:10,000 in TBST. After 1 hour incubation with the detection antibody, the blot was washed with TBST, and the membrane developed with AP substrate (Promega).

[00561] The results can be seen in Figure 53. The 217.12G transformant produced slightly higher amounts of heavy chain compared to M507 or the second transformant 217.12E. The most noticeable improvement was observed with the pTTv218 transformants. Three transformants were significantly higher than the control. The 218.25F was the obvious standout. The results for the pTTv263 transformants were more variable. Two transformants produced very little antibody heavy chain. Transformant 263.11 OF seemed to produce twice as much heavy chain as the control.

[00562] The constructs that targeted multiple proteases were more successful at improving the heavy chain expression. Overall, the pTTv218 transformants were consistently better than the M507 control. The lack in production seen in two of the pTTv263 transformants indicated that the RNAi worked too well. When the *slp2* gene was deleted the growth of the strain suffered and thus the antibody expression reduced as well. The 263.36A and 263.124C transformants grow very poorly and expressed very little *slp2*. This was confirmed by shake flask and qPCR studies.

[00563] Dry weight measurements from shake flask cultures can be seen in Table 22.5. The strains were grown in TrMM with diammonium citrate without ammonium sulfate, 100 mM PIPPS, 2% spent grain extract, 4% lactose at pH 5.5. Duplicate flasks were used for each transformant. The 263.124C transformant had difficulty growing. Generally, there was a small reduction in growth in all the strains that expressed RNAi. This effect may be related to lower *slp2* expression levels.

[00564] To confirm that *slp2* expression was indeed reduced by the expression of RNAi, qPCR studies were done with the shake flask study mycelia. RNA was purified from shake flask culture mycelia, cDNA was synthesized, and qPCR analysis made. The *slp2*, *slp3*, *slp5*, *slp6*, and *gpdI* expression were monitored with gene specific primers. Fold changes were measured against a control strain. The expression was normalized with *gpdI*.

[00565] The 263.124C transformant showed the biggest downregulation of *slp2* (Table 22.6). The large RNAi induced 36-fold downregulation of the *slp2* gene, to a point where it was nearly turned off. The other transformants showed a much milder knockdown activity ranging from 1.2- to 2.5-fold. The milder knockdown is more preferred because the strain grows better and can produce good levels of antibody.

[00566] With two transformants it was looked more closely at what other subtilisins were affected by the RNAi expression. In the 263.124C transformant it was evident that *slp3* and *slp6* were also knocked down by 6- and 2.3-fold, respectively. With the milder knockdown strain 218.25F both *slp2* and *slp3* showed reduced expression by 1.7- and 1.8-fold.

Generation of 8-Fold Deletion Strain M646 Including Slp2 deletion

[00567] The M646 slp2 deletion strain was made by transforming the pTTv1 15 deletion cassette into M564 (pyr4- version of M507). The M564 pyr4- strain was created essentially as described in Example 3 for removal of the pyr4 blaster cassette from the strain M195 (Apepl). Consecutive 5-FOA selection steps were carried out to ensure that the clones selected were originating from single cells.

[00568] The deletion cassette containing the slp2 flanks and pyr4 marker was removed from the vector via PmeI digestion and the correct fragment was purified from an agarose gel using a QIAquick Gel Extraction Kit (Qiagen). Approximately 5 µg of the deletion cassette was used to transform the MAB01 production strain M564 (ApeplAtsplAslplAgaplAgap2Apep4Apep3, pyr4-). Preparation of protoplasts and transformation were carried out essentially as described in Example 1 for the strains M181 and M195 using pyr4 selection.

[00569] Transformants were picked as first streaks. Growing streaks were screened by PCR (using the primers listed in Table 22.3) for correct integration and loss of slp2 ORF. Clones giving the expected signals were purified to single cell clones and rescreened by PCR using the primers listed in Table 22.3. The correct clone was designated as strain M646.

Fermentation of strains M507, M665, M666, M667, and M646

[00570] The M507 strain was cultivated in fermentor cultivation series FTR104 under the same conditions as M665, M666, M667, and M646. The M646 was the slp2 deletion strain. The M665, M666, and M667 were strains with RNAi silencing. The FTR104 cultivations were grown in *Trichoderma* minimal medium (TrMM) plus 20 g/L yeast extract, 40 g/L cellulose, 80 g/L cellobiose, and 40 g/L sorbose at pH 5.5. The temperature was shifted from 28°C to 22°C after 48 hours. The cultures were grown for 6 days. *Trichoderma* minimal medium contains 5 g/L ammonium sulphate, 5 g/L potassium dihydrogen phosphate, 1 ml/L trace elements, 4.1 ml of 1M calcium chloride per L, and 2.4 ml of 1M magnesium sulphate per L of medium.

[00571] Total antibody concentrations were determined from day 3-6. On day 6, the M667 strain reached 3.81 g/L, see Table 22.8. After day 5 the expression of antibody dropped in the M507, M665, and M666 cultivations. On day 6 the M507 strain produced 2.2 g/L, M665 reached 2.7 g/L, and M666 made 2.8 g/L. Thus the strains with the small RNAi target sequences produced slightly more antibody than M507 indicating that the silencing is working in those strains. The strain M646 with the slp2 deletion grew more slowly than the other strains. The slp2 deletion strain produced slightly over 2 g/L on day 6.

Fermentation of strains M507, M665, M666, and M667

[00572] The 217.12G (M665), 218.25F (M666), and 263.1 10F (M667) were grown in 1 L fermentors with 30 g/l glucose, 60 g/l lactose, 20 g/l WSG, 20 g/l SGE plus lactose feeding at pH 5.5 starting at 28°C and shifted to 22°C later in the culture. The MAB01 heavy and light chain expression was assayed by immunoblotting from supernatant samples collected each day of the culture. The supernatants were diluted in pH 5.5 citrate buffer, so that 0.1 µl could be loaded per well. LSB+BME was added and heated together for 5 minutes at 95°C. The samples were loaded into a 4-15% Criterion SDS PAGE gel. The proteins were transferred to nitrocellulose with the Criterion blotter at 100 volts for 30 minutes. The nitrocellulose membrane was blocked with 5% milk in TBST for 1 hour. The heavy chain was detected with anti-heavy chain (Sigma #A3188) and anti-light chain (Sigma #A3813) AP conjugated antibody diluted 1:10,000 in TBST. After 1 hour incubation with the detection antibody, the blot was washed with TBST, and the membrane developed with AP substrate (Promega).

[00573] The total antibody expression was measured after protein G purification and the values are presented in Table 22.4, along with the results from two control strains. The M507 strain was cultivated with and without SBTI inhibitor under the same conditions. The expression levels of MAB01 in the M667 strain were higher than those measured in the M507 parent strain. On day 9, for instance, the expression level was twice as high for M667. The expression levels observed with M667 resembled the cultivation done with addition of SBTI. The M665 and M666 strains produced levels slightly lower or similar to the control. There was a clear 2-fold increase in antibody expression compared to the standard M507 strain.

[00574] The protease activity from the cultivations listed in Table 22.4 was measured in order to determine how the total protease activities were affected by the RNAi. The protease activity measurements with casein as the substrate can be seen in Table 22.9. The total protein concentrations from all the supernatant samples were measured. The total protein concentration for all samples was normalized in sodium citrate buffer pH 5.5 to 0.625 mg/ml for all days of the cultivation.

[00575] 100 μ l of all the diluted supernatants were added into the 96 well plate. Three replicate wells per sample were made. Added 100 μ l of casein FL diluted stock (10 μ g/ml) made in sodium citrate buffer pH 5.5. The casein stock solution from the vial was 1000 μ g/ml diluted in 200 μ l of PBS. For each sample a background control was included with 100 μ l of diluted supernatant and 100 μ l of sodium citrate buffer pH 5.5. Incubated plates containing supernatants and substrate covered in a plastic bag at 37°C. The fluorescence was measured in the plates after 4 hours of incubation. The readings were done on a fluorescent plate reader using 485 nm excitation and 530 nm emission.

[00576] The protease activity in the supernatant of the M665 strain was the lowest overall. Throughout the culture it was almost half that of M507. The large hairpin vector M667 activity was low as well, but it began to decrease after day 5 and was lowest on day 10. This was where the antibody production for the M667 strain was highest, on day 10. At the end of the culture both the M665 and M667 culture supernatants had half the protease activity as compared to the M507 control. When the M507 culture was supplemented with SBTI protease inhibitor, the protease activity also dropped from day 6 until day 8 and remained lower than the M507 strain. The low protease activity at the end of the culture explains why the M667 strain produced twice as much antibody as compared to the M507 strain.

Table 22.1: Primers used for creation of the silencing vectors.

Primer	Sequence
T846_pTTv217_top	CTTGAGCAGTTAATTAATTTGAATGGCCGGCCGCACACTTTC AAG ATTGGCTTCAAGAGAGCCAATCTTGAAAGTGTGCTTGCGATCGCG GATCCACTTAACGTTACTGAAATCAT
T847_pTTv217_bottom	ATGATTTTCAGTAACGTTAAGTGGATCCGCGATCGCAAGCACACTT TCAAGATTGGCTCTCTTGAAGCCAATCTTGAAAGTGTGCGGCCGG

	CCATTCAAATTAATTAAGTCTCAAG
T848_pTTv218_top	CTTGAGCAGTTAATTAATTTGAATGGCCGGCCGTACGGTGTGGCC AAGAAGTTCAAGAGACTTCTTGGCAACACCGTACTTGCGATCGCG GATCCACTTAACGTTACTGAAATCAT
T849_pTTv218_bottom	ATGATTTTCAAGTAACGTTAAGTGGATCCGCGATCGCAAGTACGGTG TTGCCAAGAAGTCTCTTGAAGTCTTGGCAACACCGTACGGCCGG CCATTCAAATTAATTAAGTCTCAAG
T965_fw_sense_loop_ascl	CCGCTTGAGCAGTTAATTAATTTAAATGGCCGGCCTATATGGCGC GCCGTAAGTTTTGCACAGCCGC
T967_rev_sense_loop_asisI	GTCAAGCTGTTTGATGATTTCAAGTAACGTTAAGTGGATCCGCGAT CGCCGACTCGACGCCCTTGAC
T1006_rev_antisense_fscl	CCTTATTCCTTTGAACCTTT
T1007_fw_antisense_ascl	GCAACGTGCTCAGGAGTTGC

Table 22.2: Target sequences in the RNAi vectors.

Name	Target sequence
pTTv217	GCACACTTTCAAGATTGGC
pTTv218	GTACGGTGTGGCCAAGAAG
pTTv263	GTTGAGTACATCGAGCGCGACAGCATTGTGCACACCATGCTTCCCCTCGAGTCCA AGGACAGCATCATCGTTGAGGACTCGTGCAACGGCGAGACGGAGAAGCAGGCTC CCTGGGGTCTTGCCCGTATCTCTCACCGAGAGACGCTCAACTTTGGCTCCTTCAAC AAGTACCTCTACACCGCTGATGGTGGTGAGGGTGTGATGCCTATGTCATTGACA CCGGCACCAACATCGAGCACGTCGACTTTGAGGGTCTTGCCAAGTGGGGCAAGA CCATCCCTGCCGGCGATGAGGACGAGGACGGCAACGGCCACGGCACTCACTGCT CTGGTACCGTTGCTGGTAAGAAGTACGGTGTGCCAAGAAGGCCACGTCTACGC CGTCAAGGTGCTCCGATCCAACGGATCCGGCACCATGTCTGACGTCTCAAGGGC GTCGAGTACG

Table 22.3: Primers for screening pTTvll5/Aslp2-pyr4 cassette integration and strain purity.

For screening integration of pTTvll5 (*Aslp2-pyr4*)

Primer	Sequence
T054_slp2_5screen_F	GATGCACCGCTGCGGCC (SEQ ID NO: 327)
T1084_screen_5flk_pyr_rev	TCTTGAGCACGACAATCGAC
T055_slp2_3screen_R	GCGGTTGCTCCCATGCG (SEQ ID NO: 330)
T028_Pyr4_flank_rev	CATCCTCAAGGCCTCAGAC (SEQ ID NO: 329)

For screening deletion of *slp2* (trel23244) ORF

T111_slp2_ORF_F	ATGCGGTCCGTTGTGCGCC (SEQ ID NO: 331)
T112_slp2_ORF_R	TTACTCGGAGAGCTCAGAGA (SEQ ID NO: 332)

Table 22.4: Total MABOI antibody expression levels from fermentation cultures of RNAi strains and control strains. Protein G purified immunoglobulins.

Total mAB (mg/L)	T86 M507	T89 M507 + SBTI	T113 M665	T114 M666	T115 M667
day 6	581	987			
day7	719	1415	485	436	1217
day8	890	1695	744	518	1471
day9	825	1908	945	696	1684
day10	1082	1863	1025	787	1835
day11	1094	1769			

Table 22.5: Dry weight measurements from shake flask culture mycelium. Two flasks were grown for each transformant and control strain. The strains are expressing RNAi directed at reducing the *slp2* expression.

Dry weight	Day 3	Day 5	Day 6	Day 7
	grams/20 ml	grams/20 ml	grams/20 ml	grams/20 ml
217.12E	0,015	0,035	0,042	0,047
217.12E	0,022	0,035	0,049	0,047
218.25F	0,031	0,048	0,052	0,059
218.25F	0,038	0,046	0,051	0,056
218.67A	0,027	0,043	0,052	0,061
218.67A	0,024	0,046	0,051	0,059
263.110F	0,032	0,042	0,047	0,056
263.110F	0,025	0,049	0,043	
263.124C	0,002	0,009	0,020	0,020
263.124C	0,006	0,005	0,016	0,022
M507	0,038	0,049	0,060	0,063
M507	0,039	0,053		0,066

Table 22.6: Down regulation of *slp2* expression in strains containing RNAi constructs

Fold downregulation of <i>slp2</i>	
217.12E	no change
218.25F	-1,8
218.67A	-1,2
263.110F	-2,5
263.124C	-36,3

Table 22.7: Down regulation of *slp2*, *slp3*, *slp5*, and *slp6* expression in strains with RNAi constructs.

Fold downregulation of slp genes				
	slp2	slp3	slp5	slp6
218.25F	-1,6	-1,8	no change	no change
263.124C	-31,1	-6,0	no change	-2,3

Table 22.8: FTR104 cultivations were grown in TrMM plus 20 g/L yeast extract, 40 g/L cellulose, 80 g/L cellobiose, and 40 g/L sorbose at pH 5.5. The temperature was shifted from 28°C to 22°C after 48 hours. The total antibody titers are expressed in g/L.

Day	M507	M646	M665	M666	M667
Total Ab	g/L	g/L	g/L	g/L	g/L
3	1,4	0,7	1,5	1,5	1,5
4	2,6	1,3	2,6	2,8	2,8
5	3,1	1,8	3,4	3,5	3,6
6	2,2	2,0	2,7	2,8	3,8

Table 22.9: Protease activity measurements of fermentation supernatants from strains with RNAi and control strains. Total protease activity at pH 5.5 with casein substrate.

Protease activity					
Fluorescent units					
Day	T86-M507	T89-M507 + SBTI	T113-M665	T114-M666	T115-M667
1	0,7	0,2	1,3	-0,6	1,1
2	2,1	1,1	-1,1	-0,8	1,4
3	16,7	23,4	1,1	6,6	17,5
4	18,7	18,7	8,6	15,0	17,5
5	19,4	18,1	12,7	19,0	19,0
6	19,7	21,7	10,6	19,3	16,9
7	19,5	17,3	10,5	21,3	15,8
8	17,6	14,3	10,4	21,9	13,5
9	19,9	14,9	10,8	21,4	11,8
10	21,6	17,3	13,9	21,8	10,3
11	23,8	20,2			

EXAMPLE 23 - GENERATION OF ANTIBODY FRAGMENT EXPRESSING TRICHODERMA REESEI STRAINS

[00577] Seven *Trichoderma reesei* strains were generated to express antibody fragments (Fabs, multimeric single domain antibodies (sd-Ab's) and scFVs) from different protease deletion backgrounds as listed in Table 23. The architecture of the genetic expression cassettes applied for this purpose was based on the regulatory elements (promoter and terminator) of the cellobiohydrolase I (*cbhl*) gene. The catalytic domain of the CBHI protein was modified to remove intron sequences and used as fusion partner to enhance antibody fragment expression and secretion. A recognition motif for the Kex2 protease was inserted in between the fusion partners to promoter co-secretory release of the antibody fragments from the CBHI carrier protein. The expression cassettes were flanked by homologous regions to allow targeted integration to the *Trichoderma reesei cbhl* locus. The entire construct was stored in a cloning vector.

[00578] In order to prepare the flanked expression cassettes for transformation the corresponding fragments were released from their respective vector backbones by *PmeI* restriction digestion and purified using the illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare).

[00579] As listed in Table 23, *T. reesei* protease deletion strains were transformed with the purified expression cassettes using PEG-mediated protoplast transformation. The transformants were selected for Hygromycin B resistance or acetamidase prototrophy by plating them onto medium containing Hygromycin B as a selective agent or acetamide as the sole nitrogen source, respectively. Up to 48 transformants each were screened by PCR for homologous integration of the expression cassette to the *cbhl* locus using a forward primer outside the 5' flanking region fragment of the construct and the reverse primer inside the modified CBHI catalytic domain (5' integration) as well as a forward primer inside the Hygromycin B or acetamidase selection marker, respectively, and a reverse primer outside the 3' flanking region fragment (3' integration). From each transformation, five to seven independent transformants, for which the PCR screening proved correct integration of the construct to the *cbhl* locus, were selected for single spore purification to obtain uninuclear clones. Proper integration of the disruption cassette

was reconfirmed by PCR using the same primer combinations as described above and the absence of the parental CBHI locus was verified by using a primer combination targeted to the *cbhl* open reading frame. Correct integration of the disruption cassette was additionally verified for all clones applying Southern hybridization. Genomic DNA of the uninuclear clones as well as the parental strain was independently digested with two different restriction enzyme combinations and probed against the 5' and 3' flanks of the *cbhl* gene to confirm modification of the *cbhl* locus as expected.

Expression and titer analysis of antibody fragments (Fabs, single domain antibodies and scFVs)

[00580] Expression of antibody fragments was facilitated by the cellobiohydrolase I promoter. Strains were grown in batch fermentations for 7 days, in media containing 2% yeast extract, 4% cellulose, 8% cellobiose, 4% sorbose, 5g/L KH_2PO_4 , and 5g/L $(\text{NH}_4)_2\text{SO}_4$. Culture pH was controlled at pH 5.5 (adjusted with NH_4OH) and temperature was constantly kept at 28 °C. Fermentations were carried out in 4 parallel 2 L glass vessel reactors (DASGIP) with a culture volume of 1 L. Culture supernatant samples were taken during the course of the runs and stored at -20 °C. Samples were collected daily from the whole course of these cultivations, and production levels were analyzed by affinity liquid chromatography for all molecules. For each antibody fragment the maximum titer, strain ID and protease deletion background is indicated in Table 23.

Table 23: Expression levels of various antibody fragments

Antibody Fragment	Titer (g/L)	Strain	Parent Strain	Deletion Background	Clipping* (SEC after ALC)
FAb1	3.8	TR090	M307	4	~5%
FAb2	2.8	TR102	M400	6	~5%
FAb3	2.6	TR104	M400	6	nd
sdAb-1	1.9	TR066	M307	4	nd
sdAb-2	1.2	TR101	M400	6	~45%
scFV1-His	2.5	TR112	M400	6	nd
scFV2	2.5	TR111	M400	6	nd

*provided percentages are approximated (~) or not determined (nd)

Titer determinations

Mabs and sdAb

[00581] Mab and sdAb concentrations were quantified by HPLC - Protein A chromatography, which is based on affinity chromatography with UV detection. The Fc-domain of human immunoglobulines of the G-class (subtype-class: IgG1, IgG2, IgG4, except IgG3) binds specifically to protein A which is covalently linked to the stationary phase. The binding affinity of protein A to the Fc-domain is pH dependent. After binding at pH 7.5 the monoclonal antibody was eluted under acidic conditions at pH 2.0 and detected at 280 nm.

Fab

[00582] Fab concentrations were quantified by HPLC - anti-Lambda chromatography, which is based on affinity chromatography with UV detection. The lambda chain of human Fab fragments binds specifically to a camelid-derived anti-lambda ligand which is covalently linked to the stationary phase. After binding at pH 7.5, the monoclonal antibody was eluted under acidic conditions at pH 1.4 and detected at 280 nm.

scFV2

[00583] scFV2 concentrations were quantified by HiTrap Protein L purification using an Akta™ avant system and subsequent UV detection. The kappa light chain part of scFV2 binds specifically to the Protein L ligand which is covalently linked to the stationary phase. After binding at pH 7.2, scFV2 was eluted under acidic conditions with 0.1 mM HCl and detected at 280 nm.

scFV1-His

[00584] scFV1-His concentrations were quantified by HisTrap HP purification using an Akta™ avant system and subsequent UV detection. The histidine tag of the protein binds

specifically to Ni sepharose. After binding, the protein was eluted using 500 mM Imidazol and detected at 280 nm.

CLAIMS

We claim:

1. A filamentous fungal cell comprising at least three endogenous proteases having reduced activity, and a recombinant polynucleotide encoding a heterologous polypeptide, wherein the polypeptide is produced at a level of at least two-fold higher than the production level of the polypeptide in a corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity.
2. The filamentous fungal cell of Claim 1, with the proviso that, when the cell is an *Aspergillus* cell, the total protease activity is reduced to 50% or less of the total protease activity of the corresponding parental *Aspergillus* cell in which the proteases do not have reduced activity.
3. The filamentous fungal cell of claim 1 or 2, wherein the total protease activity is reduced to 49% or less, preferably 31% or less, of the total protease activity of the corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity.
4. The filamentous fungal cell of any one of claims 1-3, wherein at least three genes encoding endogenous proteases each comprise a mutation that reduces or eliminates the corresponding protease activity.
5. The filamentous fungal cell of any one of claims 1-4, wherein at least four genes encoding endogenous proteases each comprise a mutation that reduces or eliminates the corresponding protease activity.
6. The filamentous fungal cell of any preceding claim, wherein the fungal cell is a *Trichoderma* fungal cell, a *Myceliophthora* fungal cell, an *Aspergillus* fungal cell, a *Neurospora* fungal cell, a *Penicillium* cell, or a *Chrysosporium* fungal cell.
7. The filamentous fungal cell of any preceding claim, wherein the fungal cell is *Trichoderma reesei*.
8. The filamentous fungal cell of Claim 6 or 7, wherein said cell is wild type for pep4 protease.

9. The filamentous fungal cell of claim 6, 7 or 8, wherein the cell has reduced or no protease activity in at least the following three proteases: either pep1, tspl and slpl or gap1, slp1, and pep1.
10. The filamentous fungal cell of claims 6 or 7, wherein the cell has reduced or no detectable protease activity in at least three or four proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, pep8, pep11, pep12, tspl, slpl, slp2, slp3, slp7, gap1, and gap2.
11. The filamentous fungal cell of claim 10, wherein each of the genes encoding the three or four proteases with reduced or no detectable protease activity comprises a mutation that reduces or eliminates the corresponding protease activity.
12. The filamentous fungal cell of claim 6 or 7, wherein the cell has reduced or no protease activity in at least eight proteases, each of the genes encoding the eight proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the eight proteases are pep1, tspl, slpl, gap1, gap2, pep4, pep3, and pep5.
13. The filamentous fungal cell of claim 6 or 7, wherein the cell comprises three to six proteases having reduced or no detectable activity, and each of the three to six proteases are selected from the group consisting of pep1, pep2, pep3, pep4, pep5, tspl, slpl, slp2, slp3, gap1, and gap2.
14. The filamentous fungal cell of any one of Claims 6-13, wherein the cell comprises a gene encoding an additional protease which comprises a mutation that reduces the corresponding protease activity, and the additional protease is selected from the group consisting of pep7, pep8, pep11, pep12, tppl, gap2, slp3, slp5, slp6, slp7, and slp8.
15. The filamentous fungal cell of any preceding claim, wherein the heterologous polypeptide is a mammalian polypeptide.
16. The filamentous fungal cell of claim 15, wherein the mammalian polypeptide is glycosylated.

17. The filamentous fungal cell of claim 15, wherein the mammalian polypeptide is selected from the group consisting of an antibody and their antigen-binding fragments, a growth factor, an interferon, a cytokine, and an interleukin.
18. The filamentous fungal cell of claim 15, wherein the mammalian polypeptide is selected from the group consisting of insulin-like growth factor 1 (IGF1), human growth hormone (hGH), and interferon alpha 2b (IFNa2b).
19. The filamentous fungal cell of any preceding claim, wherein the fungal cell further comprises ALG3 having reduced activity.
20. The filamentous fungal cell of claim 19, wherein the gene encoding ALG3 comprises a mutation that reduces or eliminates the corresponding activity.
21. The filamentous fungal cell of any one of claims 1-20, wherein the fungal cell further comprises a polynucleotide encoding an α -1,2-mannosidase.
22. The filamentous fungal cell of any preceding claim, further comprising an N-acetylglucosaminyltransferase I catalytic domain, and, optionally, an N-acetylglucosaminyltransferase II catalytic domain.
23. The filamentous fungal cell of claim 22, further comprising a first polynucleotide encoding the N-acetylglucosaminyltransferase I catalytic domain and, optionally, a second polynucleotide encoding the N-acetylglucosaminyltransferase II catalytic domain.
24. The filamentous fungal cell of any preceding claim, further comprising a polynucleotide encoding a mannosidase II and/or a galactosyl transferase.
25. A method of improving stability of a polypeptide, comprising
 - a) providing the filamentous fungal cell of any preceding claim, and
 - b) culturing the cell such that the heterologous polypeptide is expressed,

wherein the heterologous polypeptide exhibits increased stability compared to the heterologous polypeptide produced in a corresponding parental filamentous fungal cell in which the proteases do not have reduced activity.

26. A method of making a heterologous polypeptide, comprising
 - a) providing the filamentous fungal cell of any of claims 1-24,
 - b) culturing the cell such that the heterologous polypeptide is expressed, and
 - c) purifying the heterologous polypeptide.
27. The method of claim 25 or claim 26, wherein the filamentous fungal cell further comprises a carrier protein.
28. The method of claim 27, wherein the carrier protein is CBH1.
29. The method of any one of claims 26-28 wherein the culturing is in a medium comprising a protease inhibitor.
30. The method of any one of claims 26-29 wherein the culturing is in a medium comprising one or two protease inhibitors selected from SBT1 and chymostatin.




Figure 1





Figure 2




Generation of single protease deletion strains M181 and M195
M181 = repurified clone 9-20A-1 (i.e. originating from 9-20A)
M195 = repurified clone 9-35A-1 (i.e. originating from 9-35A)

Expected signals:

- A) *pep1* ORF: >8 kb from parent M127, no signal from transformants
- B) *pep1* 5'flank: >8 kb from parent M127, 4 kb from transformants
- C) *pep1* 3'flank: >8 kb from parent M127, 4.2 kb from transformants

Figure 3



Generation of rituximab, pep1 deletion strain M182

M182 = 11-1A

M169, parent = Rx25A_1

Expected signals:

- A) *pep1* ORF: >8 kb from parent M169, no signal from transformants
- B) *bar*: 1.0 + 1.7 kb from transformants, 3.1 kb from pTTv41, nothing from M169
- C) *bar*: 1.8 + 2.8 kb from transformants, 3.1 kb from pTTv41, nothing from M169

Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17





Figure 18



Generation of *pep1tsp2* deletion strain M194 (for MAB01 transformations)

M194 = 13-172D

M181 = parent

Expected signals:

A) *tsp1* ORF: kb from parent M181, no signal from transformants

B) *bar*: 1.4 + 2.5 kb from transformants, 2.9 kb from pTTv42, nothing from M181

C) *bar*: 1.9 + 3.2 kb from transformants, 2.9 kb from pTTv42, nothing from M181

Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30





Figure 31




Generation of quintuple protease deletion strain M369, clone 7-30A = M369

Expected signals:

- A, gap2 ORF: 4.9 kb from parent (M307), no signals from transformant
- B, gap2 5'flank: 4.9 kb from parent, 2.3 kb from transformant, 2.3 kb from plasmid control pTTv145
- C, gap2 3'flank: 4.9 kb from parent, 3.8 kb from transformants, 3.8 kb from plasmid control pTTv145

Figure 32



Generation of pyr4⁻ from the quintuple protease deletion strain M369, resulting strain M381 (clone 14)

M307 = 4-fold del strain, M369 = 5-fold del strain

Expected signals:

- D) gap2 5'flank: 1.5 kb from all strains, 4.1 kb from plasmid control pTTv145

- E) gap2 3'flank: 3.6 kb from M307, 2.7 kb from M369 + loopout clones, 3.8 kb from plasmid control pTTv145

Figure 32 Continued





Figure 33



Generation of 6-fold protease deletion strains M396 and M400


M396 = 25-120A

M400 = 25-120A-a, i.e. repurified clone from M396

Expected signals:

- Aa & Ab) pep4 ORF: 6.3 kb from M307 and M369, no signals from transformants

Figure 34




Generation of 6-fold protease deletion strains M396 and M400
M396 = 25-120A

Expected signals:

- B) pep4 5' flank: 6.3 kb from M307 and M369, 4.8 kb from transformants, 4.0 kb from pTTv181
- C) pep4 3' flank: 6.3 kb from M307 and M369, 2.1 kb from transformants, 4.0 kb from pTTv181

Figure 34 Continued



Generation of *pyr4*- from 6-fold protease deletion strains M396
 M396 = 25-120A (> repurified clone 25-120A-a = M400)

Expected signals:

- D) *pep4* 3' flank: 6.3 kb from M307 and M369, 2.1 kb from repurified transformants, 4.9 kb from the loopout clones

Figure 34 Continued




Figure 35




Figure 36




Figure 37





Figure 38


Δ pep1 improves heavy chain stability



2 mg/ml large shake flask supernatant (Δ pep1 and M124); 2 mg/ml fed batch fermentation supernatant; 18 hour incubation at 37°C at pH 5.5

Figure 39

Δ tsp1 improves the rituximab heavy chain production levels on day 5.




Lanes: 1) 50 ng Rx control, 2 & 3) parental strain Rx 25A Δ tsp1 4) 12-2A, 5) 12-16A, 6) 12-19A, 7) 12-20A, 8) 12-34A

transformants in lane 4 and 5, clearly show more heavy chain than in lane 2 and 3.

Figure 40

MAB01 heavy chain degradation is reduced in triple deletion strain supernatant M277



2.5-fold more heavy chain on day 5

4-fold more heavy chain on day 7

Supernatants diluted to 6 mg/ml, spiked with MAB01 0.05 $\mu\text{g}/\mu\text{l}$, and incubated at 37°C. M277 is $\Delta pep1 \Delta tsp1 \Delta s/p1$; M124 is full protease containing control strain.

Figure 41




Figure 42




Figure 43




Figure 44




Figure 45




Figure 46




Figure 47




Figure 48




Figure 49A




Figure 49B




Figure 50A




Figure 50B




Figure 51




Figure 52





Figure 53.

A.



B.




Figure 54




Figure 55